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Bis(thiosemicarbazone) ligand derivatives (Figure 1) and their metal complexes (Figure 2) have 
long been of interest as they have applications as anticonvulsants, super-oxide dismutase-like 
radical scavengers, in ƚŚĞŝŶǀĞƐƚŝŐĂƚŝŽŶŽĨůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞĂŶĚĚŝĂgnostic imaging.  
      Figure 1                                                                                 Figure 2
 
Copper (II) bis(thiosemicarbazone) derivatives have been used extensively in the imaging of 
oxygen deficient (hypoxic) cells for the detection and imaging of cancerous tissues and heart 
disease via Positron Emission Tomography (PET). It is possible to fine tune the 
bis(thiosemicarbazone) complexes redox potentials and lipophilicity by altering the substituents 
on the Q1 and Q2 position and the R1, R2, R3 and R4 locations respectively. To date only symmetric 
bis(thiosemicarbazone) ligands  (R1=R3, R2=R4) have been evaluated for hypoxia imaging. This 
thesis reports the synthesis of dissymmetric ligands (R1A?Z3, R2A?Z4) in order to gain further control 
of the properties of the complexes and therefore the locations they will migrate to. A range of 
ligands has also been synthesised for the monitoring of copper metabolism within the brain for 
the investigation of ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞĂŶĚŽƚŚĞƌŶĞƵƌŽĚĞŐĞŶĞƌĂƚŝǀĞĚŝƐŽƌĚĞƌƐ ?>ŝŐĂŶĚƐǇŶƚŚĞƐŝƐ
has been achieved by controlling the condensation reactions between dicarbonyl compounds and 
4-substituted-3-thiosemicarbazides. Synthesis via an alternative acetal protecting method has also 
been investigated. 
Thirty bis(thiosemicarbazone) ligands have been successfully synthesised, of which thirteen are 
symmetric and seventeen dissymmetric. From this library of ligands, eighteen copper complexes 
have been synthesised along with twenty zinc complexes. The zinc complexes have the potential 
to act as convenient precursors for the rapid synthesis of radio-copper complexes via a 
transmetalation method.  
All ligands, complexes and intermediates have been fully characterised by a range of techniques 
including IR spectroscopy, Raman spectroscopy, NMR spectroscopy, UV-vis spectroscopy, 
elemental analysis and mass spectroscopy.  A new cyclic by-product from the ligand synthesis has 
also been isolated and fully characterised.  
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AD ůǌŚĞŝŵĞƌ ?ƐĚisease 
ATP Adenosine triphosphate 
BBB Blood brain barrier 
BDO 2,3-Butanedione 
Cr(acac)3 Chromium (III) acetylacetonate 
CT X-ray computer tomography 
PS-DMAP Dimethyl aminopyridine on polystyrene 
DMA 2,2-Dimethoxyacetaldehyde 
DMB 3,3-Dimethoxy-2-butanone 
DMF N,N-Dimethyl formamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
ECG Electro-cardiogram 
FDG Fluorodeoxyglucose 
FTIR Fourier transform infrared 
GLY Glyoxal 
HCl Hydrochloric acid 
HIF-1 Hypoxia inducible transcription factor 
HMBC Heteronuclear multiple bond correlation  
HMQC Heteronuclear multiple-quantum correlation  
keV Kilo-electronvolt 
LiBF4 Lithium tetrafluoroborate 
MeV Mega electronvolt 
mmHg Millimetre of mercury 
MRI Magnetic resonance imaging 
Na2CO3 Sodium carbonate 
NADH Nicotinamide adenine dinucleotide 
NADP+ Nicotinamide adenine dinucleotide phosphate (reduced) 
NADPH Nicotinamide adenine dinucleotide phosphate (oxidised) 
NaI Sodium iodide 
NaOH Sodium hydroxide 
 NMR Nuclear magnetic resonance  
NOESY Nuclear overhauser effect spectroscopy  
PADA pyruvic aldehyde dimethyl acetal 
PDO 2,3-Pentandione 
PET Positron emission tomography 
pO2 Tissue oxygen partial pressure 
PVP Poly (4-vinyl pyridine) 
RNA Ribonucleic acid 
SOD Superoxide dismutase 
SPECT Single photo emission computed tomography 





1.1. Nuclear medicine 
Nuclear medicine can be defined as the medical use of radioactive agents to diagnose and treat 
patients.1 The radioactive agent sometimes called a radio-tracer, a termed first coined by the 
father of nuclear mĞĚŝĐŝŶĞ ?'ĞŽƌŐĞĚĞ,ĞǀĞƐǇ ?ŝŶƚŚĞ ? ? ? ? ?Ɛ2, is a radioactive element which is 
either administered in its elemental form or attached to a bio-active molecule. This bio-active 
molecule can be a protein, peptide or a neurotransmitter3 which possess the correct interactions 
within the body in order to allow the radionuclide to be transported to the desired biological 
target. Small radiolabelled coordination complexes may also be utilised in nuclear medicine as 
their use may overcome problems experienced with molecules with large molecular masses such 
as antibodies which may lead to slow uptake in the target cells.4 Once at the target site the 
products of the decaying radionuclide are either detected for diagnostic imaging or used to 
irradiate the tissue for therapeutic applications.  
1.1.1. Diagnosis 
/ŶƚŚĞůĂƚĞ ? ? ? ? ?Ɛ,ĞƌŵĂŶŶůƵŵŐĂƌƚĂŶĚ^ŽŵĂtĞŝƐƐ ?ƚǁŽƉŚǇƐŝĐŝĂŶƐĂƚƚŚĞDĂƐƐĂĐŚƵƐĞƚƚƐ
General hospital, first pioneered diagnostic nuclear medicine by using a solution of radium-C, 
which is the historic name for 214Bi, to study the velocity of blood. Blumgart is regarded as the 
father of diagnostic nuclear medicine.2  ŝĂŐŶŽƐƚŝĐŶƵĐůĞĂƌŵĞĚŝĐŝŶĞ ?ƐƐƚƌĞŶŐƚŚ lies in that it 
ŝŵĂŐĞƐƚŚĞďŽĚǇ ?ƐďŝŽĐŚĞŵŝƐƚƌǇŝŶŽƌĚĞƌƚŽĂƐĐĞƌƚĂŝŶƚŚĞŵĞƚĂďŽůŝĐŽƌƉŚǇƐŝŽůŽŐŝĐĂůĨƵŶĐƚŝŽŶĂůŝƚǇ
of a tissue or organ compared to other techniques commonly used in imaging procedures whose 
main strengths are showing anatomy.5, 6 The area has progressed to such an extent that almost 
every organ can be imaged, as there are tracers available for nearly all tissues (bone, liver, kidney, 
heart, lung, gastro-oesophageal tract, etc.)  and fluids (blood, cerebro-spinal liquid, urinary 
excretion tract, etc.).7  Diagnostic imaging makes up by far the majority of all nuclear medicine 
procedures with 85-90% of the nuclear medicine procedures being for diagnosis.1 Generally, the 
radionuclides used in diagnostic procedures are short-lived gamma or positron emitters such as 
technetium-99m and fluorine-18 which aids to limit adverse effects on the patients due to the 
emitted radiation.  Once the radiotracer has migrated to the target tissue, the products of the 
radioactive decay are detected by a suitable camera at many different angles around the target 
site and the data from the detected events is used to build up an image.   
An example of a diagnostic tracer is [18F]Fluorodeoxyglucose, also known as [18F] FDG, which is a 
18F labelled analogue of glucose (Figure 1.1.1.1.).  [18F] FDG is a substrate for the hexokinase 
enzyme in glucose metabolism. Hexokinase phosphorylates FDG to form two molecules (2-
deoxyglucose-6-phosphate and FDG-6-phosphate) which are unable to enter the glycolysis cycle 
so are trapped within the cell.8 This enables [18F]FDG to be used in the imaging of glucose 
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metabolism for the detection, staging and response monitoring of malignant and benign 
tumours.2, 8, 9 
Figure 1.1.1.1. Structures of D-Glucose and [18F]Fluorodeoxyglucose based on.10, 11 
 
1.1.2. Therapy 
Therapeutic nuclear medicine usually involves a single administration of a radionuclide that emits 
ĞŝƚŚĞƌĞůĞĐƚƌŽŶƐ ?ďĞƚĂŵŝŶƵƐ ?ɴ-) decay) or gamma rays in order to induce the cellular destruction 
of any unwanted cells. The main objective of therapy is to remove the capacity of the cancer cells 
to multiply. High energy radiation has the ability to remove the cancer cells ability to divide and 
proliferate by causing damage to cells genetic material such as DNA (deoxyribonucleic acid).12 This 
principle exploits the fact that rapidly dividing cells are particularly sensitive to radiation damage.1 
The first use of nuclear medicine was for therapy in 1901 where Henri Aleandre Danlos and 
Eugene Bloch treated a tuberculosis skin lesion by placing it in contact with radium.13   
An example of a radionuclide used for therapeutic applications is 131Iodine which when 
administered to a patient accumulates in the thyroid. This allows for the beta minus emitter to be 
used in thyroid cancer therapy or treatment of non-malignant thyroid disorders.1 It is worth 
noting that radiation cannot be used in the treatment of conditions where the cells need to be 
stabilised or regenerated.7       
1.1.3. Types of radioactive decay 
A radionuclide is a radioactive element that gains stability by undergoing one or more modes of 
radioactive decay, resulting in a loss of mass or charge.1 The reasons why an element may 















































ůƉŚĂ ?ɲ ?ĚĞĐĂǇ 
Elements with a high atomic number or with an atomic mass >210 such as 238U, 226Ra and 230Th 
achieve stability by emitting alpha particles and occasionally gamma photons are emitted as well.2 
An alpha particle consists of two neutrons and two protons. The emission of this alpha particle 
ƌĞƐƵůƚƐŝŶĂƌĞĚƵĐƚŝŽŶŝŶƚŚĞŶƵĐůŝĚĞ ?ƐĂƚŽŵŝĐĂŶĚŵĂƐƐŶƵŵďĞƌǁŚŝĐŚĂůůŽǁƐƚŚĞŶƵĐůŝĚĞƚŽ
achieve a more stable state. Alpha particles have kinetic energies in the range of 4-9 MeV2. For an 
alpha emitting nucleus each decay will yield alpha particles with the same energy. Therefore alpha 
particles can be termed mono-energetic particles. Alpha particles are about 7,000 times heavier 
than electrons and can be stopped by organic tissue. When a collision occurs the alpha particle 
ionises the tissue and indirectly cuts it or allows chemical transformation which in the case of 
collisions with DNA or RNA can cause death to the cell.7 The extremely high level of damage that 
alpha emitters cause coupled with their short range which limits the zone of interaction with 
neighbouring cells means alpha emitters have an ideal profile for use in destroying cancerous 
cells.7 Due to the large amount of damage alpha particles can inflict, alpha emitting 
radiopharmaceuticals need to possess a very high level of affinity to the target site, in order to 
avoid undesirable damage to the rest of the body. The added down fall of alpha emitters is once 
they are absorbed or ingested it is impossible to detect the alpha radiation which means 
accidental contamination is difficult to localise which would cause problems for production, 
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transportation and implementation of alpha emitters for medical procedures.7 The use of alpha 
emitters would not be first choice if another radionuclide that decays via a different route is 
available.   
ĞƚĂŵŝŶƵƐ ?ɴ-) decay 
Beta minus decay is when a neutron (n) in a neutron rich nucleus is converted in to a proton (p), 
an electron (e-) and an anti-neutrino ( ). The electron and the anti-neutrino are ejected from the 
nucleus. In this decay route the atomic mass of the nuclide stays constant but the atomic number 
increase by one. The kinetic energies of the emitted electrons can vary greatly, the range of this 
variation is a characteristic of the nuclide.2 There is not a role in nuclear medicine for the 
weightless anti-neutrino, but electrons which have a continuous energy spectrum and a tendency 
to be absorbed by matter, are greatly useful in therapy.7 When the electron is absorbed by matter 
X-rays are sometimes generated and the remainder of the energy is deposited as heat. This 
process can cause free radicals which can lead to molecular re-arrangements. This high potential 
for destruction coupled with their specific half-life means that beta emitters can be used for 
localised cell destruction.7   
WŽƐŝƚƌŽŶ ?ɴ+) decay 
Also known as beta plus decay, this type of radioactive decay is more commonly seen in elements 
with lower atomic numbers. Positron decay is a mechanism which allows the neutron deficient 
nucleus to gain increased stability by decreasing the number of positive charges (protons) it 
contains. In positron decay a proton in the nucleus transforms into a neutron, positron and a 
neutrino. The positron can be thought as an anti-electron. The positron and the neutrino are 
ejected from the nucleus resulting in a daughter nuclide which comprises of a lower atomic mass 
number but a constant mass number. Just as with the beta decay, there is variation in the 
energies of the positron as their energy is dependent on how much energy is carried away by the 
neutrino.2 Even though the neutrino is not of any use in nuclear medicine,7 the gamma ray 
emissions which are the product of positron annihilation are of great importance for diagnostic 
imaging techniques such as Positron Emission Tomography (PET). After travelling a few 
millimetres the positron will undergo an inelastic collision with an electron which will result in 
both the particles undergoing annihilation.7 dŚĞĂŶŶŝŚŝůĂƚŝŽŶƉƌŽĐĞƐƐĐĂƵƐĞƐƚŚĞƉĂƌƚŝĐůĞƐ ?ŵĂƐƐĞƐ
to be converted in two 511 keV photons2 which are emitted at 180o from each other.14 If two 
detectors are placed on each side of the patient, as is done in PET, after a few disintegrations it is 





Gamma radiation is electromagnetic radiation that is emitted from a nucleus that is in an excited 
state, which can be produced by the electron capture and isomeric transition mechanisms. 
Gamma rays are ideal for diagnosis due to their very high penetrative ability.7 They can pass 
through large thicknesses of matter or far further in air. Gamma rays can however, be stopped or 
strongly attenuated with dense materials such as lead or concrete. Gamma rays can be detected 
by gamma cameras or used in Single Photon Emission Computed Tomography (SPECT) for 
diagnostic procedures.14 High energy gamma radiation has also the ability to damage the DNA of 
cancerous cells which allows them to be routinely used in therapeutic applications for the 
treatment of various cancers.12 
Electron capture 
An alternative mechanism with which a neutron deficient nucleus can become more stable is a 
process called electron capture. This is when an electron (usually in the K-shell) is captured by the 
parent nucleus resulting in a proton being converted into a neutron and a neutrino. The daughter 
nucleus produced has an atomic number which is one lower than the parent nucleus whilst the 
mass number remains unchanged.  Electron capture can also produce characteristic X-rays14 
and/or Auger electrons, due to the vacancy in the K-shell or gamma photons produced when a 
daughter nucleus in an excited state falls back down to the ground state.2 Auger electrons which 
ĂƌĞĞůĞĐƚƌŽŶƐǁŚŝĐŚŚĂǀĞďĞĞŶĞũĞĐƚĞĚĨƌŽŵŽŶĞŽĨƚŚĞĂƚŽŵ ?ƐĞůĞĐƚƌŽŶŝĐƐŚĞůůƐŚĂǀĞĂůŽƚůĞƐƐ
ĞŶĞƌŐǇƚŚĂŶɴ- particles but show therapeutic applications due to their ability to cause destruction 
to only a few layers of cells.7 
Isomeric Transition (IT) 
Isomeric transition occurs when a daughter nucleus has undergone one of the above decay routes 
but still remains in an exciƚĞĚƐƚĂƚĞ ?dŚŝƐůŽŶŐůŝǀĞĚŵĞƚĂƐƚĂďůĞƐƚĂƚĞ ?ĚĞŶŽƚĞĚďǇĂŶ ‘ŵ ? ?ƌĞƐƵůƚƐŝŶ
the emission of gamma photons when the daughter nucleus drops to the ground state. As the 
ground state nuclide and the metastable nuclide only differ in energy they can be described as 
isomers2, hence the term isomeric transition. 
1.2. Single Photon Emission Computed Tomography (SPECT) 
Out of approximately 40 million radiopharmaceutical based clinical scans that are made annually 
worldwide, 95% is comprised of SPECT scans.15 The technique Single Photon Emission 
Tomography (SPECT) is based on using radio-nuclides that undergo decay routes resulting in the 
emission of gamma rays or X-rays. Technetium-99m (99mTc), with its 140 keV gamma ray 
emissions, is the most commonly used radionuclide in SPECT imaging14, 15 but other radio-nuclides 
are also used, as shown in table 1.2.1.  
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Table 1.2.1. Other commonly used radio-nuclides for SPECT Imaging, based on 
14
. 
Radionuclide Symbol Half-life Emitted Photon Energies (keV) 
Thallium 201 201Tl 73 days A? ? ?-80, 167 
Technetium 99m 99mTc 6 hours 140 
Iodine 123 123I 13 days 159 
Iodine 131 131I 8 days 364 
Indium 111 111In 2.8 days 172, 245 
Gallium 67 67Ga 78 hours 93, 184, 300, 393 
 
When a photon is emitted by the chosen radionuclide, it radiates from the body in a random 
direction.  The photon is then detected by a gamma camera which is fitted with a lead collimator 
with multiple parallel holes.  The collimator only allows the photons that are emitted roughly 
perpendicular to the face of the gamma camera to interact with the sodium iodide (NaI) crystals 
and hence be detected14 (Figure 1.2.2.). A projection view of the radiotracer in the body is built up 
by the detection of the accumulated events hence, the precision of the projection increase with 
longer acquisition times.  In order to produce a complete image, a series of projections at 
successive angles need to be measured. This is achieved by the camera being mounted on a 
gantry that can orbit the body. Most routine clinical SPECT systems are based on dual-head 
variable 180 degree or variable angle cameras or triple-head variable angle cameras.2 A typical 
angular increment is 3-6 degrees,16 resulting in a total of 60 projections for a 180 degree orbit.14 
The total scan time of a full 360 degree is between 15-20 minutes.16 Applying linear analysis to the 
acquired data allows a three-dimensional image of the target area to be obtained.7  
 
Figure 1.2.2. Detection of a photon by a gamma camera in SPECT, based on 
14
. Four different emission 
photon trajectories are depicted. Only one (indicated by the solid line) will be detected at this camera angle 
because of the lead collimator. 
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SPECT is a less efficient method of acquiring data than methods such as Positron Emission 
Tomography (PET) due to only the photons that are emitted in the plane of the collimator being 
detected, this can be roughly 1 in 5,000, depending on the design of the collimator.2 With PET, all 
photon pairs emitted in the same plane as the detector ring will be detected. A second 
disadvantage with SPECT is that each angle projection has to be measured individually while with 
PET all angles are acquired simultaneously.14 However for preclinical small animal studies SPECT 
can achieve higher resolution than PET.15 A number of physical effects, such as collimator blur, 
statistical noise, scatter and attenuation all have negative effects which ultimately limit the image 
quality and accuracy of a SPECT image.14  
Collimator blur arises due to the collimator accepting photons with a range of incident angles 
instead of only the photons that are travelling exactly perpendicular to the collimator face. This 
causes a decrease in spatial resolution. Statistical noise arises due to the acquisition of only a 
limited number of photons. Photons can be scattered by tissues whilst travelling through the 
body, this can result in either the photon being diverted from the plane of the detector and hence 
not detected or the photon losing to much energy before reaching the gamma camera. If the 
energy loss is large enough the gamma camera will reject the event. Most photons with 140 keV 
of energy would be scattered rather than be absorbed.5 Attenuation is when a photon that is 
travelling on a path that would otherwise be detected becomes either scattered or absorbed, 
resulting in the photon not being detected. Attenuation results in loss of quantitative accuracy 
and increased noise of the resulting image.14 The imaging of moving organs, for example the 
heart, can also add difficultly in terms of image acquisition and interpretation7 even though there 
are specific SPECT systems, such as the Cardius system (Digirad) which has been optimised for 
cardiac imaging.2 SPECT myocardial perfusion imaging is well established as a non-invasive tool for 
the diagnosis of ischaemic coronary disease.16 SPECT can be combined with the anatomic imaging 
capabilities of X-ray computed tomography (CT) to form SPECT/CT or computed tomography 
coronary angiography16 which enables physicians to access improved diagnosis capabilities than if 
SPECT was used alone.1, 2, 14   
1.3. Positron Emission Tomography (PET) 
 
The versatility of Positron Emission Tomography (PET) is the reason why PET is gaining popularity 
in functional imaging.7 This is supported by the fact that between 2005 and 2011 in the UK the 
number of static PET scanners increased from 14 to 35.17 PET relies on the detection of the decay 
products of, neutron-deficient, positron emitting nuclides. These nuclides can be incorporated 
into a pharmaceutical that is designed in order to detect a specific metabolic pathway. After 
emission, the particularly unstable positron, which lasts about 10-10 seconds, interacts randomly 
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with the surrounding tissue. This interaction causes a loss of energy until then energy of the 
positron is sufficiently small, when it is able to annihilate upon collision with a free electron.2, 5, 7, 
14, 18 This annihilation process produces two photons of 511 KeV which corresponds to the rest 
mass of both the electron and positron.14 The two photons are emitted at 180 degrees from each 
other, however the angle can be slightly more or less than 180 degrees, typically +/- 0.25o, if the 
positron-electron system is not a rest at the moment of annihilation.2, 14 This process is illustrated 
in figure 1.3.1. The detection of a high level of coincidental events can generate an image of the 
distribution of the detected annihilation photons, hence the position of the positron emissions 
reflects the distribution of the labelled pharmaceutical. Typically, coincidental events are two 
photons that are detected between 6-12 nanoseconds from each other.14 The distance the 
positron travels before annihilating is called the positron range and depends on the initial energy 
of the particle. A low positron energy is desirable in order to limit the positron range and optimize 
spatial resolution.18 
Figure 1.3.1. A diagram of the positron emission and of the detection of both gamma photons generated by 




Typical to most PET scanners, the coincidental events are detected by numerous detector rings 
arranged in a cylindrical detector in order to make maximum use of the radiation which is 
emitted.14 Not all emitted photons will be used in the formation of the resulting PET image. As the 
photons are emitted in all directions from the patient they may not be travelling in the same 
plane in order for them to be detected by the detector rings, even though each photon is 
contributing to a radiation does to the patient.  Modern PET scanners have the ability to acquire 
data in 2-D or 3-D modes,7 in 2-D acquisitions only photon pairs detected by a single detector ring 
is used in the image formation whilst in the 3-D mode photons pairs detected by any combination 
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of detector rings are used.14 The PET image is constructed by subjecting the acquisition data to 
algorithms, filter functions and statistical methods.14 As PET does not require the use of a 
collimator, PET can achieve a significantly higher sensitivity than SPECT by approximately two to 
three orders of magnitude.19 PET can also be used to quantify the absolute trace concentration in 
a target tissue, but before this can be achieved, the acquired data has to be subjected to 
corrections in order to take into account system and physical effects. The effects that need to be 
accounted for include, but are not limited to, detector efficiency variations, random coincidences, 
photon attenuation and scattered radiation.14 
The PET system also suffers from a number of limitations. One limitation is that individual crystals 
that make up the detector may have differing light output and decay times. It is therefore 
necessary for the each photomultiplier tube to be assessed and correction maps generated in 
order to ensure uniform response from the detector. Photomultiplier gain adjustments are part of 
the detector setup and calibration procedures.14 A limitation on overall count performance is 
 ‘ƉƵůƐĞƉŝůĞƵƉ ? ?WƵůƐĞƉŝůĞƵƉŝƐǁŚĞŶƚǁŽƉŚŽƚŽŶƐŽƌŝŐŝŶĂƚŝŶŐĨƌŽŵƚǁŽĚŝĨĨĞƌĞŶƚĂŶŶŝŚŝůĂƚŝŽŶ
events interact with the detectors crystals within a very short time frame. If this time frame is too 
short then the two photons cannot be distinguished as two separate photons, but only as one 
high energy event. If the sum of the two photons energy is above the upper energy discrimination 
level then the event shall be discarded. If this is the case then both of the photons involved shall 
be lost. Pulse pile up can be reduced by the use of scintillator with short decay times.14 The main 
limitation that is faced by PET is the insurmountable resolution limit, which is due to PET 
detecting the products of annihilation, which occurs after the positron has travelled a few 
millimetres from the site of the radiotracer. The mean distance the positron can travel before 
annihilating can vary from a fraction of a millimetre to 4-6mm, depending on the radionuclide 
used.2 This means that there is an unavoidable limit to the ultimate image resolution attainable by 
the PET technique.7 Despite this resolution limit of a few millimetres, the resolution of PET images 
is still regarded as excellent.7, 20 PET is also used in animal model based research for a large 
number of human diseases, this is known as small-animal PET. Due to the reduction in size of the 
subject that is being imaged, state of the art human PET systems, with spatial resolutions of 4-
6mm, are not adequate which means that there is a range of small animal PET scanner systems on 











Does not require lead collimator. Many radionuclides require to be produced 
on site from a cyclotron. 
Uses biologically interesting radionuclides, 
such as 11C, 15O, 13N. 
High cost of a cyclotron, imager and 
radiochemistry facility.  
Can accurately measure the amount of 
radiopharmaceutical present in a region of 
the body. 
 
Spatial resolution of about 5mm.  
 
For moving objects, such as the heart, gating can be used in order to improve the image quality of 
the objects. Gating works by synchronising the movement of the heart with a particular emission 
frame which can be achieved exploiting the data from an electrocardiogram (ECG).14  Just like 
SPECT, the PET system can also be coupled with X-ray tomography to form PET-CT.  PET-CT 
enables the functional data of PET and the anatomical data of CT to be combined together in to 
one image.22  Another advantage that PET-CT has over PET alone is that the data acquired from 
the CT scanner can be used in order to correct for photon attenuation effects in PET.14 PET 
scanners can also be combined with Magnetic Resonance Imaging (MRI) in the case of PET/MRI.1, 
19 A particular benefit of this combined modality is that the high spatial and temporal resolution of 
MRI can compensate for the lower spatial and temporal resolution of PET.  Another significant 
advantage of the PET/MRI systems is that they can be used to image the hallmarks of cancer by 
using the two complimentary techniques for validation or image one or two biological factors 
independently or simultaneously. One application for this powerful technique is preclinical drug 
development for cancers such as Glioma, the most aggressive form of brain tumour.19      
1.4. Copper radioisotopes in nuclear medicine.  
 
Copper has the versatility of a transition metal element but because its chemistry is dominated by 
the +1 and +2 oxidation states, copper does not suffer the complexities that a large range of 
oxidation states can introduce. Copper in its +1 oxidation state has a full third shell (3d10) which 
results in diamagnetic complexes that tend to be either colourless or yellow.23 Cu(I) forms 
complexes without any crystal-field stabilization energy and therefore the resulting Cu(I) 
complexes typically lack sufficient kinetic stability for radiopharmaceutical applications24 even 
though, there is a recent report of a stable copper (I) complex that can be used for 
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radiopharmaceutical applications.25 Copper (II) on the other hand, has a 3d9 electron 
configuration and forms complexes that are paramagnetic. The unsaturated d-shell gives rise to 
crystal field stabilisation energy that dictates preferences to coordination numbers of four, five 
and six. Four co-ordinate complexes typically exhibit square-planar geometries whilst five co-
ordinate complexes tend to form square-pyramidal or trigonal-bipyramidal geometries, six co-
ordinate complexes on the other hand exhibit octahedral configurations.23, 24, 26 As copper in its 2+ 
oxidation state straddles the line between a hard and soft cation, most ligands that effectively 
chelate with Cu2+ tend to contain uncharged nitrogen donors and anionic sulphur or oxygen 
donors in order to neutralise the charge of the Cu2+ cation.26 Cu(II) is less labile towards ligand 
exchange because of crystal-field stabilization energy which means that Cu(II) is the best 
candidate for the incorporation into radiopharmaceuticals.24 In vivo Cu2+ can undergo reduction in 
hypoxic (oxygen deficient) tissues. This reduction is not limited to free copper ions but also can 
occur in a Cu2+ complex leading to Cu+ which is usually not as stably bound by the same ligands as 
Cu2+. This results in a release of the copper in to the hypoxic tissue. This means that a stable Cu2+ 
complex should ideally be able to withstand reducing conditions so that no Cu+ is released from 
the complex and accumulating in non-target cells.27 This lends Cu2+complexes to the application of 
radio-tracer for medical imaging. 
/ƚŝƐƉŽƐƐŝďůĞƚŽŽďƚĂŝŶĐŽƉƉĞƌŝŶƚŚĞA? ?ŽǆŝĚĂƚŝŽŶƐƚĂƚĞ ?ďƵƚƉĂƌƚŝĐƵůĂƌůǇƐƚƌŽŶŐʋ-donating anionic 
ligands are required, for example deprotonated amide nitrogen ligands.23, 24 The geometry of the 
resulting 3d8 complexes tends be the square planar.  Copper in the +3 state has not currently 
been observed within biology28 so just copper in the +2 (cupric) and +1 (cuprous) oxidation states 
are applicable to biological systems,29, 30 with the +2 state being the most relevant.26 
ŽƉƉĞƌŝƐĂƚƌĂĐĞĞůĞŵĞŶƚ ?ǁŝƚŚƚŚĞĂǀĞƌĂŐĞĂĚƵůƚŵĂůĞĐŽŶƚĂŝŶŝŶŐŽŶůǇA? ? ? ?ŵŐŽĨĐŽƉƉĞƌ30 and 
the adult recommended daily intake being 0.9-10mg/day.31  Despite the small quantity within the 
body copper is an essential bio-metal involved in a number of critical cell functions.32 As a product 
ŽĨĐŽƉƉĞƌ ?ƐĂďŝůŝƚǇƚŽĂĐĐĞƉƚĂŶĚĚŽŶĂƚĞĞůĞĐƚƌŽŶƐĞŶǌǇmes require copper as a cofactor for 
respiratory oxidation, neurotransmitter synthesis, pigment formation and iron metabolism.29, 30, 33 
ĞƐƉŝƚĞĐŽƉƉĞƌ ?ƐŝŵƉŽƌƚĂŶĐĞŝŶƚŚĞĐĞůů ?ƐďŝŽůŽŐǇ ?ŚŝŐŚƌĞĂĐƚŝǀĞŝŽŶŝĐ ? ‘ĨƌĞĞ ? )ĐŽƉƉĞƌĐĂŶĞǆĞƌƚ
cytotoxic effects. In order to prevent these effects cells have developed complex mechanisms in 
order to chaperone copper around the body to where it is required.32, 34 When copper 
homeostasis is disrupted, the subsequent copper imbalance is a pathology that a range of 
ĚŝƐĞĂƐĞƐƐŚĂƌĞ ?ƐƵĐŚĂƐtŝůƐŽŶ ?ƐĚŝƐĞĂƐĞ,35 neurodegenerative diseases,30, 32, 35-37 cancer29 and 
Menkes disease.23, 38 Copper also has an involvement in celiac disease which is the autoimmune 
disease linked to an intolerance to gluten (the protein fraction of cereal grains).35, 39 tŝůƐŽŶ ?Ɛ
disease is due to a mutation on chromosome 13 which leads to a functional deficit in the copper 
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transporter protein ATP7B, this results in an accumulation of copper in the liver, brain, kidneys 
and eyes.40 The disease, which can be fatal, can be managed by the administration of 
penicillamine, a copper-chelating agent which controls copper levels by liberating isolated copper 
and facilitating its excretion.23 Menkes disease is a recessive neurodegenerative disorder linked to 
a gene mutation on the X sex chromosome. This gene in question codes for a copper transport 
protein, and when the mutation is present, an inability for copper to be incorporated in to several 
enzymes arises which causes several biochemical pathways to malfunction.23, 38    
In a nuclear medicine context copper is a highly versatile radio-nuclide due to the number of 
different isotopes of copper that are available, as summarised in Table 1.4.1. These different 
radio-isotopes of copper fortuitously have a range of different decay mechanisms which yield 
different decay products which can be utilised for diagnostic and therapeutic applications.41 
Copper isotopes could also be of interest in the new field of theranostics, where one agent can be 
used for both diagnostic and therapeutic applications depending on which copper isotope is 
incorporated in to it.18, 25 Nuclear reactions can be written in a shorthand format42 which is 
64Ŷ ?Ɖ ?ɲ ) 61Cu. This format shows that the 64Zn target atom had a proton (p) collide with it. The 
result of this collision was the emission of an alpha particle to form an atom of 61Cu. The letters d 
and n represent a deuterium atom and a neutron respectively.  
Table 1.4.1. Physical properties of copper radionuclides for imaging and therapy, based on 

















873 4.4 cyclotron 




527 2.6 cyclotron 
62Cu 0.16 ɴ+ (98) 
EC (2) 
511 1315 6.6 Generator/ cyclotron 













66Cu 0.09 ɴ- (100)  1109 5.6 Reactor/cyclotron 
67Cu 62 ɴ- (100) 93 121 0.61 Reactor/cyclotron 
Ep сĞŶĞƌŐǇŽĨƚŚĞŵŽƐƚĂďƵŶĚĂŶƚƉĞŶĞƚƌĂƚŝŶŐ ?ɶ ?ƌĂĚŝĂƚŝŽŶĨŽůůŽǁŝŶŐthe corresponding decay.  
Enp = average energy of the most abundant non-ƉĞŶĞƚƌĂƚŝŶŐ ?ɴ+/ɴ-) radiation.  
Rnp = Average range of non-penetrating radiation in tissue. 
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Copper 60  
The short lived 60Cu, with a half-ůŝĨĞŽĨ ? ?ŵŝŶƵƚĞƐ ?ŝƐĂƌĂĚŝŽŶƵĐůŝĚĞŽĨĐŽƉƉĞƌƚŚĂƚĚĞĐĂǇƐǀŝĂɴ+ 
(93%) decay and electron capture (7%). 60Cu is not produced by a generator but via a small 
cyclotron by either 61Ni(p,n) 60Cu  or a 61Ni(d,2n) 60Cu reaction on 61Ni-enriched targets.23 Due to 
its short half live it must be synthesised on site. 
Copper 61 
61Cu decays via positron emission (62%) with a mean energy range of 0.242-0.527 MeV44 as well 
as by electron capture (38%). 61Cu has a half-life of 3.4 hours and large activities can be produced 
by using 61Ni(p,n) 61Cu using a highly enriched nickel target. The high activities of 61Cu produced 
come at a high cost due to the need for the expensive enriched 61Ni targets. A significantly 
cheaper approach is using a zinc target to utilise the 64Ŷ ?Ɖ ?ɲ ) 61Cu reaction.44 Due to its longer 
half-life, this radioisotope of copper is able to be produced off site and transported to the 
required location instead of having to be produced on site.  
Copper 62 
62ƵƵŶĚĞƌŐŽĞƐɴ+ (98%) decay and owing to its short half-life (9.8 minutes) 62Cu can be used as a 
PET tracer for short timescale studies.45 The half-life of 62Cu means that it is compatible with 
relatively long image acquisitions times for good counting statistics as well as being short enough 
in order to allow repeat scanning within an single imaging session.46 62Cu can be obtained by 
eluting it from a 62Zn/62Cu generator or by the more expensive method of using the 62Ni(p,n) 62Cu 
reaction in a small cyclotron.23 The 62Cu generator contains 62Zn that is produced by irradiating a 
copper disc in a nuclear reactor in order to perform the nuclear reaction 63Cu(p,2n)62Zn using 
protons with energies between 21-26 MeV. An anion-exchange resin is used to isolate the 62Zn 
from the target copper.2, 46 When dissolved in an acidic solution the 62Zn can be loaded on to 
second anion-exchange resin column and the daughter 62Cu can be eluted from the column when 
it is required. Due to the limitations of the very short half-life this radionuclide needs to be 
produced within a very close proximity to where it is required for use.  
Copper 64 
The versatile 64Cu radionuclide undergoes a range of different decay routes which includes 
ĞůĞĐƚƌŽŶĐĂƉƚƵƌĞ ? ? ?A? ?A? ? ? ? ?ĂŶĚ ? ? ? ?ŬĞs ) ?ɴ- ĚĞĐĂǇ ? ? ?A? ?A? ? ? ? ? ?ŬĞs )ĂŶĚɴ+ decay (18%, 
Emax = 660 keV, Eaverage = 288 keV) 
43 (Figure 1.4.2.). 64Cu yields positrons with relatively low 
energies that produce high-quality PET images47 with spatial resolution which is equivalent to 18F 
images.25 Positrons from 64Cu have a mean positron range of 0.7 mm and a max range of 2.2 mm 
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which is comparable to the mean and maximum range of positrons from 18F at 0.6 mm and 2.1 
mm respectively.18       
The electron capture decay route can yield Auger electrons which can be used for therapeutic 
applications,23 when the copper is deposited close to the nucleus of the cell.29 Its 12.7 hour half-
life enables the use of more time consuming chelation methods which has allowed the 
development of a range of 64Cu containing radio-pharmaceuticals. 64Cu is best incorporated into a 
radio-pharmaceutical by the formation of a thermodynamically stable and kinetically inert 
coordination complex47, 48 but also can be integrated in to larger bio-molecular probes based on 
antibodies,41, 49, 50 nanoparticles or peptides.29, 41 However, 64CuCl2 on its own has shown potential 
for being used as a prostate cancer tracer.51  
64Cu has a sufficient half-life in order to allow for it to be synthesised off site and shipped to the 
research institution or hospital without excessive decay.26  64Cu can be produced by either by the 
64Zn(n,p)64Cu nuclear reaction24, 52 or by using a cyclotron to exploit the 64Ni(p,n)64Cu24, 53 or the 
64Ni(d, 2n)64Cu54 nuclear reactions.  The 64Ni(p,n)64Cu method in a biomedical cyclotron is by the 
far the most common method used to obtain 64Cu26 and requires an expensive enriched 64Ni 
target (99.6%, natural abundance of nickel is 0.95%) which is electroplated on to a gold disk.18  














This short lived radionuclide with a half-ůŝĨĞŽĨ ? ? ?ŵŝŶƵƚĞƐĚĞĐĂǇƐĞǆĐůƵƐŝǀĞůǇǀŝĂɴ- decay (100%) 
ƚŽƉƌŽĚƵĐĞĂƌĞůĂƚŝǀĞůǇŚŝŐŚĞŶĞƌŐǇɴ- particle (2.6 MeV) which makes 66Cu suitable for targeted 
ƚŚĞƌĂƉǇŽĨůĂƌŐĞ ?A?1 cm) tumours.23 66Cu can be synthesised by using a reactor with an enriched 
65Cu target. Other systems involving nickel, copper and zinc as target materials are under 
investigation.  
Copper 67 
67Cu, with a half-life of 62 hours, has the longest half-life of all of the radionuclides of copper. The 
ƌĂĚŝŽŶƵĐůŝĚĞƵŶĚĞƌŐŽĞƐĚĞĐĂǇɴ-  ? ? ? ?A? ) ?ďƵƚǀŝĂĨŽƵƌĚŝĨĨĞƌĞŶƚƌŽƵƚĞƐǁŚŝĐŚǇŝĞůĚƐɴ- emissions 
with energies ranging between 395 and 577 keV.55 dŚĞŐĞŶĞƌĂƚŝŽŶŽĨɴ- particles makes 67Cu a 
candidate for the use in therapeutic procedures,55 particularly for tumours with a diameter of 1.6 
- 2.8 mm.56 67Cu has also been used for radio-immunotherapy using molecular antibodies and 
antibody fragments.29 Due to the varying decay routes 67Cu yields gamma rays with three different 
energies of 91, 93 and 185 keV.23 The production of these gamma rays allows the utilisation of 
SPECT, which permits imaging of the radioisotope destination during therapy.  67Cu can be 
produced using the 67Zn(n,p) 67Cu reaction which involves the irradiation of zinc with neutrons or 
by taking advantage of the 64Eŝ ?ɲ ?Ɖ )67 Cu nuclear reaction,23 the latter is a less practice method.55 
1.5. Bis(thiosemicarbazone) ligands 
 
A diverse range of tetradentate bis(thiosemicarbazone) ligands and their resulting complexes 
ŚĂǀĞďĞĞŶƐǇŶƚŚĞƐŝƐĞĚƐŝŶĐĞƚŚĞ ? ? ? ? ?Ɛ,57-59 however the synthesis of this class of ligands was first 
reported in 1902.60, 61 IŶƚŚĞ ? ? ? ? ?ƐƚŚĞǇǁĞƌĞĚŝƐĐŽǀĞƌĞĚƚŽďĞŽĨƵƐĞŝŶĂŵĞĚŝĐŝŶĂůĐŽŶƚĞǆƚĚƵĞ
to them possessing anti-tumour properties.3, 62-64 More recently bis(thiosemicarbazone) ligands 
that have been co-ordinated with positron-emitting isotopes, for example 64Cu, have been the 
focus of research for use as diagnostic imaging agents.65 Over 60 years later, there is still 
considerable interest in the biological activity of both the free ligands and the related metal 
complexes (Figure 1.5.1.).66 A summary of the history of the bis(thiosemicarbazone) ligands and 
their copper complexes along with their medical applications have recently been published as part 
of a book chapter.60 Papers have also been ƉƵďůŝƐŚĞĚŝŶƚŚĞĞĂƌůǇ ? ? ? ? ?ƐŝŶǀĞƐƚŝŐĂƚŝŶŐ 
bis(selenosemicarbazone) ligands, where both the sulphur atoms are substituted for selenium 






Figure 1.5.1. The general structures of a bis(thiosemicarbazone) pro-ligand and the resulting complex based 
on 
57, 66, 69, 70
.  
Bis(thiosemicarbazone) ligand Bis(thiosemicarbazone) complex
 
Bis(thiosemicarbazone) ligands should more accurately be referred to as pro-ligands due to the 
need to de-protonate the pro-ligand in order to expose the true ligand for chelation with a metal.  
The pro-ligands exist as thione-thiols tautomers which are able to bind to a metal ion either in a 
neutral or anionic form,71 this is illustrated in (Figure 1.5.2.). 





Bis(thiosemicarbazone) pro-ligands can be described as symmetric when the substituents on the 
terminal nitrogen atoms are the same (NR1R2= NR3R4). The ligand is termed as dissymmetric when 
the substituents on the terminal nitrogen atoms are dissimilar (NR1R2A?EZ3R4). Dissymmetric 
ligands can be further described as singly dissymmetric or doubly dissymmetric in respect to 
symmetry of the backbone substituents. When the substituents on the backbone are identical 
(Q1=Q2) they can be classed as singly dissymmetric and if they are dissimilar (Q1A?Y2) the ligand is 
said to be doubly dissymmetric. Singly dissymmetric pro-ligands only have one constitutional 
isomer irrespective of which carbonyl group each of the two dissimilar 4-substituted-3-
thiosemicarbazides react with. Doubly dissymmetric pro-ligands on the other hand, have two 
constitutional isomers depending on which 4-substituted-3-thiosemicarbazide reacts with which 
carbonyl group. Illustrations of singly and doubly dissymmetric ligands can be found below (Figure 
1.5.3.).   
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Figure 1.5.3. An illustration of singly and doubly dissymmetric ligands. 
Doubly dissymmetric pro-ligand 
(alternative constitutional isomer)




Synthesis of symmetric pro-ligands is relatively simple and is widely reported.6, 59, 62, 72-78 Even 
though a range of reaction conditions and solvents have been reported, the general principle of 
adding a chosen di-ketone to a warm solution (normally aqueous or ethanolic) containing at least 
two equivalents of a 4-substituted-thiosemicarbazide in the presence of an acid catalyst (Figure 
1.5.4.) holds true. The product forms a precipitate that can be recovered via filtration and washed 
with a suitable solvent such as ethanol, methanol, water or diethyl ether.   





The synthesis of dissymmetric bis(thiosemicarbazone) pro-ligands however, is not as straight 
forward as symmetric pro-ligands. The desire to synthesize dissymmetric pro-ligands has been 
growing as they give the ability to gain greater control on the functionality of the pro-ligands and 
the resulting metal complexes. This gives the capability of making subtle adjustments to the 
pharmacokinetics of the complexes, which is highly advantageous when optimising any potential 
radio-tracer for medical applications. M. Christlieb and J. R. Dilworth published a paper66 on 
identifying potential methods of synthesising dissymmetric bis(thiosemicarbazone) pro-ligands by 
retrosynthetic analysis. (Figure 1.5.5.) illustrates three potential disconnections. M. Christlieb and 
J. R. Dilworth illustrate the reason for making bis(thiosemicarbazone) pro-ůŝŐĂŶĚƐďǇƐƚĂƚŝŶŐ P ‘dŚĞ
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synthesis of bis(thiosemicarbazones) is challenging, but their importance in molecular imaging 
ŵĂŬĞƐƵŶĚĞƌƐƚĂŶĚŝŶŐƚŚĞŝƌĐŚĞŵŝƐƚƌǇĞƐƐĞŶƚŝĂů ?.66 
Figure 1.5.5. Retrosynthetic analysis of routes to dissymmetric bis(thiosemicarbazone)pro-ligands based on 
66
. 
Route A: Disconnection 
of N-C bond
Route B: Disconnection of 
N=C bond
Route C: Disconnection 
of C-N bond
+ R2NCS (R1=H)





The authors then reported their experience with each of the routes A-C. Route A was described as 
a potentially convenient route for dissymmetric pro-ligand synthesis and a bis(thiosemicarbazone) 
was successfully synthesised in a respectable yield. Reported limitations on route A includes that 
the strategy is restricted to 1,2-diketone-derived dihydrazones and the presence of the reactive 
functional groups in the isothiocyanate synthesis limits the generality of the route. A considerable 
problem the authors experienced was that products containing mixtures could not be separated. 
Route C unfortunately is limited to the synthesis of symmetric compounds as the synthesis of 
dissymmetric compounds is complicated by the formation of statistical mixtures. A few different 
methods have been reported for route B which involves the formation of a C=N. The route is the 
ŵŽƐƚĐŽŵŵŽŶĂŶĚŝƐŝŶƚŚĞĂƵƚŚŽƌƐ ?ĞǆƉĞƌŝĞŶĐĞŝƐƚŚĞŵŽƐƚƐƵĐĐĞƐƐĨƵůŽĨƚŚĞƚŚƌĞĞƌŽƵƚĞƐ ?KŶĞ
method reported for route B is reacting isonitroacetone with a chosen thiosemicarbazide, 
exploiting that the ketone group will react first in order to give a mono-thiosemicarbazone 
intermediate. The intermediate is then reacted with a dissimilar thiosemicarbazide in order to 





Figure 1.5.6. Dissymmetric bis(thiosemicarbazone)pro-ligand synthesis, using isonitrosoacetone as a starting 










The authors successfully isolated the mono-thiosemicarbazone intermediate but then, upon 
reacting the intermediate with a second thiosemicarbazide, gave a product that was a mixture of 
symmetric and dissymmetric bis(thiosemicarbazones). An article by Green et al.79 reported 
difficulty with repeating the method illustrated in (Figure 1.5.6.).  
An alternative reported approach for route B is using an acetal functionality to act as protecting 
groups in order to ensure only one of the carbonyl groups reacts with the first thiosemicarbazide. 
The hydrolysis of the acetal group would then reveal the carbonyl moiety ready to be reacted 


























This approach has successfully been used by L. J. Ackerman et al.80, 81 and J. K. Lim et al.79 to 
synthesise dissymmetric bis(thiosemicarbazones). Both authors only reported the synthesis of 
dissymmetric bis(thiosemicarbazones) pro-ligands that contain Q1 = CH3 and Q2 = H substituents. 
J. K. Lim et al.79 noted that their attempts to hydrolyse the acetal groups in a protic media also 
resulted in the hydrolysis of the imine, which lead to mixed bis(thiosemicarbazones) in the 
resulting product. This problem however was resolved by using the mild Lewis acid, lithium 
tetrafluoroborate (LiBF4), in the hydrolysis reaction that lead to a single dissymmetric 
bis(thiosemicarbazone) product. L. J. Ackerman et al.80, 81 also reported the successful use of LiBF4.  
By far, the method that seems to be most widely adopted synthetic method for dissymmetric pro-
ligands is using a di-ketone as the starting pre-cursor.  In this method a cold (normally around 0oC) 
acidified aqueous or alcoholic solution of a chosen thiosemicarbazide is reacted with an excess of 
a di-ketone. This reaction exploits that, under these conditions, the thiosemicarbazide only reacts 
with one of the carbonyl groups on the diketone before precipitating out of solution, thus forming 
a mono-thiosemicarbazone intermediate. This intermediate is then reacted with a dissimilar 
thiosemicarbazide either in DMF at room temperature with an acetic acid catalyst82 or refluxed in 





Figure 1.5.8. Dissymmetric bis(thiosemicarbazone) pro-ligand synthesis by exploiting the different 
reactivities of carbonyl groups on a di-ketone precursor, based on  










This method has been used to make dissymmetric bis(thiosemicarbazones) pro-ligands with Q1 = 
Q2 = Me,
57, 65, 73, 82-85 and Q1 = Me, Q2 = H.
66, 82 D. Calatayud et al.86 attempted to synthesise ligands 
with Q1 = Q2 = Ph and R1= hydrazinequinoline, R2=H,  R3=H,  R4=H. Despite being able to isolate the 
intermediate product upon the addition of the second thiosemicarbazide, the reaction yielded a 
mixed product that contained the desired compound, a symmetric pro-ligand (R1 = R3 = H, R2= R4 = 
hydrazinequinoline) and a cyclic by-product.  Cyclic by-products have been observed by other 
authors such as J. Holland et al.57 during the synthesis of a ligand from 2,3-butanedione (Q1 = Q2 = 
Me) with R1= Me,  R2= Ph,  R3=H,  R4A?, ?ƐŝŵŝůĂƌĐŽŵƉŽƵŶĚƚŽ,ŽůůĂŶĚ ?ƐǁŚĞƌĞY1 = Q2 = Me, R1= 
R3 = Me and R2= R4 = Ph was also observed to form a cyclic product by M. Christlieb et al.
58 
However, M. Christlieb et al.58 suggest that the bis(thiosemicarbazone) pro-ligand is able to 
undergo cyclisation reactions as a decomposition product instead of being formed from the 
intermediate. These cyclisation reactions are explained further by J. Casa et al.87, who attribute 
them to the presence of the two nucleophilic centres (R-N-H and S-H) along with a polar double 
bond within the two tautomeric structures of thiosemicarbazones. Mono-thiosemicarbazone 
intermediates where Q1 = Q2 = Ph seem to be particularly keen to undergo cyclization reaction as 
L. Alsop et al.59  and M. Blanco et al.88 have encountered in their work. Most of the 
bis(thiosemicarbazone) pro-ligands are highly hydrophobic which results in a low water solubility. 
There have been attempts to improve the low water solubility of these pro-ligands, for example 
by introducing a carbohydrate moiety89 or an aromatic sulfonate82 functional group into the pro-
ligands ? structure. 
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Recent publications are showing that interest is growing on attaching further larger functional 
groups to the R substituents of the thiosemicarbazide side arms in order to impart further 
desirable properties upon the pro-ligands and their resulting complexes.  A hydrazonequinoline 
limb was introduced to a pro-ligand by D. Calatayud90 in order to improve the fluorescence 
properties of the resulting cadmium and mercury complexes. J. Holland et al.91 introduced a 
styrene moiety in order to allow the simultaneous labelling of the bis(thiosemicarbazone) with 
18fluorine and a biologically active molecule.      
Attachment of these pendant functional groups is possible by synthesising a dissymmetric 
bis(thiosemicarbazone) that has one thiosemicarbazide arm which contains a primary amine such 
aƐƚŚŝŽĐĂƌďŽŚǇĚƌĂǌŝŶĞ ?ZA?, ?Z ?A?E,2)57, 60, 65, 84, 85 or 4-N-(2-tbutoxycarbonylaminoethyl)-3-
thiosemicarbazide.92 This primary amine can then be reacted with a carbonyl functionality on the 
pendant group in a condensation reaction in order to produce a target functionalised 
bis(thiosemicarbazone) pro-ligand. This is summarised in (Figure 1.5.9.).  
Figure 1.5.9. An example of a reaction between a primary amine and a carbonyl group of a pyrene 




P.Waghorn et al.92 added a fluorophore to bis(thiosemicarbazone) pro-ligands in order for the 
resulting zinc, copper and nickel complexes to be of use in fluorescence microscopy.  A similar 
product was synthesised by S. Lim et al.84  where the pendant functionality was the four fused 
aromatic ring pyrene group (Figure 1.5.9.), for the use in confocal fluorescence microscopy. R. 
Hueting et al.85 used this synthesis method in order to attach a range of functional groups to the 
bis(thiosemicarbazone) pro-ligand, one of which was a derivative of the amino acid bombesin. A 
bombesin functionalised bis(thiosemicarbazone) was also synthesised by B. Paterson et al.73 but, 
instead of using a primary amine, the authors used a bis(thiosemicarbazone) that contained 4,4-
dimethyl-3-thiosemicarbazide ( R1 = Me, R2 = Me). This dimethyl functional group was then 
reacted with a chosen carboxylic acid which contained a primary amine that acted as a linker to 
the bombesin molecule. A. Cowley et al.93 used a slightly different approach by reacting the OH 
group of a benzoic acid functionalised thiosemicarbazide to attach the peptide lysine. There are 
also reports of   bis(thiosemicarbazones) with a primary amine functionality being used to 
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synthesise bimetallic bis(thiosemicarbazone) complexes65, 83 (Figure 1.5.10.). Recently J. Dilworth 
et al.
94 have also published sulphonamide conjugates of ATSM.  
Figure 1.5.10. A bimetallic bis(thiosemicarbazone) zinc complex, based on 
65
. 
The attachment of a radiolabelled pendant group was very recently reported by R. Hueting et al.95 
The group attached an 123I labelled functionality to produce a complex (Figure 1.5.11.) that can be 
dual labelled for the monitoring of the fate of the ligand after the copper has dissociated it in 
hypoxic conditions.   




I, based on 
95
. 
1.6. Complexes of bis(thiosemicarbazone) pro-ligands 
 
Bis(thiosemicarbazone) pro-ligands and their related compounds can be readily chelated to a 
range of metals in order to form complexes. Literature over the recent years reports  
bis(thiosemicarbazone) complexes of copper,57, 66, 69, 84, 96 zinc,57, 76, 83, 84  nickel,78, 80, 89 platinum,97 
palladium,72, 98 cadmium86, 90 and mercury.86, 90 It is also possible to make complexes of ligands that 
have structural similarities to bis(thiosemicarbazone) pro-ligand that chelate with gallium,99 
chromium100 and zirconium101 as well as palladium102 and mercury.103  
1.6.1. Copper bis(thiosemicarbazone) complexes 
Bis(thiosemicarbazone) pro-ligands in the presence of a copper salt such as copper acetate57, 71, 80, 
85 (when heated) or copper chloride85 (at room temperature), in a methanolic or ethanolic 
solution, readily form the related copper complexes. This reaction is illustrated in (Figure 1.6.1.1.). 
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In this chelation reaction, the pro-ligand is double de-protonated by losing the two hydrogens 
highlighted in red (Figure 1.6.1.1.). The copper then forms two co-ordinate bonds with each of the 
two thione sulphur atoms and two dative bonds with the lone pairs from both the imine nitrogen 
atoms. The result is a neutral, lipophilic, square planar complex with the central copper ion being 
in the 2+ oxidation state.23, 84, 85, 104 Copper (II) complexes of this class tend to yield products that 
are brown, reddish brown or red in appearance.57, 73, 80, 89, 91   
Synthesis of radio ATSM can be achieved ďǇƚĂŬŝŶŐ ? ?ʅ>ŽĨĂŶd^DƐŽůƵƚŝŽŶŝŶĚŝŵĞƚŚǇů
sulfoxide (1 mg/mL) and adding it to hydrochloride buffered radioactive copper chloride. The 
reaction takes 2 minutes. The radioactive Cu-ATSM can be eluted in ethanol using a C-18 Sep-Pak 
cartridge. 80% of the ethanol volume is evaporated by blowing argon gas over the solution and 
diluting the solution in saline prepares it for injection. HPLC and radio-TLC analysis show high 
radiochemical purity (>95%) and a high radio-yield (>95%) in the final product.105   
1.6.2. Applications of copper bis(thiosemicarbazone) complexes 
When bis(thiosemicarbazone) pro-ligands are chelated with a positron emitting isotope of copper 
(e.g. 64Cu or 62Cu), the resulting complex can be used as a tracer for PET. Copper 
bis(thiosemicarbazone) complexes have been used in the imaging of hypoxic tissues, which is the 
main focus of this project, but derivatives such as Cu(II)-PTSM (Figure 1.6.2.0.1.) have also been 
used for imaging cerebral45 and myocardial perfusion (blood flow).3, 6, 23, 106 The perfusion data 
obtained from Cu(II)-PTSM can also be coupled with the hypoxia information for Cu(II)-ATSM 
(Figure 1.6.2.1.2.) for evaluating lung tumours.107 Cu(II)-KTS (Figure 1.6.2.0.1.) complexes have 
also been shown to have anti-tumour properties. When just the pro-ligand H2KTS was 
administered to rats on a copper free diet the anti-tumour activity of KTS diminished, indicating 
that the anti-tumour activity was probably attributed to Cu(II)-KTS.60 The mode of action of Cu(II)-
KTS is due to that it can inhibit the incorporation of thymidine into DNA and uridine into RNA, but 
it is also suggested it can disrupt cellular respiration and ATP (adenosine triphosphate) 
production.6 Superoxide (O2
-) is a reactive oxygen species and is a factor of many disease states. 
Superoxide dismutase (SOD) is an endogenous enzyme that eliminates superoxide. Certain copper 
bis(thiosemicarbazone) complexes have shown to be SOD mimetics, with Cu(II)-ATSM (Figure 
1.6.2.1.2.) displaying the highest activity.6 Copper bis(thiosemicarbazone) complexes have also 
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been shown to process antimicrobial activity, which is suspected to be due to redox damage as a 
result of the release of the reduced Cu(I) species.70 In bacterial infections, copper 
bis(thiosemicarbazone) complexes have been shown to inhibit bacterial respiration by inhibiting 
NADH dehydrogenase and complex 1 in the mitochondrial electron transport chain.108 In this 
project the focus is in the hypoxia and copper metabolism imaging.   





1.6.2.1. Hypoxia imaging 
Hypoxia is a term to describe when there is insufficient oxygen to meet the metabolic needs of a 
tissue.105, 109 Hypoxia is normally defined as the oxygen tension at which the metabolic demand in 
stoma, endothelial cells and tumour cells exceeds the supply.110 Hypoxia can be caused when the 
vascular supply is interrupted such as in a stroke or myocardial infraction or when a tumour 
outgrows its vascular supply.109 
When a healthy tissue suddenly loses its oxygen supply to the point that there is insufficient 
oxygen for oxidative phosphorylation, the cells die either by necrosis (un-programmed cell death) 
or apoptosis (cell initiated death). This occurs in conditions such as strokes, myocardial infraction 
or when there is poor perfusion in arthritic joints.109 Tissues in tumours become hypoxic gradually, 
however, instead of the cells dying they start to adapt to the lack of oxygen by up-regulating the 
production of more than 100 proteins that promote their survival and increases the 
aggressiveness of hypoxic cells.105, 111, 112 The most important regulatory factor of the hypoxia 
signalling pathway activity in cells is the protein hypoxia-inducible transcription factor 1 (HIF-1) 
which mediates adaptive responses to reduced oxygen availability. It has been suggested that HIF-
1 could be used as a reliable intrinsic marker for tumour hypoxia and prognosis.113, 114 These 
proteins cause the slowing of the rate of cellular growth by directing the mitochondria to undergo 
glycolysis (the anaerobic conversion of glucose to adenosine triphosphate (ATP)), inhibit apoptosis 
and promote metastasis (cell spreading).109 Hypoxia also may down regulate the expression of 
adhesion molecules which facilitates tumour cell detachments. Hypoxia in tumours was first 
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described by R. Thomlinson and L. Gray, who observed that heterogeneous regions of hypoxic 
cells formed just beyond the diffusion distance of oxygen from blood vessels (100- ? ? ?ʅŵ )
adjacent to the necrotic core.115, 116 Nearly all solid tumours consist of either hypoxic (serve or 
intermediate) or anoxic (no oxygen present) cells and the presence of hypoxia does not depend 
on tumour size, stage, pathology or nodal status.112 Tumour hypoxia occurs from three distinct 
causes: 1) perfusion related(acute) inadequate blood flow; 2) diffusion related (chronic) hypoxia 
caused by increased oxygen dŝĨĨƵƐŝŽŶĚŝƐƚĂŶĐĞ ?A? ? ? ?-   ?ʅŵ )ĚƵĞƚŽƚŚĞŝŵďĂůĂŶĐĞŽĨƚƵŵŽƵƌ
growth and vascular neogenesis (new growth of blood vessels); 3) anemic hypoxia which may be 
caused by tumour-related cachexia (wasting away) or treatment.105, 117-121 Tumour hypoxia is a 
spatial and temporal heterogeneous phenomenon, resulting from the combined effect of many 
factors such as tumour type, tumour volume, disease site (specific organ or tissue), regional 
micro-vessel density, blood flow, oxygen diffusion and consumption rates.113  
The presence of hypoxia can lead to negative effects on the response of the tumour to treatment 
by chemotherapy, surgery or radiotherapy.122 In 1955, Thomlinson and Gray suggested that 
human epithelial tumours may be hypoxic and therefore radio-resistant.116, 121 Commonly studied 
cells lines were found to be roughly half-maximally resistant to ionising radiation when 
moderately hypoxic.121 Resistance to chemotherapy is a consequence of compromised drug 
delivery activity in a hypoxic/acidic tumour. The acidity of the hypoxic cells comes from the 
accumulation of lactic acid which is a by-product of anaerobic respiration.123 Surgery resistance 
occurs because hypoxia promotes the mobility and invasion of the tumour cells meaning the 
tumour is likely to have spread (metastasis) by the time of treatment.122 Hypoxia induced 
resistance to radiotherapy was first shown in 1909 by G. Schwarz when he demonstrated that the 
ƐŬŝŶ ?ƐƌĞƐƉŽŶƐĞƚŽƌĂĚŝĂƚŝŽŶǁĂƐŵĂƌŬĞĚůǇĚĞĐƌĞĂƐĞĚŝĨĂƉůŝĞĚƚŽĂŶĂƌĞĂǁŝƚŚƌĞĚƵĐĞĚďůŽŽĚĨůŽǁ
which was caused by compression.124, 125 In radio therapy ionising radiation damages the DNA of 
the tumours cells. The damage occurs in several ways, the most common is that the double strand 
is broken by radical products that are in the vicinity of the DNA. The radical needs to then react 
with oxygen in order to make the damage permanent. If there is insufficient oxygen to achieve 
this, small thiols can repair radical damage.109, 114, 118, 126 It has been determined that the radiation 
dose has to be 2.8-3 times higher in the absence of oxygen compared with the presence of oxygen 
in order to achieve the same biological effect.110 It has been shown that modifying tumour 
hypoxia by breathing hyperbaric oxygen or carbogen (95% oxygen and 5% carbon dioxide) can be 
beneficial during treatment, however it was noted that benefits differ between and within 
tumour sites.117 This has led to the suggestion that hypoxia imaging could potentially be used in 
selecting which cancer patients would benefit from treatments that overcome, circumvent or take 
advantage of the presence of hypoxia. Imaging could also be used to document whether or not 
and to what extent re-oxygenation occurs in tumours during radiotherapy.105 There is an idea that 
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potentially could overcome the problems with hypoxia induced radio-resistance in order to 
improve the effectiveness of radio therapy. The idea of dose painting correlates the dose of radio 
therapy that a particular region of the tumour receives against the level of the hypoxia that each 
tumour region experiences i.e. increasing the dose to areas with increased hypoxia. This concept 
is still in its infancy and success will depend on the solving of challenges such as accurate 
conversion of hypoxia measurements into effective doses and accounting for the variations of PET 
hypoxia tracers in accurately reporting hypoxic information.120, 127-129 Dose painting could also 
prevent some patients from receiving unnecessary treatments and their consequential side 
effects as well as supporting the use of hypoxia selective drugs like tirapazamine or nimorazole 
which are hypoxic radio-sensitizers.112    
There is no specific value for oxyhaemoglobin (O2Hb) concentration, haemoglobin saturation 
percentage or tissue oxygen partial pressure (pO2) that defines the transition from normoxia to 
hypoxia. Arterial pO2 is typically stated at 75 mm Hg while venous blood normally averages 40 mm 
Hg.121 The biological consequences of hypoxia depend on duration and the needs of the individual 
cell,109, 130 which means that physoxia (the normal oxygen level in a specific tissue/organ) varies 
widely between different organs. For example, physoxia in the brain has a pO2 of 35 mmHg whilst 
physoxia in the kidneys is around 72 mmHg.122 The median pO2 for lung tissues has been found to 
be 43 mm Hg, however the critical pO2 level where there is a negative impact upon the cellular 
function of the tissue is proposed to range between 8 and 10 mm Hg in most non-small-cell lung 
cancers.130 The gold standard of measuring pO2 is the direct measurement by using a pO2 probe. 
These polarographic/needle electrodes can provide direct measurements of pO2 at each location 
point and when controlled by a computer driven stepper motor, can typically achieve one reading 
every 10 seconds. A distinct disadvantage of a pO2 probe is that it is an invasive technique and 
therefore can only be used in readily accessible tumours such as head and neck, uterine, cervix, 
prostate and breast tumours. The technique also only provides one dimensional information on 
hypoxia compared to the 3 dimensional information obtained from PET.113, 118, 127, 128, 131, 132 The 
pO2 values obtained by these probes are also restricted by sampling error as it is not possible to 
extract measurements from the entire tumour in order to overcome the heterogeneous nature of 
tumour hypoxia. Probes cannot differentiate between necrotic (dead) and living anoxic tissue 
regions within the tumour.112   
It is also possible to quantify hypoxia by immunohistochemical staining with hypoxic markers such 
as pimonidazole, which is an exogenous bio-reductive nitroimidazole compound.117, 133 
Immunohistochemical staining is an invasive technique and repetitive measurements of changes 
of hypoxic fractions after cancer treatment is not realistic in a clinical setting.112  Hypoxic fraction 
is the fraction of the tumour that is hypoxic.122 [18F] FMISO (Figure 1.6.2.1.1.) is currently the most 
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used hypoxia PET tracer in the clinic127, 128, 134 and generally considered to be the gold standard for 
PET hypoxia imaging.110 However, [18F] FAZA (Figure 1.6.2.1.1.) is becoming a more popular PET 
hypoxia tracer as it is more hydrophilic than [18F] FMISO, which allows faster clearance and a 
higher tumour-to-background ratio.112, 135 The ideal PET hypoxia tracer should be able to target 
just cellular pO2 and not vascular PO2, at clinically relevant oxygen concentrations only in viable 
cells. The tracer should be lipophilic enough to have uniform and rapid cell entry, but hydrophilic 
enough for rapid cell clearance from normoxic cells as well as yielding a high target-to-background 
ratio independent of perfusion whilst being resistant to non-hypoxia dependent metabolism.122 2-
nitroimidazole derived tracers have the similar initial trapping mechanism as Cu(II)-ATSM (Figure 
1.6.2.3.), in a normoxic cell the agent enters the cell and is reduced and then re-oxidised in a 
catalytic cycle. However in hypoxic cells the reduced nitroimidazole is not re-oxidised but instead 
reacts with intracellular proteins rendering it permanently trapped.136 








FAZA, based on 
110, 135
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The radio-copper bis(thiosemicarbazone) complex Cu(II)-ATSM (Figure 1.6.2.1.2.) can be used as a 
hypoxia imaging agent.  







Cu(II)-ATSM has several advantages over other hypoxia PET tracers including a simpler method of 
synthesis, faster clearance from normoxic tissues, which allows for a reduced time between 
injection and imaging, as well as simpler method for quantification.138 It is possible to select the 
copper isotope which best suits the application in terms of half-life and decay products.136    
As Cu(II)-ATSM is neutral and lipophilic it is highly membrane permeable and can freely diffuse in 
and out of cells. When in the cell the Cu(II)-ATSM gets reduced by intracellular agents (such as 
NADH and NADPH) to form Cu(I)-ATSM. In normoxic cells the Cu(I)-ATSM is substantially stable 
and capable of resisting Cu(I) dissociation and therefore can be re-oxidised to Cu(II)-ATSM which 
is free to diffuse back out of the cell, however in hypoxic cell the Cu(I)-ATSM cannot be re-
oxidised causing the negatively charged complex to be trapped within the cell.6, 105, 109, 130, 138-140 
Related copper complexes that dissociate rapidly when reduced to Cu(I), such as Cu-PSTM, show 
no selectivity for hypoxia but deposits copper into cells and tissues in proportion to their delivery, 
making Cu(II)-PTSM an effective blood flow tracer.41 K.Price et al.141 expanded this theory by 
adding that for the two complexes Cu(II)-ATSM and Cu(II)-GTSM the data strongly suggested that 
two complexes may be taken into cells by both passive and facilitated (protein carrier mediated) 
mechanisms. Also the authors observed that both the complexes rapidly effluxed from cells 
through active mechanisms, even though it was not known if it was the ionic copper or the intact 
complexes that was being observed.    
Cu(II) and Cu(I) show different co-ordination geometries and therefore different affinities for 
different donor atoms. As Cu(I) is only weakly chelated to ATSM it can become substituted by 
macromolecular bio-ligands present inside the cell, causing the copper to be trapped within 
hypoxic cells.126 However cellular metabolism can wash Cu(I) that has become dissociated from 




Figure 1.6.2.1.3. The suspected mechanism of hypoxia selectivity of copper bis(thiosemicarbazone) 
complexes, based on 
43, 126, 130, 142
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J. Dearling and A. Packard published a paper in 2010 with some thoughts on the mechanism of 
cellular trapping of Cu(II)-ATSM.136 The authors explain that there is a range of factors 
contributing to the trapping of Cu(II)-ATSM in hypoxic cells. They then go on to state that the 
complex is transiently trapped through reduction of the Cu(II) by cellular thiols to form [Cu(I)-
ATSM]-, which decreases the complexes lipophilicity and increases its residence time within the 
cell. This results in an increased likelihood that the reduced [Cu(I)-ATSM]- complex will dissociate 
or interact with the mitochondria causing the copper to become trapped within the cell. The 
cellular trapping mechanism is described as biphasic, with the first phase being the 
reduction/oxidation cycle involving cellular thiols and molecular oxygen and the second phase 
being the interactions with proteins within the mitochondria leading to more permanent 
retention of the tracer. This biphasic mechanism may explain some of the early data that showed 
that 1-2 hours post injection Cu(II)-ATSM accumulation does not represent hypoxia within the 
tumour but 16-20 hours post injection the location of Cu(II)-ATSM correlates well with alternative 
methods of hypoxia detection e.g. [18F]FMISO  tracers and Eppendorf oxygen electrodes. The 
authors suggest that this biphasic mechanism may also be responsible for the differences seen in 
tissue uptake and site of reduction for different cells lines because of the variation in their 
metabolism. The investigators concluded that experimental data on the trapping mechanism is 
still not complete and a number of questions about the trapping mechanism still remain 
unanswered which need to be answered in order to fully understand and exploit this potentially 
very useful tracer. A very recent investigation by R. Hueting95 and co-workers attempted to shed 
light on the fate of the dissociated ligands. A complex was synthesised that had very similar 
physicochemical characteristics to Cu-ATSM which could be labelled wither by 64Cu or 123I (Figure 
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1.5.11.). The team showed unequivocal evidence that in vitro the complexes undergo rapid 
dissociation but unfortunately the complex was not retained effectively in the hypoxic areas of 
the tumour.  A study by F.Shaughnessy et al.143 investigated if changes in the antioxidant 
glutathione, which is the most abundant intercellular thiol, whose redox status changes in cancer 
cells and ischaemic myocardium, changed the hypoxia selectivity of [64Cu] Cu-ATSM. It was found 
that modification of glutathione levels did not impact on the pharmacokinetics or hypoxia 
selectivity of [64Cu] Cu-ATSM. A slightly earlier investigation by P. Bernard et al.144 used UV/visible 
spectroscopy to establish if Cu(II)-ATSM is stable in the presence of glutathione. The results 
showed that the Cu(II)-ATSM is stable in the presence of glutathione, indicating that glutathione is 
not a strong enough reducing agent in order to reduce Cu(II)-ATSM. 
The mechanism and selectivity of copper bis(thiosemicarbazone) is a complex one, which is 
believed to be dependent on many factors such as lipophilicity, planarity, molecular weight, pKa 
and redox potential.123 As copper bis(thiosemicarbazone) complexes have very low water 
solubility, the determination of reliable pKa values experimentally has not been possible.
123 
Investigations in to the structure activity relationships of copper bis(thiosemicarbazone) complex 
was initially carried out by J.Dearling et al.77, 145 and then later P. Blower et al.69, R. Maurer et al.146 
and  J. Holland et al.123 used density functional theory (DFT) in order to further understand the 
hypoxia selectivity of the copper bis(thiosemicarbazone) complexes. The studies was undertaken 
in order to investigate if the lowering of the redox potential of a copper bis(thiosemicarbazone) 
complex would result in the complex only being trapped in a more reducing environment than 
normal, like hypoxic cells. The complexes that were tested along with their name designations are 
illustrated in (Figure 1.6.2.1.4.).    






The investigations showed that altering the substituents at the diimine backbone (Q1 and Q2 
positions) primarily controlled the redox potential of the complex, i.e. the potential that the 
copper (II) in the complex would be reduced resulting in the release of copper (I) in to the hypoxic 
cell. If an electron donating group is at one or both Q positions the complex will have an 
intermediate or low reduction potential respectively. However, if a substituent with poor electron 
donating ability (i.e. hydrogens) were at the Q positions then the reduction potential would be 
high, this is illustrated in (Figure 1.6.2.1.5.). Alkyl substitutions on the terminal amino groups (R1 
and R2 positions) do not significantly affect the redox potential or the hypoxia selectivity.
6  




The lipophilicity of the copper can be controlled by adding more lipophilic/ less lipophilic 
substituents on the terminal amino positions (R1 and R2) which will influence where in the body 
the complex will migrate to. Lipophilicity was shown not to correlate with cellular uptake either 
under hypoxic or normoxic conditions or with hypoxia selectivity.77 
It was shown that complexes with lower redox potentials are more hypoxic selective e.g. Cu-
ATSM, while complexes with higher redox potentials such as Cu-GTS have little or no hypoxia 





Figure 1.6.2.1.6.The relationship of the redox potential of the copper bis(thiosemicarbazone) and hypoxic 




There is a very strong grouping based on number of carbons on the back bone, the group far left 
with the lowest redox potential and highest hypoxia selectivity all have 2-4 carbons on the 
backbone substituents (Me/Me, Me/Et and Et/Et). The middle group all have one carbon on the 
backbone (Me/H) and the group to the far left, which has little or no hypoxia selectivity, only have 
two hydrogens (H/H) on the backbone.   
Through using DFT calculations it was found that the most stable conjugate acid results from 
protonation at the X position. Protonation at the Y and Z position leads to a decrease in the 
conjugate acid stability by 58.0 and 73.3 kJ mol-1 respectively when compared to X (Figure 
1.6.2.1.7(a)). Figure 1.6.2.1.7. image (b) shows the electrostatic potentials of Cu(II)GTS. The red 
indicates regions of net negative charge. All the Cu(II) complexes were found to be highly acidic 
and consequently will only be protonated in strongly acidic conditions.123    
Figure 1.6.2.1.7. (a) Illustration of the potential protonation sites for Cu(II)GTSH
+
. (b) Illustration of 





The work by P. Blower et al.69 suggested a path forward by analysing dissymmetric ligands which 
should give greater control on hypoxia selectivity. Quasi-combinatorial synthesis was investigated 
which resulted in a product containing a number of symmetric and dissymmetric pro-ligands.  
A study by R. Hueting et al.147 yielded evidence to question the common thoughts on the hypoxia 
selectivity mechanism of [64Cu] Cu-ATSM. Radio-copper retention in cancer cells in vivo and in 
vitro after administration of [64Cu] Cu-ATSM and [64Cu] Cu-acetate was measured. The results 
showed that the distribution of 64Cu from [64Cu] Cu-ATSM and [64Cu] Cu-acetate was very similar 
which suggests that retention of radio-copper could be effected by copper metabolism rather 
than being solely a direct indicator of hypoxia.   
Early work by Y. Fujibayashi148 and co-workers compared [64Cu] Cu-ATSM with [11C] acetate, a 
regional perfusion tracer, to visualise hypoxic rat heart tissue. It was discovered that in ischemic 
regions (areas of reduced blood supply to tissues), where there was low uptake of [11C] acetate, 
there was a high accumulation of [64Cu] Cu-ATSM compared to normal regions. Furthermore areas 
of low blood flow, low uptake of [11C] acetate, are surrounded by regions that have a high uptake 
of [64Cu] Cu-ATSM indicated that these hypoxic regions contain viable myocardial tissue. J. Lewis 
and co-workers undertook studies to further illustrate that the uptake of [60Cu] Cu-ATSM 
significantly increases in hypoxic tissue.149, 150  
The first report of Cu-ATSM being used in a human study was in 2000 where [62Cu] Cu-ATSM was 
used in subjects who had lung cancer. Intense uptake was observed in all lung cancer patients 
reaching a plateau within a few minutes after injection. However, the distribution of [62Cu] Cu-
ATSM was different from that of FDG or blood flow.151  The hypoxic selectivity of a large number 
of Cu(II)-bis(thiosemicarbazone) complexes was correlated with their reduction potential, stability 
of the Cu(I) species and the pKa values. The data gathered supports that intercellular reduction of 
Cu(II) to a Cu(I) species can lead to two distinct patterns of behaviour. Non-hypoxia selective 
complexes undergo rapid acid catalysed dissociation but for hypoxia selective complexes they are 
resistant to dissociation allowing for back-oxidation by molecular oxygen in normal tissues.126 
Lewis et al.150 used a canine ischaemic myocardial model to show that [64Cu] Cu-ATSM has a half-
life of 7-8 minutes. The hypoxia selectivity of the copper bis(thiosemicarbazone) complexes arises 
from a delicate balance between enzyme-mediated one-electron reduction and subsequent back-
oxidation by di-oxygen in normal tissue against protonation and ligand dissociation in hypoxic 
tissues.126 The first clinical study undertaken compared the quality of images obtained when using 
[60Cu] Cu-ATSM and [64Cu] Cu-ATSM for imaging a cohort of ten women with cervical carcinoma on 
separate days. Image quality was assessed qualitatively and the tumour-to-muscle activity ratio 
was measured for each tracer. The study found that a 925MBq dose of [64Cu] Cu-ATSM  produced 
images with less noise and therefore a higher quality than the images obtained by a 740MBq dose 
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of [60Cu] Cu-ATSM.132, 138, 140, 152 The authors selected the respective doses in order to achieve the 
same number of decays in the 30- to 60-min-postinjection scan.152 Results from toxicology studies 
in animals and patient monitoring indicated that the doses used for both isotopes in the study 
were safe to be clinically employed.60 One of the biggest drawbacks of [64Cu] Cu-ATSM is that it 
has a perceived high logP (around 1.5-1.6) and a high liver uptake. The most successful 
modification in order to overcome the high lipophilicity was the introduction of a glucose 
molecule as a pendant arm to ATSM to yield a water soluble complex with a logP of 0.5 without 
affecting its hypoxia selectivity.20, 153, 154 Bio-distribution in preclinical mice models show that early 
uptake occurs in the heart (8.75%) and brain (10.46%) which then diminished to 3.81% and 3.34% 
respectively after 40 minutes post injection. A similar uptake pattern was observed in the kidneys 
but with a far greater initial uptake (23.45%). Liver uptake gradually increased from 7.75% (1 
minute post injection) to 29.83% (40 minutes post injection). From this it was suspected that the 
metabolism of ATSM occurs in the liver and the kidneys. In human studies activity was seen in the 
liver, kidneys and spleen, however very little trace was detected in the bladder and bowel despite 
the proposed site of metabolism being the liver and kidneys. Human data showed that the 
kidneys received a much lower dose, which was just above background. It is recommended that 
the liver should be the human dose limiting organ for dose calculations.139, 155     
In the application of Cu-ATSM acting as an imaging agent for myocardial infractions, it has been 
shown that Cu-ATSM is not retained in necrotic tissue, thus Cu-ATSM can be used to differentiate 
between hypoxic, viable tissue and non-functional, dead, myocardial tissue.110 [61Cu] Cu-ATSM was 
used by T.Bradshaw et al.156 along with two other tracers in order to measure and compare the 
spatial distributions of three biological properties, glucose metabolism ([18F] FDG), cellular 
proliferation ([18F] FLT) and hypoxia ([61Cu] Cu-ATSM), in canine tumours. It was concluded that 
the relationship of glucose metabolism, proliferation and hypoxia was heterogeneous across the 
two tumour types tested. The uptake of [64Cu] Cu-ATSM is highest in anoxic cell but is also 
significant in normoxic cells, but after this initial period the uptake of [64Cu] Cu-ATSM is dependent 
on cell line and the oxygenation conditions which can lead retention to decrease in some 
circumstances.157 Yuan and colleagues evaluated [64Cu] Cu-ATSM as a hypoxia imaging agent and 
concluded that Cu-ATSM may be a valid hypoxia imaging agent for some tumour types, but 
cannot be extrapolated to all tumour types therefore it cannot be used as a universal hypoxia 
marker which prevented widespread acceptance of Cu-ATSM as a hypoxia PET tracer.122 Cu-ATSM 
has also been evaluated in patients with rectal and cervical cancer.158 K. Chao et al.159 
demonstrated the feasibility of using Cu-ATSM PET coupled with CT images for the determining 
hypoxia of a tumour. The information gathered can then be used for intensity-modulated 
radiation therapy (IMRT) or dose painting which would allow the escalation of radiation dose to 
the tumour whilst maintaining low does to the surrounding normal tissue.   
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 K. Matsumoto et al.160  showed that when directly compared [64Cu] Cu-ATSM and [18F] FMISO 
under different levels of hypoxia only resulted in a positive correlation with [18F] FMISO uptake 
while [64Cu] Cu-ATSM was found to not be able to detect the varying changes in hypoxia. So 
despite some clinical uses for [64Cu] Cu-ATSM, more studies are required in order to confirm that 
[64Cu] Cu-ATSM is truly a hypoxia specific tracer.112 A more recent investigation by S. Carlin et al.161 
compared the hypoxia selectivity of [64Cu] Cu-ATSM with three other hypoxia tracers ([18F] FMISO, 
[18F] FAZA and [18F]-HX4). The highest tumour uptake was observed with [64Cu] Cu-ATSM with little 
renal clearance. However, the distribution of [64Cu] Cu-ATSM did not correlate with the 
immunohistochemistry hypoxia markers which cast further doubt on the hypoxia selectivity of 
[64Cu] Cu-ATSM. A selected review by M. Bourgeois162 and co-workers also compared [64Cu] Cu-
ATSM and [18F] FMISO. The conclusion of the authors was despite [64Cu] Cu-ATSM having less 
favourable dosimetry than [18F] FMISO ďĞĐĂƵƐĞŽĨƚŚĞĂƐƐŽĐŝĂƚĞĚɴ- emission from 64Cu, [64Cu] Cu-
ATSM was found to be superior in terms of imaging performance. [18F] FMISO has a slow in vivo 
accumulation and a weak image contrast of the hypoxic area. 
An investigation carried out by V. Keremans et al.163 showed that the use of anaesthetic and 
carrier gas can influence the tumour uptake of hypoxia imaging agents, [64Cu] Cu-ATSM, [99mTc] 
HL91 and [18F]-FMISO.20 Handley et al.164 used the rat isolated heart model165, 166, the same model 
that was used by Y. Fujubayashi74 and co-workers to show that the retention of [62Cu] Cu-ATSM 
was inversely correlated with the accumulation of a myocardial blood flow tracer, in order to 
screen structural variants of [62Cu] Cu-ATSM for the application of cardiac hypoxia. Handley made 
the structural variants at the Q1, Q2, R1 and R2 positions (Figure 1.6.2.5.).Out of the nine Cu-ATSM 
analogues [64Cu] Cu-ATS and [64Cu] Cu-CTS (Figure 1.6.2.1.8.) demonstrated better cardiac hypoxia 
selectivity and imaging characteristics than the current lead hypoxia tracers, [64Cu] Cu-ATSM and 
[18F]-FMISO. Their improvement in imaging performance is due to their reduced lipophilicity 
which improves their rate of washout from normoxic tissues and increases hypoxic-to-normoxic 
tissue contrast. The redox potentials of the both copper complexes remained similar to [64Cu] Cu-
ATSM. 







M. Handley167 and co-workers have also used a novel, low cost, reusable incubation system in 
order to quantify the accumulation of [64Cu] Cu-ATSM in rat heart muscle cells under  oxic (95 or 
21% O2/5% CO2) or hypoxic gas (95% N2/5% CO2). It was found that total cellular retention 
increased during hypoxia, but this was not localised in any particular compartment of the cell. At 
the time of publication M. Handley168 reported that Cu-ATSM is the only copper 
bis(thiosemicarbazone) complex that has been tested for cardiac imaging. Hendley then goes on 
to state that development and screening of more members of the bis(thiosemicarbazone) family 
is essential.  
[64Cu] Cu-ATSM has also been studied for targeted therapy by utilising the Auger electrons in 
order to deliver a cytotoxiĐĚŽƐĞƚŽĂƚĂƌŐĞƚƚŝƐƐƵĞ ?ƐƚŚĞƵŐĞƌĞůĞĐƚƌŽŶƐŚĂǀĞĂƐŚŽƌƚƌĂŶŐĞ ?A? ?
ʅŵ )ƚŚĞƌĂĚŝŽƚŽǆŝĐĞĨĨĞĐƚƐĂƌĞůŝŵŝƚĞĚƚŽƚŚĞƚĂƌŐĞƚĐĞůůƐ.6 In a preclinical trial [64Cu] Cu-ATSM was 
shown to increase the survival time of 50% of hamsters bearing colon cancer tumours from 20 
days to 135 days with no acute toxicity side effects.6, 43, 169 [61Cu] Cu-ATSM was demonstrated to 
have a very stable spatial distribution during radiation therapy.170 M. Carter171 and co-workers 
showed that [64Cu] Cu-ATSM and [64Cu] Cu-GTSM can be used in therapeutic applications for 
treating cancerous prostate cell lines. It was noted that increasing the extra-cellular copper 
concentration enhances the effectivity of both [64Cu] Cu-ATSM and [64Cu] Cu-GTSM and that the 
pro-ligands ATSM and GTSM were not toxic to cancerous prostate cells. D. Palanimuthu172 also 
reported that certain copper bis(thiosemicarbazone) complexes, particularly complexes with only 
hydrogens as the backbone substituents, showed to have anti-tumour activity in mice models. 
The activity was similar to the anticancer drug Adriamycin. The compounds mode of action was to 
inhibit DNA synthesis and to induce apoptosis.  A very recent article by C. Yip et al.130 nicely 
summarises studies that have compared Cu-ATSM uptake against invasive measurements of 
tumour hypoxia as well as the results of clinical studies using Cu-ATSM as a imaging agent for non-
small-cell lung cancer. One such study concluded by stating that [62Cu] Cu-ATSM is useful for 
predicting prognosis of patients with non-small-cell lung cancer.173 A general overview of Cu-
ATSM in the evaluation of hypoxia in clinical oncology is presented by.132   
An interesting study by D. Williamson and co-workers.132, 174 tested [64Cu] Cu-ATSM and [64Cu] Cu-
ATSE (Figure 1.6.2.1.4.) as imaging agents for brain hypoxia, however despite the ability of the 
tracers to rapidly enter and efflux from the brain there was no significant accumulation of either 




1.6.2.2. Imaging copper metabolism for the  investigation of neurodegenerative 
disorders 
Imbalances in copper homeostasis can be identified in a range of inherited and acquired 
ƉĂƚŚŽůŽŐŝĐĂůĐŽŶĚŝƚŝŽŶƐƐƵĐŚĂƐtŝůƐŽŶ ?ƐĚŝƐĞĂƐĞ ?ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ? )ĂŶĚĐĂŶĐĞƌ.29 Over 95% 
of AD cases are sporadic and only 2-7% of cases are genetically determined.36 ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ
is a fatal progressive neurodegenerative disease and is the most common form of dementia. 
Dementia is defined as the loss of ordered neural function leading ultimately to synaptic failure 
and neuronal death. The loss of neural function can manifest in loss of abilities like storing new 
memory, impairment of judgement or reasoning abilities and language, to name but a few.175-178 
ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞŝƐĐŚĂƌĂĐƚĞƌŝƐĞĚďǇƚŚĞƉƌĞƐĞŶĐĞŽĨĞǆƚƌĂĐĞůůƵůĂƌĂŵǇůŽŝĚƉůĂƋƵĞƐǁŚŝĐŚĂƌĞ
ĐŽŵƉŽƐĞĚŽĨŝŶƐŽůƵďůĞĂŵǇůŽŝĚɴƉĞƉƚŝĚĞƐ ?ǁŚŝĐŚĐŽŶƐŝƐƚƐŽĨ ? ?-43 amino acid residues.6, 29, 31, 76, 
179 It is believed that reactive oxygen species from copper metabolism can promote cross linking 
ĂŶĚĂŐŐƌĞŐĂƚŝŽŶŽĨĂŵǇůŽŝĚɴƉĞptides.180 
dŚĞĂŵǇůŽŝĚɴƉĞƉƚŝĚĞŝƐŐĞŶĞƌĂƚĞĚĨƌŽŵƚŚĞďƌĞĂŬĚŽǁŶŽĨĂůĂƌŐĞƚƌĂŶƐŵĞŵďƌĂŶĞƉƌŽƚĞŝŶĐĂůůĞĚ
the amyloid precursor protein.31 ,ŽǁĞǀĞƌ ?ƚŚĞƉƌĞƐĞŶĐĞŽĨĂŵǇůŽŝĚɴplaques do not consistently 
correlate with cognitive impairment leading some to argue that the smaller soluble oligomeric 
species are the toxic species that are responsible for neuronal death.176 Currently AD is diagnosed 
by tests that establish progressive impairment of memory and at least one other area of cognition 
and definite diagnosis is only obtained by post mortem investigations of the presence of plaques 
and neurofibrillary tangles.179 The highly insoluble neurofibrillary tangles contain hyper-
phosphorylated forms of the normally soluble tau protein.181    
Both the peptides and proteins can isolate and reduce copper, and the elevated copper 
deposition has been observed in these plaques.29 Along with copper, metals such zinc and iron 
have significantly elevated concentration in the brain of sufferers of AD and other 
neurodegenerative diseases when compared to brains of the same age without a 
neurodegenerative condition.182 /ŶĨĂĐƚĂŐŐƌĞŐĂƚĞĚĂŵǇůŽŝĚɴƉĞƉƚŝĚĞƐŚĂǀĞďĞĞŶĚĞƐĐƌŝďĞĚĂƐ
metal sinks due to their abnormally high content of Cu, Zn and Fe.6, 31 It is thought that copper 
ďŝŶĚŝŶŐŝƐŝŶǀŽůǀĞĚŝŶƚŚĞĂŐŐƌĞŐĂƚŝŽŶŽĨƚŚĞɴƉĞƉƚŝĚĞǁŚŝĐŚŚĂƐĚĞǀĞůŽƉĞĚŝŶƚĞƌĞƐƚŝŶŚŝŐŚ
affinity copper chelators for therapeutic applications. Other potential pharmacotherapeutic 
targets for AD are nicely reported by Y.Biran and co-authors.182 Copper bis(thiosemicarbazone) 
complexes, such as Cu-GTSM due to its ability to cross the blood brain barrier (BBB) and release 
copper in to cells, are of interest as potential diagnostic PET tracers.29 These complexes can be 
ƵƐĞĚƚŽŝŵĂŐĞĐŚĂŶŐĞƐŝŶĐŽƉƉĞƌŚŽŵĞŽƐƚĂƐŝƐĂŶĚƚƌĂŶƐƉŽƌƚŝŶĚŝƐĞĂƐĞƐƐƵĐŚĂƐůǌŚĞŝŵĞƌ ?Ɛ
disease, other dementias, MenkeƐ ?ĚŝƐĞĂƐĞĂŶĚtŝůƐŽŶ ?ƐĚŝƐĞĂƐĞ.41     
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Copper bis(thiosemicarbazone) complexes have been of interest on both the diagnostic and 
therapeutic front for AD and other neurodegenerative diseases. In terms of therapy, P. Donnelly, 
K. Price and co-workers76, 180 tested a number of copper and zinc bis(thiosemicarbazone) 
complexes derivatives in order to ascertain which complexes could transport the metal across the 
blood brain barrier and release the metal in to the brain resulting in an increase of metal 
bioavailability. This modulation of bioavailability then could lead to potential therapeutic effects 
by the reduction ŽĨƐĞĐƌĞƚĞĚĂŵǇůŽŝĚɴƉĞƉƚŝĚĞ ?dŚĞƌĞƐƵůƚƐƐŚŽǁĞĚĂ ? ? ?-200 fold increase in 
copper levels178 and a 10 fold increase in zinc levels. The administration of the copper complexes 
resulted in the decrease of extracelluůĂƌĂŵǇůŽŝĚɴƉĞƉƚŝĚĞƐ ?dŚĞĂƵƚŚŽƌƐĐŽŶĐůƵĚĞĚďǇƐƚĂƚŝŶŐ
that both copper and zinc bis(thiosemicarbazone) derivatives have potential as therapeutic agents 
for AD. Cu-GTSM has shown to have potential use as a clinical treatment as it has the ability to 
increase intracellular copper concentrations by several hundred fold which leads to signalling 
pathways which inhibits the glycogen synthase kinase enzyme which regulates the accumulation 
ŽĨĂŵǇůŽŝĚɴĂŐŐƌĞŐĂƚĞƐ.181, 183 Increasing the intercellular copper concentrations also allows Cu-
GTSM to decrease the level of tau phosphorylation.181 
Cu-GTSM is easier to reduce than Cu-ATSM because of the hydrogen substituents on the imine 
carbons, whilst still processing membrane permeability, it can be reduced in most cells thus 
allowing transportation of Cu species to the brain. A significant uptake (40%) of [64Cu] Cu-GTSM 
was shown in transgenic mice compared to [64Cu] Cu-ATSM.184 This approach does not directly 
ŵĞĂƐƵƌĞƉĂƚŚŽůŽŐŝĞƐ ?ɴƉůĂŐƵĞƐŽƌŶĞƵƌŽŶĂůĚǇƐĨƵŶĐƚŝŽŶ )ŚŽǁĞǀĞƌ ?ŝƚĚŽĞƐŚĂǀĞƚŚĞƉŽƚĞŶƚŝĂů
to offer complementary information to other diagnostic procedures.176 A slightly different 
approach was to develop a copper bis(thiosemicarbazone) complex CuIIL1 (Figure 1.6.2.2.1.) which 
ŝƐĨƵŶĐƚŝŽŶĂůŝƐĞĚǁŝƚŚĂŶɴƉůĂŐƵĞƚĂƌŐĞƚŝŶŐƐƚŝůďĞŶĞŐƌŽƵƉ ? 









The copper complex was added to human AD brain tissue and examined by fluorescent 
microscopy. The results ǁĞƌĞĐŽŵƉĂƌĞĚƚŽŝŵŵƵŶĞɴƐƚĂŝŶŝŶŐŵĞƚŚŽĚƐƚŚĂƚƐŚŽǁĞĚƐƚƌŽŶŐĐŽ-
localisation.176, 185 This approach was further explored by J. Hickey et al.179 who synthesised three 
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copper complexes with similar structures to CuIIL1 of which two of them successfully bound to 
ĂŵǇůŽŝĚɴƉůĂƋƵĞƐ ? 
Another functionalised copper bis(thiosemicarbazone) complex was also synthesised by J. Holland 
and co-workers186 ĨŽƌƚŚĞĚŝĂŐŶŽƐŝŶŐWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ? The complex contained dopamine and 
tropinone like groups, ĂƐƚŚĞƐĞŐƌŽƵƉƐĂƌĞƉƌĞƐĞŶƚŝŶŵŽƐƚWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞŝŵĂŐŝŶŐĂŐĞŶƚƐ ?
Cu-ATSM has also got potential therapeutic applications in the treatment of Amyotrophic Lateral 
Sclerosis.187 Cu-ATSM has also been used to assess oxidative stress in a variety of 
neurodegenerative ĚŝƐŽƌĚĞƌƐƐƵĐŚĂƐWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ.132 Oxidative stress is the imbalance in 
redox couples such as NADPH/NADP+, causing a disparity between the productions of oxygen 
reactive species and protecting antioxidant species.188 
1.6.3. Zinc bis(thiosemicarbazone) complexes 
Generally zinc bis(thiosemicarbazone) complexes can be readily made by refluxing a chosen 
bis(thiosemicarbazone) pro-ligand in ethanol or methanol whilst in the presence of Zinc (II) 
acetate as shown in (Figure 1.6.3.1.) The product can be recovered by filtration and washed with a 
solvent such as diethyl ether or methanol. Although the resulting product is commonly a 
yellow/orange colour, some red products have also been reported.57, 83, 91, 185, 189 According to the 
literature, this reflux method seems to be the most popular method however there are two 
different methods that are worth mentioning. Firstly, Donnelly et al.76 reported an alternative 
method where the pro-ligand was dissolved in a small quantity of DMF along with zinc (II) acetate 
and stirred at room temperature for 1 hour.  The product precipitated out of solution upon the 
addition of water and was washed with ethanol and diethyl ether. Secondly, V. Bocokic et al.190 
combined the construction of the ligand and the chelation of the zinc all in one reaction. This was 
done by reacted a mono-thiosemicarbazone intermediate with a dissimilar thiosemicarbazide and 
zinc (II) acetate at once. 
Studies on Zn-ATSM (Q1=Q2= Me, R1=R3=Me, R2=R4=H) by Cowley et al.
189 shows that zinc can form 
a 5th coordination bond with an oxygen atom in a solvent molecule of DMSO. This 5th bond is axial 
and produces a complex that has a square pyramidal geometry.      









Zinc bis(thiosemicarbazone) complexes are of interest for a number of reasons, firstly they are 
weakly fluorescent which allows their uptake and intracellular distribution within cells to be 
tracked by fluorescence microscopy.76, 83, 84, 91, 189, 191 Secondly due to zinc bis(thiosemicarbazone) 
complexes being diamagnetic they can be characterised by NMR something which is not possible 
with the related paramagnetic copper complexes.57 Finally the zinc complexes can be convenient 
precursors in the production of the related radio-copper bis(thiosemicarbazone) complexes by 
transmetalation. S. Kadwoaki75 and co-workers have recently showed that a zinc 
bis(thiosemicarbazone) complex shows promise for acting as an oral antidiabetic agent.  
1.6.3.1. Transmetalation 
In 1992, K.Matsumoto et al.192 and in 1993, H.Saji et al.193 published the first reports on the use of 
the transmetalation approach.57 M.Chrislieb et al.83 reported that when a chosen zinc 
bis(thiosemicarbazone) complex is added to one equivalent of copper(II) in aqueous methanol the 
transmetalated copper bis(thiosemicarbazone) complex is rapidly formed. This principle lends 
itself to be translated in to the rapid synthesis of copper bis(thiosemicarbazone) complexes by 
using polymer bound zinc bis(thiosemicarbazone) complexes as the precursor. The 
transmetalation process relies on the fact that the zinc complexes are constrained in a pseudo-
square-planar conformation which allows the zinc to form an axial fifth coordination bond with 
another donor atom, just like in A.Cowley et al.189 Instead of a solvent molecule of DMSO, a fifth 
bond can be formed between the zinc atom and the nitrogen lone pair of a pyridine functionality 
which is attached to a solid polystyrene polymer support. Upon addition of a Cu2+ solution the 
copper undergoes transmetalation with the zinc in the complex in order to form a copper 
bis(thiosemicarbazone). As the Jahn-Teller distortion disfavours the coordination of the axial fifth 
bond in the resulting copper complex, the copper-pyridine bond does not form leading to only the 
transmetalated square planar copper bis(thiosemicarbazone) complex to be released from the 
resin.137, 183 This process is illustrated in (Figure 1.6.3.1.1.).   
Betts et al.137 used a 4-(dimethylamino)pyridine (DAMP)- functionalised polystyrene resin that 
was cross-linked with 2% divinylbenzene. Loading of the chosen zinc bis(thiosemicarbazone) on to 
the resin was achieved by stirring the resin in an acetone/methanol (10%) solution of zinc 
complex at room temperature for 30 minutes. The resin was then recovered via filtration, washed 



















J. Holland et al.57 studied the kinetics of the copper transmetalation with a glucose functionalised 
zinc bis(thiosemicarbazone) complex and found that the second-order reaction was very rapid 
and upon efficient mixing can be completed within 1 second at room temperature. A study by A. 
Aphaiwong et al.194 involved testing a number of different polymers for application in zinc-copper 
transmetalation reactions. The authors concluded that out of the polymers that they tested a 
pyridine functionality was found to be optimal and that further work to improve loading and 
release of metal ligands from their polymeric supports is warranted.  A slightly older report of 
solid phase synthesis has been found for the production of [18F]FDG by using a solid bound FDG 
substrate which is selectively cleaved upon reaction with [18F] fluoride ions.10 
1.7. Thesis hypothesis, aims and objectives 
 
Reports of the evaluation of copper bis(thiosemicarbazone) complexes for the diagnosis of 
hypoxia via positron emission tomography have been dominated by the symmetric complexes.  
Even though the majority of reports are in respect to Cu-ATSM other symmetric complexes have 
been investigated69, 77, 123, 164, 168. These other symmetric complexes are structurally similar to Cu-
ATSM except having different substituents at the Q1, Q2, R1 and R2 positions. These substituents 
are typically H, CH3, CH2CH3 and C6H5 (Figure 1.6.2.1.4.). As mentioned earlier in this chapter the 
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Q1 and Q2 positions influence the reduction potential of the copper complexes which dictates in 
which environments the copper complexes release their radio copper ion. Independently the R1 
and R2 positions control the lipophilicity of the complexes which prescribes where in the body the 
copper complexes will migrate to. The ideal copper complex will be lipophilic enough in order to 
passively diffuse through the cell membrane but hydrophilic enough to allow faster clearance 
from non-target cells resulting in a higher target to background ratio. By synthesising 
dissymmetric copper bis(thiosemicarbazone) complexes with different substituents on the two 
terminal amines, the greater the range of complexes with slightly different lipophilicity values that 
can be evaluated for hypoxia selectively. If a range of copper complexes can be screened the 
more likely it is to find a complex which is superior to the symmetric complexes, or at the very 
least will suggest further complex designs for the next generation of bis(thiosemicarbazone) 
copper complexes.  Additionally, if a copper complex is synthesised that has the correct reduction 
potential and is lipophilic enough to cross the blood brain barrier then that complex could be 
utilised for the application of brain imaging for investigating neurodegenerative disorders.  
With this in mind, the main focus of this thesis is investigating the synthesising of dissymmetric 
copper complexes to fill this gap. From previous work by P.J.Blower et al.69 and  J. Dearling et al.77 
it is known that complexes with two alkyl groups on the Q1 and Q2 positions have a lower 
reduction potential and a higher hypoxia selectively. Therefore, it is desirable to synthesise 
copper complexes with Me/Me and Me/Et on the backbone with R1 and R2 substituents with 
varying lipophilicity for the evaluation of hypoxia imaging. A secondary aim is to synthesise copper 
complexes with Me/H and H/H on the Q1 and Q2 positions and more lipophilic R1 and R2 
substituents, as these are expected to have less negative reduction potentials which could allow 
the complexes to deposit their radio copper ion in to the brain irrespective of hypoxia.  
The initial aim of this project is to establish a suitable method for the synthesis of the 
dissymmetric bis(thiosemicarbazone) ligands. There are a handful of methods reported in the 
literature.66 Out of these, the method of using acetal protecting groups and the method of 
exploiting the reactivity of carbonyl groups are going to be investigated in order to determine 
which method is most suitable for this project. Throughout the synthesis of each class of 
dissymmetric ligands the related symmetric complexes are also going to be synthesised to act as 
both a comparison of pharmacokinetic properties, but also to establish knowledge about the 
synthesis and characterisation of that class of ligands which can be applied to the case of the 
dissymmetric ligands. Once a ligand is reacted with radio-copper to form a radio complex there is 
very little time for lengthy purification procedures as the copper complex is constantly decaying. 
So in order to cut down the need for purification procedures post radio labelling the target purity 
ĨŽƌĞĂĐŚůŝŐĂŶĚŝƐA? ? ?A? ? 
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From the literature, the method that seems to be most used for synthesising copper 
bis(thiosemicarbazone) complexes, in the milligram to gram scale, is refluxing the chosen 
bis(thiosemicarbazone)  ligand in a solvent such as ethanol80 and methanol57 with a copper (II) salt 
such as copper acetate. Off course for these methods to work the ligands must at least be 
moderately soluble in methanol or ethanol. As the aim of this project is to synthesise ligands with 
a range of lipophilicity values an objective is to devise a method that can be applied to the entire 
ligand library which produces complexes with high purity and reasonable yield. Due to NMR 
spectroscopy not being available for the analysis of the copper complexes, high purity will be 
regarded as CHN analysis within +/- 0.3 of the theoretical percentage. These objectives will also 
be set for the synthesis of zinc (II) bis(thiosemicarbazone) complexes. It is desirable to synthesise 
zinc complexes from the library of ligands because, besides most of them being expected to be 
novel, they can act as potential precursors for the rapid synthesis of their related copper 
complexes via the transmetalation reaction.57, 137 A further objective is to determine if the 
transmetalation synthetic approach can be applied to the range of ligands that are to be 
synthesised in this project.  
Due to restrictions in the facilities that are available, it will not be possible to routinely synthesise 
radio copper complexes. The complexes will be synthesised using stable copper and zinc isotopes 
for the purposes of synthesis optimisation and comprehensive characterisation of each complex. 
Characterisation data shall be collected on all intermediates, ligands and complexes. There is not 
currently a source of comprehensive unified characterisation data for the bis(thiosemicarbazone) 
ligands and their related complexes. The techniques that shall be utilised shall be NMR 
spectroscopy (except for paramagnetic copper complexes). Vibrational spectroscopy in the form 
of infrared and Raman spectroscopy which can be used as a very quick verification of the identity 
of a product, but also for establishing if zinc complexes have been successfully loaded upon 
polymers for the transmetalation investigation. Mass spectrometry will give compelling evidence 
that the desired copper or zinc complex have been successfully produced. Uv-vis lambda max and 
extinction coefficients shall also be collected. In order to establish the purity of the ligands and 
the complexes produced, CHN analysis shall be employed.   
Once fully characterised by the techniques listed above, the next objective is to collect logP and 
reduction potentials for each of the copper complexes. This work shall be carried out by 
collaborating with the Division of Imaging Sciences and Biomedical Engineering at King's College 
London. The data will give an indication of the lipophilicity of the complexes and at what level of 
hypoxia the copper (II) complexes will be reduced so that the radio copper ion can be deposited 
within the hypoxic environment. The logP value for each copper complex will be determined by 
synthesising the related 64Cu complex and partitioning it between water and octanol phases. The 
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partition coefficient shall be established by using a gamma counter to count the proportion of the 
complex in each the water and octanol phase. It is expected that the redox potential shall be 
obtained using cyclic voltammetry.  
From the logP data and reduction potential of each copper complex, a list of copper complexes 
candidates can be complied for screening in the isolated heart model164-166 in order to establish 
the hypoxia selectivity of the candidate complexes. J. Dearling et al.77 reports that Cu-ATSM, with 
a Cu(II/I) reduction potential of -0.59V and a logP of 1.48, had the greatest hypoxia selectively at 
60 minutes post injection out of the range of symmetric copper complexes tested. The 
experiment set up used a glassy carbon electrode, a Pt gauze auxiliary electrode and an Ag/AgCl 
reference electrode. It is also suggested that for a copper bis(thiosemicarbazone) complex to be 
hypoxia selective it has to have a reduction potential below -0.5V. Copper complexes synthesised 
in this project with a reduction potential of below -0.5V would be candidates for screening in the 
isolated heart model. The priority complexes would be any which have a lower reduction 
potential than Cu-ATSM (-0.59V).  For the copper complexes that J. Dearling et al.77 screened 
which showed hypoxia selectivity, the Log P range of these complexes was 0.65-2.69. The non-
hypoxic selective complexes had a Log P of 0.45-0.84. With this in mind it is suggested that the 
copper complexes that are synthesised in this project with a Log P in the range of 0.65-2.69 are of 
interest for screening. The ones with Log P values at the top end of this range or higher than 2.69 
should be regarded as priority complexes. An interesting result with PTSP was obtained; PTSP has 
Me/H on the backbone and H/Ph substituents on the terminal amine. Despite having a relatively 
high reduction potential of -0.3, PTSP showed a small level of hypoxia selectivity. Synthesis of 
dissymmetric complexes with Me/H on the backbone containing phenyl substituents on the 
terminal amine will be worth evaluating for hypoxia selectivity.      
Copper complexes which would be candidates for the application of brain imaging for the 
investigation of neurodegenerative disŽƌĚĞƌƐǁŽƵůĚďĞĂŶǇĐŽŵƉůĞǆĞƐǁŚŽ ?ƐůŝƉŽƉŚŝůŝĐŝƚǇǀĂůĞƐĂƌĞ
at the higher end of the range for the all synthesised complexes and who possess reduction values 
of above -0.5V. A potential way of screening these candidate complexes would be in vivo rat 
testing in order to determine, via PET, the proportion of the radio copper complex that is able to 
migrate to and remain with in the brain. Using what has been discussed above the hypothesis, 
aim and objectives for this thesis are set out as: 
1.7.1. Hypothesis 
The use of radio labelled dissymmetric copper bis(thiosemicarbazone) complexes offers the 
opportunity to achieve superior imaging capabilities in diagnostic imaging of hypoxia by positron 




The aims derived from the hypothesis of this thesis are:  
1. Synthesise a range of dissymmetric bis(thiosemicarbazone) ligands.  
2. Create a library of symmetric bis(thiosemicarbazone) ligands related to the planned 
dissymmetric ligands. 
3. Explore the coordination of copper (II) ions with the library of bis(thiosemicarbazone) 
ligands. 
4. Collect characterisation data on all ligands, complexes and intermediates that were 
created. 
5. Evaluate the copper complexes pharmacokinetics in order to establish candidates for 
biological screening.   
1.7.3. Objectives  
From the aims the following objectives have been set out:  
1. Compare the acetal protection method and the exploitation of carbonyl reactivity method 
for synthesis of dissymmetric bis(thŝŽƐĞŵŝĐĂƌďĂǌŽŶĞ )ůŝŐĂŶĚƐǁŝƚŚĂƚĂƌŐĞƚƉƵƌŝƚǇŽĨA? ? ?A? ? 
2. Produce a library of symmetric ligands using previously reported methods. 
3. Where possible, optimise the synthetic methods for both the synthesis of dissymmetric 
and symmetric ligands. 
4. Improve the synthesis of copper complexes so that it is suitable for the entire library of 
bis(thiosemicarbazone) ligands. 
5. Synthesise a range of zinc (II) bis(thiosemicarbazone) complexes for the evaluation of an 
alternative copper complex synthetic approach via transmetalation.  
6. Characterise all ligands, intermediates and complexes by NMR (except copper 
complexes), IR and Raman spectroscopy. Obtain CHN analysis on all ligands and 
complexes which are believed to be novel. Utilise mass spectrometry for the analysis of 
novel zinc and copper complexes.  
7. Collaborate with the Division of Imaging Sciences and Biomedical Engineering at King's 
College London to obtain lipophilicity and redox potentials for the library of copper 
complexes produced.  
8. Based on lipophilicity and redox daƚĂƐĞŶĚ<ŝŶŐ ?ƐŽůůĞŐĞĐĂŶĚŝĚĂƚĞƐĨŽƌďŝŽůŽŐŝĐĂů
screening using the isolated heart model164-166 in order to determine hypoxia selectivity.  
9. Based on lipophilicity and reĚŽǆĚĂƚĂƐĞŶĚ<ŝŶŐ ?ƐŽůůĞŐĞĐĂŶĚŝĚĂƚĞƐĨŽƌƚŚĞĞǀĂůƵĂƚŝŽŶŽĨ





2. Synthesis of symmetric and dissymmetric 
bis(thiosemicarbazone) ligands. 
2.1. Introduction 
This chapter reports the synthesis and characterisation of a range of symmetric and dissymmetric 
bis(thiosemicarbazones). The primary consideration was to synthesise the ligands with a high level 
of purity irrespective of yield in order for the ligands to be of use in a radio-pharmaceutical 
application. The ligands are split in to four broad groups depending what substituents are present 
at the Q1 and Q2 positions of the backbone precursor. 30 ligands have been synthesised with 13 
being symmetric and 17 being dissymmetric ligands. Out of the 17 dissymmetric ligands 2 are 
singly dissymmetric and 15 are doubly dissymmetric. Alongside these a new cyclic by product was 
observed and is reported in this chapter.  
2.1.1. Abbreviations used to describe the bis(thiosemicarbazone) ligands  
A new abbreviation system has been devised in order to clearly show the subtle variation 
between the ligands.  
 The abbreviation contains three components in a specific order all with a hyphen between them: 
1. An abbreviation to represent the backbone used to form the imine substituents (Q1-Q2). 
2. Substituents on the terminal amine of the 4-substituted-3-thiosemicarbazide that was 
reacted with the carbonyl group on the methyl ketone.  
3. Substituents on the terminal amine of the 4-substituted-3-thiosemicarbazide that was 












The abbreviations used to represent the backbones are: 
Abbreviation Chemical Name Chemical Structure 























The abbreviations used to describe substituents on the terminal nitrogen of the 4-substituted-3-
thiosemicarbazide are: 


















 Figure 2.1.1.1. Examples of the abbreviations used for the bis(thiosemicarbazone) ligands.  
2.1.2 Abbreviations for the intermediates 
In the case of the synthesis of the dissymmetric bis(thiosemicarbazone) ligands an intermediate 
mono-substituted thiosemicarbazone was prepared first. An abbreviation is constructed by using: 
1. The abbreviation to represent the backbone used to form the imine substituents 
2. Substituents on the terminal nitrogen of the 4-substituted-3-thiosemicarbazide that was 
reacted with the carbonyl group on the methyl ketone.  
3. dŚĞƐǇŵďŽů ‘A?K ?ŝƐĂƚƚĂĐŚĞĚƚŽƐŚŽǁƚŚĞƉƌĞƐĞŶĐĞŽĨĂŶƵŶƌĞĂĐƚĞĚŬĞƚŽŶĞ ?ĂůĚĞŚǇĚĞ ? 
PDO-Et=OBDO-Me=O









2.2. Synthesis of dissymmetric bis(thiosemicarbazone) ligands by 
the protecting approach. 
The synthesis of some dissymmetric ligands with Me/H on the backbone was initially attempted 
by using the acetal protecting approach as described in the literature.66, 79-81, 195 The approach first 




DMF, 72 hrs, 60 oC
3 Å Molecular sieves 
98% acetonitrile / 2% H20, 1hr,         
60 oC, 2 eqv LiBF4
 
DMF, 72 hrs, 60 oC
3 Å Molecular sieves 
 
 
 R1 R2 R3 R4 
PADA-Me-NH2 CH3 H H H 
PADA-NH2-Me H H CH3 H 
Figure 2.2.0.1. The reaction conditions first used in the acetal protection approach. 
For the purposes of this section the resulting product, when a 4-substituted-3-thiosemicarbazide 
is reacted with PADA shall be the given the abbreviation PADA-R1,2-(OMe)2 in order to distinguish 
between when the acetal protecting groups are present and when they are absent (PADA- R1,2=O). 









Figure 2.1.0.2. Example of the abbreviations used for the mono-substituted thiosemicarbazone 
intermediates with Me/H on the backbone. 
All protected intermediates derived from DMB shall also be giving abbreviation DMB-R1,2-(OMe)2 
but once the protected intermediate undergoes a de-protecting step the abbreviation shall revert 
back to BDO- R1,2=O, to keep in line with abbreviations that are used throughout.   
De-protection step
BDO-NH2=ODMB-NH2-(OMe)2
Figure 2.1.0.3. Example of the abbreviations used for the mono-substituted thiosemicarbazone 
intermediates with Me/Me on the backbone.   
2.2.1. Method of synthesis 
Synthesis of PADA-Me-NH2: 
PADA-Me-(OMe)2:  
4-methyl-3-thiosemicarbazide (1.315 g, 0.013 mol) was dissolved in DMF (40 mL), followed by the 
addition of methylglyoxal-1,1-dimethylacetal (1.5 mL, 0.012 mol, 1.5 g). The resulting solution was 
left to stir (3 days).  The volume of DMF was reduced under vacuum until a viscous solution was 
formed. A small amount of diethyl ether was added to the solution and then cooled on ice 
overnight. The precipitate was isolated, washed with diethyl ether (4 x 1 mL) and dried. A clear 
crystalline solid (0.585 g) was recovered (24% yield).  
PADA-Me=O:  
PADA-Me-(OMe)2 (0.146 g, 0.0007 mol) was dissolved in an acetonitrile solution (15 mL, 98% 
acetonitrile, 2% de-ionised water). LiBF4 (0.139 g, 0.0015 mol) was added and the resulting 
solution was left to stir (60 oC, 1 hour). To the solution a saturated solution of Na2CO3 (30 mL) was 
53 
 
added rapidly resulting in the formation of a bright yellow solution. The product was extracted 
with diethyl ether (3 x 50 mL) and the organic solution was dried over magnesium sulfate. The 
magnesium sulfate was filtered off and the solvent was removed. A brown solid (0.084 g) was 
recovered (75% yield).     
PADA-Me-NH2:  
Freshly activated molecular sieves (3 Å, 0.051 g) was added to DMF (10 mL, 60 oC), followed by 
the addition of PADA-Me=O (0.083 g, 0.0005 mol) and thiosemicarbazide (0.049 g, 0.0005 mol). 
The solution was left to stir (60 oC, 6 hours) then allowed to continue stirring overnight (room 
temperature). Removed the DMF under vacuum and the crude product was washed with ethyl 
acetate (1 x 14 mL, 1 x 7 mL, 1 x 3.5 mL) and a little acetone. The solid was then dried. A white 
solid (0.042 g) was recovered (36 % yield).  
Synthesis of PADA-NH2-Me 
PADA-NH2-(OMe)2:  
Freshly activated molecular sieves (3 Å, 0.801 g) was added to DMF (15 mL, 60 oC), followed by 
the addition of thiosemicarbazide (0.770 g, 0.0084 mol). This was followed by the addition of 
methylglyoxal-1,1-dimethylacetal (1 mL, 0.0083 mol, 1 g). The resulting solution was left to stir 
(room temperature, 3 days). The molecular sieves were filtered off and the DMF was removed 
under vacuum. The crude product was washed with a little diethyl ether and dried. An off white 
solid (0.769 g) was recovered (48% yield). 
PADA-NH2=O:  
PADA-NH2-(OMe)2 (0.754 g, 0.004 mol) was dissolved in an acetonitrile solution (15 mL, 98% 
acetonitrile, 2% de-ionised water, 60 oC). LiBF4 (0.720 g, 0.008 mol) was added and the resulting 
solution was left to stir (60 oC, 1 hour). A saturated solution of Na2CO3 (30 mL) was added rapidly 
resulting in the formation of a brown/orange solution. The product was extracted with diethyl 
ether (1 x 50 mL, 2 x 25 mL) and the organic solution was dried over magnesium sulfate. The 
magnesium sulfate was filtered off and the solvent was removed. A brown solid (0.137 g) was 
recovered (24% yield).     
PADA-NH2-Me:  
Freshly activated molecular sieves (3 Å, 0.075 g) was added to DMF (17 mL, 60 oC), followed by 
the addition of PADA-NH2=O (0.131 g, 0.0009 mol) and 4-methyl-3-thiosemicarbazide (0.101 g, 
0.0010 mol). The heat was turned off and the solution was left to stir (3 days, cooling down to 
room temperature). The molecular sieves were filtered off and the DMF was removed under 
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vacuum. The crude product was washed with a little ethyl acetate and diethyl ether (1 x 25 mL) 
and dried. A sawdust coloured solid (0.130 g) was recovered (62% yield).  
2.2.2. Characterisation data for ligands synthesised by the protection method 
As this method of synthesis was superseded by a different method most the characterisation data 
collected was just enough to ascertain the likely structure of the product.  
PADA-Me-(OMe)2:  
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.94 (q, 1 H, H3C-NH, J= 4.4 Hz), 4.49 (s, 1 
H, O-CH), 3.25 (s, 6 H, O-CH3), 2.93 (d, 3 H, HN-CH3, J= 4.4 Hz), 1.78 (s, 3 H, N=C-CH3). 
13C {1H} NMR 
(DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 148.60 (C=N), 106.87 (HC-O), 55.16 (O-CH3), 31.39 (HN-
CH3), 11.17 (N=C-CH3). IR (neat): cm
-1= 3279 (m), 3227 (w), 2936 (w), 1537 (m), 1504 (m), 1435 
(m), 1410 (m), 1366 (m), 1325 (m), 1271 (m), 1213 (m), 1192 (m), 1115 (m), 1072 (s), 1057 (s), 986 
(s), 949 (s), 860 (m), 660 (m), 559 (s), 494 (m). Raman (neat), laser = 784.15 nm: cm-1= 1642 (s), 
1539 (w), 1499 (w), 1450 (w), 1437 (w), 1324 (w), 1277 (w), 1224 (w), 1156 (w), 1062 (w), 1044 
(w), 1022 (w), 985 (m), 963 (w), 860 (s), 799 (s), 660 (w), 632 (w), 582 (m), 573 (s), 495 (w), 435 
(w), 354 (w), 308 (m), 272 (m).Melting point: >84-88 oC. 
PADA-Me=O: 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 9.32 (s, 1 H, O=CH), 9.01 (m, 1 H, H3C-NH), 
2.99 (d, 3 H, HN-CH3, J= 4.8 Hz), 1.90 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?
192.16 (C=O), 179.46 (C=S), 145.93 (C=N), 31.69 (HN-CH3), 9.68 (N=C-CH3). IR (neat): cm
-1= 3352 
(w), 3173 (m), 2963 (w), 2843 (w), 1694 (m), 1593 (m), 1537 (m), 1504 (m), 1410 (m), 1369 (m), 
1200 (s), 1146 (m), 1111 (m), 1047 (s), 1001 (s), 856 (m), 789 (m), 665 (s), 594 (s), 569 (s), 534 (s), 
503 (m).  
 PADA-Me-NH2:  
1H NMR (DMSO-d6,  ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.36 (s, 1 H, N-NH), 8.50 (q, 1 H, H3C-NH, 
J= 4.4 Hz), 8.29 (s, 1 H C-NH), 7.88 (s, 1 H C-NH), 7.62 (s, 1 H, N=CH), 2.95 ( d, 3 H, HN-CH3, J= 4.4 
Hz), 2.10 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 178.63 (C=S), 
147.54 (C=N), 142.97 (C=N), 31.58 (HN-CH3), 11.52 (N=C-CH3). IR (neat): cm
-1= 3414 (w), 3138 (w), 
2984 (w), 1605 (w), 1533 (m), 1501 (m), 1464 (w), 1337 (w), 1267 (w), 1213 (m), 1069 (s), 924 (m), 







1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.23 (s, 1 H, C-NH), 7.72 (s, 1 H, C-NH), 4.48 
(s, 1 H, O-CH), 3.24 (s, 6 H, O-CH3), 1.78 (s, 3 H, N=C-CH3).
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?
179.90 (C=S), 149.02 (C=N), 106.78 (HC-O), 55.16 (O-CH3), 11.21 (N=C-CH3). 
PADA-NH2=O:  
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 9.31 (s, 1 H, O=CH), 8.78 (s, 1 H, C-NH), 
8.38 (s, 1 H, C-NH), 1.90 (s, 3 H, N=C-CH3). 
13C {1H} NMR (d6-D^K ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O),
180.52 (C=S), 146.30 (C=N), 9.70 (N=C-CH3).   
PADA-NH2-Me:  
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.33 (s, 1 H, N-NH), 8.38 (quartet 
overlapping a singlet, 1 H, H3C-NH, J= 4.4 Hz), 8.35 (singlet overlapping a quartet, 1 H C-NH), 7.60 
(s, 1 H C-NH), 7.61 (s, 1 H, N=CH), 2.95 ( d, 3 H, HN-CH3, J= 4.4 Hz), 2.04 (s, 3 H, N=C-CH3). 
13C {1H} 
NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 178.24 (C=S), 148.02 (C=N), 142.55 (C=N), 31.47 (HN-
CH3), 11.62 (N=C-CH3). 
2.2.3. Monitoring the de-protection of PADA via spectral methods 
Figure 2.2.3.1. shows a 1H spectrum of PADA-Me-(OMe)2 shows the presence of the protecting 
acetal groups, as seen by the singlet at 3.25 ppm with an integral of six protons corresponding to 
the six hydrogen atoms on both the acetal groups. An indirect indicator of the presence of the 
proƚĞĐƚŝŶŐŐƌŽƵƉƐŝƐƚŚĞƐŝŶŐůĞƚĂƚ ? ? ? ?ƉƉŵǁŚŝĐŚŝƐĚƵĞƚŽŚĞŚǇĚƌŽŐĞŶůĂďĞůůĞĚ ‘ ? ?ŝĨƚŚĞ
product was PADA-Me=O or PADA-Me with a second 4-substituted-3-thiosemicarbazide bound, 











Figure 2.2.3.1. A 
1
H spectrum of PADA-Me-(OMe)2, with assigned peaks. PADA-Me-(OMe)2 was obtained by 
the reacting methylglyoxal-1,1-dimethyl acetal with 4-methyl-3-thiosemicabrazide.  
 
Figure 2.2.3.2. is a 13C spectrum of PADA-Me-(OMe)2 which further supports the presence of the 
acetal protecting groups. The main peak of interest is the peak at 55.16 ppm which is due to the 
ĐĂƌďŽŶƐŝŶƉŽƐŝƚŝŽŶ ‘& ? ?^ŝŵŝůĂƌƚŽǁŚĂƚǁĂƐƐĞĞŶŝŶƚŚĞ1H spectrum above, if the product was 
PADA-Me=O or PADA-Me with a second 4-substituted-3-thiosemicarbazide attached environment 
 ‘ ?ǁŽƵůĚƐŚŝĨƚƚŽĐŝƌĐĂ ? ? ?ƉƉm or 142-148 ppm respectively.  
Figure 2.2.3.2. A 
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IR spectroscopy (Figure 2.2.3.3.) was used to further corroborate the presence of PADA-Me-
(OMe)2, but due to the limitation of the technique the only thing that can be ascertained with any 
level of confidence is that there is no strong absorption between 1800-1600 cm-1, which would be 
the expected position of a peak due to the C=O bond of the aldehyde group of PADA-Me=O 
(indicated by the red box). Unlike the NMR spectra above FTIR cannot easily be used to confirm 
the presence of PADA-Me-(OMe)2 nor the absence of a symmetric or dissymmetric complete 
ligand, but it can be used relatively easily to show the presence of the carbonyl group as a result 
of a successful de-protection step.    
Figure 2.2.3.3. A FTIR spectrum of PADA-Me-(OMe) 2.The red box highlights the absence of a C=O bond 
indicating that the two acetal functionalities are present.  
 
The 1H spectrum of PADA-Me=O (figure 2.2.3.4.) clearly shows the complete absence of the acetal 
ŚǇĚƌŽŐĞŶĞŶǀŝƌŽŶŵĞŶƚƉƌĞǀŝŽƵƐůǇƐĞĞŶĂƚ ? ? ? ?ƉƉŵ ?ĂƐǁĞůůĂƐƚŚĞƐŝŶŐůĞƚůĂďĞůůĞĚ ‘ ?ǁŚŝĐŚǁĂƐ
situated at 4.49 ppm and has now shifted downfield to 9.32 ppm. All these changes in the spectra 






Figure 2.2.3.4. A 
1
H spectrum of PADA-Me=O, with assigned peaks. PADA-Me=O was obtained by using LiBF4 
to cleave the acetal functionalities of PADA-Me-(OMe)2.  
 
The 13C spectrum of PADA-Me=O (figure 2.2.3.5.)shows the peak locations related to PADA-Me=O. 
&ŝƌƐƚůǇƚŚĞĐĂƌďŽŶƉĞĂŬĨŽƌƚŚĞĂĐĞƚĂůĐĂƌďŽŶƐĂƚ ? ? ? ? ?ƉƉŵŚĂƐǀĂŶŝƐŚĞĚ ?ĂůƐŽĞŶǀŝƌŽŶŵĞŶƚ ‘ ?Śas 
shifted downfield to 192.16 ppm indicating the presence of a C=O group.  
Figure 2.2.3.5. A 
13
C spectrum of PADA-Me=O, with assigned peaks. Carbon environment E illustrates that 




Finally the FTIR spectrum of PADA-Me=O (Figure 2.2.3.6.) clearly shows the presence of a strong 
absorption at 1694 cm-1 (indicated by the red box), this further indicates the presence of the C=O 
bond of the carbonyl group on the aldehyde. 
Figure 2.2.3.6. A FTIR spectrum of PADA-Me=O. The red box highlights the presence of a C=O bond 
indicating that the two acetal functionalities have been successfully removed. 
 
Proton NMR data has been reported for compounds PADA-Me-(OMe)2, PADA-Me=O, PADA-Me-
NH2, PADA-NH2-(OMe)2, PADA-NH2=O, PADA-NH2-Me by J. Lim et al.,
79 of which the data collected 
show strong agreement to the figures published. The literature value for the melting point for 
PADA-Me-(OMe)2 is reported as 87-88
oC79 which is in accord with the value of 84-88oC observed. 
This corroboration by the literature increases confidence in that the molecules are correctly 
identified and that the synthesis of dissymmetric bis(thiosemicarbazone) ligands via the 
deprotection approach is achievable.   
2.2.4. Attempts to synthesise dissymmetric ligands from DMB 
Using the same protecting method that was used to synthesise dissymmetric ligands from PADA, 
attempts were undertaken to synthesis dissymmetric ligands from DMB in order to obtain ligands 




Figure 2.2.4.1. Illustrates the planned synthetic route first attempted for the synthesis of 




DMF, 72 hrs, 60 oC
3 Å Molecular sieves 
98% acetonitrile / 2% H20,             
1hr, 60 oC, 2 eqv LiBF4
 
DMF, 72 hrs, 60 oC
3 Å Molecular sieves 
 
Figure 2.2.4.1. Summary of the reaction conditions first used. 
The first intermediate that was attempted was BDO-NH2-(OMe)2. The reaction conditions in figure 
2.2.4.1. was used, but the product turned out not to be the one that was expected. The identity of 
this unknown product was not able to be solved. Subsequent reactions were run with similar 
reaction conditions as figure 2.2.4.1. but with different temperature and stir time parameters. 
Throughout the method development process, heating above 60 oC was avoided and where 
possible, this exposure was limited to the shortest length of time. The reason for this was that the 
literature57, 66, 79, 81 reported that dissymmetric bis(thiosemicarbazone) ligands under certain 
conditions where prone to scrambling resulting in a product that contained a mixture of the 
target  dissymmetric bis(thiosemicarbazone) and related symmetric bis(thiosemicarbazones). This 
idea is illustrated in figure 2.2.4.2. 
Scrambling
Figure 2.2.4.2. Illustration of the products of scrambling. 
A range of temperature and stir profiles was used. Some conditions that were tried was stirring at 
room temperature for 72 hours and stirring at 60 OC for 6 hours.  All these attempts failed to yield 
the desired product and only produced either unreacted reagents or a more complex mixture of 
unreacted reagents with small proportions of what was thought to be BDO-NH2=O and BDO-NH2-
NH2. One attempt that was partially successful yielded a product that turned out to be a mixture 
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of BDO-NH2=O and BDO-NH2-NH2 with estimated proportions of 85% and 15% respectively. This 
partially successful attempt was not run with any significant alteration in conditions except a 
slightly larger excess of DMB.  
 
The crude BDO-NH2=O was then reacted with 4-methyl-3-thiosemicarbazide in a 1:1 
stoichiometric ratio (see reaction 3 Figure.2.2.4.1.). The reaction duration was altered from 72 
hours to 6 hours as PADA-Me-NH2 was successfully synthesised when stirred at 60 
oC for only 6 
hours followed by stirring overnight at room temperature. The resulting product contained 
predominantly BDO-NH2-Me with signs of BDO-NH2=O and BDO-NH2-NH2 impurities. The 
proportions of the impurities were not able to be estimated due the BDO-NH2-NH2 peaks lying 
beneath the BDO-NH2-Me peaks. This is illustrated in the 
1H NMR spectrum below (Figure 
2.2.4.3.). The blue boxes show the peaks that are due to the presence of BDO-NH2=O and the 
purple boxes show the peaks that are due to the presence of BDO-NH2-NH2.  The singlet at 2.12 
ppm has a larger integral than is expected due to the two methyl groups on the backbone of the 
BDO-NH2-NH2 impurity, owing to each environment having very similar chemical shifts.  
Figure 2.2.4.3. An assigned 
1
H NMR spectrum of BDO-NH2-Me synthesised by the acetal protecting 
approach. The spectrum suggests the presence of BDO-NH2=O (blue boxes) and BDO-NH2-NH2 (purple 
boxes). 
 
 In order to achieve a greater purity of either BDO-NH2-(OMe)2 or BDO-NH2=O the reaction solvent 
was changed to ethanol with the hope that one of the desired intermediates would precipitate 
out of solution upon its formation resulting in a purer intermediate. Due to the low solubility of 
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thiosemicarbazide in ethanol, the 4-substituted-thiosemicarbazide was changed to 4-methyl-
thiosemicarbazide due to its higher solubility in ethanol (Figure 2.2.4.4.).  
and / or
 
Ethanol, 48 hrs, 60 oC 
Figure 2.2.4.4. Figure showing the changes made to the reaction conditions. 
When treating the reaction solution three products were recovered. Each time a precipitate was 
observed it was filtered off and bottled, the reaction mixture was put back on the heat and 
stirred. The first precipitate was formed in the reaction mixture while it was at 60 oC, which was 
identified as the symmetric ligands BDO-Me-Me. After the filtrate was kept in the freezer for 36 
hours the second precipitate formed which was unreacted 4-methyl-3-thiosemicarbazide. The 
solvent in the resulting filtrate was allowed to evaporate to yield the third product, which was a 
mixture of BDO-Me-(OMe)2 and unreacted 4-methyl-3-thiosemicarbazide. This third product was 
then washed with diethyl ether in an attempt to remove the 4-methyl-3-thiosemicarbazide, but 
when the washed product was analysed again it was found that it was the ratio of BDO-Me-
(OMe)2 that had reduced.  
 
With all the previous observations taken in to account the following reaction methods (Figure 
2.2.4.5) were devised for the synthesis of BDO-Me-(OMe)2 and BDO-Me=O. 




98%acetonitrile/2% H20, 1hr, 
60oC, 2 eqv LiBF4
 
1) Ethanol, 36 hrs, 60oC  
 
Figure 2.2.4.5. The reactions conditions used for the synthesis of BDO-Me-(OMe)2 (1) and  BDO-Me=O (2). 
 
The 1H spectrum (Figure 2.2.4.6.) of the product from reaction 1 shows the peaks that would be 
expected given the target molecules structure. From the spectrum it is possible to see that there 
are a few impurity peaks. The product contains some unreacted 4-methyl-3-thiosemicarbazide 
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despite using a slight excess of 3,3-dimethoxy-2-butanone, these peaks are highlighted with 
purple boxes.  
 
Figure 2.2.4.6. An assigned 
1
H NMR spectrum of the novel compound DMB-Me-(OMe)2. DMB-Me-(OMe)2 
was obtained by the reacting 3,3-dimethoxy-2-butanone with 4-methyl-3-thiosemicabrazide. The purple 
boxes suggest a small presence of unreacted 4-methyl-3-thiosemicarbazide.  
 
Figure 2.2.4.7. An assigned 
1
H NMR spectrum of BDO-Me=O. BDO-Me=O was obtained by using LiBF4 to 




The 1H spectrum of BDO-Me=O (Figure 2.2.4.7.) shows that the target intermediate for reaction 2 
was successfully synthesised with a good level of purity. The only significant impurity that is 
present is BDO-Me-Me (highlighted by red boxes) in a quantity of around 1%, this value was 
estimated by using the NMR integrals.  There is a trace of ethanol present which was carried over 
from the reaction solvent. It is suspected that the water peak comes from the slightly wet DMSO-
d6 which was used as the NMR solvent. A slight trace of acetone can be seen which is carryover 
from the cleaning of the NMR tubes.  
 
The FTIR spectrum of BDO-Me=O (Figure 2.2.4.8.), helps support that the product is in its de-
protected form and not in its protected form as DMB-Me-(OMe)2. The spectrum shows a strong 
absorbance at 1670 cm-1 which corresponds to the C=O bond of the ketone carbonyl group. 
 
 
Figure 2.2.4.8. A FTIR spectrum of BDO-Me=O, synthesised by successfully deprotecting DMB-Me-
(OMe)2.The red box illustrates the presence of the deprotected carbonyl functionality.   
 
The synthesis was not taken any further due to an alternative method of synthesis was 
discovered57. This method managed to synthesise intermediates (e.g. BDO-Me=O) without the 
need of a protecting group by exploiting the reactivity differences of a selected di-ketone (e.g. 
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2,3-butandione). A dissimilar 4-sustituted-3-thiosemicarbazide was then reacted to produce the 
desired dissymmetric ligand. Following this method it was possible to produce dissymmetric 
ligands with greater yields and purity whilst removing the requirement for a de-protection step 
and in doing so reducing the overall synthesis time from start to finish. It was decided to abandon 
using the protection method and to pursue this new method.     
2.2.5. Synthetic methods 
DMB-Me-(OMe)2  
4-methyl-3-thiosemicarbazide (0.890 g, 0.0085 mol) was dissolved in ethanol (30 mL, 60 oC ), 
followed by the addition of 3,3-dimethoxy-2-butanone (1.25 mL, 0.0093 mol, 1.23 g). The 
resulting solution was left to stir (60 oC, 36 hours). The precipitate was filtered off and discarded. 
The solvent was removed and the resulting solid was extracted with diethyl ether (1 x 50 mL, 2 x 
25 mL). The diethyl ether was removed and the remaining solid was dried. A white solid (0.308 g) 
was recovered (17% yield).   
BDO-NH2=O 
Freshly activated molecular sieves (3 Å, 0.808 g) were added to DMF (15 mL, 60 oC), followed by 
the addition of thiosemicarbazide (0.773 g, 0.0085 mol and 3,3-dimethoxy-2-butanone (1.5 mL, 
0.011 mol, 1.48 g). The resulting solution was left to stir (60 oC, 3 days). The molecular sieves plus 
any solid by-products were filtered off, the DMF under was removed under vacuum and the 
sample was dried. A brown solid (0.342 g) was recovered (20% yield). 
BDO-Me=O 
DMB-Me-(OMe)2 (2.357 g, 0.011 mol) were dissolved in an acetonitrile solution (30 mL, 98% 
acetonitrile / 2% de-ionised water, 60 oC). LiBF4 (1.969 g, 0.021 mol) was added and the resulting 
solution was left to stir (60 oC, 1 hour). A saturated solution of Na2CO3 (40 mL) was added rapidly 
resulting in the formation of a bright yellow solution. The solution was left to stir (10 minutes). 
The product was extracted with diethyl ether (4 x 50 mL) and the organic solution was dried over 
magnesium sulfate (4 large spatulas). The magnesium sulfate was filtered off and the solvent was 
removed. The pale yellow solid was extracted with hot diethyl ether (1 x 25 mL, 1 x 50 mL). The 
mixture was cooled in the freezer and the precipitate was removed by filtration. The solid was left 
to dry. A light yellow solid (0.212 g) was recovered (11% yield).     
BDO-NH2-Me 
Freshly activated molecular sieves (3 Å, 0.060 g) was added to DMF (18 mL, 60 oC), followed by 
the addition of BDO-NH2=O (0.170 g, 0.0008 mol) and 4-methyl-3-thiosemicarbazide (0.088 g, 
0.0008 mol). The heat was turned off and the solution was left to stir (cooling down to room 
temperature, 6 hours). The molecular sieves were filtered off and the DMF was removed under 
66 
 
vacuum. The crude product was washed with a little acetone and dried. A brown solid (0.158 g) 
was recovered (80% yield).  
2.2.6. NMR spectral data 
DMB-Me-(OMe)2  
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.01 (m, 1 H, H3C-NH), 3.06 (s, 6 H, O-CH3), 
2.96 (d, 3 H, HN-CH3, J= 4.8 Hz), 1.86 (s, 3 H, N=C-CH3), 1.37 (s, 3 H, O-C-CH3). 
BDO-NH2=O 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.69 (s, 1 H, C-NH), 8.07 (s, 1 H, C-NH), 2.35 
(s, 3 H, O=C-CH3), 1.91 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O),
180.30 (C=S), 146.40 (C=N), 25.31 (O=C-CH3), 10.59 (N=C-CH3).   
BDO-Me=O 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.59 (m, 1 H, H3C-NH), 3.01 (d, 3 H, HN-CH3, 
J= 4.8 Hz), 2.38 (s, 3 H, O=C-CH3), 1.92 (s, 3 H, N=C-CH3). 
BDO-NH2-Me  
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ?0.21 (s, 1 H, N-NH), 10.16 (s, 1 H, N-NH), 8.37 (singlet 
overlapping a quartet, 1 H C-NH), 8.34 (quartet overlapping a singlet, 1 H, H3C-NH, J= 4.4 Hz), 7.82 
(s, 1 H C-NH), 2.97 ( d, 3 H, HN-CH3, J= 4.4 Hz), 2.16 (s, 3 H, N=C-CH3), 2.12 (s, 3 H, N=C-CH3). 
13C 
{1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 178.97 (C=S), 148.92 (C=N), 148.43 (C=N), 31.74 
(HN-CH3), 12.26 (N=C-CH3), 12.07 (N=C-CH3). 
 
The above results are in accord to literature reports of BDO-Me=O,57, 190 which was synthesised by 
an alternative synthetic route. Characterisation data for compounds BDO-NH2=O, BDO-Me=O and 
BDO-NH2-Me shows strong agreement to the same compounds that are reported later in this 
chapter which were synthesised by the synthetic route reported by J. Holland et al.57 It is believed 
that this is the first reports of the compound DMB-Me-(OMe)2.  
2.2.7. Discussion 
Using acetal groups for a protection based approach for the synthesis of dissymmetric 
bis(thiosemicarbazones) is possible, table 2.2.7.1. summarises the compounds synthesised during 
in this section. However, numerous problems were encountered such as the clean cleavage of the 
acetal functionalities with LiBF4 was often found to be labour intensive and temperamental. The 
presence of the acetal protection prevented the use of acid catalysts resulting in long reaction 
times, often up to three days. If the reaction conditions resulted in the successful cleavage of the 
acetal groups the resulting sample often contained a mixture of dissymmetric, symmetric and 
intermediate products. The multiple poor yielding steps (sometimes as low as 11%) meant that 
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the resulting ligands where often recovered in unworkably small quantities. Limits in the 
equipment that was available made running the samples in DMF undesirable as the removal of 
DMF could only be achieved on a vacuum line for long periods, using temperatures above 60OC . 
This raised concerns about increase the risk of potential scrambling of the ligands. Once the DMF 
was fully removed a very crude, often a sludge like product was obtained. The absence of a 
suitable purification method made the ligands unsuitable for the use in a medical context.  
 
Based on these issues it was decided to back away from this approach and focus on the 
development of the exploitation of the di-carbonyl method.57 If the above issues could be 
rectified in order to give a method that gives a pure compound with a higher yield and preferably 
in a reduced time span, the protection based method may be of greater use. However, it is 
unlikely to outperform the exploitation of the di-carbonyl method in terms of producing a clean 
ligand in a relatively short time period without the need for labour intensive methods. 
Table 2.2.7.1. A summary of the compounds synthesised during the investigation of the acetal protecting 
approach. 
Ligand Novel Yield 
PADA-Me-(OMe)2 
 
No79, 80 24% 
PADA-Me=O 
 







































2.3. Ligands with Me/H backbones 
Application 
This class of ligands is of interest for the application of monitoring the copper trafficking within 
the brain in order to study neurodegenerative diseases such as ůǌŚĞŝŵĞƌ ?Ɛdisease, as described 
in the introduction. In order to achieve this, the ligand once chelated with copper must be 
lipophilic enough to cross the blood Wbrain barrier (BBB). The complex must also have a redox 
potential that allows the copper to be deposited in the brain, irrespective of hypoxic or normoxic 
conditions. Once the radio-ĐŽƉƉĞƌŚĂƐďĞĞŶĚĞƉŽƐŝƚĞĚƚŚĞĐŽƉƉĞƌ ?ƐŵŝŐƌĂƚŝŽŶĐĂŶďĞŵŽŶŝƚŽƌĞĚ
via PET.  
To keep the redox potential within an appropriate range, it is desirable to make ligands with 
hydrogen and a methyl group on the backbone. In order to achieve the lipophilicity required to 
cross the blood-brain barrier, a range of ligands was made with varying combinations of 4-
substituted-3-thiosemicarbazides that have relatively lipophilic substituents such as methyl, ethyl, 
dimethyl and phenyl.     
The main aim was to make a number of different ligands that fulfilled the above criteria for 
screening in order to establish the optimal ligand configuration or to suggest further refinement 
of the ligands ? substituents.  
2.3.1. Symmetric ligands with Me/H backbones 
Overview of reaction 
The synthesis of this subgroup of ligands requires one equivalent of methylglyoxal-1,1-dimethyl 
acetal (PADA) to be reacted with two equivalents (in excess) of a chosen 4-substituted-3-
thiosemicarbazide, under acidic conditions, in water at 50 oC to give the desired symmetric ligand 










Figure 2.3.1.1. The general reaction for the synthesis of symmetric ligands with Me/H backbones. 
Conc. HCl
 
 R1 R2 
PADA-Me-Me CH3 H 
PADA-(Me)2-(Me)2 CH3 CH3 
PADA-Et-Et CH2CH3 H 





 Figure 2.3.1.2. Structures of the symmetric ligands with Me/H backbones that were synthesised. 
2.3.2. Methods  
PADA-Me-Me 
4-methyl-3-thiosemicarbazide (1.100 g, 0.0105 mol) was dissolved in de-ionised water (40 mL, 50 
oC) and HCl (32%, 2 drops) was added. Methylglyoxal-1,1-dimethylacetal (0.58 mL, 0.0048 mol, 
0.566 g) was added rapidly and left to stir (50 oC, 5 minutes). The precipitate was removed by 
filtration and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 oC). The 
crude product was dissolved in DMSO (17 mL). The solution was filtered, recrystallised with de-
ionised water (34 mL). The precipitate was removed via filtration, washed with water (50 mL) and 




4,4-dimethyl-3-thiosemicarbazide (0.321 g, 0.0027 mol) was dissolved in de-ionised water (50 mL, 
50 oC) and HCl (32%, 2 drops) was added. Methylglyoxal-1,1-dimethylacetal (0.15 mL, 0.0012 mol, 
0.15 g) was added rapidly and left to stir (50 oC, 1 hour). The precipitate was removed by filtration 
and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 oC). The crude 
product was dissolved in DMSO (3 mL). The solution was filtered, and the product was 
recrystallised with de-ionised water (6 mL). The precipitate was recovered by filtration, washed 
with water (50 mL) and dried. A yellow solid (0.065 g) was recovered (20% yield).  
PADA-Et-Et 
4-ethyl-3-thiosemicarbazide (1.251 g, 0.0105 mol) was dissolved in de-ionised water (50 mL, 50 
oC).  The insoluble particulates were filtered and HCl was added (32%, 2 drops). Methylglyoxal-1,1-
dimethylacetal (0.58 mL, 0.0048 mol, 0.57 g) was added rapidly and left to stir (50 oC, 5 minutes). 
The precipitate was removed by filtration and washed with de-ionised water (50 mL). The crude 
product was dissolved in DMSO (35 mL). The solution was filtered and the product was 
recrystallised with de-ionised water (70 mL). The precipitate was isolated via filtration, washed 
with water (50 mL) and dried. A yellowish white solid (0.870 g) was recovered (66% yield).  
PADA-Ph-Ph 
4-phenyl-3-thiosemicarbazide (0.439 g, 0.00263 mol) was dissolved in de-ionised water/ethanol 
solution (25 mL water, 13 mL ethanol, 50 oC). The insoluble particulates were filtered and HCl 
(32%, 2 drops) was added. Methylglyoxal-1,1-dimethylacetal (0.15 mL, 0.0012 mol, 0.146 g) was 
added rapidly and left to stir (50 oC, 5 minutes). The precipitate was removed by filtration and 
washed with de-ionised water (50 mL, room temperature and 50 mL, 80 oC). The crude product 
was dissolved in DMSO (15 mL). The solution was filtered, the product was recrystallised with de-
ionised water (30 mL). Precipitate filtered and washed with water (50 mL) and dried. The sample 
was further washed with ethanol (2 x 25 mL), de-ionised water (50 mL, 80 oC) and dried. A 
mustard coloured solid (0.244 g) was recovered (55% yield).  
2.3.3. Characterisation data for symmetric ligands with Me/H backbones 
PADA-Me-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.33 (s, 1 H, N-NH), 8.49 (m, 1 H, H3C-NH, 
J= 4.4 Hz), 8.38 (m, 1 H H3C-NH, J= 4.8 Hz), 7.62 (s, 1 H, N=CH), 2.94 ( two over lapping doublets, 6 
H, HN-CH3, J= 4.4 Hz), 2.12 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6, 100 D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 
178.22 (C=S), 147.63 (C=N), 142.40 (C=N), 31.58 (HN-CH3), 31.47 (HN-CH3), 11.62 (N=C-CH3). IR 
(neat): cm-1= 3302 (w), 3142 (w), 1531 (s), 1489 (s), 1431 (m), 1408 (m), 1354 (w), 1213 (s), 1152 
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(m), 1088 (s), 1024 (s), 914 (m), 820 (m), 548 (s), 517 (m). Raman (neat): cm-1= 2909 (w), 1785 (w), 
1657 (w), 1577 (s), 1442 (w), 1364 (w), 1279 (w), 1226 (w), 1124 (w), 1017 (w), 879 (w), 775 (w), 
560 (w), 405 (w), 115 (w). Melting point: >214 oC (decomposed). 
PADA-(Me)2 -(Me)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 9.59 (s, 1 H, N-NH), 7.78 (s, 1 H, N=CH), 
3.23 (s, 6 H, N-(CH3)2), 2.05 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 
180.89 (C=S), 150.11 (C=N), 144.54 (C=N), 42.80 (N-(CH3)2), 42.47 (N-(CH3)2), 11.37 (N=C-CH3). IR 
(neat): cm-1= 3404 (w), 2922 (w), 1533 (s), 1490 (m), 1362 (m), 1328 (s), 1281 (m), 1229 (s), 1150 
(s), 1113 (m), 1057 (m), 1022 (m), 905 (s), 785 (m), 542 (m). Raman (neat): cm-1= 2917 (w), 1581 
(s), 1436 (w), 1381 (w), 1281 (w), 1237 (m), 1132 (w), 1027 (w), 864 (w), 718 (w), 546 (w), 438 (w), 
394 (w), 171 (w), 107 (w). Melting point: >106 oC (decomposed). 
PADA-Et-Et 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.24 (s, 1 H, N-NH), 8.52 (t, 1 H, H2C-NH, 
J= 6.0 Hz), 8.41 (t, 1 H H2C-NH, J= 6.0 Hz), 7.62 (s, 1 H, N=CH), 3.52 (m, 4 H, H2C-NH), 2.13 (s, 3 H, 
N=C-CH3), 1.07 (two overlapping triplets, 6 H, H2C-CH3, J= 7.2 Hz). 
13C {1H} NMR (DMSO-d6, 100 
D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 177.15 (C=S), 147.66 (C=N), 142.41 (C=N), 39.01 (N-CH2), 38.87 (N-CH2), 
15.01 (H2C-CH3), 14.87 (H2C-CH3), 11.38 (N=C-CH3). IR (neat): cm
-1= 3289 (m), 3161 (w), 2967 (m), 
1526 (s), 1476 (s), 1427 (s), 1315 (m), 1229 (s), 1198 (s), 1096 (s), 1043 (s), 934 (s), 808 (s), 664 
(m), 579 (s), 550 (s). Raman (neat): cm-1= 3375 (w), 2936 (w), 1578 (s), 1516 (w), 1436 (w), 1365 
(m), 1284 (w), 1236 (w), 1202 (w), 1132 (w), 1020 (w), 874 (w), 757 (w), 541 (w), 457 (w). Melting 
point: >220 oC (decomposed). 
PADA-Ph-Ph 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.75 (s, 1 H, N-NH), 10.19 (s, 1 H, Ph-NH), 
10.01 (s, 1 H, Ph-NH), 7.82 (s, 1 H, N=CH), 7.50 (m, 4 H, H(2,6) aryl ), 7.32 (m, 4 H,  H(3,5)  aryl), 7.17 
(m, 2 H, H(4) aryl ), 2.25 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 
176.76 (C=S), 148.49 (C=N), 143.48 (C=N), 139.48 (C(1) aryl), 139.45 (C(1) aryl), 128.66 (C(3,5) aryl), 
126.55 (C(4) aryl), 126.09 (C(2,6) aryl), 11.97 (N=C-CH3). IR (neat): cm
-1= 3292 (w), 3136 (w), 2980 (w), 
1595 (m), 1518 (s), 1491 (s), 1445 (m), 1350 (m), 1256 (m), 1173 (s), 1070 (m), 1026 (m), 934 (m), 
750 (m), 689 (s), 640 (m), 559 (m). Raman (neat): cm-1= 3061 (w), 1579 (s), 1433 (w), 1370 (w), 
1285 (w), 1254 (m), 1178 (w), 1122 (w), 1023 (w), 942 (w), 1864 (w), 744 (w), 614 (w), 257 (w), 




2.3.4. Spectral examples of a symmetric ligand with a Me/H backbone 
Figures 2.3.4.1-4. Spectral examples of ligand PADA-(Me)2-(Me)2.  
Figure 2.3.4.1. An assigned 
1
H NMR spectrum of PADA-(Me)2-(Me)2. PADA-(Me)2-(Me)2 was synthesised by 
reacting methylglyoxal-1,1-dimethylacetal with two equivalents of 4,4-dimethyl-3-thiosemicarbazide. 
Figure 2.3.4.2. An assigned 
13
C NMR spectrum of PADA-(Me)2-(Me)2. 
74 
 
Figure 2.3.4.3. A FTIR spectrum of PADA-(Me)2-(Me)2. 





All four ligands where synthesised successfully and in a high purity. It is believed that the 
synthesis of symmetric ligands of this class by using methylglyoxal-1,1-dimethyl acetal as a 
precursor has not been attempted previously and as a pre-cursor it is cheaper than the 
methylglyoxal (Sigma-Aldrich200, 201). It was also more convenient to handle methylglyoxal-1,1-
dimethyl for reactions as it comes as a neat liquid whilst methylglyoxal is only available as a 40% 
solution in H2O. 
The only noticeable impurity is the respective mono-substituted thiosemicarbazone which is 
present despite the addition of a slight excess (typically 10%) of 4-substituted-3-
thiosemicarbazide. By comparing the integrals of the respective ligands 1H NMR spectra it is 
estimated that the mono-substituted thiosemicarbazone is only present in the quantity of less 
than 1% with the exception of PADA-Me-Me where the impurity content raises to around 2%.   
No significant problems where encountered with the synthesis of these ligands, the only slight 
issue was adapting the amount of water used to dissolve the 4- substituted-3-thiosemicarbazides 
which became more challenging as the substitutes on the terminal nitrogen got more lipophilic. 
With the 4-phenyl-3-thiosemicarbazide it was necessary to add a quantity of ethanol the water in 
order to achieve full dissolution. It was important to maintain a reaction mixture that is free of 
insoluble particulates so when the product precipitates out of solution the insoluble impurities 
would not mix with the product. It is possible to run the reaction in alternate solvents, such as 
dimethylformamide, in which the precursors dissolve easily. The setback with this method is that 
the product does not precipitate out of the reaction mixture, requiring the solvent to be 
evaporated off, leaving behind a crude product that contains a mixture of the desired product, 
and undesired components such as intermediates and unreacted reagents. Later on in the project 
it was discovered that H2O could be added to the DMF reaction mixture to cause the product to 
crystallise out of solution so that it could be recovered by filtration.  
/ƚŝƐŶŽƚŬŶŽǁŶŝĨW ?ƐĂĐĞƚĂůŐƌŽƵƉƐĂƌĞŚǇĚƌŽůǇƐĞĚƵŶĚĞƌƚŚĞĂĐŝĚŝĐĐŽŶĚŝƚŝŽŶƐŽĨƚŚĞƌĞĂĐƚŝŽŶ
mixture initially to form the ketone/aldehyde precursor, methylglyoxal, followed by the addition 
of the two 4-substituted-3-thiosemicarbazides or if the PADA-mono-substituted-3-
thiosemicarbazone is formed, followed by the hydrolysis of the acetal groups to a aldehyde which 
is then able to react with the second 4-substituted-3-thiosemicarbazide. 
There has been a report of W ?ƐĂĐĞƚĂůŐƌŽƵƉƐďĞŝŶŐ used as protecting groups79 in the 
synthesis of dissymmetric ligands, but in protic media the acetal groups where easily hydrolysed 
resulting in a mixture of bis(thiosemicarbazones). This observation, coupled with all the NMR 
spectra of the successfully synthesised ligands shown no trace of the mono-substituted-3-
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thiosemicarbazone of PADA where the protecting groups are intact may indicate that the 
hydrolysis of P ?ƐĂĐĞƚĂůŐƌŽƵƉƐŽĐĐƵƌƐĨŝƌst.  
There are a large number of reports of symmetric ligands with Me/H on the backbone.6, 45, 63, 69, 77, 
82, 106, 123, 145, 146, 164, 202 However, the scope of these reports is aimed towards biological screening 
for the use as imaging agents or other pharmaceutical applications. Due to this characterisation 
data such as NMR, IR or Raman data have not been identified in these articles. However, data 
obtained from ligands with different substituents on the imine backbone and/or terminal amine 
that can be linked to the literature can be used to corroborate peak positions and assignments are 
feasible. For ligands of this class, on comparison to data from related ligands, there is confidence 
in the data obtained and assignments of that data.      
The table (Table 2.3.5.1.) below illustrates all four ligands, what the main impurity is and an 
estimate of the percentage. 
Table 2.3.5.1. Summary of purity for the symmetric ligands with Me/H backbones. 





63, 66, 69, 



































*Estimated by 1H NMR spectra on an average of three integrals where possible. Typically the integrals were 
taken from the peaks due to the N=CH, N=C-CH3 and N-NH environments. 
2.3.6. Dissymmetric ligands with Me/H backbones 
Overview of reaction 
The synthesis of the dissymmetric ligands firstly requires the synthesis of a PADA-mono-
substituted-3-thiosemicarbazone intermediate. This intermediate is synthesised by reacting PADA 
and a 4-substituted-3-thiosemicarbazone in the stoichiometric ratio of 1:1 under acidic 
conditions. Once isolated the intermediate is then reacted with 1 equivalent of a dissimilar 4-
substituted-3-thiosemicarbazone catalysed under slightly acidic conditions to produce the desired 
dissymmetric ligand (Figure 2.3.6.1.). 
1) Conc. HCl
2)
       10% HCl
 
 R1 R2 R3 R4 
PADA-Me-NH2 CH3 H H H 
PADA-Me-(Me)2 CH3 H CH3 CH3 
PADA-Me-Et CH3 H CH2CH3 H 
PADA-Me-Ph CH3 H C6H5 H 
PADA-Et-NH2 CH2CH3 H H H 
PADA-Et-Me CH2CH3 H CH3 H 
PADA-Et-(Me)2 CH2CH3 H CH3 CH3 
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PADA-Et-Ph CH2CH3 H C6H5 H 
PADA-Ph-NH2 C6H5 H H H 
PADA-Ph-Me C6H5 H CH3 H 
PADA-Ph-(Me)2 C6H5 H CH3 CH3 
PADA-Ph-Et C6H5 H CH2CH3 H 
Figure 2.3.6.1. The general reaction for the synthesis of dissymmetric ligands with Me/H backbones. 


















Figure 2.3.6.4. Dissymmetric ligands from PADA-Ph=O. 
2.3.7. Synthesis of the PADA-mono-substituted-3-thiosemicarbazone 
intermediates 
In order to make the twelve dissymmetric ligands, these three intermediates had to be 
successfully synthesised (Figure 2.3.7.1.). 
PADA-Ph=OPADA-Et=OPADA-Me=O
 Figure 2.3.7.1. Structures of the three PADA-mono-substituted-3-thiosemicarbazone intermediates. 
 2.3.8. Methods 
PADA-Me=O 
4-methyl-3-thiosemicarbazide (2.500 g, 0.024 mol) was dissolved in de-ionised water (100 mL, 50 
oC) and HCl (32%, 5 drops) was added. Methylglyoxal-1,1-dimethylacetal (8.70 mL, 0.072 mol, 8.49 
g) was added rapidly and vigorously stirred (50 oC, 5 minutes). The precipitate was recovered via 
filtration, washed with de-ionised water (10 x 50 mL) and dried. A yellow solid (2.473 g) was 
recovered (65% yield).  
PADA-Et=O 
4-ethyl-3-thiosemicarbazide (2.288 g, 0.0192 mol) was dissolved in de-ionised water (200 mL, 
warm), the insoluble particulates was filtered off and then the solution was cooled to room 
temperature. HCl was added (32%, 8 drops) followed by the rapid addition of methylglyoxal-1,1-
dimethylacetal (6.96 mL, 0.058 mol, 6.79 g). The solution was vigorously stirred (50 oC, 1 hour). 
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The precipitate was recovered via filtration, washed with de-ionised water (8 x 50 mL) and dried. 
A pale yellow solid (2.047 g) was recovered (62% yield).  
PADA-Ph=O 
4-phenyl-3-thiosemicarbazide (0.803 g, 0.0048 mol) was dissolved in de-ionised water/ethanol 
solution (50 mL water, 25 mL ethanol, 50 oC). The insoluble particulates were filtered off and HCl 
(32%, 3 drops) was added. Methylglyoxal-1,1-dimethylacetal (1.74 mL, 0.0144 mol, 1.698 g) was 
added rapidly and the solution was vigorously stirred (50 oC, 5 minutes). The precipitate was 
recovered via filtration, washed with de-ionised water (2 x 50 mL) and dried. A yellow solid (0.821 
g) was recovered (77% yield).  
2.3.9. Characterisation data for the PADA-mono-substituted-3-
thiosemicarbazone intermediates 
PADA-Me=O 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 9.32 (s, 1 H, O=CH), 8.98 (m, 1 H, H3C-NH, 
J= 4.4 Hz), 2.98 (d, 3 H, HN-CH3, J= 4.4 Hz), 1.90 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6, 100 
D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O), 179.45 (C=S), 145.94 (C=N), 31.67 (HN-CH3), 9.66 (N=C-CH3). IR (neat): cm-
1= 3350 (m), 3171 (m), 2845 (w), 1692 (m), 1593 (m), 1537 (m), 1504 (s), 1410 (m), 1369 (m), 1200 
(s), 1146 (m), 1113 (m), 1047 (s), 1001 (s), 856 (s), 789 (m), 665 (s), 592 (s), 569 (s), 534 (s). Raman 
(neat): cm-1= 3354 (w), 3179 (w), 2921 (w), 2848 (w), 1696 (m), 1577 (s), 1433 (w), 1278 (w), 1227 
(w), 1192 (w), 1116 (w), 1045 (w), 856 (w), 783 (w), 567 (w), 357 (w), 296 (w), 237 (w). Melting 
point: >156 oC (decomposed). 
PADA-Et=O 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 9.34 (s, 1 H, 0=CH), 9.01 (t, 1 H, H2C-NH, J= 
5.6 Hz), 3.56 (dq, 2 H, H2C-NH, J= 7.2, 5.6 Hz), 1.90 (s, 3 H, N=C-CH3), 1.03 (t, 6 H, H2C-CH3, J= 7.2 
Hz). 13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O), 178.41 (C=S), 146.00 (C=N), 39.19 (N-
CH2), 14.54 (H2C-CH3), 9.68 (N=C-CH3).  IR (neat): cm
-1= 3319 (w), 3142 (m), 2976 (w), 2835 (w), 
1688 (s), 1587 (m), 1541 (s), 1489 (m), 1422 (m), 1368 (m), 1279 (m), 1188 (s), 1126 (s), 1086 (m), 
1059 (m), 1007 (m), 939 (m), 849 (m), 710 (m), 660 (s), 538 (w). Raman (neat): cm-1= 3325 (w), 
3146 (w), 2910 (w), 2835 (w), 1686 (m), 1586 (s), 1437 (w), 1367 (w), 1331 (w), 1272 (w), 1183 
(w), 1145 (w), 1121 (w), 1060 (w), 1008 (w), 938 (w), 811 (w), 776 (w), 668 (w), 626 (w), 578 (w), 
540 (w), 374 (w). Melting point: >132-134oC. 
PADA-Ph=O 
1H NMR (d6-D^K ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.57 (s, 1 H, Ph-NH), 9.45 (s, 1 H, O=CH), 




{1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O), 178.24 (C=S), 146.53 (C=N), 139.48 (C(1) aryl), 
139.11 (C(1) aryl), 128.33 (C(3,5) aryl), 126.40 (C(4) aryl), 126.24 (C(2,6) aryl), 9.88 (N=C-CH3). IR (neat): 
cm-1= 3277 (w), 3150 (m), 2968 (w), 2851 (w), 1697 (m), 1593 (m), 1520 (s), 1495 (s), 1447 (m), 
1425 (m), 1366 (m), 1229 (m), 1167 (s), 1157 (s), 1119 (m), 1016 (m), 935 (m), 831 (m), 748 (m), 
698 (s), 615 (s), 590 (s). Raman (neat): cm-1= 3283 (w), 3068 (w), 2918 (w), 2860 (w), 1695 (s), 
1590 (s), 1518 (m), 1448 (w), 1346 (w), 1292 (m), 1227 (m), 1146 (m), 1117 (m), 1030 (w), 1005 
(s), 933 (w), 834 (w), 770 (w), 752 (m), 680 (w), 617 (m), 607 (m), 448 (w), 411 (w), 269 (w). 
Melting point: >151 oC (decomposed). 
2.3.10. Spectral examples of a PADA-mono-substituted-3-thiosemicarbazone 
intermediate 
Figures 2.3.10.1-4. Spectral examples of the PADA-mono-substituted-3-thiosemicarbazone 
intermediate PADA-Et=O. 
Figure 2.3.10.1. An assigned 
1
H NMR spectrum of PADA-Et=O, synthesised by the exploitation of carbonyl 
reactivity approach by reacting excess methylglyoxal-1,1-dimethylacetal with one equivalent of 4-ethyl-3-
thiosemicarbazide.The purple boxes suggest a small impurity of PADA-Et-Et.   
The purple boxes indicate a small presence of the related symmetric bis(thiosemicarbazone), in 
this example it is PADA-Et-Et. This is commonly seen in the other intermediate forming reactions 
of this class.  
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Figure 2.3.10.2. An assigned 
13
C NMR spectrum of PADA-Et=O. 
 
Figure 2.3.10.3.  A FTIR spectrum of PADA-Et=O. 
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Figure 2.3.10.4. A Raman spectrum of PADA-Et=O. 
2.3.11. Discussion 
All three intermediates were successfully made with a good level of purity. Obtaining the 
intermediates of this class by this method (Figure 2.3.6.1.) is believed to be novel. The only 
reports of methods found in the literature were either using methyl glyoxal as a precursor82 or 
PADA followed by hydrolysis of the protecting acetal groups in a separate reaction by using 
LiBF4.
79-81 For the same reasons for the symmetric ligands of this class, PADA was used because it 
was readily available from investigating the synthesis of dissymmetric ligands via the protection 
approach and also that PADA is cheaper than methyl glyoxal. 
Using the method illustrated in (Figure 2.3.6.1.) it is theoretically possible that the formation of 
the mono-substituted-3-thiosemicarbazone could take two isomeric forms depending on which 
carbonyl group the chosen 4-substitued-3-thiosemicarbazide reacts with. The diagram below 
illustrates these forms (Figure 2.3.11.1.): 
                                 
Isomer 1 Isomer 2
                                                        




By consulting the respective NMR spectra of the successfully synthesised intermediates it is 
possible to conclude that the intermediates are in the form of isomer 1. There are two peaks that 
relate to the environments that allows this to be claimed, the first is the singlets found between 
9.32-9.45 ppm which relates to the O=C-H environments. The second is the singlets found 
between 1.90-1.97 ppm which relates to the N=C-CH3 environments. If the intermediates were 
present in the same arrangement as isomer 2 then  we would observe two different sets of peaks, 
the first owing to the N=C-H environment which would be expected between 7.61-7.84 ppm. The 
second set of peaks due to the O=C-CH3 environment which would be predicted between 2.28-
2.38 ppm.  All of the NMR spectra contain a small presence of these peaks but it is thought that 
these are due to the formation of the related symmetric ligands as there are extra peaks that 
relate just to the symmetric ligands extra environments (Figure 2.3.10.1.). If this was not the case 
then a second peak would be present in the carbon spectra owing to the presence of a second 
carbonyl group, which is absent. Even though it must be highlighted that it is possible that isomer 
2 is present, but in very small proportions that are not detectable in the carbon spectra. If this 
was the situation then it is still reasonable to claim that the vast majority of the intermediate is 
still present in the form of isomer 1.       
The NMR spectra of the respective ligands suggest that the main impurity tends to be the 
symmetric ligand of the respective mono-substituted-3-thiosemicarbazone despite the addition of 
excess PADA (typically 3 equivalents). By comparing the 1H NMR integrals of the intermediate and 
the symmetric by-product it is estimated that the symmetric by-product does not occur in the 
three intermediate samples in quantities larger than 5%. In the case of the synthesis of PADA-
Ph=O there is sign of one or more impurities in low proportions which are absent in the NMR 
spectra of PADA-Me=O and PADA-Et=O. No investigation was taken to identify these other 
impurities, these impurities may be cyclisation products PADA-Ph=O of which similar structures 
have be observed in the literature.57-59, 87, 88, 205    
Attempts were made to synthesise the intermediate PADA-NH2=O by using a similar method to 
the other three, but it was found that the formation of PADA-NH2-NH2 as a by-product is a little 
more  favourable giving rise to an elevated level of contamination of the desirable intermediate 
by the PADA-NH2-NH2 product. When the reaction was run at 50
 oC it was found that PADA-NH2-
NH2 became the major product (circa 90 %) and the desired PADA-NH2=O intermediate only 
present in about 10 % despite the present of the large excess of PADA. The same reaction was run 
at room temperature instead of 50 oC and it was found that the resulting product contained only 
about 13 % of the symmetric by-product and the PADA-NH2=O intermediate became the major 
product at 87 %. One explanation for this is that the evaluated temperature coupled with the 
effects of the NH2 substituent increases the reactivity of the aldehyde group so that it has a 
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similar reactivity to the methyl ketone making the formation of the PADA-NH2-NH2 by product 
more favourable than the formation of the PADA-NH2=O intermediate. This was not seen with the 
other 4-substituted-3-thiosemicarbazides so it is reasonable to suggest that this is due to a 
property unique to thiosemicarbazide. As the brief was to make lipophilic ligands the decision was 
made to not pursue the clean synthesis of the PADA-NH2=O intermediate as the NH2 substituent is 
likely to make the resulting ligand more hydrophilic instead of lipophilic.  It was however, possible 
to make isomers with NH2 substituents from the intermediates already synthesised, without the 
need for the PADA-NH2=O intermediate. For example, PADA-Me-NH2 can be synthesised from the 
intermediate PADA-Me=O which is the isomer of PADA-NH2-Me. If it was found that the presence 
of the NH2 substituent is favourable then the clean synthesis of the PADA-NH2=O intermediate 
can be revisited.   
It was decided not to attempt the synthesis of the intermediate PADA-(Me)2 =O due to the high 
cost of 4,4-dimethyl-3-thiosemicarbazide, coupled with the expected low yields which would give 
un-workable quantities of intermediate. However, if ligands from the PADA-(Me)2=O intermediate 
was desirable then this synthesis can be pursued.     
Despite two of out of the three intermediates being previously reported in the literature79-81 there 
is scarce information in terms of characterisation data for the intermediates as the authors seem 
to only report data for the final ligand/complex. There is a report of NMR (1H + 13C) data for the 
intermediate PADA-Me=O.206 The NMR data reported was all in accord with the data obtained 
except for two proton peak assignments. The literature assignments for the proton environments 
at 11.18 and 9.36 were N-NH and O=CH respectively. This thesis reports the proton environments 
at 11.16 and 9.32 were O=CH and N-NH respectively. HMQC NMR spectrum shows a coupling 
between the O=CH proton at 9.32 ppm and O=CH at 192.10 ppm. Also the HMBC NMR spectrum 
shows that the peak 9.32 has a coupling to the backbone environments C-CH3 and C-CH3 but no 
coupling between these carbon environments and the proton peak at 11.16. This supports the 
assignments for the proton environments at 11.18 and 9.36 being N-NH and O=CH respectively. 
Despite no literature NMR data for the other two intermediates, their proton and carbon peak 
positions show strong similarity for the positions reported for PADA-Me=O, discounting any 
expected shift in the peaks and extra peaks due to varying substituents on the terminal amine. 
There are reports of NMR data for the intermediate BDO-Ph=O57, 83, 190 and BDO-Et=O57 which can 
be used for a partial comparison to the intermediates PADA-Ph=O and PADA-Et=O respectively. 
Excluding the peaks attributing to the structural variations of the two intermediates BDO-Ph=O 
and PADA-Ph=O, the NMR data is in accord to the peak locations and assignments for the novel 
PADA-Ph=O intermediate. This is also the case for BDO-Et=O and PADA-Et=O.  
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J. Holland et al.57 has attempted to assign the carbon environments in the NMR spectra of BDO-
Ph=O of which the meta and ortho assignments agree with the above assignments. However 
there is a discrepancy between the assignments for the peaks at 139.48 and 126.40ppm. J. 
Holland et al.57 assigned the two peaks as C4 aryl and C1 aryl respectively while this thesis assigns 
the peaks at 139.48 and 126.40 ppm as C1 aryl and C4 aryl respectively. The reason the latter 
assignments are believed to be true is that HMQC NMR data on 4-Phenylthiosemicarbazide shows 
couplings to support these assignments.  
 It was not possible to find any reports of IR data for the intermediates of this class, this was even 
the case for the well reported intermediates with Me/Me on the backbone where only NMR data 
or mass spectrometry data is reported. The IR spectra of all three samples show peaks in the 
regions expected for the characteristic functional groups (Table 2.3.11.2.). These assignments 
were made based on reported IR data of bis(thiosemicarbazone) ligands78, 80 and IR spectroscopy 
text books.207, 208  
Intermediate N-H C=O C=N C=S 
PADA-Me=O 3352 1697 1537 831 
PADA-Et=O 3319 1687 1541 848 
PADA-Ph=O 3277 1692 1519 856 
Table 2.3.11.2. Tentative assignment of IR peaks of key functional groups in PADA-mono-substituted-3-
thiosemicarbazone intermediates. 
The table below (Table 2.3.11.3.) illustrates all three intermediates, what the main impurity is and 
an estimate of percentage impurity. 
Table 2.3.11.3. Summary of purity for the PADA-mono-substituted-3-thiosemicarbazone intermediates, 
synthesised by the exploitation of carbonyl reactivity approach.  






















*Estimated by 1H NMR spectra on an average of three integrals where possible. Typically the integrals were 
taken from the peaks due to the N=CH, N=C-CH3 and N-NH environments. 
2.3.12. Dissymmetric ligands from PADA-Me=O 
Methods  
PADA-Me-NH2 
PADA-Me=O (0.510 g, 0.0032 mol) was dissolved in DMF (3 mL) and filtered. Thiosemicarbazide 
(0.292 g, 0.0032 mol) was dissolved in DMF (10 mL), HCl (10%, 2 drops) was added and filtered. 
The two solutions were combined and left to stir (room temperature, 5 hours). De-ionised water 
(26 mL) was added, the precipitate was filtered off and washed with de-ionised water (50 mL, 
room temperature and 50 mL, 80 oC). The crude product was dissolved in DMSO (10 mL) the 
resulting solution was filtered and recrystallised with de-ionised water (20 mL). The precipitate 
was recovered via filtration, washed with de-ionised water (50 mL, room temperature and 50 mL, 
80 oC) and dried. A white solid (0.456 g) was recovered (61% yield).  
PADA-Me-(Me)2 
PADA-Me=O (0.255 g, 0.0016 mol) was dissolved in DMF (1.5 mL) and filtered. 4,4-dimethyl-3-
thiosemicarbazide (0.191 g, 0.0016 mol) was dissolved in DMF (3 mL), HCl (10%, 1 drop) was 
added and filtered. The two solutions were combined and left to stir (room temperature, 5 
hours). De-ionised water (9 mL) was added, the precipitate was filtered off and washed with de-
ionised water (50 mL, room temperature and 50 mL, 80oC). The crude product was dissolved in 
DMSO (9 mL), filtered and recrystallised with de-ionised water (18 mL). The precipitate was 
recovered by filtration, washed with de-ionised water (50 mL) and dried. A yellow solid (0.158 g) 





PADA-Me=O (0.255 g, 0.0016 mol) was dissolved in DMF (1 mL) and filtered. 4-ethyl-3-
thiosemicarbazide (0.191 g, 0.0016 mol) was dissolved in DMF (5 mL), HCl (10%, 1 drop) was 
added and filtered. The two solutions were combined and left to stir (room temperature, 5 
hours). De-ionised water (12 mL) was added, the precipitate was filtered and washed with de-
ionised water (50 mL, room temperature and 50 mL, 80 oC). The crude product was dissolved in 
DMSO (6 mL), filtered and recrystallised with de-ionised water (12 mL). The precipitate was 
recovered by filtration, washed with de-ionised water (50 mL) and dried. A cream solid (0.191 g) 
was recovered (46% yield).  
PADA-Me-Ph 
PADA-Me=O (0.255 g, 0.0016 mol) was dissolved in DMF (2 mL) and filtered. 4-phenyl-3-
thiosemicarbazide (0.268 g, 0.0016 mol) was dissolved in DMF (2.5 mL), HCl (10%, 1 drop) was 
added and filtered. The two solutions were combined and left to stir (room temperature, 5 
hours). De-ionised water (9 mL) was added, the precipitate was filtered and washed with de-
ionised water (50 mL, room temperature and 50 mL, 80 oC). The crude product was dissolved in 
DMSO (12 mL), filtered and recrystallised with de-ionised water (24 mL). The precipitate was 
recovered by filtration, washed with ethanol (2 x 25mL), de-ionised water (50 mL, 80 oC) and 
dried. An off white solid (0.313 g) was recovered (63% yield).  
Characterisation data for dissymmetric ligands from PADA-Me=O 
PADA-Me-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.35 (s, 1 H, N-NH), 8.50 (q, 1 H, H3C-NH, 
J= 4.8 Hz), 8.28 (s, 1 H C-NH), 7.87 (s, 1 H C-NH), 7.61 (s, 1 H, N=CH), 2.94 ( d, 3 H, HN-CH3, J= 4.8 
Hz), 2.09 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 178.59 (C=S), 
147.54 (C=N), 142.95 (C=N), 31.58 (HN-CH3), 11.52 (N=C-CH3). IR (neat): cm
-1= 3414 (w), 3148 (m), 
1988 (w), 1607 (m), 1531 (s), 1497 (s), 1458 (m), 1364 (m), 1335 (m), 1269 (m), 1217 (s), 1155 (m), 
1070 (s), 924 (m), 833 (s), 656 (m), 565 (s). Raman (neat): cm-1= 2915 (w), 1672 (w), 1600 (m), 
1585 (s), 1374 (w), 1336 (w), 1268 (w), 1223 (w), 1126 (w), 1013 (w), 878 (w), 792 (w), 481 (w), 
307 (w), 219 (w).Elemental analysis: Found: C, 31.1; H, 5.1; N, 36.1. Calc. for C6H12N6S2: C, 31.0; H, 
5.1; N, 36.2%. Melting point: >217 oC (decomposed). 
PADA-Me-(Me)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.41 (s, 1 H, N-NH), 8.45 (q, 1 H, H3C-NH, 




13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 178.82 (C=S), 147.56 (C=N), 
143.95 (C=N), 42.96 (N-(CH3)2), 31.56 (HN-CH3), 11.65 (N=C-CH3). IR (neat): cm
-1= 3306 (m), 3200 
(m), 2999 (w), 1589 (w), 1526 (s), 1495 (s), 1406 (m), 1354 (m), 1273 (s), 1225 (s), 1142 (m), 1107 
(s), 1045 (s), 966 (m), 935 (s), 878 (m), 812 (m), 658 (m), 623 (s), 584 (s), 565 (s). Raman (neat): 
cm-1= 1589 (m), 1570 (s), 1417 (m), 1363 (m), 1295 (m), 1275 (m), 1225 (m), 1143 (m), 1064 (m), 
1016 (m), 876 (m), 744 (m), 583 (w), 314 (w), 131 (w). Elemental analysis: Found: C, 37.0; H, 6.2; 
N, 32.2. Calc. for C8H16N6S2: C, 36.9; H, 6.2; N, 32.3%. Melting point: >205 
oC (decomposed). 
PADA-Me-Et 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.33 (s, 1 H, N-NH), 8.50 (q, 1 H, H3C-NH, 
J= 4.4 Hz), 8.42 (t, 1 H H2C-NH, J= 6.0 Hz), 7.62 (s, 1 H, N=CH), 3.52 (dq, 2 H, H2C-NH, J=7.2, 6.0 
Hz),2.94 (d, 3 H, N-CH3, J= 4.4 Hz), 2.13 (s, 3 H, N=C-CH3), 1.08 (t , 3 H, H2C-CH3, J= 7.2 Hz). 
13C {1H} 
NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 177.17 (C=S), 147.64 (C=N), 142.44 (C=N), 38.86 (N-
CH2), 31.58 (N-CH3), 15.01 (H2C-CH3), 11.68 (N=C-CH3). IR (neat): cm
-1= 3374 (w), 3316 (w), 3165 
(w), 2988 (w), 1537 (s), 1497 (s), 1435 (m), 1412 (m), 1327 (m), 1219 (s), 1159 (m), 1084 (s), 1042 
(m), 935 (m), 814 (m), 664 (m), 619 (m), 546 (s). Raman (neat): cm-1= 2902 (w), 1580 (s), 1518 (w), 
1364 (w), 1284 (w), 1220 (w), 1130 (w), 1016 (w), 879 (w), 773 (w), 572 (w), 461 (w), 307 (w), 236 
(w), 180 (w). Elemental analysis: Found: C, 37.0; H, 6.25; N, 32.2. Calc. for C8H16N6S2: C, 36.9; H, 
6.2; N, 32.3%. Melting point: >220 oC (decomposed). 
PADA-Me-Ph  
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.40 (s, 1 H, N-NH), 9.97 (s, 1 H, Ph-NH), 
8.55 (q, 1 H, CH3-NH, J=4.4 Hz), 7.73 (s, 1 H, N=CH), 7.48 (d, 2 H, H(2,6) aryl, J=8.0 Hz), 7.33 (dd, 2 H,  
H(3,5)  aryl, J=8.0 Hz), 7.17 (dd, 1 H, H(4) aryl, J=8.0 Hz ),2.96 (d, 3 H, N-CH3, J= 4.4 Hz), 2.18 (s, 3 H, 
N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 176.68 (C=S), 147.50 (C=N), 143.50 
(C=N), 139.44 (C(1) aryl), 128.63 (C(3,5) aryl), 126.53 (C(4) aryl), 126.06 (C(2,6) aryl), 31.61 (N-CH3), 11.71 
(N=C-CH3). IR (neat): cm
-1= 3331 (w) cm-1, 3285 (w) cm-1, 3136 (w) cm-1, 2988 (w) cm-1, 1589 (w) 
cm-1, 1541 (s) cm-1, 1499 (s) cm-1, 1449 (m) cm-1, 1400 (m) cm-1, 1356 (m) cm-1, 1315 (m) cm-1, 
1263 (m) cm-1, 1200 (s) cm-1, 1072 (s) cm-1, 934 (m) cm-1, 745 (m) cm-1, 691 (m) cm-1, 665 (m) cm-1, 
635 (m) cm-1, 569 (s) cm-1. Raman (neat): cm-1=  3044 (w) cm-1, 1585 (s) cm-1, 1513 (w) cm-1, 1367 
(w) cm-1, 1278 (w) cm-1, 1236 (w) cm-1, 1118 (w) cm-1, 1016 (w) cm-1, 934 (w) cm-1, 873 (w) cm-1, 
745 (w) cm-1, 638 (w) cm-1, 410 (w) cm-1, 290 (w) cm-1, 224 (w) cm-1. Elemental analysis: Found: C, 






2.3.13. Dissymmetric ligands from PADA-Et=O 
Methods  
PADA-Et-NH2 
PADA-Et=O (0.554 g, 0.0032 mol) was dissolved in DMF (2 mL) and filtered. Thiosemicarbazide 
(0.292 g, 0.0032 mol) was dissolved in DMF (10 mL), HCl (10%, 2 drops) was added and filtered. 
The two solutions were combined and left to stir (room temperature, 5 hours). De-ionised water 
(24 mL) was added, the precipitate was filtered off and washed with de-ionised water (50 mL, 
room temperature and 50 mL, 80 oC). The crude product was dissolved in DMSO (25 mL), filtered 
and recrystallised with de-ionised water (50 mL). The precipitate was recovered by filtration, 
washed with de-ionised water (50 mL, room temperature and 50 mL, 80 oC), and dried. An off 
white solid (0.386 g) was recovered (49% yield).  
PADA-Et-Me 
PADA-Et=O (0.554 g, 0.0032 mol) was dissolved in DMF (2 mL) and filtered. 4-methyl-3-
thiosemicarbazide (0.337 g, 0.0032 mol) was dissolved in DMF (6 mL), HCl (10%, 2 drops) was 
added and filtered. The two solutions were combined and left to stir (room temperature, 5 
hours). De-ionised water (50 mL) was added, a gelatinous precipitate was recovered by filtration 
and washed with de-ionised water (50 mL, room temperature and 50 mL, 80oC). The crude 
product was left on the water pump until its volume decreased then dissolved in DMSO (6 mL), 
filtered and recrystallised with de-ionised water (60 mL). The waxy gelatinous precipitate was 
recovered by filtration, washed with de-ionised water (50 mL, room temperature and 50 mL, 80 
oC), and dried. The product was further washed with de-ionised water (50 mL, room temperature 
and 50 mL, 80 oC), and dried.  A yellowish white solid (0.118 g) was recovered (14% yield).  
PADA-Et-(Me)2 
PADA-Et=O (0.277 g, 0.0016 mol) was dissolved in DMF (1.5 mL) and filtered. 4,4-dimethyl-3-
thiosemicarbazide (0.191 g, 0.0016 mol) was dissolved in DMF (3 mL), HCl (10%, 1 drop) was 
added and filtered. The two solutions were combined and left to stir (room temperature, 5 
hours). De-ionised water (24 mL) was added, the precipitate was filtered and washed with de-
ionised water (2 x 50 mL). The crude product was dissolved in DMSO (7 mL), filtered and 
recrystallised with de-ionised water (14 mL). The precipitate was recovered by filtration, washed 





Characterisation data for dissymmetric ligands from PADA-Et=O 
PADA-Et-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.26 (s, 1 H, N-NH), 8.53 (t, 1 H H2C-NH, J= 
6.0 Hz), 8.28 (s, 1 H, C-NH), 7.88 (s, 1 H, C-NH), 7.62 (s, 1 H, N=CH), 3.52 (dq, 2 H, H2C-NH, J=7.2, 
6.0 Hz), 2.09 (s, 3 H, N=C-CH3), 1.07 (t , 3 H, H2C-CH3, J= 7.2 Hz). 
13C {1H} NMR (DMSO-d6, 100 
D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 177.67 (C=S), 147.62 (C=N), 142.93 (C=N), 38.99 (N-CH2), 14.87 (H2C-CH3), 
11.53 (N=C-CH3). IR (neat): cm
-1= 3292 (w), 3148 (m), 2982 (m), 1593 (m), 1530 (s), 1493 (s), 1456 
(m), 1352 (m), 1310 (m), 1269 (m), 1202 (s), 1090 (s), 926 (m), 829 (s), 662 (m), 548 (s). Raman 
(neat): cm-1= 2978 (w), 2908 (w), 1583 (s), 1425 (w), 1350 (w), 1270 (w), 1209 (w), 1128 (w), 1014 
(w), 936 (w), 874 (w), 800 (w), 483 (w), 307 (w), 209 (w). Elemental analysis: Found: C, 34.0; H, 
5.8; N, 34.0. Calc. for C7H14N6S2: C, 34.1; H, 5.7; N, 34.1%. Melting point: >207 
oC (decomposed). 
PADA-Et-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.24 (s, 1 H, N-NH), 8.53 (t, 1 H H2C-NH, J= 
6.0 Hz), 8.39 (q, 1 H, H3C-NH, J= 4.4 Hz), 7.62 (s, 1 H, N=CH), 3.52 (dq, 2 H, H2C-NH, J=7.2, 6.0 Hz), 
2.95 (d, 3 H, N-CH3, J= 4.4 Hz), 2.12 (s, 3 H, N=C-CH3), 1.07 (t , 3 H, H2C-CH3, J= 7.2 Hz). 
13C {1H} 
NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 177.69 (C=S), 147.70 (C=N), 142.37 (C=N), 39.00 (N-
CH2), 31.47 (N-CH3), 14.87 (H2C-CH3), 11.62 (N=C-CH3). IR (neat): cm
-1= 3366 (w), 3129 (w), 2982 
(w), 1518 (s), 1491 (s), 1425 (m), 1364 (m), 1242 (m), 1204 (s), 1076 (s), 1040 (m), 914 (m), 812 
(m), 631 (m), 600 (m), 540 (s), Raman (neat): cm-1= 1581 (s), 1434 (w), 1362 (w), 1328 (w), 1275 
(w), 1204 (w), 1125 (w), 1023 (w), 917 (w), 873 (w), 774 (w), 598 (w), 420 (w), 298 (w), 211 (w). 
Elemental analysis: Found: C, 37.0; H, 6.3; N, 32.2. Calc. for C8H16N6S2: C, 36.9; H, 6.2; N, 32.3%. 
Melting point: >220 oC (decomposed). 
PADA-Et-(Me)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.36 (s, 1 H, N-NH), 8.46 (t, 1 H H2C-NH, J= 
6.0 Hz), 7.75 (s, 1 H, N=CH), 3.52 (dq, 2 H, H2C-NH, J=7.2, 6.0 Hz), 3.21 ( s, 6 H, HN-(CH3)2), 2.05 (s, 
3 H, N=C-CH3), 1.08 (t , 3 H, H2C-CH3, J= 7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?
(C=S), 177.76 (C=S), 147.57 (C=N), 144.09 (C=N), 42.90 (HN-(CH3)2), 39.00 (N-CH2), 14.87 (H2C-CH3), 
11.67 (N=C-CH3). IR (neat): cm
-1= 3341 (w), 3134 (m), 2988 (m), 1589 (w), 1526 (s), 1489 (s), 1410 
(m), 1348 (m), 1269 (s), 1206 (s), 1140 (m), 1049 (s), 920 (s), 868 (m), 806 (m), 783 (m), 660 (m), 
625 (m), 581 (m) cm-1. Raman (neat): cm-1= 2936 (w), 1575 (s), 1361 (w), 1284 (w), 1274 (w), 1206 
(w), 1143 (w), 1102 (w), 1016 (w), 964 (w), 934 (w), 870 (w), 742 (w), 626 (w), 308 (w). Elemental 
analysis: Found: C, 39.4; H, 6.7; N, 30.6. Calc. for C9H18N6S2: C, 39.4; H, 6.6; N, 30.6%. Melting 
point: >180 oC (decomposed). 
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2.3.14. Dissymmetric ligands from PADA-Ph=O 
Methods  
PADA-Ph-NH2 
PADA-Ph=O (0.354 g, 0.0016 mol) was dissolved in DMF (2.5 mL) and filtered. Thiosemicarbazide 
(0.146 g, 0.0016 mol) was dissolved in DMF (5 mL), HCl (10%, 1 drop) was added and filtered. The 
two solutions were combined and left to stir (room temperature, 5 hours). De-ionised water (15 
mL) was added, the precipitate was filtered and washed with de-ionised water (50 mL, room 
temperature and 50 mL, 80 oC). The crude product was dissolved in DMSO (7 mL), filtered and 
recrystallised with de-ionised water (14 mL). The precipitate was recovered by filtration, washed 
with de-ionised water (50 mL, room temperature and 50 mL, 80 oC), and dried. An off yellowish 
white solid (0.273 g) was recovered (58% yield).  
PADA-Ph-Me 
PADA-Ph=O (0.354 g, 0.0016 mol) was dissolved in DMF (2.5 mL) and filtered. 4-methyl-3-
thiosemicarbazide (0.168 g, 0.0016 mol) was dissolved in DMF (4 mL), HCl (10%, 1 drop) was 
added and filtered. The two solutions were combined and left to stir (room temperature, 5 
hours). De-ionised water (13 mL) was added, the precipitate was filtered and washed with de-
ionised water (50 mL, room temperature and 50 mL, 80 oC). The crude product was dissolved in 
DMSO (10 mL), filtered and recrystallised with de-ionised water (20 mL). The precipitate was 
recovered by filtration, washed with de-ionised water (50 mL, room temperature and 50 mL, 80 
oC), and dried. An off cream solid (0.319 g) was recovered (65% yield).  
PADA-Ph-Et 
PADA-Ph=O (0.354 g, 0.0016 mol) was dissolved in DMF (2.5 mL) and filtered. 4-ethyl-3-
thiosemicarbazide (0.191 g, 0.0016 mol) was dissolved in DMF (5 mL), HCl (10%, 1 drop) was 
added and filtered. The two solutions were combined and left to stir (room temperature, 5 
hours). De-ionised water (15 mL) was added, the precipitate was filtered and washed with de-
ionised water (50 mL, room temperature and 50 mL, 80 oC). The crude product was dissolved in 
DMSO (11 mL), filtered and recrystallised with de-ionised water (22 mL). The precipitate was 
recovered by filtration, washed with de-ionised water (50 mL, room temperature and 50 mL, 80 






Characterisation data for dissymmetric ligands from PADA-Ph=O 
PADA-Ph-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.71 (s, 1 H, N-NH), 10.15 (s, 1 H, Ph-NH), 
8.32 (s, 1 H, C-NH), 7.92 (s, 1 H, C-NH), 7.71 (s, 1 H, N=CH), 7.50 (d, 2 H, H(2,6) aryl, J=8.0 Hz), 7.31 
(dd, 2 H,  H(3,5)  aryl, J=8.0 Hz), 7.15 (dd, 1 H, H(4) aryl, J=8.0 Hz ), 2.16 (s, 3 H, N=C-CH3). 
13C {1H} 
NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 177.27 (C=S), 148.54 (C=N), 142.93 (C=N), 139.48 (C(1) 
aryl), 128.64 (C(3,5) aryl), 126.09 (C(4) aryl), 125.91 (C(2,6) aryl), 11.77 (N=C-CH3). IR (neat): cm
-1= 3449 
(w), 3296 (w), 3157 (m), 2974 (w), 1595 (m), 1516 (s), 1493 (s), 1447 (m), 1366 (m), 1335 (m), 
1267 (m), 1250 (m), 1179 (s), 1090 (s), 1069 (m), 1024 (m), 935 (m), 824 (m), 756 (m), 694 (s), 588 
(s). Raman (neat): cm-1= 3054 (w), 1580 (w), 1373 (w), 1277 (w), 1253 (w), 1172 (w), 1124 (w), 
1017 (w), 937 (w), 870 (w), 781 (w), 758 (w), 608 (w), 423 (w), 259 (w), 206 (w). Elemental 
analysis: Found: C, 44.7; H, 4.8; N, 28.5. Calc. for C11H14N6S2: C, 44.9; H, 4.8; N, 28.55%. Melting 
point: >215 oC (decomposed). 
PADA-Ph-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.70 (s, 1 H, N-NH), 10.14 (s, 1 H, Ph-NH), 
8.43 (q, 1 H, H3C-NH, J= 4.4 Hz), 7.71 (s, 1 H, N=CH), 7.50 (d, 2 H, H(2,6) aryl, J=8.0 Hz), 7.31 (dd, 2 H,  
H(3,5)  aryl, J=8.0 Hz), 7.15 (dd, 1 H, H(4) aryl, J=8.0 Hz ), 2.96 (d, 3 H, N-CH3, J= 4.4 Hz),  2.20 (s, 3 H, 
N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) Pɷ= 178.29 (C=S), 177.23 (C=S), 148.63 (C=N), 142.39 
(C=N), 139.48 (C(1) aryl), 128.64 (C(3,5) aryl), 126.06 (C(4) aryl), 125.89 (C(2,6) aryl), 31.49 (N-CH3), 11.87 
(N=C-CH3). IR (neat): cm
-1= 3291 (w), 3157 (w), 2999 (w), 1595 (w), 1518 (s), 1495 (s), 1477 (s), 
1447 (m), 1352 (m), 1250 (m), 1173 (s), 1090 (m), 1038 (m), 932 (m), 797 (m), 748 (m), 687 (m), 
559 (s). Raman (neat): cm-1= 1577 (s), 1514 (w), 1367 (w), 1286 (w), 1247 (w), 1174 (w), 1128 (w), 
1020 (w), 934 (w), 874 (w), 773 (w), 602 (w), 541 (w), 435 (w), 194 (w).  Elemental analysis: 
Found: C, 46.6; H, 5.2; N, 27.6. Calc. for C12H16N6S2: C, 46.7; H, 5.2; N, 27.25%. Melting point: >210 
oC (decomposed). 
PADA-Ph-Et 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.69 (s, 1 H, N-NH), 10.15 (s, 1 H, Ph-NH), 
8.47 (t, 1 H H2C-NH, J= 6.0 Hz), 7.71 (s, 1 H, N=CH), 7.50 (d, 2 H, H(2,6) aryl, J=8.0 Hz), 7.32 (dd, 2 H,  
H(3,5)  aryl, J=8.0 Hz), 7.15 (dd, 1 H, H(4) aryl, J=8.0 Hz ), 3.54 (dq, 2 H, H2C-NH, J=7.2, 6.0 Hz), 2.21 (s, 
3 H, N=C-CH3), 1.09 (t , 3 H, H2C-CH3, J= 7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?
(C=S), 148.63 (C=N), 142.42 (C=N), 139.48 (C(1) aryl), 128.64 (C(3,5) aryl), 126.06 (C(4) aryl), 125.90 
(C(2,6) aryl), 38.90 (N-CH2), 15.00 (H2C-CH3), 11.93 (N=C-CH3). IR (neat): cm
-1= 3294 (w), 3132 (m), 
2970 (w), 1591 (w), 1518 (s), 1491 (s), 1447 (m), 1335 (m), 1277 (m), 1227 (s), 1182 (s), 1123 (m), 
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1072 (m), 937 (m), 787 (m), 748 (m), 696 (s), 635 (m), 577 (s). Raman (neat): cm-1= 2966 (w), 1582 
(s), 1445 (w), 1372 (w), 1253 (w), 1177 (m), 1125 (w), 1019 (w), 924 (w), 865 (w), 751 (w), 527 (w), 
419 (w), 293 (w), 206 (w). Elemental analysis: Found: C, 48.3; H, 5.6; N, 26.0. Calc. for C13H18N6S2: 
C, 48.4; H, 5.6; N, 26.0%. Melting point: >207 oC (decomposed). 
2.3.15 Spectral examples of a dissymmetric ligand with a Me/H backbone 
Figures 2.3.15.1-4. Spectral examples of the dissymmetric ligand PADA-Me-Ph.  
Figure 2.3.15.1. An assigned 
1
H NMR spectrum of PADA-Me-Ph, successfully synthesised by reacting PADA-
Me=O with 4-phenyl-3-thiosemicarabzide. The spectrum suggests a small presence of PADA-Ph-Ph (purple 
box) and PADA-Me-Me (Blue box). This is commonly seen in other dissymmetric ligand reactions of this class. 
Figure 2.3.15.2. An assigned 
13
C NMR spectrum of PADA-Me-Ph.  
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Figure 2.3.15.3. A FTIR spectrum of PADA-Me-Ph. 





All ten ligands were synthesised with varying levels of purity by following a slightly altered version 
of a previously reported method.82 Most of the ligands are expected to present in purity of in an 
excess of 90% except for the ligands synthesised from PADA-Ph=O where the purity percentage 
falls mostly to the high 80% mark. Despite almost identical reaction conditions attempts to 
synthesise ligands PADA-Ph-(Me)2 and PADA-Et-Ph resulted in large impurity (10-25%) of the 
symmetric ligand PADA-Ph-Ph.  One explanation for this is could be that 4-phenyl-3-
thiosemicarbazide has the ability to displace the thiosemicarbazone from the intermediate hence 
ƉƌŽŵŽƚŝŶŐƚŚĞ ‘ƐĐƌĂŵďůŝŶŐ ?ŽĨƚŚĞĚŝƐƐŝŵŝůĂƌĂƌŵƐ ? It was decided to not pursue the synthesis of 
the PADA-Ph-(Me)2 and PADA-Et-Ph ligands. The table below (Table 2.3.16.1.) illustrates all twelve 
dissymmetric ligands, what the main impurity is and an estimate of percentage impurity. 
There is a little more published characterisation data for the dissymmetric ligands of this class. 
The proton and carbon NMR data of PADA-Me-(Me)2 has been reported before.
206 The data that 
was collected in this project closely agrees with the reported literature. This was also the case for 
PADA-Et-Me which also matched the reported literature81 in terms of peak positions. One 
discrepancy was the assignment of the peaks at 8.53 ppm and 8.39 ppm. The literature reported 
the 8.53 ppm peak as a doublet and the 8.39 ppm position as a triplet and assigning them as the 
NHCH3 and NHC2H5 environments respectively. In this project the 8.53 ppm peak resembled a 
triplet and the one at 8.39 ppm as a quartet. Based on these splitting patterns the 8.53 peak was 
assigned as the NHC2H5 proton and the peak at 8.39 as the NHCH3 environment. These 
assignments are backed up in other ligands synthesised with methyl and/or ethyl groups on the 
terminal amine. In the same article81 a melting point for PADA-Et-Me was given as 228-230oC 
which is similar to the melting point of 220oC observed however it was suspected that instead of 
melting the ligand decomposed as the sample started to turn brown. Infrared data was reported 
by L. Ackerman et al.80 for ligands PADA-Me-Et and PADA-Et-Me. The recorded IR positions show 
close agreement the C=S bond however there was discrepancies of a few tens of wavenumbers 
for the C=N, R-N-H and N-N-H bonds. 
Table 2.3.16.1. Summary of purity for the dissymmetric Ligands with CH3/H backbones, synthesised by the 









































































































*Estimated by 1H NMR spectra on an average of three integrals where possible. Typically the integrals were 
taken from the peaks due to the N=CH, N=C-CH3 and N-NH environments. 
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2.4. Ligands with Me/Me backbones 
Application 
This class of ligands along with ligands with Me/Me backbones are of interest for the imaging of 
hypoxia tissues which can be pathologies in a range of diseases including heart disease and 
cancer.105, 109, 111 In order to do this, the complex must be able to migrate to the tissue and be 
reduced in hypoxic conditions, but not in normoxic conditions. The reduction of the ligand will 
allow the release and trapping of the copper radioisotope which can then be detected via PET.  
It has been found that ligands made from di-ketones with Me/Me or Me/Et on the backbone have 
redox potential in the appropriate range. The more lipophilic the substituents on the 4-sustituted-
3-thiosemicarbazide arm; the slower the clearance from normoxic cells and thus the longer it 
takes to achieve a suitable hypoxic: normoxic ratio in order to give informative images.      
The aim was to synthesise a range of ligands with Me/Me or Me/Et on the backbone and with 4-
sustituted-3-thiosemicarbazide arms with a restricted number of methyl/ethyl substituents in 
order to control lipophilicity. 
2.4.1. Symmetric ligands with Me/Me backbones 
Overview of reaction 
The synthesis of this subgroup of ligands requires one equivalent of 2,3-butanedione (BDO) to be 
reacted with two equivalent of a chosen 4-substituted-3-thiosemicarbazide under acidic 
conditions in water, at circa 60oC, to give the desired symmetric ligand (Figure 2.4.1.1.). A total of 
four ligands where synthesised (Figure 2.4.1.2.). 
Conc. HCl
 
 R1 R2 
BDO-NH2-NH2 H H 
BDO-Me-Me CH3 H 
BDO-(Me)2-(Me)2 CH3 CH3 
BDO-Et-Et CH2CH3 H 







 Figure 2.4.1.2. Structures of the symmetric ligands with Me/Me backbones that were synthesised. 
2.4.2. Methods  
BDO-NH2-NH2 
Thiosemicarbazide (0.388 g, 0.004 mol) was dissolved in de-ionised water (10 mL, 60 oC). HCl 
(32%, 1 drop) was added, followed by the rapid addition of 2,3-butanedione (0.17 mL, 0.002 mol, 
0.17 g) and the solution was left to stir (60 oC, 1 hour). The precipitate was recovered by filtration 
and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 oC). The solid was 
dried. An off white solid (0.448 g) was recovered (96% yield).  
BDO-Me-Me 
4-methyl-3-thiosemicarbazide (1.789 g, 0.017 mol) was dissolved in ethanol (50 mL, 72 oC).  HCl 
(32%, 5 drops) was added followed by the rapid addition of 2,3-butanedione (0.7 mL, 0.0080 mol, 
0.687 g).  The solution was left to stir (72 oC, 1 hour). The precipitate was filtered off and washed 
with ethanol (3 x 30 mL) and diethyl ether (3 x 30 mL). The solid was dried. The crude product was 
dissolved in DMSO (55 mL), filtered and recrystallised with de-ionised water (30 mL). The 
precipitated was recovered by filtration, washed with acetone (25 mL), and dried.  An off white 
solid (1.618 g) was recovered (78% yield).  
BDO-(Me)2-(Me)2 
4,4-dimethyl-3-thiosemicarbazide (0.262 g, 0.0022 mol) was dissolved in de-ionised water (15 mL, 
60 oC). HCl (32%, 1 drop) was added followed by the rapid addition of 2,3-butanedione (0.09 mL, 
0.0010 mol, 0.088 g). The solution was left to stir (60 oC, 5 minutes). The precipitate was filtered 
off and washed with de-ionised water (50 mL, room temperature and 50 mL, 80 oC). The solid was 




4-ethyl-3-thiosemicarbazide (0.316 g, 0.0027 mol) was dissolved in de-ionised water (13 mL, 60 
oC) and filtered off the insoluble particulates. HCl (32%, 1 drop) was added followed by the rapid 
addition of 2,3-butanedione (0.10 mL, 0.0011 mol, 0.098 g). The solution was left to stir (60 oC, 1 
hour). The precipitate was filtered off and washed with de-ionised water (50 mL, room 
temperature and 50 mL, 80 oC). The solid was dried. An off white solid (0.189 g) was recovered 
(60% yield).  
2.4.3. Characterisation data for symmetric ligands with Me/Me backbones 
BDO-NH2-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.35 (s, 1 H, C-NH), 8.37 (s, 2 H, C-NH), 7.81 
(s, 2 H, C-NH), 2.04 (s, 6 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 148.84 
(C=N), 12.12 (N=C-CH3). IR (neat): cm
-1= 3404 (s), 3246 (m), 3184 (s), 3146 (s), 1587 (s), 1489 (s), 
1454 (s), 1369 (s), 1290 (s), 1248 (m), 1153 (m), 1082 (m), 1013 (s), 947 (m), 831 (s), 716 (m), 650 
(m), 598 (s). Raman (neat): cm-1= 2916 (w), 1608 (s), 1590 (m), 1377 (w), 1335 (m), 1126 (m), 
1004 (w), 856 (w), 758 (w), 467 (w), (Fluorescence present). Melting point: >215 oC 
(decomposed). 
BDO-Me-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.34 (m, 2 H, H3C-NH, J= 4.4 Hz), 2.97 (d, 6 
H, HN-CH3, J= 4.4 Hz), 2.16 (s, 6 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 
148.51 (C=N), 31.74 (HN-CH3), 12.21 (N=C-CH3). IR (neat): cm
-1= 3356 (m), 3233 (m), 2936 (w), 
1688 (w), 1612 (w), 1543 (s), 1485 (s), 1350 (m), 1215 (m), 1169 (m), 1128 (m), 1070 (m), 955 (m), 
816 (s), 640 (m), 540 (s). Raman (neat): cm-1= 1605 (s), 1548 (w), 1383 (w), 1325 (w), 1239 (w), 
1130 (w), 1003 (w), 846 (w), 736 (w), 583 (w), 458 (w), 398 (w), 320 (w), 271 (w), 209 (w). Melting 
point: >219 oC (decomposed). 
BDO-(Me)2 -(Me)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ?Ɛ ? ?, ?E-NH), 3.23 (s, 12 H, N-(CH3)2), 2.09 (s, 6 H, N=C-
CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 150.29 (C=N), 42.75 (N-(CH3)2), 11.60 
(N=C-CH3). IR (neat): cm
-1= 3323 (w), 2926 (w), 1526 (s), 1452 (m), 1423 (m), 1366 (m), 1312 (s), 
1200 (s), 1161 (s), 1125 (s), 1099 (s), 1055 (m), 893 (m), 773 (s), 633 (m), 509 (m). Raman (neat): 
cm-1= 3327 (w), 2927 (w), 1578 (s), 1545 (w), 1378 (w), 1364 (w), 1295 (w), 1206 (w), 1133 (w), 






1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.39 (t, 2 H, H2C-NH, J= 6.0 Hz), 3.55 (dq, 4 
H, H2C-NH, J=7.2, 6.0 Hz), 2.16 (s, 6 H, N=C-CH3), 1.07 (t, 6 H, H2C-CH3, J= 7.2 Hz). 
13C {1H} NMR 
(DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 148.48 (C=N), 39.08 (N-CH2), 14.91 (H2C-CH3), 12.22 (N=C-
CH3). IR (neat): cm
-1= 3347 (m), 3211 (w), 2967 (w), 2884 (w), 1686 (w), 1614 (w), 1522 (s), 1485 
(s), 1385 (m), 1362 (m), 1308 (m), 1258 (m), 1213 (m), 1167 (m), 1130 (s), 1065 (m), 970 (m), 943 
(m), 812 (m), 665 (m), 544 (s). Raman (neat): cm-1= 3214 (w), 2984 (w), 1606 (s), 1533 (w), 1395 
(w), 1342 (w), 1256 (w), 1208 (w), 1127 (w), 1005 (w), 840 (w), 746 (w), 462 (w), 398 (w), 299 (w), 
198 (w). Melting point: >223 oC (decomposed). 
2.4.4. Spectral examples of a symmetric ligand with a Me/Me backbone 
Figures 2.4.4.1-4 Spectral examples of ligands BDO-Me-Me. 
Figure 2.4.4.1. An assigned 
1
H NMR spectrum of BDO-Me-Me. BDO-Me-Me was synthesised by reacting 2,3-
butanedione with 4-methyl-3-thiosemicarbazide. The red boxes highlight a small presence of BDO-Me=O. 
The presence of the corresponding mono-substituted-3-thiosemicarbazone is very typical in the synthesis of 
this class of ligand.  
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Figure 2.4.4.2. An assigned 
13
C NMR spectrum of BDO-Me-Me. The red boxes highlight a small presence of 
BDO-Me=O.  
Figure 2.4.4.3. A FTIR spectrum of BDO-Me-Me. 
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Figure 2.4.4.4. A Raman spectrum of BDO-Me-Me. 
2.4.5. Discussion  
The target ligands have been made with a respectable yield by following the well reported 
methods in the literature.6, 57, 75, 77, 96 The synthesis of this class of ligand was the first to be 
attempted as symmetric ligands with Me/Me on the backbone are one of the most reported 
bis(thiosemicarbazones) ligands in the literature. This gave a convenient starting point for the 
synthesis of dissymmetric ligands with a variety of backbone substituents.   
The synthesis of this type of class of ligands seems to be particularly plagued with the presence of 
the mono-substituted-3-thiosemicarbazone as an impurity in far higher proportions that has been 
observed with either the corresponding symmetric ligands with Me/H or Me/Et groups on the 
backbone.  This is particularly observed in the synthesis of BDO-Et-Et where the impurity content 
was a disappointing 33% (Figure 2.4.5.1.); even when a 20% excess of 4-ethyl-3-thiosemicarbazide 
was used coupled with a reaction run time of one hour.  It should be noted that the DMSO/H2O 
recrystallisation step was removed for this synthesis because the re-crystallised product produced 
very small particulates which the majority of the sample was unable to be isolated through 
filtration.  The DMSO/H2O recrystallisation step was also removed from the synthesis method for 




Figure 2.4.5.1. A section of a 
1
H NMR of BDO-Et-Et showing the significant impurity content of BDO-Et=O.   
The addition of an excess of 4-substituted-3-thiosemicarbazide seems to be of limited use when 
attempting to reduce the mono-substituted-3-thiosemicarbazone impurity. A reaction was run in 
order to synthesize BDO-Me-Me in the presence of a 50% excess of 4-methyl-3-thiosemicarbazide 
with a reaction time of five hours.  The resulting product still had roughly a 14% impurity of BDO-
Me=O. Various solvents have been used in washing steps ranging from water, ethanol, water and 
hot water, none of which resulting in the complete removal of the impurity. A DMSO/H2O 
recrystallisation step is thought to improve the purity, but a toll is paid in regards to yield, the 
magnitude of the toll is dependent on the ligand ?s structure. It has been observed that ligands 
containing 4,4-dimethyl-3-thiosemicarbazide seem to be partially prone to significant loss with 
the DMSO/H2O recrystallisation step. No meaningful relationship has been detected between 
reactions conditions (excess of arm, run time, temperature) and impurity content of product. It 
may be possible to use preparatory HPLC in order to further purify the ligands, but due to 
restraints on equipment this avenue was not explored.   
Despite the numerous reports of the symmetric ligands of this class in the literature (Table 
2.4.5.2.) there seems to be only a small amount of characterisation data for just the ligand instead 
of the resulting copper complex. The Infra-red data reported for BDO-NH2-NH2
96, BDO-Me-Me75, 
78, 146 and BDO-(Me)2-(Me)2
78 all agree with the data obtained from the synthesised ligands in this 
project. Proton NMR data for BDO-Me-Me published by S. Kadowaki et al.75 shows very strong 
agreement to NMR data reported above.  Unfortunately, no characterisation data was identified 
from the literature in regards to BDO-Et-Et.  
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As the symmetric ligands have been reported in a number of publications (Table 2.4.5.2.) and as 
the dissymmetric ligands are the main focus in respect of the proposed application/screening it 
was decided to avoid spending long periods of time improving the yield and purity of the 
synthesis and concentrate on the clean synthesis of the dissymmetric ligands. Also, it is expected 
that if it is not possible to completely remove the mono-substituted-3-thiosemicarbazone 
impurities, the complex formation step should remove the impurity. This is expected because 
when sample is mixed with the chosen copper salt then symmetric/dissymmetric ligand will form 
a complex with the copper and will precipitate out of solution, leaving the un-complexed mono-
substituted-3-thiosemicarbazone impurity in solution. It is worth noting that there are reports in 
the literature209 of some mono-substituted-3-thiosemicarbazones forming complexes, which also 
have some biological activity. The table below (Table 2.4.5.2.) illustrates all four ligands, what the 
main impurities are and an estimate of the percentage. 












No6, 57, 69, 
70, 75-78, 123, 
145, 146, 164, 























*Estimated by 1H NMR spectra on an average of three integrals where possible. Typically this was to include 
the integrals from the peaks due to the N=C-CH3 and N-NH environments. 
Table 2.4.5.2. Summary of purity for the symmetric Ligands with Me/Me backbones. 
2.4.6. Dissymmetric ligands with Me/Me backbones 
Overview of reaction 
The synthesis of the dissymmetric ligands requires the synthesis of three mono-substituted-3-
thiosemicarbazone intermediates. These intermediates are synthesised by reacting BDO and a 4-
substituted-3-thiosemicarbazone in the stoichiometric ratio of 1:1 at reduced temperatures and 
under acidic conditions. Once isolated the intermediate is then reacted with 1 equivalent of a 
dissimilar 4-substituted-3-thiosemicarbazone catalysed under slightly acidic conditions to produce 
the desired dissymmetric ligand (Figure 2.4.6.1.). The two ligands that where synthesised are 
shown in the figure below (Figure 2.4.6.2.). 
2)
1) Conc. HCl, 0-5 oC
       10% HCl
 
 R1 R2 R3 R4 
BDO-Me-NH2 CH3 H H H 
BDO-NH2-(Me)2 H H CH3 CH3 




 Figure 2.4.6.2. Structures of the two dissymmetric ligands with Me/Me backbones that were synthesised.   
2.4.7. Synthesis of the BDO-mono-substituted-3-thiosemicarbazone 
intermediates 
In order to make the two dissymmetric ligands, three intermediates were synthesised (Figure 
2.4.7.1.). 
BDO-(Me)2=OBDO-Me=OBDO-NH2=O
Figure 2.4.7.1. The structures of the three intermediates that where synthesised. 
Methods 
BDO-NH2=O 
Thiosemicarbazide (1.55 g, 0.017 mol) was dissolved in de-ionised water (100 mL, warm). Solution 
cooled (5 oC) over ice, followed by the addition of HCl (32%, 20 drops). 2,3-butanedione (5.97 mL, 
0.068 mol, 5.86 g) was added rapidly and vigorously stirred (5 oC, 10 minutes). The precipitate was 
recovered via filtration, washed with de-ionised water (6 x 50 mL) and dried. An off white solid 
(1.687 g) was recovered (62% yield).  
BDO-Me=O 
4-methyl-3-thiosemicarbazide (0.89 g, 0.0085 mol) was dissolved in de-ionised water (100 mL). 
The solution was cooled (4 oC) over ice, followed by the addition of HCl (32%, 2 drops). 2,3-
butanedione (7.15 mL, 0.0815 mol, 7.01 g) was added rapidly and vigorously stirred (4 oC, 1 hour). 
The precipitate was recovered via filtration, washed with de-ionised water (3 x 30 mL), ethanol 
(20 mL, cold), diethyl ether (25 mL, cold) and dried. The crude product was dissolved in ethanol 
(50 mL, warm) and left to recrystallise in a freezer. The crystalline solid was filtered off and left to 




4,4-dimethyl-3-thiosemicarbazide (0.500 g, 0.0042 mol) was dissolved in de-ionised water (60 
mL). Solution cooled (4 oC) over ice, followed by the addition of HCl (32%, 2 drops). 2,3-
butanedione (0.36 mL, 0.041 mol, 0.35 g) was added rapidly and vigorously stirred (5 oC, 1 hour). 
The precipitate was recovered via filtration, washed with de-ionised water (2 x 30 mL).The crude 
product was dissolved in ethanol (15 mL, hot). The resulting solution was filtered and left to 
recrystallise in a freezer. The crystalline solid was filtered off, washed with petroleum ether (bp 
range: 40  W 60 oC, 2 x 10 mL) and left to dry. A bright yellow crystalline solid (0.191 g) was 
recovered (25% yield).  
2.4.8. Characterisation data for the BDO-mono-substituted-3-
thiosemicarbazone intermediates 
BDO-NH2=O 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.67 (s, 1 H, C-NH), 8.05 (s, 1 H, C-NH), 2.33 
(s, 3 H, O=C-CH3), 1.90 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O),
180.27 (C=S), 146.39 (C=N), 25.28 (O=C-CH3), 10.59 (N=C-CH3). IR (neat): cm
-1= 3443 (m), 3323 
(m), 3165 (m), 1682 (s), 1587 (s), 1504 (s), 1452 (m), 1418 (m), 1364 (m), 1290 (m), 1107 (s), 1045 
(m), 993 (m), 949 (m), 853 (s), 712 (m), 621 (s), 608 (s), 556 (s). Raman (neat): cm-1= 3445 (w), 
3323 (w), 3175 (w), 3000 (w), 2956 (w), 2905 (w), 1675 (s), 1605 (s), 1462 (w), 1426 (w), 1371 (w), 
1307 (w), 1284 (w), 1107 (s), 1045 (w), 1008 (w), 946 (w), 846 (w), 741 (w), 608 (w), 464 (w), 315 
(w), 143 (w). Melting point: >173 oC (decomposed). 
BDO-Me=O 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.59 (m, 1 H, H3C-NH, J= 4.4 Hz), 3.01 (d, 3 
H, HN-CH3, J= 4.4 Hz), 2.38 (s, 3 H, O=C-CH3), 1.91 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6, 100 
D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O), 179.49 (C=S), 146.49 (C=N), 31.94 (HN-CH3), 25.31 (O=C-CH3), 10.57 (N=C-
CH3). IR (neat): cm
-1= 3285 (m), 1670 (s), 1593 (w), 1537 (m), 1495 (s), 1427 (m), 1410 (s), 1360 
(m), 1207 (s), 1152 (s), 1126 (s), 1105 (s), 1047 (s), 999 (m), 835 (m), 725 (w), 667 (m), 629 (m), 
606 (s), 577 (s). Raman (neat): cm-1= 3289 (w), 2919 (w), 1671 (m), 1591 (s), 1409 (w), 1367 (w), 
1304 (w), 1213 (w), 1128 (w), 1106 (w), 1000 (w), 947 (w), 836 (w), 725 (w), 609 (w), 578 (w), 318 
(w). Melting point: >149 oC (decomposed). 
BDO-(Me)2=O 
1H NMR (DMSO-d6,  ? ? ?D,ǌ ) PɷA? ? ? ? ? ?Ɛ ? ?, ?E-NH), 3.27 (s, 6 H, N-(CH3)2,), 2.28 (s, 3 H, O=C-
CH3), 1.91 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O), 182.39 (C=S), 
147.05 (C=N), 43.16 (N-(CH3)2), 24.83 (O=C-CH3), 10.07 (N=C-CH3). IR (neat): cm
-1= 3362 (w), 2920 
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(w), 1670 (s), 1578 (m), 1537 (m), 1429 (m), 1354 (s), 1290 (s), 1198 (s), 1150 (s), 1107 (s), 1063 
(s), 1005 (m), 901 (m), 804 (s), 702 (m), 611 (m), 602 (m), 527 (s). Raman (neat): cm-1= 3364 (w), 
2923 (w), 1669 (s), 1580 (s), 1364 (m), 1342 (m), 1289 (w), 1194 (m), 1150 (w), 1009 (m), 946 (w), 
903 (w), 805 (w), 701 (w), 633 (w), 603 (w), 525 (w), 457 (w), 370 (w), 217 (w). Melting point: 
>129oC (decomposed). 
2.4.9. Spectral examples of a BDO-mono-substituted-3-thiosemicarbazone 
intermediate 
Figures 2.4.9.1-4. Spectral examples of the BDO-mono-substituted-3-thiosemicarbazone 
intermediate BDO-NH2=O. 
Figure 2.4.9.1. An assigned 
1
H NMR spectrum of BDO-NH2=O. BDO-NH2=O was synthesised by reacting 2,3-
butanedione with thiosemicarbazide at 5
o
C.  The red boxes indicate a very small presence of BDO-NH2-NH2. 
This is consistent with the rest of the reactions synthesising BDO based intermediates.  
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Figure 2.4.9.2. An assigned 
13
C NMR spectrum of BDO-NH2=O. 
Figure 2.4.9.3. A FTIR spectrum of BDO-NH2=O. 
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Figure 2.4.9.4. A Raman spectrum of BDO-NH2=O. 
2.4.10. Discussion  
All three intermediates were successfully made in high purity by using methods as per the 
published literature.57, 66, 73 No significant problems had to be overcome during the synthesis. As 
observed in the PADA-mono-substituted-3-thiosemicarbazones synthesis, the main impurity tends 
to be the respective symmetric ligand. The only thing to note is the low yield for the synthesis of 
BDO-(Me)2=O. A depressed yield is consistently observed in reactions involving 4,4-dimethyl-3-
thiosemicabazide.  Fortunately in the case of the BDO backbone it is inconsequential which order 
the 4-substituted-3-thiosemicarbazide arms are attached. This coupled with 4,4-dimethyl-3-
thiosemicabazide being relatively precious and low yielding, it is preferable to choose to 
synthesise a higher yielding intermediate first then attach the 4,4-dimethyl-3-thiosemicarbazide 
arm.  There are numerous reports of proton and carbon NMR data in the literature57, 73, 83, 190 of 
which the data obtained in this project close agreement with. Unfortunately no infrared data was 
reported in these articles. J. Holland et al.57 reported the melting point of BDO-Me=O as 157-
159oC which is close to the melting point obtained of 149oC. At 149oC signs of decomposition 
were observed, browning of the solid/liquid. The report does not state is if the sample melted 
properly or showed signs of decomposition. As BDO-(Me)2=O is believed to be novel no 
characterisation is available, it was also not possible to locate data for BDO-NH2=O. However, the 
data obtained from these intermediates is in accord with BDO-Me=O when the structural 
alterations are ignored.  
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Table 2.4.10.1. Reports the intermediates that have been successfully made along with the main 
impurity present and at what proportion this impurity is estimated at. 
























*Estimated by 1H NMR spectra on an average of three integrals where possible. Typically this was to include 
the integrals from the peaks due to the N=C-CH3 and N-NH environments. 
Table 2.4.10.1. Summary of purity for the PDO-mono-substituted-3-thiosemicarbazone intermediates, 
synthesised by the exploitation of carbonyl reactivity approach.  




Thiosemicarbazide (0.158 g, 0.0017 mol) was dissolved in ethanol (50 mL, 50 oC) and added HCl 
(10%, 1 drop). BDO-Me=O (0.300 g, 0.0017 mol) added to the solution and left to stir (50 oC, 5 
hours). The precipitate was recovered by filtration, dissolved in DMSO (5 mL) and recrystallised 
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with de-ionised water (5 mL). The precipitate was filtered off, washed with a little amount of 
acetone and dried. A white solid (0.145 g) was recovered (35% yield).  
BDO-NH2-(Me)2 
BDO-NH2=O (0.255 g, 0.0016 mol) was dissolved in DMF (1.5 mL) and filtered. 4,4-dimethyl-3-
thiosemicarbazide (0.191 g, 0.0016 mol) dissolved in DMF (2.5 mL), HCl (10%, 2 drops) was added 
and filtered. The two solutions were combined and left to stir (room temperature, 5 hours). De-
ionised water (33 mL) was added, the precipitate was recovered by filtration and washed with de-
ionised water (50 mL, room temperature and 50 mL, 80 oC). The crude product was dissolved in 
DMSO (3 mL), filtered and recrystallised with de-ionised water (6 mL). The precipitate was filtered 
off, washed with de-ionised water (50 mL, room temperature and 50 mL, 80 oC) and dried. A 
yellow solid (0.170 g) was recovered (41% yield).  
2.4.12. Characterisation data for the dissymmetric ligands from the BDO-mono-
substituted-3-thiosemicarbazone intermediates 
BDO-Me-NH2 
1H NMR (DMSO-d6, 400 D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.37 (singlet overlapped with a quartet, 1 
H, C-NH),  8.34 (quartet overlapped with a singlet, 1 H, H3C-NH, J= 4.4 Hz), 7.82 (s, 1 H, C-NH), 2.97 
( d, 3 H, HN-CH3, J= 4.4 Hz), 2.16 (s, 3 H, N=C-CH3),  2.12 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6, 
 ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 178.97 (C=S), 148.92 (C=N), 148.43 (C=N), 31.74 (HN-CH3), 12.26 (N=C-
CH3), 12.07 (N=C-CH3). IR (neat): cm
-1= 3414 (m), 3352 (w), 3215 (m), 3150 (m), 1605 (m), 1553 
(m), 1489 (s), 1362 (m), 1288 (m), 1231 (m), 1169 (m), 1142 (m), 1080 (s), 953 (m), 854 (m), 826 
(m), 716 (m), 644 (m), 565 (s), 544 (s). Raman (neat): cm-1= 3212 (w), 2913 (w), 1604 (s), 1589 (m), 
1461 (w), 1374 (m), 1329 (w), 1237 (w), 1123 (w), 1005 (w), 854 (w), 747 (w), 461 (w), 398 (w), 
216 (w). Elemental analysis: Found: C, 34.2; H, 5.8; N, 34.0. Calc. for C7H14N6S2: C, 34.1; H, 5.7; N, 
34.1%. Melting point: >215 oC (decomposed). 
BDO-NH2-(Me)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 9.49 (s, 1 H, N-NH), 8.38 (s, 1 H, C-NH), 7.83 
(s, 1 H, C-NH), 3.22 ( s, 6 H, N-(CH3)2), 2.11 (s, 3 H, N=C-CH3),  2.10 (s, 3 H, N=C-CH3). 
13C {1H} NMR 
(DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 179.35 (C=S), 150.00 (C=N), 148.96 (C=N), 42.80 (N-(CH3)2), 
11.96 (N=C-CH3), 11.70 (N=C-CH3). IR (neat): cm
-1= 3395 (w), 3221 (m), 3148 (m), 1591 (m), 1545 
(m), 1460 (m), 1412 (m), 1396 (m), 1368 (m), 1261 (m), 1221 (m), 1134 (m), 1103 (m), 1055 (m), 
968 (m), 847 (m), 708 (m), 606 (m), 515 (s). Raman (neat): cm-1= 2913 (w), 1603 (m), 1586 (s), 
1498 (w), 1463 (w), 1397 (w), 1371 (w), 1338 (m), 1263 (w), 1229 (w), 1128 (m), 1110 (w), 1006 
(w), 850 (w), 736 (w), 612 (w), 461 (w). Elemental analysis: Found: C, 36.9; H, 6.2; N, 32.3. Calc. 




2.4.13. Spectral examples of a dissymmetric ligand with a Me/Me backbone 
Figures 2.4.13.1-4. Spectral examples of the dissymmetric ligand BDO-NH2-(Me)2. 
Figure 2.4.13.1. An assigned 
1
H NMR spectrum of BDO-NH2-(Me)2.. This ligand was successfully synthesised 
by the exploitation of carbonyl reactivity approach by reacting BDO-NH2=O with 4,4-dimethyl-3-
thiosemicarbazide. The purple and blue boxes indicate a very small presence of BDO-NH2=O and BDO-NH2-
NH2 respectively.  .   
Figure 2.4.13.2. An assigned 
13
C NMR spectrum of BDO-NH2-(Me)2. 
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Figure 2.4.13.3. A FTIR spectrum of BDO-NH2-(Me)2. 





Both the dissymmetric ligands were made successfully and in high purity by following the method 
reported by G. Buncic et al.82 which was also the method used when synthesising dissymmetric 
ligands with H/Me on the backbone. Once the BDO-mono-substituted-3-thiosemicarbazone 
intermediate was isolated in a relatively high purity, the attachment of a second dissimilar 4- 
substituted-3-thiosemicarbazone was relatively straight forward. The attempt to synthesise BDO-
(Me)2-Me was an exception. Both intermediates that could be used to make this ligand, BDO-
(Me)2=O and BDO-Me=O were obtained with a high level of purity. It is worth re-emphasising that 
as all ligands with BDO backbones, it does not matter which order the two dissimilar 4- 
substituted-3-thiosemicarbazones are attached. It was found that the constructing a dissymmetric 
ligand from BDO-(Me)2=O was not feasible. The two main reasons were that 4,4-dimethyl-3-
thiosemicarbazide is significantly more expensive than any of the other 4- substituted-3-
thiosemicarbazones and secondly that the reaction to create the BDO-(Me)2=O intermediate had 
a considerably low yield. Both attempts to synthesise BDO-(Me)2-Me/ BDO-Me-(Me)2 using either 
BDO-(Me)2=O and BDO-Me=O respectively failed to produce the desired product. On closer 
inspection of the 1H NMR spectra of both products all the expected peaks were present (plus 
some impurity peaks), but the integrals of the peaks did not add up to what was expected. After a 
significant amount of time on this problem, a suitable explanation for this observation still has not 
been reached. This reaction requires further investigation, but due to the heavy cost of the 
synthesis, the decision was made to concentrate on the synthesis of dissymmetric ligands with 
different back bones.   
Despite BDO-Me-NH2 being cited in the literature,
198, 199 it was not possible to find any 
characterisation data for the ligand. It is believed that BDO-NH2-(Me)2 has not been reported 
before. However, the ligands BDO-Me-(Me)2 has been reported before
73, 82, 190 and despite the 
ligand not being one of those that have been synthesised in this project, the NMR characterisation 
data can be used as a partial comparison. The NMR data reported73, 190 show an acceptable level 
of similarity to the NMR data for BDO-Me-NH2 and BDO-NH2-(Me)2 when the structural variations 
are discounted.   
Table 2.4.14.1. reports the two dissymmetric ligands that have been successfully made along with 























*Estimated by 1H NMR spectra on an average of three integrals where possible. Typically this was to include 
the integrals taken from the peaks due to the N=C-CH3 and N-NH environments. 
Table 2.4.14.1. Summary of purity for the dissymmetric Ligands with Me/Me backbones, synthesised by the 
exploitation of carbonyl reactivity approach.  
2.5. Ligands with Me/Et backbones  
Application 
This class of ligands along with ligands with Me/Me backbones are of interest for the imaging of 
hypoxic tissues which can be a common pathology in a range of diseases including heart disease 
and cancer.109, 113, 115 In order to achieve this, the complex must be able to migrate to the tissue 
and be reduced only in hypoxic conditions but not in normoxic conditions. The reduction of the 
ligand will allow the release and trapping of the copper radioisotope ion which can then be 
detected via PET.  
It is expected that ligands made from di-ketones with Me/Me or Me/Et on the backbone have 
redox potential in the appropriate range. The more lipophilic the substituents on the 4-
substituted-3-thiosemicarbazide arm; the slower the clearance from normoxic and thus the longer 
it takes to achieve a suitable hypoxic: normoxic ratio in order to give informative images.      
The aim is to synthesise a range of ligands with Me/Me or Me/Et on the backbone and with 4- 
substituted -3-thiosemicarbazide arms with a limited number of methyl/ethyl substituents.   
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2.5.1. Symmetric ligands with Me/Et backbones 
Overview of reaction 
The synthesis of this subgroup of ligands requires one equivalent of 2,3-pentanedione (PDO) to be 
reacted with two equivalents of a chosen 4-substituted-3-thiosemicarbazide, under acidic 
conditions, in water at  60oC to give the desired symmetric ligand (Figure 2.5.1.1.). Three 
symmetric ligands have been synthesised (Figure 2.5.1.2.). 
Conc. HCl
 
 R1 R2 
PDO-NH2-NH2 H H 
PDO-Me-Me CH3 H 
PDO-Et-Et CH2CH3 H 






Figure 2.5.1.2. Structures of the symmetric ligands with Me/Et backbones that were synthesised. 
2.5.2.Methods  
PDO-NH2-NH2 
Thiosemicarbazide (0.775 g, 0.0085 mol) was dissolved in de-ionised water (50 mL, 60 oC). HCl 
(32%, 5 drops) was added, then 2,3-pentanedione (0.44 mL, 0.0042 mol, 0.42 g) was added 
rapidly and left to stir (60 oC, 1 hour). The precipitate was filtered and washed with diethyl ether 
(2 x 25 mL). The crude product was dissolved in DMSO (12 mL), filtered and recrystallised with de-
ionised water (24 mL). The precipitate was recovered by filtration, washed with a small quantity 




4-methyl-3-thiosemicarbazide (0.894 g, 0.0085  mol) was dissolved in de-ionised water (50 mL, 60 
oC). HCl (32%, 5 drops) was added, then 2,3-pentanedione (0.44 mL, 0.0042 mol, 0.42 g) was 
added rapidly and left to stir (60 oC, 1 hour). The precipitate was filtered and washed with diethyl 
ether (2 x 25 mL). The crude product was dissolved in DMSO (15 mL), filtered and recrystallised 
with de-ionised water (30 mL). The precipitate was recovered by filtration, washed with a small 
quantity of water, diethyl ether (2 x 25 mL) and dried. A white solid (0.474 g) was recovered (78% 
yield).  
PDO-Et-Et 
4-ethyl-3-thiosemicarbazide (1.013 g, 0.0085 mol) was dissolved in ethanol (50 mL, 60 oC). HCl 
(32%, 5 drops) was added, then 2,3-pentanedione (0.44 mL, 0.0042 mol, 0.42 g) was added 
rapidly and left to stir (60 oC, 1 hour). The precipitate was filtered and washed with diethyl ether 
(2 x 25 mL). The crude product was dissolved in DMSO (12 mL), filtered and recrystallised with de-
ionised water (24 mL). The precipitate was recovered by filtration, washed with a quantity of 
water and dried. A creamy white solid (0.729 g) was recovered (57% yield).  
2.5.3. Characterisation data for symmetric ligands with Me/Et backbones 
PDO-NH2-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.19 (s, 1 H, N-NH), 8.38 (s, 2 H, C-NH2), 
7.79 (s, 1 H, C-NH), 7.79 (s, 1 H, C-NH), 2.81 (q, 2H, C-CH2, J= 7.6 Hz), 2.10 (s, 3 H, N=C-CH3), 0.84 
(t, 3 H, C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ?0 (C=S), 179.36 (C=S), 
152.68 (C=N), 147.81 (C=N), 17.46 (C-CH2), 12.23 (N=C-CH3), 11.56 (C-CH2-CH3). IR (neat): cm
-1= 
3418 (w), 3202 (m), 3152 (m), 2986 (m), 1599 (s), 1493 (s), 1447 (s), 1366 (w), 1290 (m), 1244 (m), 
1155 (m), 1086 (s), 1059 (m), 988 (m), 924 (w), 841 (m), 793 (w), 642 (m), 590 (m). Raman (neat): 
cm-1= 2908 (w), 1604 (s), 1589 (s), 1473 (w), 1366 (w), 1345 (m), 1308 (w), 1246 (w), 1125 (s), 
1054 (w), 989 (w), 923 (w), 865 (w), 744 (w), 467 (w). Melting point: >202 oC (decomposed). 
PDO-Me-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? (s, 1 H, N-NH), 10.18 (s, 1 H, N-NH), 8.31 (quartet 
overlapping a quartet, 1 H, H3C-NH, J= 4.8 Hz), 8.30 (quartet overlapping a quartet, 1 H, H3C-NH, 
J= 4.4 Hz), 2.98 (m, 6 H, HN-CH3), 2.87 (q, 2H, C-CH2, J= 7.2 Hz), 2.14 (s, 3 H, N=C-CH3), 0.90 (t, 3 H, 
C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 152.36 (C=N), 147.53 
(C=N), 31.74 (HN-CH3), 31.70 (HN-CH3), 17.25 (C-CH2), 12.29 (N=C-CH3), 11.35 (C-CH2-CH3). IR 
(neat): cm-1= 3308 (w), 2938 (w), 1539 (s), 1477 (s), 1460 (s), 1433 (s), 1410 (m), 1354 (m), 1219 
(s), 1169 (m), 1128 (s), 1086 (s), 1065 (s), 1042 (s), 991 (m), 826 (m), 781 (m), 660 (m), 608 (m), 
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565 (s). Raman (neat): cm-1= 3379 (w), 2936 (w), 1598 (m), 1573 (s), 1390 (m), 1336 (w), 1296 (w), 
1235 (w), 1160 (w), 1134 (w), 1026 (w), 992 (w), 734 (w), 673 (w), 577 (w), 453 (w), 324 (w). 
Melting point: >217 oC (decomposed). 
PDO-Et-Et 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.13 (s, 1 H, N-NH), 8.35 (t, 1 H, H2C-NH, 
J= 6.0 Hz), 8.29 (t, 1 H, H2C-NH, J= 6.0 Hz), 3.55 (dq, 4 H, HN-CH2, J=7.2, 6.0  Hz), 2.86 (q, 2H, C-CH2, 
J= 7.2 Hz), 2.15 (s, 3 H, N=C-CH3),1.09 (two overlapping triplets, 6 H, N-CH2-CH3, J=7.2), 0.86 (t, 3 
H, C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 152.28 (C=N), 147.51 
(C=N), 39.10 (HN-CH2), 39.08 (HN-CH2), 17.41 (C-CH2), 14.89 (N-CH2-CH3), 12.35 (N=C-CH3), 11.38 
(C-CH2-CH3). IR (neat): cm
-1= 3345 (w), 3211 (w), 2967 (w), 2880 (w), 1522 (s), 1491 (s), 1437 (s), 
1385 (m), 1306 (m), 1261 (m), 1209 (s), 1167 (m), 1136 (s), 1078 (m), 1061 (s), 959 (m), 924 (m), 
818 (m), 783 (m), 658 (m), 530 (s).  Raman (neat): cm-1= 2876 (w), 1600 (s), 1531 (w), 1400 (w), 
1346 (w), 1247 (w), 1208 (w), 1128 (w), 1048 (w), 992 (w), 738 (w), 675 (w), 458 (w), 306 (w), 200 
(w). Elemental analysis: Found: C, 43.7; H, 7.3; N, 27.8. Calc. for C11H22N6S2: C, 43.6; H, 7.3; N, 
27.7%. Melting point: >215 oC (decomposed). 
2.5.4. Spectral examples of a symmetric Ligand with a Me/Et backbone 
Figures 2.5.4.1-4. Spectral examples of ligand PADA-NH2-NH2. 
Figures 2.5.4.1. An assigned 
1
H NMR spectrum of PDO-NH2-NH2. The PDO-NH2-NH2 ligand was produced by 
reacting 2,3-pentanedione with thiosemicarbazide. The purple boxes indicate a small presence of PDO-
NH2=O. This is typical throughout the synthesis of this class of ligands.  
An interesting observation worth noting is that when the thiosemicarbazide is bound to the PDO 
backbone the terminal NH2 groups are seen as a singlet and a doublet of equal integrals. This is 
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not observed with the other backbones when the NH2 group is seen as two singlets with equal 
integrals. As this phenomenon is only observed with the PDO backbone it is reasonable to predict 
that the doublet is due to the NH2 group of the 4-ethyl-3-thiosemicarbazide that has reacted with 
the carbonyl group of the ethyl ketone. It is thought that the ethyl group induces some level of 
hindered rotation of the NH2 group and in doing so allows the NMR spectrometer to resolve two 
slightly different proton environments. No further investigation was undertaken, but a possible 
investigation that could be undertaken is reacting 2 equivalents of thiosemicarbazide with 3,4-
hexane-dione to see if the singlet is replaced by a second doublet. Some variable temperature 
NMR studies could also be undertaken in order to establish if heating up the sample would result 
in the doublet being observed as a singlet.  
Figure 2.5.4.2. An assigned  
13
C NMR spectrum of PDO-NH2-NH2. 
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Figure 2.5.4.3. A FTIR spectrum of PDO-NH2-NH2.  




2.5.5. Discussion  
All three ligands were successfully synthesised in high purity. It is estimated that none of the three 
ligands have a purity, in respect to impurities related to the bis-(thiosemicarbazones), of less than 
95%. Symmetric ligands of this class have been reported before therefore methods are well 
described.23, 77, 164 It seems that alongside the normal expected intermediate a different isomeric 
form of the mono-substituted-3-thiosemicarbazone intermediate is being formed as a minor 
product. The general structures of the two expected impurities are shown below (Figure 2.5.5.1.). 
Isomer A Isomer B
 
Figure 2.5.5.1. The two expected impurities in the synthesis of the symmetric ligands with Me/Et backbones. 
It is hypothesized that the ethyl substituent on the di-ketone reduces the reactivity difference 
between the two ketones causing the formation of the new intermediate to become favourable. 
Discussion of this new intermediate will be addressed in the intermediate section below (section 
2.5.11.).  
Despite symmetric ligands with Me/Et on the backbone have been reported by numerous 
articles69, 77, 145, 146, 164 for biological screening studies for the use of these ligands for hypoxia 
imaging, there is no NMR or IR/Raman characterisation data reported alongside the biological 
results. Structural based searching of databases, such as SciFinder, did not locate any 
characterisation data on these compounds. By comparing the data from this class of ligands with 
data of ligands with different backbones/amine substituents it is believed that data has been 
assigned accurately. Table 2.5.5.2. below illustrates all three ligands, what the main impurities are 















































*Estimated by 1H NMR spectra on an average of three integrals where possible. Typically this was to include 
the integrals from the peaks due to the N=C-CH3 and N-NH environments. 
 Table 2.5.5.2. Summary of purity for the symmetric Ligands with Me/Et backbones, synthesised by the 
exploitation of carbonyl reactivity approach.  
2.5.6. Dissymmetric ligands with Me/Et backbones 
Overview of reaction 
The synthesis of the dissymmetric ligands firstly requires the synthesis of PDO based mono-
substituted-3-thiosemicarbazone intermediates. These intermediates are synthesised by reacting 
PDO and a 4-substituted-3-thiosemicarbazone in the stoichiometric ratio of 1:1 at reduced 
temperatures and under acidic conditions. Once isolated the intermediate is then reacted with 1 
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equivalent of a dissimilar 4-substituted-3-thiosemicarbazone catalysed under slightly acidic 
conditions to produce the desired dissymmetric ligand (Figure 2.5.6.1.). 
1) Conc. HCl
2)
       10% HCl
 
 R1 R2 R3 R4 
PDO-NH2-Me H H CH3 H 
PDO-NH2-(Me)2 H H CH3 CH3 
PDO-NH2-Et H H CH2CH3 H 
PDO-Me-NH2 CH3 H H H 
PDO-Et-NH2 CH2CH3 H H H 
Figure 2.5.6.1. The general reaction for the synthesis of dissymmetric ligands with Me/Et backbones. 










Figure 2.5.6.2. Dissymmetric ligands from PDO-Me=O and PDO-Et=O. 
2.5.7. Synthesis of the PDO-mono-substituted-3-thiosemicarbazone 
intermediates 
In order to make the five dissymmetric ligands, these three intermediates had to be successfully 
synthesised (Figure 2.5.7.1.). 
PDO-Et=OPDO-Me=OPDO-NH2=O
 Figure 2.5.7.1. Structures of the three PDO-mono-substituted-3-thiosemicarbazone intermediates that have 
been synthesised by the exploitation of carbonyl reactivity approach.  
2.5.8. Methods 
PDO-NH2=O 
Thiosemicarbazide (1.55 g, 0.017 mol) was dissolved in de-ionised water (200 mL, warm). Solution 
cooled (10oC) over ice, followed by the addition of HCl (32%, 20 drops). 2,3-pentanedione (7.12 
mL, 0.068 mol, 6.81 g) was added rapidly and vigorously stirred (10oC, 10 minutes). The 
precipitate was recovered via filtration, washed with de-ionised water (2 x 50 mL) and dried. An 
off white solid (1.957g) was recovered (66% yield).  
PDO-Me=O 
4-methyl-3-thiosemicarbazide (1.788 g, 0.017 mol) was dissolved in a solution of de-ionised water 
(200 mL) and ethanol (80 mL). The solution was cooled (-10oC) in a salt/ice bath (300g ice, 100g 
table salt), followed by the addition of HCl (32%, 6 drops). 2,3-pentanedione (3.56 mL, 0.034 mol, 
3.41 g) was added rapidly and vigorously stirred (circa -10oC, 5 minutes). The precipitate was 
recovered via filtration, washed with de-ionised water (4 x 50 mL) and dried. An off white solid 





4-ethyl-3-thiosemicarbazide (1.013 g, 0.085 mol) dissolved in a solution of de-ionised water (100 
mL) and ethanol (60 mL). The solution was cooled (-12oC) in a salt/ice bath (300g ice, 100g table 
salt), followed by the addition of HCl (32%, 3 drops). 2,3-pentanedione (1.78 mL, 0.017 mol, 1.70 
g) was added rapidly and vigorously stirred (circa -11oC, 4 minutes). The precipitate was recovered 
via filtration, washed with de-ionised water (3 x 50 mL) and dried. An off white solid (0.862g) was 
recovered (50% yield).  
2.5.9. Characterisation data for the PDO-mono-substituted-3-
thiosemicarbazone intermediates 
PDO-NH2=O 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.66 (s, 1 H, C-NH), 8.04 (s, 1 H, C-NH),2.90 
(q, 2H, C-CH2, J= 7.2 Hz), 1.92 (s, 3 H, N=C-CH3), 0.90 (t, 3 H, C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR 
(DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O), 180.25 (C=S), 145.90 (C=N), 29.64 (C-CH2), 10.88 (N=C-
CH3), 8.68 (C-CH2-CH3). IR (neat): cm
-1= 3412 (w), 3302 (m), 3177 (m), 2984 (w), 1688 (s), 1593 (s), 
1491 (m), 1422 (m), 1362 (m), 1233 (s), 1090 (s), 1043 (s), 932 (m), 843 (m), 797 (m), 700 (m), 590 
(s), 552 (s). Raman (neat): cm-1= 3302 (w), 3192 (w), 2986 (w), 2945 (w), 2919 (w), 2898 (w), 1683 
(m), 1614 (s), 1464 (w), 1364 (w), 1258 (w), 1103 (m), 1091 (m), 1045 (m), 930 (w), 838 (w), 602 
(w), 487 (w), 461 (w), 410 (w), 313 (w). Melting point: >165 oC (decomposed). 
PDO-Me=O 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.55 (q, 1 H, H3C-NH, J= 4.8 Hz), 3.00 (d, 3 
H, HN-CH3, J= 4.8 Hz), 2.93 (q, 2H, C-CH2, J= 7.2 Hz), 1.93 (s, 3 H, N=C-CH3), 0.93 (t, 3 H, C-CH2-CH3, 
J=7.2 Hz). 13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O), 179.48 (C=S), 145.60 (C=N), 31.91 
(HN-CH3), 29.59 (C-CH2), 10.84 (N=C-CH3), 8.62 (C-CH2-CH3). IR (neat): cm
-1= 3379 (w), 3210 (w), 
2982 (w), 1682 (s), 1541 (s), 1499 (s), 1429 (m), 1406 (m), 1375 (m), 1360 (m), 1207 (s), 1146 (s), 
1107 (s), 1088 (s), 1055 (m), 1034 (s), 932 (m), 835 (m), 797 (m), 652 (m), 559 (s). Raman (neat): 
cm-1= 3322 (w), 2940 (w), 1684 (m), 1677 (m), 1600 (s), 1367 (w), 1203 (m), 1143 (w), 1115 (w), 
1090 (w), 1047 (m), 831 (m), 649 (w), 561 (w), 415 (w), 315 (w). Melting point: >136-141 oC. 
PDO-Et=O 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 8.60 (t, 1 H, H2C-NH, J= 6.0 Hz), 3.58 (dq, 2 
H, HN-CH2, J=7.6, 6.0 Hz), 2.93 (q, 2H, C-CH2, J= 7.2 Hz), 1.93 (s, 3 H, N=C-CH3), 1.11 (t, 3 H, N-CH2-
CH3, J=7.6), 0.93 (t, 3 H, C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=O),
178.47 (C=S), 145.65 (C=N), 39.27 (HN-CH2), 29.59 (C-CH2), 14.66 (N-CH2-CH3), 10.86 (N=C-CH3), 
8.60 (C-CH2-CH3). IR (neat): cm
-1= 3345 (w), 3188 (w), 2974 (w), 1686 (s), 1612 (w), 1537 (s), 1499 
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(s), 1427 (m), 1364 (m), 1190 (s), 1155 (m), 1117 (m), 1092 (m), 1038 (s), 949 (m), 824 (m), 800 
(m), 600 (s), 563 (s). Raman (neat): cm-1= 3346 (w), 2913 (w), 1683 (w), 1611 (w), 1448 (w), 1366 
(w), 1265 (w), 1189 (w), 1153 (w), 1115 (w), 1039 (w), 819 (w), 654 (w), 560 (w), 304 (w). Melting 
point: >103-104 oC.  
2.5.10. Spectral examples of a PDO-mono-substituted-3-thiosemicarbazone 
intermediate 
Figures 2.5.10.1-4. Spectral examples of the PADA-mono-substituted-3-thiosemicarbazone 
intermediate PDO-Me=O. 
Figure 2.5.10.1.An assigned 
1
H NMR spectrum of the novel compound PDO-Me=O, which was successfully 
synthesised by the exploitation of carbonyl reactivity approach. This involved reacting 2,3-pentanedione 
with 4-methyl-3-thiosemicarbazide at -10
o
C. 
The purple box illustrates the presence of a second isomeric form of the target intermediate. This 
intermediate forms when the chosen 4-substituted-3-thiosemicarbazide reacts with the carbonyl 
group of the ethyl ketone instead of the methyl ketone. Due to the similarity of both of these 
isomeric forms most the related NMR peaks either overlap or cannot be fully resolved. The 1H 
ĞŶǀŝƌŽŶŵĞŶƚ ‘ ?ŝƐƚŚĞŵŽƐƚĞĨĨĞĐƚŝǀĞĞŶǀŝƌŽŶŵĞŶƚƚŽƵƐĞŝŶŽƌĚĞƌƚŽĚŝƐƚŝŶŐƵŝƐŚďĞƚǁĞĞŶƚŚĞƚǁŽ
isomeric forms of the PDO-mono-substituted-3-thiosemicarbazone intermediates. The presence 
of this second intermediate is common in the synthesis of the PDO-mono-substituted-3-
thiosemicarbazone intermediates. The blue box indicates a very small presence of the related 
symmetric bis(thiosemicarbazone), in this example it is PDO-Me-Me.  
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Figure 2.5.10.2. A 
13
C NMR spectrum of PDO-Me=O. 
Figure 2.5.10.3. A FTIR
 
spectrum of PDO-Me=O. 
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Figure 2.5.10.4. A Raman spectrum of PDO-Me=O. 
2.5.11. Discussion 
All three intermediates was successfully synthesised with an acceptable level of purity. It is 
believed that no one has reported intermediates of this class before. The method of synthesis was 
adapted from procedures that have been reported for the synthesis of intermediates with Me/Me 
on the backbone.57, 66, 73 The NMR data is very close in agreement to the NMR data reported by J. 
Holland et al.57 for the intermediates with Me/Me on the backbone, when structural variations 
have been discounted.  The Infrared and Raman spectra of each of the intermediates of this class 
also contain common peaks in the regions that N-H, C=O, C=N and C=S peaks have been identified 
for other intermediates (Table 2.3.11.2.).   
Evidence of a second isomeric form of the intermediate was present in all NMR spectra, this 
second intermediate arises when the amine of the chosen the 4-substituted-3-thiosemicarbazide 
reacts with the ethyl carbonyl group of the 2,3-pentandione instead of the methyl carbonyl group. 
It was initially expected that the amine would preferentially attack the ethyl ketone of 2,3-
pentandione as the ethyl group would be more effective at stabilising the partial positive charge 
on the carbonyl carbon than the corresponding methyl carbonyl group. If this was the case then 
the intermediate containing an unreacted methyl carbonyl group instead of an unreacted ethyl 
groups would be observed. It is expected that steric effects may cause the formation of the 
intermediate bound through the methyl ketone to be more favourable.  
It was found that if the reaction mixture was cooled to below 0oC (typically -10/-12oC) the 
formation of the second isomeric intermediate was reduced. There seems to be a limit of how 
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much you can cool the solution as just after -12oC the 4-substituted-3-thiosemicarbazide either 
precipitates out of solution or the solution mixture freezes. In the case of thiosemicarbazide it was 
noted that the solution cannot be cooled much below 10oC before the arm starts to precipitate 
out of solution.  The formation of this intermediate impurity will undoubtedly lead to the 
formation of an isomeric mixture of dissymmetric ligands when a dissimilar 4-substituted-3-
thiosemicarbazide is attached. If tests show that there is a significant difference in the 
pharmacokinetics or bio-distribution between the two isomeric forms of the dissymmetric ligands 
then it will be necessary to revise the method in order to further reduce or stop the formation of 
the intermediate impurity. 
It is clear that one of the two isomeric forms of the intermediate was formed in a significantly 
larger proportion than the other but in order to ascertain what the structure of the final ligand 
was at the end of the synthesis, it was important to identify which ligand intermediate was 









Major product Minor product
Minor product
 Figure 2.5.11.1. Illustrates what the major products will be depending on what the major isomer is.   
Figure 2.5.11.2. shows a HMBC NMR spectra of PDO-Me=O which it was hoped, would help prove 
which isomeric form of the intermediate was the major product. It is predicted that the 




Figure 2.5.11.2. A HMBC spectrum of PDO-Me=O. HMBC was not able to help elucidate the identity of the 
major isomer of PDO-Me=O.   
Unfortunately the expected long range carbon/hydrogen couƉůŝŶŐƐďĞƚǁĞĞŶƉƌŽƚŽŶ ‘C ?ǁŝƚŚ
ĐĂƌďŽŶ ‘W ?ĂŶĚ ‘X ?ǁĞƌĞŶŽƚƉƌĞƐĞŶƚ ?These absent coupling locations that would support that 
reaction A (Figure 2.5.11.1.) is correct are marked by the red boxes. If reaction B (Figure 2.5.11.1.) 
was correct then it would be expected that long range carbon/hydrogen couplings between 
ƉƌŽƚŽŶ ‘C ?ǁŝƚŚĐĂƌďŽŶ ‘V ?ĂŶĚ ‘U ?ǁŽƵůĚďĞŽďƐĞƌǀĞĚ ?ƚŚĞƐĞĂƌĞŝŶĚŝĐĂƚĞĚďǇƚŚĞƉƵƌƉůĞďŽǆĞƐ ?
dŚĞƐĞĐŽƵƉůŝŶŐƐĂƌĞĂůƐŽĂďƐĞŶƚ ?KŶĞĞǆƉůĂŶĂƚŝŽŶĨŽƌƚŚŝƐĐŽƵůĚďĞƚŚĂƚďĞĐĂƵƐĞƉƌŽƚŽŶ ‘C ?ŝƐ
directly bonded to a nitrogen atom that this is weakening the long range carbon/hydrogen 
couplings to such an extent that they are no longer detectable. This theory is backed up by the 
ĐŽƵƉůŝŶŐŵĂƌŬĞĚǁŝƚŚƚŚĞďůƵĞďŽǆǁŚŝĐŚƐŚŽǁƐĂǁĞĂŬĐŽƵƉůŝŶŐďĞƚǁĞĞŶƉƌŽƚŽŶ ‘C ?ĂŶĚĐĂƌďŽŶ
 ‘Y ? ?dŚŝƐĐŽƵƉůŝŶŐŝƐĂůŽƚǁĞĂŬĞƌƚŚĂŶŽƚŚĞƌƐƚƌŽŶŐĐŽƵƉůŝŶŐƚŚĂƚĂƌĞŽďƐĞƌǀĞĚŽǀĞƌĂƐŝŵŝůĂƌ
ŶƵŵďĞƌŽĨďŽŶĚůĞŶŐƚŚƐ ?ĨŽƌĞǆĂŵƉůĞƚŚĞĐŽƵƉůŝŶŐďĞƚǁĞĞŶƉƌŽƚŽŶ ‘D ?ĂŶĚĐĂƌďŽŶ ‘W ?ŝƐ
significantly stronger even though the coupling being observed over one bond length (H-C-C) 
ǁŚŝĐŚŚĂƐƚŚĞƐĂŵĞŶƵŵďĞƌŽĨďŽŶĚůĞŶŐƚŚƐĂƐďĞƚǁĞĞŶƉƌŽƚŽŶ ‘C ?ĂŶĚ carbon   ‘W ? ?,-N-C).  The 
only difference is the atoms which the bond is between.      
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However, it is possible to indirectly support that the reaction A (Figure 2.5.11.1.) is correct by 
looking at the 1H and 13C NMR peaks and comparing the major NMR peaks of the intermediate 
sample against the expected peaks for each isomeric form. The table below (Table 2.5.11.3.) 
illustrates this, the example intermediate used for comparison is PDO-Me=O.  Both PDO-NH2=O 
and PDO=Et=O both show major NMR peaks in very similar positions to PDO-Me=O showing that 
all intermediates follow reaction A (Figure 2.5.11.1). 
Environment Observed peaks 
In  
PDO-Me=O 
Expected peak if 
reaction A is  correct 
Expected peak  if 
reaction B is  correct 
 Major peaks   
CH2-C=O 2.93 ppm  A?2.6-7 ppm Minor peak 
CH2-C=O 29.59 ppm  A? ? ? ? ?-9 Minor peak 
CH3-C=N 1.93 ppm  A? ? ? ?ppm  Minor peak 
CH3-C=N 10.85 ppm  A? ? ? ?-10.6 ppm  Minor peak  
 Minor peaks   
CH3-C=O 2.36 ppm  Minor peak A? ? ? ?-4 ppm 
CH3-C=O 25.59 ppm  Minor peak 24.8-25.3A? ppm 
CH2-C=N 2.54 ppm  Minor peak 2.0-9 ppm 
CH2-C=N 16.67 ppm  Minor peak 17.0-5 ppm 
Table 2.5.11.3. Summarises the expected major NMR peaks that would be present depending on which 
intermediate is the major product.  
Previous data in the literature relating to PDO based intermediates was not able to found, as it is 
believed that no PDO-mono-substituted-3-thiosemicarbazone intermediate has been isolated to 
date. This means that the only data available that can be used to help determine which isomeric 
form is correct is data corresponding to BDO-mono-substituted-3-thiosemicarbazone 
intermediates. By looking at the CH3-C=O, CH3-C=N, CH2-C=O and CH2-C=N environments, the 
position of the spectral peaks can be predicted, which can be used to propose the major 
configuration of the PDO based intermediates. The observed peaks agree with the peaks expected 
for reaction A (Figure 2.5.11.1) and disagrees with the peaks expected for reaction B (Figure 
2.5.11.1). Table 2.5.11.3. supports the theory that the substituted-3-thiosemicarbazide forms an 
imine bond with the methyl carbon preferentially over the ethyl carbon. However, this conclusion 
must be treated with caution as only NMR spectroscopy has been used. Unfortunately all three 
intermediate products formed powders which were not suitable for analysis by X-ray diffraction. 
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If it is accepted that the conclusion is correct then this may advocate that the methyl ketone is 
still slightly more reactive than the ethyl ketone. This may be an important consideration in the 
respect of the clean synthesis of Me/Et dissymmetric ligands.     
Table 2.5.11.4. Reports the intermediates that have been successfully made along with the main 
impurity present and at what proportion this impurity is estimated at. 

















*Estimated by 1H NMR spectra on an average of three integrals where possible. Typically this was to include 
the integrals from the peaks due to the N=C-CH3 and N-NH environments. 
Table 2.5.11.4. Summary of purity for the PDO-mono-substituted-3-thiosemicarbazone intermediates. 
2.5.13. Dissymmetric ligands from PDO-NH2=O, PDO-Me=O and PDO-Et=O 
2.5.14. Methods  
PDO-NH2-Me 
PDO-NH2=O (0.277 g, 0.0016 mol) was dissolved in DMF (3 mL). 4-methyl-3-thiosemicarbazide 
(0.168 g, 0.0016 mol) was dissolved in DMF (4 mL) and HCl (10%, 1 drop) was added. The two 
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solutions were combined and left to stir (room temperature, 5 hours). De-ionised water (14 mL) 
was added, the precipitate was filtered and washed with de-ionised water (50 mL). The crude 
product was dissolved in DMSO (8 mL) and recrystallised with de-ionised water (16 mL). The 
precipitate was filtered off, washed with de-ionised water (50 mL), ethanol (5 x 10 mL) and dried. 
A yellow/white solid (0.275 g) was recovered (66% yield).  
PDO-NH2-(Me)2 
PDO-NH2=O (0.452 g, 0.0026 mol) was dissolved in DMF (2 mL) and filtered. 4,4-dimethyl-3-
thiosemicarbazide (0.310 g, 0.0026 mol) was dissolved in DMF (4 mL), HCl (10%, 2 drops) was 
added and filtered. The two solutions were combined and left to stir (room temperature, 5 
hours). De-ionised water (37 mL) was added and solution was put in the freezer (10 minutes). The 
precipitate was filtered off and washed with de-ionised water (50 mL, room temperature and 50 
mL, 80oC). The crude product was dissolved in DMSO (3.5 mL), filtered and recrystallised with de-
ionised water (60 mL). The precipitate was recovered by filtration, washed with de-ionised water 
(2 x 50 mL) and dried. A yellow solid (0.171 g) was recovered (24% yield).  
PDO-NH2-Et 
PDO-NH2=O (0.277 g, 0.0016 mol) was dissolved in DMF (3 mL). 4-ethyl-3-thiosemicarbazide 
(0.191 g, 0.0016 mol) was dissolved in DMF (5 mL) and added HCl (10%, 1 drop) was added. The 
two solutions were combined and left to stir (room temperature, 5 hours). De-ionised water (14 
mL) was added, the precipitate was filtered off and washed with de-ionised water (50 mL). The 
crude product was dissolved in DMSO (8 mL), filtered and recrystallised with de-ionised water (16 
mL). The precipitate was recovered by filtration, washed with de-ionised water (50 mL), ethanol (5 
x 10 mL) and dried. A yellowish-white solid (0.168 g) was recovered (38% yield).  
PDO-Me-NH2 
PDO-Me=O (0.599 g, 0.0032 mol) was dissolved in DMF (2 mL) and filtered. Thiosemicarbazide 
(0.292 g, 0.0032 mol) was dissolved in DMF (10 mL), HCl (10%, 2 drops) was added and filtered. 
The two solutions were combined and left to stir (room temperature, 5 hours). De-ionised water 
(24 mL) was added, the precipitate was filtered off and washed with de-ionised water (50 mL, 
room temperature and 50 mL, 80 oC). The crude product was dissolved in DMSO (31 mL), filtered 
and recrystallised with de-ionised water (62 mL). The precipitate was recovered by filtration, 
washed with de-ionised water (50 mL, room temperature and 50 mL, 80 oC) and dried. An off 





PDO-Et=O (0.322 g, 0.0016 mol) dissolved in DMF (2.5 mL) and filtered. Thiosemicarbazide (0.146 
g, 0.0016 mol) dissolved in DMF (5.5 mL), added HCl (10%, 1 drop) and filtered. The two solutions 
were combined and left to stir (room temperature, 5 hours). De-ionised water (16 mL) was added, 
filtered off precipitate and washed with de-ionised water (50 mL, room temperature and 50 mL, 
70oC). The crude product was dissolved in DMSO (14 mL), filtered and recrystallised with de-
ionised water (28 mL). Filtered off precipitate, washed de-ionised water (50 mL) and dried. A 
white solid (0.237 g) was recovered (54% yield).  
2.5.15. Characterisation data for dissymmetric ligands from PDO-NH2=O, PDO-
Me=O and PDO-Et=O 
PDO-NH2-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.19 (s, 1 H, N-NH), 8.40 (s, 1 H, C-NH), 
8.32 (q, 1 H, H3C-NH, J= 4.8 Hz), 7.74 (s, 1 H, C-NH), 2.97 (d, 3 H, HN-CH3, J= 4.8 Hz), 2.80 (q, 2H, C-
CH2, J= 7.6 Hz), 2.10 (s, 3 H, N=C-CH3), 0.84 (t, 3 H, C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-d6, 
 ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 178.93 (C=S), 152.24 (C=N), 147.92 (C=N), 31.76 (HN-CH3), 17.38 (C-
CH2), 12.38 (N=C-CH3), 11.45 (C-CH2-CH3). IR (neat): cm
-1= 3424 (w), 3223 (w), 2982 (w), 1603 (m), 
1551 (m), 1491 (s), 1437 (m), 1366 (w), 1290 (m), 1231 (m), 1144 (m), 1082 (s), 1063 (s), 989 (w), 
926 (w),  841 (m), 775 (w), 563 (m). Raman (neat): cm-1= 2935 (w), 1603 (s), 1457 (w), 1378 (w), 
1336 (w), 1247 (w), 1145 (w), 1124 (w), 1048 (w), 992 (w), 925 (w), 741 (w), 484 (w), 456 (w), 327 
(w), 226 (w). Elemental analysis: Found: C, 36.9; H, 6.2; N, 32.3. Calc. for C8H16N6S2: C, 36.8; H, 
6.1; N, 32.2%. Melting point: >198 oC (decomposed). 
PDO-NH2-(Me)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.53 (s, 1 H, N-NH), 8.38 (s, 1 H, C-NH), 
7.74 (s, 1 H, C-NH), 3.22 (s, 6 H, N-(CH3)2), 2.77 (q, 2H, C-CH2, J= 7.6 Hz), 2.08 (s, 3 H, N=C-CH3), 
0.88 (t, 3 H, C-CH2-CH3, J=7.6 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 179.32 
(C=S), 153.32 (C=N), 147.88 (C=N), 42.95 (N-(CH3)2), 17.04 (C-CH2), 12.01 (N=C-CH3), 10.92 (C-CH2-
CH3). IR (neat): cm
-1= 3410 (w), 3229 (m), 3148 (w), 2974 (w), 2932 (w), 1593 (m), 1541 (m), 1483 
(s), 1433 (s), 1260 (m), 1105 (s), 1076 (m), 1055 (s), 1020 (m), 989 (m),  926 (m), 843 (m), 511 (s). 
Raman (neat): cm-1= 2934 (w), 1600 (s), 1583 (s), 1495 (w), 1458 (w), 1396 (w), 1367 (w), 1345 
(w), 1246 (w), 1126 (m), 1111 (w), 991 (w), 732 (w), 633 (w), 603 (w), 461 (w), 386 (w), 332 (w). 
Elemental analysis: Found: C, 39.3; H, 6.2; N, 30.6. Calc. for C9H18N6S2: C, 39.4; H, 6.2; N, 30.6%. 





1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.19 (s, 1 H, N-NH), 8.40 (singlet 
overlapping a triplet, 1 H, C-NH), 8.60 (triplet overlapping a singlet, 1 H, H2C-NH, J= 6.0 Hz), 7.74 
(s, 1 H, C-NH), 3.54 (dq, 2 H, HN-CH2, J=7.2, 6.0 Hz), 2.80 (q, 2H, C-CH2, J= 7.2 Hz), 2.14 (s, 3 H, 
N=C-CH3), 1.09 (t, 3 H, N-CH2-CH3, J=7.2), 0.84 (t, 3 H, C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-
d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 177.90 (C=S), 152.19 (C=N), 147.86 (C=N), 39.35 (HN-CH2), 17.04 (C-
CH2), 14.89 (N-CH2-CH3), 12.39 (N=C-CH3), 11.44 (C-CH2-CH3). IR (neat): cm
-1= 3428 (w), 3210 (w), 
2982 (w), 1601 (m), 1537 (m), 1493 (s), 1435 (m), 1290 (m), 1213 (m), 1146 (m), 1080 (s), 1059 
(m), 926 (w), 837 (m), 777 (w),  716 (w), 652 (w), 565 (m), 517 (m). Raman (neat): cm-1= 2934 (w), 
1599 (s), 1589 (m), 1532 (w), 1457 (w), 1395 (w), 1368 (w), 1345 (w), 1247 (w), 1215 (w), 1120 
(m), 1049 (w), 991 (w), 741 (w), 463 (w), 318 (w). Elemental analysis: Found: C, 39.5; H, 6.5; N, 
30.55. Calc. for C9H18N6S2: C, 39.4; H, 6.6; N, 30.6%. Melting point: >218 
oC (decomposed). 
PDO-Me-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.21 (s, 1 H, N-NH), 8.39 (s, 1 H, C-NH), 
8.27 (q, 1 H, H3C-NH, J= 4.8 Hz), 7.80 (s, 1 H, C-NH), 2.98 (d, 3 H, HN-CH3, J= 4.8 Hz), 2.87 (q, 2H, C-
CH2, J= 7.2 Hz), 2.10 (s, 3 H, N=C-CH3), 0.85 (t, 3 H, C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-d6, 
 ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 178.96 (C=S), 152.89 (C=N), 147.48 (C=N), 31.80 (HN-CH3), 17.36 (C-
CH2), 12.21 (N=C-CH3), 11.53 (C-CH2-CH3). IR (neat): cm
-1= 3408 (m), 3337 (w), 3229 (m), 3150 (m), 
2978 (w), 2938 (w), 1603 (m), 1541 (m), 1491 (s), 1464 (s), 1439 (s), 1364 (m), 1227 (m), 1144 (m), 
1082 (s),  1059 (s), 860 (m), 826 (m), 797 (m), 640 (m), 509 (s). Raman (neat): cm-1= 2937 (w), 
1604 (s), 1591 (m), 1591 (w), 1380 (w), 1341 (w), 1232 (w), 1144 (w), 1123 (m), 1024 (w), 985 (w), 
737 (w), 675 (w), 481 (w), 460 (w). Elemental analysis: Found: C, 36.8; H, 6.2; N, 32.2. Calc. for 
C8H16N6S2: C, 36.9; H, 6.2; N, 32.3%. Melting point: >202 
oC (decomposed). 
PDO-Et-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ?, ?E-NH), 10.15 (s, 1 H, N-NH), 8.38 (s, 1 H, C-NH), 
8.28 (t, 1 H, H2C-NH, J= 6.0 Hz), 7.80 (s, 1 H, C-NH), 3.55 (dq, 2 H, HN-CH2, J=7.2, 6.0 Hz), 2.86 (q, 
2H, C-CH2, J= 7.2 Hz), 2.10 (s, 3 H, N=C-CH3), 1.09 (t, 3 H, N-CH2-CH3, J=7.2), 0.86 (t, 3 H, C-CH2-CH3, 
J=7.2 Hz). 13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 177.94 (C=S), 152.77 (C=N), 147.47 
(C=N), 39.07 (HN-CH2), 17.48 (C-CH2), 14.89 (N-CH2-CH3), 12.20 (N=C-CH3), 11.50 (C-CH2-CH3). IR 
(neat): cm-1= 3410 (w), 3333 (w), 3219 (m), 3152 (m), 2978 (w), 1601 (m), 1531 (m), 1493 (s), 1466 
(s), 1439 (s), 1385 (m), 1292 (m), 1250 (m), 1207 (s), 1167 (m),  1146 (m), 1080 (s), 1059 (s), 860 
(m), 818 (m), 797 (m), 652 (m), 501 (s). Raman (neat): cm-1= 2953 (w), 1602 (s), 1589 (m), 1533 
(w), 1456 (w), 1393 (w), 1373 (w), 1347 (w), 1248 (w), 1214 (w), 1146 (w), 1122 (w), 1027 (w), 990 
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(w), 741 (w), 464 (w), 306 (w). Elemental analysis: Found: C, 39.3; H, 6.5; N, 30.55. Calc. for 
C9H18N6S2: C, 39.4; H, 6.6; N, 30.6%. Melting point: >200 
oC (decomposed). 
2.5.16. Spectral examples of a dissymmetric ligand with a Me/Et backbone 
Figures 2.5.16.1-4. Spectral examples of the dissymmetric ligand PDO-Me-NH2. 
Figure 2.5.16.1. An assigned 
1
H NMR spectrum of PDO-Me-NH2, which was successfully synthesised by 
reacting PDO-Me=O with thiosemicarbazide. The red boxes show a small presence of the ligand PDO-NH2- 
Me, which is due to the 4-methyl-3-thiosemicarbazide reacting with the second isomeric form of PDO-Me=O 
(Isomer B, Figure 2.5.5.1.).   
Figure 2.5.16.2. An assigned 
13
C NMR spectrum of PDO-Me-NH2. 
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Figure 2.5.16.3. A FTIR spectrum of PDO-Me-NH2. 
Figure 2.5.16.4. A Raman spectrum of PDO-Me-NH2. 
2.5.17. Discussion 
All five ligands were made with an acceptable level of purity. No reports have been found of any 
attempts to synthesise dissymmetric ligands with Me/Et on the imine backbone so it is believed 
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that all five ligands are novel. The same method was successfully used for reacting the PDO 
intermediate with a dissimilar 4-substituted-3-thiosemicarbazide as was used for the ligands with 
Me/Me and Me/H on the backbone. Due to lack of published data on these ligands, the only 
possible comparison that could be made is with other ligands made in this project. Assignments 
made for NMR, IR and Raman for other ligands with different backbones/ amine substituents 
seem to hold roughly true with this class of ligands as well.   
 As predicted the main impurity peaks suggests the presence of the isomeric form of the target 
ligand. Just by using NMR spectroscopy, it is possible to confirm the presence of these impurities 
and determine their relative proportions by using the N=C-CH3 environment. Other peaks in the 
spectra tend to partially or fully overlap owing to very similar chemical environments. When 
overlapping of peaks occurred it was not possible to determine reliable integrals.  Some of the 
isomeric forms of the ligands have already been synthesised as they are also target ligands, where 
this is the case it is possible to directly compare the positions of their NMR peaks. This is 
illustrated by the by the 1H NMR peaks of the N=C-CH3 environments of PDO-Me-NH2 and PDO-
NH2-Me showing the presence of the second isomeric form of the target ligand (Figure 2.5.17.1.).  
 
Figure 2.5.17.1. Left: 
1
H NMR peaks of the N=C-CH3 environment of PDO-Me-NH2 showing a small presence 
of PDO-NH2-Me. Right: 
1
H NMR peaks of the N=C-CH3 environment of PDO-NH2-Me showing the presence of 
PDO-Me-NH2. 
There was also evidence of a small proportion of unreacted intermediates which have been seen 
throughout. To echo what was said earlier, as these ligands are to be initially screened for their 
appropriateness as hypoxia imaging agents, a small presence of an isomeric impurity should not 
be detrimental to the screening process. If it was found that each isomeric form had significantly 
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different pharmacokinetics or bio-distribution, it would then be necessary to revisit the method of 
synthesis in order to synthesize ligands with greater purity.  
Melting point data was collected on all the bis(thiosemicarbazone) ligands and their respective 
intermediates. It was found that all that all the ligands and most of the intermediates showed 
signs of decomposition before they melted. The exceptions to this was the intermediates PDO-
Me=O, PDO-Et=O, DMA-Me-(OMe)2 and PADA-Me-(OMe)2 which melted to form a transparent 
liquid. When the ligands and intermediates decomposed they started to turn from a white/off 
white or light yellow colour to a brown solid. The decomposition temperature was taken at the 
point when the sample first started to turn brown or discolour. For a couple of ligands, the sample 
was continued to be heated past the temperature where signs of decomposition was shown, it 
was witnessed that the solid would continue to turn browner and then will eventually melt and 
form a brownish black liquid. The range of decomposition temperatures that was collected for all 
the intermediates and ligands was 138-192oC and 180-250oC respectively. Table 2.5.17.2. reports 
the five dissymmetric ligands that have been successfully made along with the main impurity 
present and at what proportion this impurity is estimated at. 







































































*Estimated by 1H NMR spectra on an average of the integral from the peaks due to the N=C-CH3 
environment. No other peaks yielded usable integrals.  
Table 2.5.17.2. Summary of purity for the dissymmetric Ligands with Me/Et backbones, synthesised by the 








2.6. Formation of a PDO-NH2=O cyclic by-product  
 
The first reaction conditions used to attach 4-methyl-3-thiosemicarbazide to PDO-NH2=O was to 
dissolve the reagents in water and run the reaction at 6O 0C with a drop of 10% HCl (Figure 
2.6.0.1.).  The 1H NMR spectrum of the first attempt to synthesise PDO-NH2-Me (Figure 2.6.0.2.) 
showed a relatively high presence of a previously un-encountered by-product.  
Unkown by-
product
 50ml H20, 60oC, 1 drop 
10% HCl, 5Hrs
Figure 2.6.0.1. A reaction scheme showing the conditions used when the unknown by-product was first 
observed. 
Figure 2.6.0.2. A 
1
H NMR spectrum of PDO-NH2-Me attempt 1, showing the presence an unfamiliar by-
product (red boxes). 
It is possible to see that PDO-NH2-Me was successfully synthesised. The red boxes highlight the 
presence of an unfamiliar by-product in relatively high proportions. A similar reaction using PDO-
Me=O and thiosemicarbazide did not show signs of a new by-product. On consultation of the 
literature, there were reports of bis(thiosemicarbazone) ligands forming cyclic by-products and 
that some of these cyclic by-products are produced from mono-substituted-3-thiosemicarbazone 
intermediates.57-59, 87, 88  
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In an attempt to avoid the formation of this by-product the reaction was ran without acid and at 
room temperature. As the PDO-NH2=O intermediate does not fully dissolve in water at room 
temperature the reagents has to be dissolved in the minimum volume of DMF. The resulting 
product was a mixture of roughly 50% of the target molecule with the rest of the sample 
comprising up of the unreacted intermediate and 4-methyl-3-thiosemicarbazide however, the 
suspected cyclic by-product was absent. This is illustrated in Figure 2.6.0.3. 
 7 ml DMF,                   
room temperature, 3 days
Figure 2.6.0.3. Reaction conditions that yielded no by-product.  
As this new by-product was not observed in the synthesis of the intermediate PDO-NH2=O, which 
involves the presence of much higher concentrations of HCl, a hypothesis was formed that the 
acid was not responsible for the formation of this new by-product. The previous reaction was 
repeated with the presence of HCl and was only stirred for 5 hours at room temperature (Figure 
2.6.0.4.). The resulting product contained roughly 92% of the target ligand and the impurities 
where the common ones observed throughout the synthesis of this class of ligand. The new by-
product was completely absent from the resulting solid.  
 7 ml DMF, room temperature,   
1 drop 10% HCl, 5 hours
Figure 2.6.0.4. Successful synthesis of the dissymmetric ligand PDO-NH2-CH2 without the presence of the 
unknown by-product.  
In order characterise the new by-product, and to discover if it is indeed cyclic, the by-product was 
purposely synthesised (Figure 2.6.0.5.). 
Cyclic 
by-Product
 50 ml H20, 60 oC, 1 drop 10% 
HCl, 2 days
 
Figure 2.6.0.5. Conditions used to cleanly synthesise the unknown by-product. 
A yellow solid, with a high purity was produced and the solid was subjected to a range of NMR 





PDO-NH2=O (0.277 g, 0.0016 mol) was dissolved in de-ionised water (50 mL, 60 
oC) and any 
insoluble particulates was removed by filtration. HCl (10%, 1 drop) was then added and the 
solution was left to stir (60 oC, 2 days). The precipitate was filtered off and washed with de-
ionised water (100 mL) and dried. A yellow solid (0.135 g) was recovered (35% yield). 
2.6.2. Characterisation data and tentative assignments for PDO-NH2=O cyclic 
1H NMR (DMSO-d6, 400 MHz): ɷA? ? ? ? ? ? ?Ɛ ? ?, ?-NH), 10.18 (s, 1 H, N-NH), 4.77 (q, 1 H, C=CH, J= 
7.6 Hz), 1.86 (s, 3 H, N=C-CH3), 1.62 (d, 3 H, C=CH-CH3, J=7.6 Hz). 
13C {1H} NMR (DMSO-d6, 100 
D,ǌ ) PɷA? ? ? ? ? ? ? ?C=S), 147.76 (C=N), 127.27 (N-C=CH), 101.44 (C=CH), 18.52 (N=C-CH3), 11.22 
(C=CH-CH3). IR (neat): cm
-1= 3244 (m), 1713 (m), 3129 (m), 2945 (m), 1653 (m), 1607 (m), 1545 (s), 
1470 (m), 1445 (m), 1423 (m), 1398 (m), 1354 (m), 1296 (m), 1219 (s), 1140 (m),  1094 (m), 1061 
(s), 1034 (m), 735 (s), 671 (s), 617 (s), 546 (s). Raman (neat): cm-1= 2910 (w), 1653 (m), 1605 (m), 
1595 (w), 1536 (w), 1432 (w), 1370 (w), 1347 (w), 1298 (w), 1244 (w), 1212 (m), 1127 (w), 1059 
(w), 932 (w), 673 (w), 623 (w), 544 (w), 502 (m), 416 (w), 364 (w), 196.3 (w), 109 (w). 
(Fluorescence was present). Elemental analysis: Found: C, 46.3; H, 5.9; N, 26.95. Calc. for 
C6H9N3S1: C, 46.4; H, 5.8; N, 27.1%. Melting point: >196 
oC (decomposed). 
2.6.3. Proposition of the cyclic by products structure 
Using the above techniques the structure of the cyclic by-product (Figure 2.6.3.1.) is proposed.  
The cyclic by-product shall be referred to from now on as PDO-NH2 cyclic.  
 
Figure 2.6.3.1. The proposed structure of PDO-NH2 cyclic. 
Therefore the proposed reaction scheme (Figure 2.6.3.2.) is: 
 50 ml H20, 60 oC, 1 drop 10% 
HCl, 2 days
 
Figure 2.6.3.2. The reaction scheme of PDO-NH2 cyclic. 
147 
 
2.6.4. Validation of the proposed structure of PDO-NH2=O cyclic 
The proton NMR spectrum (Figure 2.6.4.1), below supports the proposed structure of PDO-NH2 
cyclic as all the integrals and splitting patterns one would expect corresponding to the proposed 
structure are present. The key difference in this spectrum that is not seen in spectra of ligands or 
intermediates with a Me/Et backbone is the quartet environment ŵĂƌŬĞĚ ‘ ?ǁŚŝĐŚŝƐĐĞntered at 
4.77 ppm.  This peak suggests the presence of a double bond as the chemical shift is within the 
range of a typical alkene. The existence of a carbon-carbon double bond would only allow a single 
ŚǇĚƌŽŐĞŶĂƚƚŚĞ ‘ ?ůŽĐĂƚŝŽŶ, the integral of 1H agrees with the suggestion that the carbon double 
bond is between carbon position  ‘ ?ĂŶĚ ‘ ?(Figure 2.6.4.2.) ?dŚĞĚŽƵďůĞƚŵĂƌŬĞĚ ‘ ?(Figure 
2.6.4.1.) is consistent with the splitting pattern you would expect when a methyl substituent is 
coupled with a C=CH group, according to the 2In+1 rule, where I is the spin quantum number and 
n is the number of adjacent hydrogen atoms . This coupled with the absence of the quartet 
centred at 2.90 ppm relating to the CH2-CH3 environment, further supports a single hydrogen at 
ƚŚĞ ‘ ?ůŽĐĂƚŝŽŶ ?dŚĞĂďƐĞŶĐĞŽĨĂŚǇĚƌŽŐĞŶĨƌŽŵƚŚĞ-NH2 environment, which is normally 
expected between 8 and 9 ppm, coupled with the single N-H location shifting from 8-9 ppm to 
10.2 ppm supports that one of the terminal hydrogen atoms of the C-NH2 group of PDO-NH2=O 
has been removed. This backs-up that the nitrogen of the remaining C-NH group is likely to be 
singly bound to another atom, most likely the carbon of the ketone carbonyl group.    
Figure 2.6.4.1. An assigned 
1
H NMR spectrum of PDO-NH2=O cyclic. 
The first supporting aspect of the carbon spectrum below (Figure 2.6.4.2.) is that the peak 
normally located at 200 ppm has shifted down to 130 ppm, this indicates that the ketone carbonyl 
group is no longer present. As the C=N group is typically found at chemical shifts of around 145 
ƉƉŵ ?ŝƚƌĞĂƐŽŶĂďůĞƚŽƐƵŐŐĞƐƚƚŚĂƚĐĂƌďŽŶ ‘ ?ŝƐŝŶĂƐŝŵŝůĂƌĞŶǀŝƌŽŶŵĞŶƚǁŚŝĐŚŝƐƐůŝŐŚƚůǇůĞƐƐ
electron withdrawing  e.g. C-E ?dŚĞƉƌĞƐĞŶĐĞŽĨƚŚĞĚŽƵďůĞďŽŶĚďĞƚǁĞĞŶĐĂƌďŽŶƐ ‘ ?ĂŶĚ ‘ ?ŝƐ
ĂůƐŽďŽƵŶĚƚŽŚĂǀĞĂŶĞĨĨĞĐƚŽĨƚŚĞƉŽƐŝƚŝŽŶŽĨƉĞĂŬ ‘ ? ?dŚĞŵŽƐƚŶŽƚĂďůĞĞŶǀŝƌŽŶŵĞŶƚĚƵĞƚŽƚŚŝƐ
148 
 
ĚŽƵďůĞďŽŶĚŝƐƉŽƐŝƚŝŽŶ ‘ ?ǁŚŝĐŚŝƐŝŶƚŚĞregion ǁŚŝĐŚƐƵŐŐĞƐƚƐĐĂƌďŽŶ ‘ ?ŝƐŝŶĂƐŝŵŝůĂƌƐŝƚĞƚŽ
R2C=CH2. 
Figure 2.6.4.2. An assigned  
13
C NMR of spectrum of PDO-NH2=O cyclic. 
Figure 2.6.4.3. A HMQC NMR spectrum of PDO-NH2=O cyclic, supporting the presence the double bond 
within the enamine functionality of PDO-NH2=O cyclic. 
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The above HMCQ NMR spectrum (Figure 2.6.4.3.) makes it possible to determine which of the 
hydrogen environments (labelled by the letters A-C) are directly bound to which carbon locations 
(labelled by the letters Y-Z). Firstly the spectra confirms that both the hydrogen locaƚŝŽŶƐ ‘ ?ĂŶĚ
 ‘ ?ĂƌĞďŽƵŶĚƚŽĐĂƌďŽŶ ‘ ?ĂŶĚĐĂƌďŽŶ ‘y ?ƌĞƐƉĞĐƚŝǀĞůǇŝŶŽƌĚĞƌƚŽĨŽƌŵƚǁŽ,3 groups on the 
backbone of the molecule.  A strong piece of evidence to the structure of this by product is that 
the HMQC spectra ƐŚŽǁƐƚŚĂƚƚŚĞƐŝŶŐůĞƉƌŽƚŽŶ ‘ ?ŝƐĚŝƌĞĐƚůǇďŽƵŶĚƚŽĐĂƌďŽŶ ‘z ?, illustrated by 
the red box, which supports the presence of a double carbon bond. There is no coupling data 
present that advocates a different structure.  
Figure 2.6.4.4.  A HMBC NMR spectrum of PDO-NH2=O cyclic, supporting the cyclic confirmation of PDO-
NH2=O cyclic. 
This HMBC spectrum (Figure 2.6.4.4.) makes it possible to look at the couplings between 
hydrogen atoms (labelled by the letters V-Z) and carbons (labelled by the letters A-F) which are 
not directly attached to each other. By looking at the spectra, the couplings are consistent with 
those which are expected for the proposed structure and there are no extra couplings which 
suggest a different structure. The two most informative couplings are indicated by the red boxes. 
dŚĞƐĞĐŽƵƉůŝŶŐƐŚŽǁƚŚĂƚƚŚĞŚǇĚƌŽŐĞŶ ‘W ?ŝƐďŽƵŶĚŝŶĂůŽĐĂƚŝŽŶƚŚĂƚĂůůŽǁƐŝƚƚŽŚĂǀĞĂ
ĚĞƚĞĐƚĂďůĞĐŽƵƉůŝŶŐǁŝƚŚĐĂƌďŽŶƐ ‘ ?ĂŶĚ ? ? ?dŚŝƐŝƐǀĞƌǇƐƚƌŽŶŐĞǀŝĚĞŶĐĞƚŚĂƚƚŚĞŶŝƚƌŽŐĞŶǁŚŝĐŚ
ƚŚĞŚǇĚƌŽŐĞŶŝƐďŽƵŶĚŝƐůŝŶŬĞĚƚŽĐĂƌďŽŶ ‘ ? ?dŚĞŽŶůǇĚŝƐĐƌĞƉĂŶĐǇƉƌĞƐĞŶƚŝƐƚŚĂƚĂĐŽƵƉůŝŶŐŝƐ
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expected ďĞƚǁĞĞŶŚǇĚƌŽŐĞŶ ‘W ?ĂŶĚĐĂƌďŽŶ ‘& ? ?ƚŚŝƐŵĂǇũƵƐƚďĞĚƵĞƚŽƚŚŝƐƉĂƌƚŝĐƵůĂƌĐŽƵƉůŝŶŐ
being particularly weak, which results in the interaction not being detected. The interaction must 
be unique to the C(=S)-N(-H)-C environment as a coupling is observed bĞƚǁĞĞŶĐĂƌďŽŶ ‘& ?ĂŶĚ
ŚǇĚƌŽŐĞŶ ‘V ? ?An article by J. Adams et al.205 reports the same cyclic by-product. There is very little 
information about the synthesis of this compound, but the proton NMR data matches.   
Proposed mechanism for the formation of PDO-NH2 cyclic: 
The following scheme (Figure 2.6.4.5.) sets out the suggested mechanism of the formation of the 
PDO-NH2 cyclic by-product, which is formed when the amine nitrogen attacks the carbonyl 
carbon. This is followed by a series of proton transfer steps in order to form the cyclic by-product. 
It is expected that the cyclic by-product should be in some level of equilibrium with the other 
mechanistic products, but as the NMR shows no significant extra peaks then it can be assumed 





Figure 2.6.4.5. The proposed mechanism for the formation of PDO-NH2=O cyclic.  
2.6.5. Summary 
All the spectra strongly support the proposed structure of PDO-NH2 cyclic (Figure 2.6.5.1.). This is 
validated by NMR data that has previously been reported.205 There are no other feasible 
alternative structures that also satisfy the experimental data. 
 
Figure 2.6.5.1. The proposed structure of PDO-NH2 cyclic. 
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2.7. Ligands with H/H backbones 
Application 
It was hoped that the synthetic methods applied for the synthesis of dissymmetric ligands 
covered in the previous sections could be easily transferred to the synthesis of dissymmetric 
ligands with H/H on the backbone.  This class of ligand may have the desired properties in be of 
interest in the study of copper trafficking within the brain, similar to the hopes for the ligands 
with Me/H on the backbone.   
The literature has reported that the symmetric copper complex of Gly-Me-Me is able to cross the 
blood brain barrier. After being reduced by intracellular processes the copper becomes available 
to the cell182. With this in mind it hoped that synthesising a range of dissymmetric ligands with 
H/H on the backbone for biological screening would identify the most effective ligand to use for 
the above application.  Donnelly et al.76 has previously investigated a range of symmetric 
bis(thiosemicarbazone) complexes, including the three ligands with H/H on the backbone, but for 
a therapeutic application instead of investigation of neurodegenerative diseases, such as 
ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ?tŝƚŚƚŚĞƐĞƚǁŽƉŝĞĐĞƐŽĨƌĞƐĞĂƌĐŚŝŶ ŵŝŶĚŝƚǁĂƐĚĞĐŝĚĞĚƚŽƚƌǇƚŽĂƚƚĞŵƉƚ
the synthesis of dissymmetric ligands with H/H on the backbone and, if successful, make a range 
of ligands with relatively lipophilic substituents on the side arms so that the resulting complexes 
can cross the blood brain barrier and deposit radio-copper in the brain. The radio-copper can then 
be monitored via PET in order to investigate the migration of the copper in neurodegenerative 
disorders in order to elucidate the cellular mechanisms which could present a potential target for 
therapy. The chemistry reported by B. Paterson et al.73 gives rise to an interest in dissymmetric 
ligands that contain a dimethyl side arm, as these could be potentially useful for the synthesis of 
dual labelled complexes. GLY-Me-(Me)2 is a ligand that is of interest for this application and 
therefore GLY-Me-(Me)2 is the initial target dissymmetric ligand to synthesise.   
2.7.1. Symmetric ligands with H/H backbones 
Even though the main focus is the synthesis of dissymmetric ligands, two symmetric ligands were 
synthesised in order to establish the precursors ? chemistry and their NMR spectroscopy and 
vibrational spectra.  
Overview of reaction 
The synthesis of this subgroup of ligands requires  glyoxal (GLY) to be combined with a chosen 4-
substituted-3-thiosemicarbazide under acidic conditions in water or a water/ethanol solution at 






 R1 R2 
GLY-Et-Et CH2CH3 H 
GLY-Ph-Ph C6H5 H 
Figure 2.7.1.1. The general reaction for the synthesis of symmetric ligands with H/H backbones. 
GLY-Et-Et GLY-Ph-Ph
 
 Figure 2.7.1.2. Structures of the symmetric ligands with H/H backbones that were synthesised. 
2.7.1. Methods  
GLY-Et-Et 
4-Ethyl-3-thiosemicarbazide (1.311 g, 0.011 mol) was dissolved in de-ionised water (75 mL, 50 oC). 
HCl (32%, 3 drops) was added, followed by the rapid addition of glyoxal (40 wt. % solution, 0.58 
mL, 0.005 mol) and the solution was left to stir (50 oC, 10 minutes). The precipitate was recovered 
by filtration and washed with de-ionised water (4 x 50 mL). The solid was dried. A cream solid 
(1.286 g) was recovered (99% yield).  
GLY-Ph-Ph 
4-phenyl-3-thiosemicarbazide (1.840 g, 0.011 mol) was dissolved in an ethanol solution (de-
ionised water 100 mL, ethanol 52 mL, 50 oC).  HCl (32%, 8 drops) was added followed by the rapid 
addition of glyoxal (40 wt. % solution, 0.58 mL, 0.005 mol).  The solution was left to stir (50 oC, 10 
minutes). The precipitate was filtered off and washed with de-ionised water (4 x 50 mL). The solid 






2.7.2. Characterisation data for symmetric ligands with H/H backbones 
GLY-Et-Et 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ? H, N-NH), 8.50 (t, 1 H, C-NH, J= 6.0 Hz), 7.68 (s, 2 H, 
N=C-H), 3.49 (dq, 4 H, H2C-NH, J=7.2, 6.0 Hz), 1.06 (t, 6 H, H2C-CH3, J= 7.2 Hz ). 
13C {1H} NMR 
(DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C=S), 140.60 (C=N), 38.92 (N-CH2), 14.89 (H2C-CH3). IR (neat): cm-
1= 3370 (m), 3130 (m), 2982 (m), 1570 (w), 1514 (s), 1470 (m), 1373 (w), 1323 (m), 1281 (m), 1207 
(s), 1070 (s), 1040 (m), 961 (w), 908 (m), 806 (m), 692 (w), 642 (m), 623 (s), 538 (s), 426 (m).  
Raman (neat): cm-1= 3370 (w), 3128 (w), 1589 (s), 1526 (m), 1413 (w), 1301 (w), 1166 (m), 1148 
(w), 1119 (w), 1046 (w), 924 (w), 791 (w), 420 (w), 207 (w), 142 (w). Melting point: >210 oC 
(decomposed).  
GLY-Ph-Ph 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ?.12 (s, 2 H, N-NH), 10.17 (s, 2 H, Ph-NH), 7.86 (s, 2 H, N=C-H), 
7.51 (d, 4 H, H(2,6) aryl), 7.32 (dd, 4 H, H(3,5) aryl), 7.16 (t, 2 H, H(4) aryl). 
13C {1H} NMR (DMSO-d6, 100 
D,ǌ ) PɷA? ? ? ? ? ? ? (C=S), 141.24 (C=N), 139.40 (C(1) aryl), 128.61 (C(3,5) aryl), 126.08 (C(2,6) aryl), 
125.89(C(4) aryl). IR (neat): cm
-1= 3296 (m), 3154 (w), 2988 (w), 1595 (m), 1537 (s), 1504 (s), 1443 
(m), 1383 (m), 1308 (w), 1252 (s), 1184 (s), 1082 (m), 1026 (m), 937 (m), 924 (m), 899 (w), 770 
(m), 748 (s), 689 (s), 658 (m), 613 (m), 581 (s), 494 (s), 469 (s).  Raman (neat): cm-1= 1588 (s), 1546 
(w), 1512 (w), 1301 (w), 1212 (w), 1169 (s), 1121 (w), 1002 (w), 930 (w), 768 (w), 745 (w), 652 (w), 
349 (w), 335 (w), 261 (w), 224 (w), 197 (w). Melting point: >250 oC (decomposed). 
2.7.3. Spectral examples of a symmetric ligand with an H/H backbone 
Figures 2.7.3.1-4. Spectral examples of ligand GLY-Ph-Ph.
Figure 2.7.3.1. An assigned 
1





Figure 2.7.3.2. A assigned 
13
C NMR spectrum of GLY-Ph-Ph.
 




Figure 2.7.3.4. A Raman spectrum of GLY-Ph-Ph. 
2.7.4. Discussion  
The synthetic method of both GLY-Et-Et and GLY-Ph-Ph was similar to the synthesis of previous 
symmetric ligands that have been reported in this chapter. Both products were recovered with 
excellent yields and with no signs of significant impurities in their NMR spectra (Table 2.7.4.1.). 
The NMR data recorded for GLY-Ph-Ph is in close agreement with the literature76 and the NMR 
and IR data for GLY-Et-Et is also a good fit to the literature values.210 No further reports on any 
characterisation data could be found for GLY-Et-Et or GLY-Ph-Ph. 
Table 2.7.4.1. A summary of purity for the symmetric ligands with H/H backbones. 





















*Estimated by 1H NMR spectra using the integrals of the N=CH environments.  
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2.7.5. Attempts to synthesise dissymmetric ligands with H/H backbones 
 
Two synthetic approaches were attempted in the pursuit of the synthesis of dissymmetric ligands 
with H/H on the backbone. The first was using the exploitation of carbonyl reactivity which has 
been successfully used to synthesise the dissymmetric ligands in sections 2.3.-2.5. The second 
method used was using acetal protecting approach, a method which was explored in section 2.2. 
2.7.6. Attempts by the exploitation of carbonyl reactivity differences 
Overview of reaction 
The first attempts used the same principal as all the previous mono-substituted-3-
thiosemicarbzone intermediates were synthesised by, which involved reacting a 4-substituted-3-
thiosemicarbazide with one of the carbonyl groups of the backbone precursor (glyoxal). The 
second unreacted ĐĂƌďŽŶǇůŐƌŽƵƉ ?ƐƌĞĂĐƚŝǀŝty should reduce enough so that the formation of the 
symmetric bis(thiosemicarbazones) would not be favourable, thus resulting in the creation  of a 
pure mono-substituted-3-thiosemicarbzone. Once this mono-substituted-3-thiosemicarbzone 
intermediate was isolated then it could be reacted with a dissimilar 4-substituted-3-
thiosemicarbzide to yield the desired dissymmetric ligand (Figure 2.7.6.1.).  This rationale was 
backed up by a paper written by P. Waghorn et al.92 which claimed that the mono-methyl-3-
thiosemicarbazone of glyoxal had been achieved by using a method that was briefly reported, 
which seems to be almost identical method which had been implemented in the formation of 
previous intermediate mono-substituted-3-thiosemicarbazones reported in this chapter.   
2)
1) Conc. HCl, 0-5 oC
       10% HCl
 





Method of the first attempt to synthesise GYL-Me=O: 
4-methyl-3-thiosemicarbazide (1.157 g, 0.011 mol) was dissolved in de-ionised water (100 mL). 
The solution was cooled (2.6 oC) over ice, followed by the addition of HCl (32%, 5 drops). The 
solution was cooled further (0.7 oC). Glyoxal (40 wt. % solution, 5.05 mL, 0.044 mol) was added 
rapidly and vigorously stirred (5 oC, 10 minutes). The precipitate was recovered via filtration, 
washed with de-ionised water (4 x 50 mL) and dried. A yellow solid (0.485 g) was recovered. 
Result: 
Disappointingly, despite excess of backbone, the product recovered was by the vast majority the 
symmetric ligand GLY-Me-Me with only a very small proportion being the desired intermediate 
GLY-Me=O. The estimated proportions of both these products were 94-93% and 6-7% 
respectively.   
Alteration 1: 
The above method was repeated but instead of cooling the reaction between 5.0-0.7 oC the 
reaction would be cooled to below 0 oC using a salt/ice bath because of this, the reaction solvent 
had to be changed to an ethanol/water mixture in order to stop the reaction mixture freezing. 
The excess of glyoxal backbone was increased and the overall reactions proportions were scaled 
up but the volume of HCl was kept the same. The justification for this was hopefully to make the 
formation of GLY-Me=O more favourable than GLY-Me-Me and even if this was not successful 
there should be enough GLY-Me=O in the resulting product in order to attempt an extraction 
method. 
Method of the first alteration for the synthesis GYL-Me=O: 
4-methyl-3-thiosemicarbazide (2.314 g, 0.022 mol) was dissolved in water/ethanol solution (200 
mL de-ionised water, 120mL ethanol). The solution was cooled (-10 oC) in a salt/ice bath (100 g 
table salt, 300 g ice), followed by the addition of HCl (32%, 5 drops). The solution was cooled 
further (-11.6 oC). Glyoxal (40 wt. % solution, 12.62 mL, 0.110 mol) was added rapidly and 
ǀŝŐŽƌŽƵƐůǇƐƚŝƌƌĞĚ ?A?-11.5 oC, 15 minutes). The precipitate was recovered via filtration, washed 
with de-ionised water (4 x 50 mL) and dried. A yellow solid (0.430 g) was recovered. 
A second precipitate formed in the filtrate which was filtered off, washed with a little water and 






It was initially found that no precipitate had formed after 10 minutes so the reaction length was 
extended by a further 5 minutes. An estimate of the first product purity by NMR integrals was 90-
89% GLY-Me-Me and 11-9% GLY-Me=O.  Analysis of the second precipitate gave a purity 
estimated of 81-84% GLY-Me-Me and 16-19% GLY-Me=O.  
The expectations from the alterations were supported by the results but disappointingly the 
difference in GLY-Me=O proportion was only small.  The method was repeated with the reaction 
solution being cooled down to low as possible using the salt/ice bath. The minimum temperature 
achieved was about -17 oC but this did not improve the proportion of GLY-Me=O.  
Extraction attempts:  
Attempts to extract the GLY-Me=O from the samples was undertaken using hot water and then 
hot diethyl ether. Water was chosen because it has observed that hot water could remove mono-
substituted-3-thiosemicarbzones when purifying bis(thiosemicarbazone) ligands and indeed had 
been used for the purpose with in the synthetic methods of bis(thiosemicarbazone) ligands 
reported earlier in this chapter.  Diethyl ether was chosen because in the exploration of 
synthesising dissymmetric ligands with Me/Me and Me/H on the backbone by the protection 
approach, diethyl ether had been used to extract the desired intermediate from a mixed product. 
Unfortunately when extractions were attempted with either water or diethyl ether they both 
yielded a product that on analysis via NMR produced messy, unsolvable NMR spectra.  
Based on the lack of success from the exploitation of the carbonyl groups method and without 
any other feasible avenue to pursue with in this method, it was decided to re-visit the acetal 
protection approach in order to see if this approach could be successful.     
2.7.7. Attempts by the acetal protection method 
Overview of plan 
The plan devised was to take 2,2-dimethoxyacetaldehyde (DMA) and react a 4-substituted-3-
thiosemicarbzide to the only carbonyl group in order to produce a protected-mono-substituted-3-
thiosemicarbzone with H/H on the backbone. The next step would entail finding a method to 
hydrolyse the acetal groups to an aldehyde functionality and attach a different 4-substituted-3-






Figure 2.7.7.1. The proposed schematic for the synthesis of dissymmetric ligands with H/H backbones via the 
acetal protection method. 
In order to achieve the protected-mono-substituted-3-thiosemicarbzone from reaction 1, it was 
decided to use water as the reaction solvent with an acid catalysis but at reduced temperature 
and 10 times excess of backbone in order to prevent formation of the symmetric 
bis(thiosemicarbazide).    
Method of the first attempt to synthesise DMA-Me-(OMe)2: 
4-methyl-3-thiosemicarbazide (0.500 g, 0.0048 mol) was dissolved in de-ionised water (30 mL). 
Solution cooled (7 oC) over ice, followed by the addition of HCl (32%, 1 drop). The solution was 
cooled further (4 oC). 2,2-dimethyoxyacetaldehyde (60 wt. % solution, 8.02 mL, 0.053 mol) was 
added rĂƉŝĚůǇĂŶĚǀŝŐŽƌŽƵƐůǇƐƚŝƌƌĞĚ ?A? ? ? ? oC, 1 hour). The precipitate was recovered via filtration 
and dried. An off white solid (0.018 g) was recovered yield (7%). 
Result: 
Overall the reaction was a success, the NMR spectra identified that DMA-Me-(OMe)2 was 
successfully synthesised even though the yield was very low.  It is believed that DMA-Me-(OMe)2 
is a novel compound. Via NMR it was estimated that there was a 1% impurity of GLY-Me-Me.  
The reaction was scaled up by a factor of 10 in order to yield suitable quantities of intermediate in 




Method of the scaled up synthesis of DMA-Me-(OMe)2: 
4-methyl-3-thiosemicarbazide (5.000 g, 0.0475 mol) was dissolved in de-ionised water (220 mL). 
Solution cooled (7 oC) over ice, followed by the addition of HCl (32%, 7 drops). The solution was 
cooled further (3 oC). 2,2-dimethyoxyacetaldehyde (60 wt. % solution, 8.02 mL, 0.053 mol) was 
added rĂƉŝĚůǇĂŶĚǀŝŐŽƌŽƵƐůǇƐƚŝƌƌĞĚ ?A? ? oC, 1 hour). The precipitate was recovered via filtration 
and dried in air. A yellow solid (3.610 g) was recovered (40% yield). 
Result: 
The yield of the reaction increased to a more workable quantity. On analysis of the NMR spectra 
the product contained DMA-Me-(OMe)2 and GLY-Me-Me in the quantities 98% and 2% 
respectively.  These estimates were calculated from the integrals from the proton NMR spectra. 
As there was a presence of GLY-Me-Me, this suggests that a little of either the backbone or the 
protected intermediate can be hydrolysed to yield the undesired symmetric ligand. This should be 
kept in mind as a change in reaction conditions could increase the hydrolysis of the acetal 
protecting groups in the reaction mixture giving an increased level of undesired impurity. 
The scaled up method above was tried again with all the reaction conditions being kept identical 
besides the drying method, which involved using an oven at 25-30 oC. The yellow product changed 
to a brown/yellow colour which suggests that the product is heat sensitive. The product produced 
turned out to contain the expected DMA-Me-(OMe)2 and GLY-Me-Me, but in the proportions of 
11% and 89% respectively. This heat sensitivity needs to be taken into account when drying the 
sample and in the design of the de-protection method.   
Characterisation data for DMA-Me-(OMe)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ?Ɛ ? ? H, N-NH), 8.25 (q, 1 H, C-NH, J= 4.8 Hz), 7.23 (d, 1 H, 
N=C-H, J= 5.6 Hz), 4.67 (d, 1 H, O-C-H, J= 5.6 Hz), 3.26 (s, 6 H, O-CH3), 2.91 (d, 3 H, N-CH3, J= 4.8 
Hz). 13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C=S), 141.25 (C=N), 102.53 (HC-O), 53.91 (O-
CH3), 31.35 (N-CH3). IR (neat): cm
-1= 3256 (w), 3154 (w), 3003 (w), 2832 (w), 1553 (m), 1531 (m), 
1443 (w), 1383 (w), 1337 (w), 1285 (m), 1254 (m), 1211 (w), 1188 (w), 1130 (m), 1063 (s), 1028 
(m), 959 (s), 806 (w), 660 (m), 608 (m), 550 (w), 501 (w). Raman (neat): cm-1= 1633 (w), 1591 (s), 
1529 (w), 1179 (m), 1143 (w), 1121 (w), 966 (w), 795 (w), 608 (w), 285 (w). Fluoresce present. 
Melting point: 106-107 oC.  
Spectral examples of DMA-Me-(OMe)2 
Figures 2.7.7.2-5. Spectral examples of DMA-Me-(OMe)2. 
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Figure 2.7.7.2. An assigned  
1
H NMR spectrum of DMA-Me-(OMe)2.This intermediate was produced by 
reacting 2,2-dimethyoxyacetaldehyde with 4-methyl-3-thiosemicarbazide. The blue boxes suggest small 
presence of an impurity that is expected to be GLY-Me-Me.  
 
Figure 2.7.7.3. An assigned
 13





Figure 2.7.7.4. A FTIR spectrum of DMA-Me-(OMe)2.  
 
Figure 2.7.7.5. A Raman spectrum of DMA-Me-(OMe)2. Fluorescence is present. 
2.7.8. Attempts by hydrolyse DMA-Me-(OMe)2 to GLY-Me=O and attach a second 
arm in one step 
Taking what was learnt from hydrolysing the acetal group of PADA in the section about ligands 
with Me/H on the backbone, it was decide to try combining the de-protection step and 
attachment of the dissimilar 4-substituted-3-thiosemicarbzide together in one reaction.  
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Method for the attempt of the synthesis of GLY-Me-(Me)2: 
4,4-dimethyl-3-thiosemicarbazide (0.215 g, 0.0018 mol) was dissolved in de-ionised water (25 
mL). HCl (32%, 5 drops) was added followed by DMA-Me-(OMe)2 (0.300g, 0.0016 mol). The 
stirring solution was gradually heated to 40 oC where the temperature was held with the mixture 
continuously stirring (40 oC, 10 minutes). The precipitate was recovered via filtration, washed with 
de-ionised water (50 mL) and dried in air. A pale yellow solid (0.240 g) was recovered. 
Result: 
A NMR spectrum of the product showed that the product contained roughly 7% DMA-Me-(OMe)2, 
51% of GLY-Me-(Me)2 and 44% of GLY-Me-Me. As it would be hard to isolate the GLY-Me-(Me)2 
from the mixture due to GLY-Me-Me being present, it was decided to try and alter the reaction 
conditions in order to encourage the purer synthesis of GLY-Me-(Me)2.   
Instead of using HCl to hydrolyse the acetal groups it was decided to try using LiBF4 which was 
used in the synthesis of dissymmetric ligands with Me/H on the back bone by J. Lim et al.79 and L. 
Ackerman 80, 81 and co-workers.  
Method for the attempt of the synthesis of GLY-Me-(Me)2 using LiBF4: 
4,4-dimethyl-3-thiosemicarbazide (0.215 g, 0.0018 mol) was dissolved in an acetonitrile solution 
(98% acetonitrile : 2% water, 15mL). DMA-Me-(OMe)2 (0.300g, 0.0016 mol) was dissolved in an 
acetonitrile solution (98% acetonitrile : 2% water, 100mL, 60 oC) and a small amount of insoluble 
particulates were removed by filtration. The two solutions where combined, followed by the 
addition of LiBF4 (0.337g, 0.0036 mol). The solution was left to stir (50 
oC, 4 hours 50 minutes). 
The precipitate was recovered via filtration, washed with de-ionised water (50 mL) and dried in 
air. A pale yellow solid (0.126 g) was recovered. 
Result: 
A NMR spectrum of the product showed that the product contained almost 100% of GLY-Me-Me 
with little sign of DMA-Me-(OMe)2 or GLY-Me-(Me)2.  
The next attempt was to use the method which had already used extensively to attach a dissimilar 
4-substituted-3-thiosemicarbzide to a mono-substituted-3-thiosemicarbzone for the synthesis of 
all of the dissimilar ligands already reported in this chapter.  It was hoped that the weaker acid 
used in this method would hydrolyse the acetal groups GLY-Me-(Me)2 before catalysing the 
attachment of the second arm.  
Method for the attempt of the synthesis of GLY-Me-(Me)2 using 10% HCl: 
DMA-Me-(OMe)2 (0.300g, 0.0016 mol) was dissolved in DMF ( 1 mL) and filtered. 4,4-dimethyl-3-
thiosemicarbazide (0.215 g, 0.0018 mol) was dissolved in DMF ( 2 mL, room temperature), HCl 
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(10%, 1 drop) was added and then the solution was filtered. The solutions were combined and left 
to stir (5 hours, room temperature). De-ionised water (6 mL) was added but only a tiny amount of 
precipitate formed (0.002 g). The filtrate was allowed to evaporate to dryness in air. An off white 
solid (0.282 g) was yielded.     
Result: 
When the precipitate was analysed by NMR spectroscopy the majority (77-78%) of the product 
was GLY-Me-Me with only 22-23% being DMA-Me-(OMe)2. There was no significant sign of the 
desired ligand, GLY-Me-(Me)2.The solid recovered from the filtrate gave very messy proton and 
carbon spectra, but evidence of  GLY-Me-(Me)2, GLY-Me-Me and DMA-Me-(OMe)2 could be 
distinguished within the spectra.  
Due to the resulting failure of the combinational approach of the reactions 2 and 3 (Figure 
2.7.7.1.), it was decided to attempt only hydrolysis of the acetal groups a single reaction, then 
attach the second arm in a separate reaction.  
Attempts by hydrolyse DMA-Me-(OMe)2 to GLY-Me=O 
The first method was derived from the synthesis of symmetric ligands with Me/H on the back 
bone from PADA where a few drops of acid were used to hydrolyse the acetal groups.  
 Method for the attempt of hydrolyse DMA-Me-(OMe)2 to GLY-Me=O using 32% HCl: 
DMA-Me-(OMe)2 (0.300g, 0.0016 mol) was dissolved in water ( 50 mL, 60 
oC) and filtered. HCl 
(32%, 5 drops) was then added and then the solution was immediately cooled (0.3 oC). The 
precipitate that formed was recovered via filtration and left to dry in air. A brownish/yellow solid 
(0.016 g) was recovered.     
Result: 
NMR spectra of the solid showed roughly 78% of the solid was GLY-Me-Me with 17% being DMA-
Me-(OMe)2 and 4% being the desired ligand GLY-Me-(Me)2. The next step was to try exchanging 
the HCl for LiBF4.  
Method for the attempt of hydrolyse DMA-Me-(OMe)2 to GLY-Me=O using LiBF4: 
DMA-Me-(OMe)2 (0.300g, 0.0016 mol) was dissolved in an acetonitrile solution (98% acetonitrile : 
2% water, 100 mL, 60 oC) and filtered. LiBF4 (0.300 g, 0.0032 mol) was added and then the 
solution was immediately cooled in an ice bath (0.0 oC). When no precipitate was formed the 
solution was cooled further (-13.8 oC) with a salt ice bath (100 g table salt, 300 g ice). When still 
no precipitate formed, the solution was allowed to dry in air overnight followed by the further 





NMR of the solid showed roughly 83% of the solid was GLY-Me-Me with 6% being DMA-Me-
(OMe)2 and 11% being GLY-Me=O. There was no noticeable sign of GLY-Me-(Me)2. It seems that 
the intermediate is undergoing some sort of scrambling reaction, even in mild conditions. The 
decision was taken to non-longer pursue the synthesis of dissymmetric ligands with H/H on the 
backbone.    
2.7.9. Discussion 
A couple of different approaches have been tried in order to obtain a dissymmetric ligand with 
H/H on the backbone. The main problem encountered was the clean synthesis of a GLY-mono-
substituted-thiosemicarbazone intermediate, which is an important pre-cursor for the formation 
of a pure dissymmetric ligand.  
The first method that was explored, was the synthesis of the intermediate GLY-Me=O. This 
approach was investigated first due to first-hand success with making intermediates similar to this 
with different substituents on the backbone and reports in the literature92claiming that GLY-
Me=O was successfully synthesised whilst using a very similar method. It seems that the 
unreacted aldehyde carbonyl group of the GLY-Me=O intermediate is too reactive and readily 
reacts with unreacted side arm, forming the undesired symmetric ligand GLY-Me-Me. As this 
occurs even in a huge excess of backbone it is reasonable to suggest that the unreacted aldehyde 
is significantly more reactive than either of the carbonyl groups of the glyoxal backbone. It was 
hoped that upon the cooling of the reaction mixture, a method that was used in the clean 
formation of other intermediates with different backbone, the reactivity of the carbonyl group on 
GLY-Me=O would be reduced enough so that the clean formation of GLY-Me=O would become 
more favourable. This method was met with only slight success, it was found that cooling the 
mixture did yield a product that contained a slightly elevated proportion of GLY-Me=O but the 
rest of the product was GLY-Me-Me by a vast majority. As the limit was met of how far the 
solution could be cooled by a salt/ice bath due to  fears of the reaction mixture freezing, it was 
decided that further exploration of this method would unlikely enable the production of a clean 
GLY-Me=O product. It would be interesting to try the reaction in a solvent with a lower melting 
point in a dry ice/acetone ice bath, even though the suspicion would be that the GLY-Me=O 
content of the resulting product would be higher but, GLY-Me-Me would still make up the 
majority of the product. Disappointingly attempts to extract the GLY-Me=O from the GLY-
Me=O/GLY-Me-Me product was not successful as it seems that even with the slight introduction 
of heat causes a product that gives unreadable NMR spectra.  
The second approach investigated was the use of acetal groups to act as protecting groups in 
order to form a clean intermediate. To date the only reports that have been identified that have 
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used this approach was the in the papers by J. Lim et al.79 and L. Ackerman et al.80, 81 who used 
this approach for the synthesis of dissymmetric ligands with Me/H on the backbone. However no 
other evidence has been found to suggest that this method has been used in synthesis attempts 
of dissymmetric ligands with different substituents on the backbone. This coupled with personal 
experience with applying this method to the synthesis of Me/Me dissymmetric ligands (see 
section 2.2), did not give much hope for success at the onset. Surprisingly, the synthesis of the 
acetal protected intermediate was relatively straight forward, of which DMA-Me-(OMe)2 was 
cleanly synthesised. It is believed that this is the first reports of this intermediate. The main 
problems arose during the attempts to de-protect and attach a second arm. It was found that it 
was hard to selectively de-protect the acetal-protected-intermediate without producing the 
undesired symmetric ligand. This result occurred even when LiBF4 was used to give milder 
hydrolysis conditions. The successful use of the Lewis acid, LiBF4, was reported by both J. Lim et 
al.
79 and L. Ackerman et al.80, 81 ŝŶƚŚĞůĂƚĞ ? ? ? ? ?Ɛ ?The reasoning behind this was that the use of a 
Lewis acid, instead of a harsher Brønsted acid, may help avoid scrambling reactions. 
Unfortunately the use of LiBF4 in the de-protection of the H/H intermediate did not help prevent 
the formation of GLY-Me-Me as the major product. The use of HCl and LiBF4 was tried but in both 
cases yield mixtures that contained the acetal-protected-intermediate, the symmetric ligand GLY-
Me-Me and a small proportion of the desired de-protected intermediate. As the only source of 
the methyl-substituted arm is in the intermediates DMA-Me-(OMe)2 and GLY-Me=O, in order for 
GLY-Me-Me to be formed there must be some hydrolytic cleavage of the imine carbon-nitrogen 
double bond (C=N) within the intermediate. This allows the theory to be postulated, that the de-
protected intermediate is unstable and that it is likely that very shortly after the de-protection of 
the acetal protected intermediate occurs, the hydrolysis of the C=N bond ensues, which gives rise 
to free methyl substituted side arm, yielding the undesired symmetric ligand.  
Due to these failed attempts and lack of any feasible avenues to explore it was decided that the 
pursuit of dissymmetric H/H ligands should be abandoned for the time being. As always, if results 
from the biological screening identify dissymmetric H/H ligands as being ligands of significant 
interest, it may be necessary to re-visit the synthesis of this class of dissymmetric ligands. If it is 
found obligatory to revisit this synthesis, the main area that need to be address is finding a way to 
stabilise the de-protected intermediate or devising another synthesis approach by using an 








In this chapter 30 bis(thiosemicarbazone) ligands have been successfully synthesised of which 13 
are believed to be novel. 13 of the ligands made are symmetric and 17 dissymmetric. Out of the 
dissymmetric ligands 2 are singly dissymmetric and 15 were doubly dissymmetric. It is believed 
that 5 of the intermediates used in the synthesis of the dissymmetric ligands have not been 
reported before. In the investigation of protection synthetic approach, 2 new protected 
intermediates are believed to be made.  
Generally the synthesis of symmetric bis(thiosemicarbazone) ligands are reasonably straight 
forward and ligands of high purity with good yields can be obtained.  Dissymmetric 
bis(thiosemicarbazone) ligands can be synthesised by using different synthetic approaches, either 
by exploitation of the carbonyl reactivity57, 73 or by using acetal protection.79-81 The method that 
was found to be the most successful was the method that exploited the reactivity of two the 
carbonyl groups. Despite the use of the exploitation of carbonyl reactivity method being 
prosperous, the synthesis of the dissymmetric ligands with different imine backbones and/or 4-
substituted-thiosemicarbazides still hold uniquely different synthetic challenges. These challenges 
can involve the presence of isomeric impurities, formation of cyclic by-products as well as 
propensity for the thiosemicarbazide side arms to undergo scrambling. These challenges coupled 
with inherent difficulties common to bis(thiosemicarbazone) ligands such as poor solubility in a 
range of common solvents still make synthesis of any dissymmetric bis(thiosemicarbazone) 










3. Synthesis of copper and zinc bis(thiosemicarbazone) 
complexes. 
3.1. Introduction 
Once the bis(thiosemicarbazone) ligands had been successfully synthesised the next step was to 
chelate copper to the ligand in order to form a complex. As shown in Chapter 1, there is a rich 
source of methods describing how to make these complexes in the literature for medical imaging, 
the purpose of this chapter is not to investigate improving the synthesis of complexes. The 
primary focus of this chapter was synthesising new complexes from the ligands which are 
believed to be novel, in a high purity, in order to report the characterisation data for these 
complexes. As a practical method for gathering characterisation data, the complexes will be made 
with a stable metal and not a radio-isotope. An initial investigation in improving the radio complex 
synthesis methods has also been under taken and this is reported in Chapter 4 of this thesis.  
Alongside the synthesis of copper bis(thiosemicarbazone) complexes it was decided to also 
synthesise zinc bis(thiosemicarbazone) complexes. The reason for this is that zinc complexes have 
been of interest in an alternative method for synthesising copper bis(thiosemicarbazone) 
complexes, where the zinc bis(thiosemicarbazone) complexes  acts as the precursors. This shall be 
discussed in more detail in Chapter 4. Zinc bis(thiosemicarbazone) complexes have received far 
less attention than copper bis(thiosemicarbazone) complexes so it is believed that the vast 
majority of the zinc bis(thiosemicarbazone) complexes synthesised will be novel and thus their 
characterisation data has not yet been reported.   
3.2. Copper bis(thiosemicarbazone) complexes 
3.2.1. Reaction overview 
As the bis(thiosemicarbazone) ligand becomes de-protonated upon complexation the starting 
bis(thiosemicarbazone) can be regarded as a pro-ligand. The de-protonation un-covers the true 
ligand which upon encountering  a suitable metal, in this case a copper (II) salt, can chelate with 
the two sulphur atoms and the lone pairs from both the imine nitrogen atoms to yield a square 
planar, tetra dentate complex (Figure 3.2.1.1.) 
Copper (II) 
acetate
Figure 3.2.1.1. The general reaction for the synthesis of copper bis(thiosemicarbazide) complexes. 
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3.2.2. Synthesis of copper bis(thiosemicarbazone) complexes 
Method selection: 
Most of the literature that has been used in the synthesis of dissymmetric ligands only seems to 
report methods for preparing very small quantities of radio-complexes in solution for biological 
screening. As the intention was to collect comprehensive characterisation data a method had to 
be used that could give a workable amount of solid product. Some methods have been published 
that gave workable amounts of product, however most of these required refluxing in 
methanol57/ethanol80 or stirring in methanol at room temperature.85 As this project produced a 
varied range of compounds it was desirable to use a method that used DMF or DMSO as the 
reaction solvent as these solvents where the only two solvents used in this project that can 
achieve full dissolution of all the ligands that have been synthesised.  To this end, a method was 
tried from a dissertation report written by Katherine Martin211  who was a third year BSc student 
alongside a further refined method.  A method used by Samuel Stringer212 in another third year 
BSc dissertation was also tested.   
K. Martin ?s method: 
BDO-Me-Me (0.312 g, 0.0012 mol) was added to a NaOH solution (1M, 25 mL, 50 oC), the 
minimum amount of DMF was added in order to achieve full dissolution. Copper (II) acetate 
monohydrate (0.280 g, 0.0014 mol) was dissolved in de-ionised water (10 mL). The solutions were 
combined and left to stir over night (whilst cooling down to room temperature). The precipitate 
was recovered via filtration, washed with methanol (3 x 25 mL) and de-ionised water (1 x 20 mL) . 
The solid was dried in air.  A brown solid (0.278 g) was recovered (72% yield).  
^ ?^ƚƌŝŶŐĞƌ ?Ɛ method: 
BDO-Me-Me (0.312 g, 0.0012 mol) was added to a NaOH solution (1M, 25 mL). Copper (II) acetate 
monohydrate (0.280 g, 0.0014 mol) was dissolved in de-ionised water (15 mL). The copper 
solution was added to the suspension and left to stir over night. The solid was recovered via 
filtration, washed with de-ionised water (2 x 50 mL) and ethanol (1 x 50 mL). The solid was dried 
in air.  A brown solid (0.357 g) was recovered (92% yield).  
Refined method: 
BDO-Me-Me (0.312 g, 0.0012 mol) was dissolved in DMF (14 mL). Copper (II) acetate 
monohydrate (0.280 g, 0.0014 mol) was dissolved in de-ionised water (15 mL). The two solutions 
were combined and further DMF (25 mL) was added to achieve full dissolution. The solution was 
left to stir over night. The precipitate was recovered via filtration, washed with de-ionised water 
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(2 x 50 mL) and ethanol (1 x 50 mL). The solid was dried in air.  A brown solid (0.101 g) was 
recovered (26% yield).  
Discussion  
All three methods gave a brown solid, unfortunately due to the paramagnetic properties of 
copper the solid could not be analysed by NMR spectroscopy in order to give an indication of 
purity.  The S. Stringer method was discounted as being a suitable general method that could be 
applied to the synthesis of the remaining copper complexes because as the BDO-Me-Me did not 
fully dissolve in the NaOH yielding a suspension. As there was a chance that all the BDO-Me-Me 
ligand may of not dissolved whilst being stirred overnight and therefore  the ligand may not had a 
chance to react with the copper to form the desired complex, the product may not be as pure as it 
could be.  The CHN data reported was significantly lower than the theoretical percentages (- 2.6%, 
2.6%, 0.4% for the percentage of carbon, nitrogen and hydrogen respectively) which suggest that 
the product was not cleanly synthesised. The refined method was also discarded because the 
yield was significantly lower than the K. Martin method. The K. Martin method was selected to be 
used as the general method for the remaining of the copper complexes because the starting 
reaction mixture was a solution and not a suspension so that it can be assumed that if a 
precipitate forms then it should be the desired copper complex whilst any unreacted ligand 
should stay in solution. The amount of DMF can be changed in order to account for any 
ĚŝĨĨĞƌĞŶĐĞƐŝŶƚŚĞƌĞŵĂŝŶŝŶŐůŝŐĂŶĚƐƐŽůƵďŝůŝƚǇŝŶEĂK, ?< ?DĂƌƚŝŶ ?ƐĚŝƐƐĞƌƚĂƚŝŽŶƌĞƉŽƌƚƐƚŚĂƚŚĞƌ
CHN analysis results agreed very closely with her theoretical percentages (within +/- 0.3%, 0.3%, 
0.1% for the percentage of carbon, nitrogen and hydrogen respectively), this gives some 
ĂƐƐƵƌĂŶĐĞƚŚĂƚ< ?DĂƌƚŝŶ ?ƐŵĞƚŚŽĚŚĂƐƚŚĞĂďŝůŝƚǇƚŽƉƌŽĚƵĐĞƉƵƌĞĐŽƉƉĞƌĐŽŵƉůĞǆĞƐ ? 
General methods: 
Depending on the amount of the ligand that was available the general methods used was:  
General method A: 
The chosen bis(thiosemicarbazone) ligand ( X g, 0.0006 mol) was added to a NaOH solution (1M, 
13 mL, 50 oC), the minimum amount of DMF was added in order to achieve full dissolution. 
Copper (II) acetate monohydrate (0.140 g, 0.0007 mol) was dissolved in de-ionised water (5 mL). 
The solutions were combined and left to stir over night (whilst cooling down to room 
temperature). The precipitate was recovered via filtration, washed with methanol (3 x 10 mL) and 




General method B: 
The chosen bis(thiosemicarbazone) ligand ( X g, 0.0004 mol) was added to a NaOH solution (1M, 9 
mL, 50 oC), the minimum amount of DMF was added in order to achieve full dissolution. Copper 
(II) acetate monohydrate (0.100 g, 0.0005 mol) was dissolved in de-ionised water (3.5 mL). The 
solutions were combined and left to stir over night (whilst cooling down to room temperature). 
The precipitate was recovered via filtration, washed with methanol (3 x 7 mL) and de-ionised 
water (1 x 7 mL) .The product was dried in air.   
The method used for each complex is summarised in table 3.2.2.1., along with the reaction yield 




Yield Appearance of 
product 




Cu-GLY-Et-Et A 74 % Brown solid No76, 141, 177, 180  
Cu-GLY-Ph-Ph A 69% Brown solid No76, 141, 177, 180  
Cu-PADA-Me-
Me 
A 65% Brown solid  No6, 45, 69, 77, 106, 




B 61% Brown solid Yes  
Cu-PADA-Et-
Et 































72% Brown solid No6, 69, 70, 76, 77, 






B 59% Brown solid Yes  
Cu-PDO-NH2-
NH2 
A 58% Brown solid No69, 77, 145, 164  
Cu-PDO-NH2-
Me 
B 15% Brown solid Yes  
Cu-PDO-NH2-
(Me)2 













A 54% Brown solid Yes DMSO/H20 
Recrystallisation 
Cu-PDO-Et-Et A 49% Brown solid Yes  
Cu-PDO-Et-
NH2 
A 34% Brown solid Yes DMSO/H20 
Recrystallisation 
Table 3.2.2.1. A table summarising which general method was used for the synthesis of each complex.  
3.2.3. Characterisation data for copper bis(thiosemicarbazone) complexes 
Copper bis(thiosemicarbazone) complexes with H/H on the backbone 
Cu-GLY-Et-Et: 
IR (neat): cm-1= 3325 (m), 2970 (w), 2926 (w), 2878 (w), 1516 (s), 1435 (s), 1416 (s), 1385 (m), 
1371 (m), 1339 (s), 1290 (m), 1234 (s), 1200 (s), 119 (m), 1092 (m), 1055 (m), 1012 (m), 926 (w), 
860 (m), 824 (w), 760 (w), 685 (m), 602 (m), 509 (s), 455 (m), 419 (m). Raman (neat), laser = 
623.81 nm: cm-1= 1579 (w), 1537 (s), 1443 (s), 1342 (w), 1298 (w), 1221 (w), 1053 (w), 1018 (s), 
684 (w), 605 (m), 499 (w). Melting point: >220 oC (decomposed). UV-Vis absorptions:  ʄmax/nm 
 ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 20 000), 370 (sh), 498 (9 200) and 540 (sh). Mass spectrometry 





IR (neat): cm-1= 3416 (w), 3325 (w), 3051 (w), 1597 (w), 1541 (m), 1520 (m), 1493 (m), 1452 (m), 
1420 (s), 1315 (m), 1244 (m), 1175 (s), 1153 (m), 899 (w), 870 (m), 826 (w), 745 (s), 687 (s), 610 
(m), 583 (m), 542 (m), 501 (m). Raman (neat), laser = 623.81 nm: cm-1= 3055 (w), 3043 (w), 2973 
(w), 2949 (w), 2896 (w), 2869 (w), 2850 (w), 2534 (w), 2454 (w), 2161 (w), 2134 (w), 2035 (w), 
1953 (w), 1932 (w), 1594 (w), 1526 (s), 1447 (s), 1420 (s), 1310 (w), 1249 (w), 1174 (w), 1075 (w), 
1007 (m), 921 (w), 897 (w), 819 (w), 630 (w), 606 (w), 506 (w), 387 (w), 288 (w). UV-Vis 
absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 17 900), 406 (16 100), 508 (14 000) and 560 
(sh). 
Copper bis(thiosemicarbazone) complexes with Me/H on the backbone 
Cu-PADA-Me-Me 
IR (neat): cm-1= 3325 (m), 3269 (m), 3256 (m), 1531 (s), 1449 (m), 1400 (m), 1381 (s), 1348 (m), 
1238 (m), 1225 (m), 1179 (m), 1123 (m), 924 (m), 872 (w), 808 (w), 773 (w), 664 (w), 592 (w), 474 
(s), 433 (s), 428 (s). Raman (neat), laser = 532.00 nm: cm-1= 2979 (w), 2918 (w), 2703 (w), 2122 
(w), 2057 (w), 1550 (w), 1512 (w), 1471 (s), 1370 (w), 1246 (w), 1178 (w), 996 (w), 924 (w), 776 
(w), 662 (w), 591 (w). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 19 400), 360 
(sh), 488 (7 000) and 540 (sh). 
Cu-PADA-Me-Ph 
IR (neat): cm-1= 3294 (m), 1597 (w), 1547 (m), 1524 (s), 1497 (m), 1458 (s), 1435 (s), 1391 (s), 1368 
(m), 1344 (m), 1317 (m), 1248 (m), 1219 (s), 1194 (s), 1179 (s), 1134 (m), 1123 (m), 926 (m), 897 
(w), 881 (w), 808 (w), 758 (s), 687 (s), 664 (m), 631 (m), 610 (m), 586 (m), 507 (m), 446 (m), 419 
(m). Raman (neat), laser = 623.81 nm: cm-1= 1595 (w), 1540 (s), 1519 (m), 1466 (s), 1425 (w), 
1348 (w), 1311 (w), 1242 (w), 1218 (m), 1131 (w), 993 (w), 922 (w), 820 (w), 664 (w), 590 (m), 485 
(w), 358 (w). Elemental analysis: Found: C, 38.9; H, 3.7; N, 22.6. Calc. for Cu1C12H14N6S2: C, 39.0; H, 
3.8; N, 22.7%. Melting point: >220 oC (decomposed). UV-Vis absorptions:  ʄmax/nm (DMSO) 320 
 ?ɸ ?Ěŵ3 mol-1 cm-1 18 900), 378 (13 100), 496 (9 700) and 540 (sh). Mass spectrometry (ESI): m/z 
(Calc.) 370.0092 (370.0096) {M + H+}. 
Cu-PADA-Et-(Me)2 
IR (neat): cm-1= 3321 (m), 2965 (w), 2926 (w), 1514 (s), 1483 (m), 1462 (s), 1391 (m), 1366 (s), 
1339 (s), 1310 (s), 1258 (m), 1234 (s), 1179 (s), 1138 (s), 1059 (m), 1013 (m), 916 (m), 862 (m), 826 
(m), 800 (m), 658 (m), 594 (m), 525 (s), 474 (s). Raman (neat), laser = 632.81 nm: cm-1= 1589 (w), 
1538 (m), 1482 (s), 1460 (m), 1373 (w), 1312 (m), 1225 (m), 1008 (m), 931 (m), 661 (w), 632 (w), 
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596 (m), 351 (w). Elemental analysis: Found: C, 32.3; H, 4.7; N, 25.2. Calc. for Cu1C9H16N6S2: C, 
32.2; H, 4.8; N, 25.0%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 21 500), 360 
(sh), 492 (9 500) and 540 (sh). Mass spectrometry (ESI): m/z (Calc.) 336.0255 (336.0252) {M + H+}. 
Cu-PADA-Ph-NH2 
IR (neat): cm-1= 3289 (m), 3073 (m), 1632 (w), 1591 (m), 1541 (m), 1497 (s), 1408 (s), 1368 (s), 
1319 (s), 1256 (m), 1244 (m), 1184 (s), 1150 (s), 928 (m), 891 (m), 864 (m), 847 (m), 820 (m), 750 
(s), 735 (m), 685 (s), 640 (m), 617 (m), 600 (m), 584 (s), 505 (s), 463 (s). Raman (neat), laser = 
623.81 nm: cm-1= 1528 (s), 1470 (s), 1431 (m), 1314 (w), 1237 (m), 1185 (w), 996 (w), 929 (w), 670 
(w), 618 (w), 599 (w), 359 (w), 300 (w). Elemental analysis: Found: C, 37.2; H, 3.3; N, 23.4. Calc. 
for Cu1C11H12N6S2: C, 37.1; H, 3.4; N, 23.6%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-
1 cm-1 21 000), 372 (13 300), 494 (9 600) and 540 (sh). Mass spectrometry (ESI): m/z (Calc.) 
355.9935 (355.9939) {M + H+}. 
Cu-PADA-Ph-Me 
IR (neat): cm-1= 3279 (w), 3213 (w), 2932 (w), 1597 (m), 1582 (w), 1545 (m), 1493 (s), 1433 (s), 
1346 (s), 1321 (s), 1279 (s), 1244 (m), 1196 (s), 1148 (s), 1043 (m), 934 (m), 891 (w), 847 (m), 822 
(m), 745 (s), 685 (s), 610 (m), 584 (m), 503 (s), 484 (m). Raman (neat), laser = 623.81 nm: cm-1= 
1576 (m), 1507 (s), 1470 (s), 1429 (m), 1383 (w), 1351 (w), 1312 (w),1273 (m), 1243 (m), 1192 (w), 
994 (w), 932 (m), 676 (w), 600 (m), 542 (w), 479 (w), 368 (w), 130 (w). Elemental analysis: Found: 
C, 38.9; H, 3.7; N, 22.6. Calc. for Cu1C12H14N6S2: C, 39.0; H, 3.8; N, 22.7%. UV-Vis absorptions:  
ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 20 600), 380 (sh), 492 (10 100) and 540 (sh). Mass 
spectrometry (ESI): m/z (Calc.) 370.0092 (370.0096) {M + H+}. 
Copper bis(thiosemicarbazone) complexes with Me/Me on the backbone 
Cu-BDO-NH2-NH2 
IR (neat): cm-1= 3402 (w), 3285 (m), 3144 (m), 1628 (m), 1593 (m), 1541 (w), 1479 (m), 1421 (s), 
1360 (m), 1304 (m), 1217 (s), 1186 (m), 1138 (m), 1078 (m), 995 (m), 835 (m), 716 (m), 658 (m), 
602 (m), 515 (m), 473 (s), 457 (s). Raman (neat), laser = 623.81 nm: cm-1= 1533 (s), 1470 (m), 
1367 (w), 1290 (s), 1182 (m), 1003 (w), 829 (m), 705 (w), 606 (w), 394 (w), 340 (w).  UV-Vis 
absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 23 400), 350 (sh), 476 (6 400) and 530 (sh). 
Cu-BDO-NH2-(Me)2 
IR (neat): cm-1= 3426 (w), 3289 (w), 3157 (w), 2918 (w), 1622 (m), 1589 (w), 1541 (m), 1499 (m), 
1439 (m), 1387 (s), 1362 (s), 1296 (s), 1258 (s), 1217 (s), 1171 (s), 1140 (m), 1115 (s), 1055 (s), 999 
(m), 908 (s), 841 (s), 762 (m), 706 (m), 610 (m), 596 (m), 515 (m), 430 (s). Raman (neat), laser = 
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532.00 nm: cm-1= 2837 (w), 2807 (w), 2144 (w), 1901 (w), 1804 (w), 1598 (w), 1543 (m), 1497 (m), 
1298 (s), 1263 (w), 1204 (w), 1003 (w), 921 (w), 846 (w), 602 (w). Elemental analysis: Found: C, 
29.7; H, 4.2; N, 25.9. Calc. for Cu1C8H14N6S2: C, 29.85; H, 4.4; N, 26.1%. UV-Vis absorptions:  
ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 17 900), 350 (sh), 481 (6 700) and 540 (sh). Mass 
spectrometry (ESI): m/z (Calc.) 322.0097 (322.0096) {M + H+}. 
Cu-BDO-Me-Me 
IR (neat): cm-1= 3327 (m), 3267 (w), 1530 (s), 1460 (m), 1385 (s), 1246 (m), 1223 (s), 1159 (m), 
1078 (m), 841 (m), 606 (m), 540 (m), 507 (s), 456 (s), 438 (s). Raman (neat), laser = 632.81 nm: 
cm-1= 3331 (w), 1602 (w), 1552 (s), 1488 (s), 1388 (w), 1371 (w), 1325 (m), 1264 (m), 1242 (m), 
1185 (w), 994 (w), 841 (m), 773 (w), 600 (m), 452 (w), 437 (w), 352 (m), 325 (w), 292 (w), 184 (w). 
Raman (neat), laser = 532.00 nm: cm-1= 2158 (w), 2097 (w), 1930 (w), 1556 (s), 1492 (s), 1444 (w), 
1372 (w), 1328 (m), 1266 (w), 1245 (m), 996 (w), 843 (w), 773 (w), 603 (m), 451 (w), 441 (w). 
Melting point: >270 oC (decomposed). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-
1 22 100), 350 (sh), 476 (7 200) and 530 (sh). 
Cu-BDO-Me-NH2 
IR (neat): cm-1= 3458 (w), 3321 (m), 3287 (w), 3136 (w), 1626 (m), 1549 (m), 1504 (m), 1443 (s), 
1396 (m), 1364 (m), 1344 (s), 1287 (s), 1221 (s), 1188 (m), 1150 (m), 1099 (m), 1057 (m), 1038 (m), 
984 (m), 841 (m), 756 (w), 733 (m), 700 (m), 629 (m), 610 (m), 563 (m), 527 (m), 509 (s), 419 (s). 
Raman (neat), laser = 632.81 nm: cm-1=  1542 (m), 1496 (s), 1379 (w), 1284 (s), 1184 (w), 998 (w), 
837 (w), 697 (w), 609 (w), 588 (w), 390 (w), 346 (w), 316 (w), 271 (w), 253 (w), 138 (w). Melting 
point: >266 oC (decomposed). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 22 
500), 350 (sh), 476 (6 900) and 520 (sh). Mass spectrometry (ESI): m/z (Calc.) 307.9935 (307.9939) 
{M + H+}. 
Copper bis(thiosemicarbazone) complexes with Me/Et on the backbone 
Cu-PDO-NH2-NH2 
IR (neat): cm-1= 3447 (w), 3377 (w), 3273 (w), 3102 (w), 1630 (m), 1618 (m), 1589 (m), 1533 (w), 
1477 (m), 1423 (s), 1327 (m), 1294 (m), 1236 (w), 1211 (m), 1181 (m), 1138 (m), 1059 (w), 1022 
(w), 943 (w), 841 (w), 789 (w), 716 (m), 594 (m), 527 (m), 486 (m), 420 (s). Raman (neat), laser = 
632.81 nm: cm-1= 1588 (w), 1529 (s), 1467 (m), 1374 (w), 1325 (w), 1289 (m), 1237 (w), 1182 (w), 
1079 (w), 1024 (w), 1000 (w), 946 (w), 841 (w), 788 (w), 705 (w), 600 (w), 393 (w), 338 (w), 260 
(w), 174 (m). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 23 500), 350 (sh), 480 (6 




IR (neat): cm-1= 32292 (w), 3146 (w), 1626 (w), 1541 (m), 1518 (w), 1479 (m), 1445 (m), 1391 (m), 
1335 (w), 1217 (m), 1190 (m), 1152 (m), 1107 (w), 1061 (w), 951 (w), 779 (w), 727 (w), 592 (m). 
Raman (neat), laser = 532.00 nm: cm-1= 2127 (w), 2075 (w), 1537 (m), 1515 (m), 1480 (w), 1335 
(m), 1249 (m), 1025 (w), 794 (w), 604 (m). Elemental analysis: Found: C, 29.7; H, 4.3; N, 26.0. Calc. 
for Cu1C8H14N6S2: C, 29.85; H, 4.4; N, 26.1%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-
1 cm-1 11 300), 350 (sh), 480 (4 100) and 530 (sh). Mass spectrometry (ESI): m/z (Calc.) 322.0135 
(322.0096) {M + H+}. 
Cu-PDO-NH2-(Me)2 
IR (neat): cm-1= 3360 (w), 3285 (w), 3129 (w), 3129 (w), 2931 (w), 1632 (m), 1585 (w), 1537 (m), 
1493 (m), 1456 (s), 1389 (s), 1321 (m), 1300 (s), 1258 (s), 1240 (s), 1213 (s), 1169 (s), 1115 (s), 
1061 (m), 957 (m), 910 (m), 847 (w), 795 (m), 706 (m), 631 (m), 598 (m), 536 (s), 517 (s), 496 (s), 
428 (s). Raman (neat), laser = 532.00 nm: cm-1= 1590 (w), 1536 (w), 1497 (w), 1320 (w), 1302 (w), 
1247 (w), 633 (w), 598 (w). Melting point: >220 oC (decomposed). Elemental analysis: Found: C, 
32.4; H, 4.8; N, 24.9. Calc. for Cu1C9H16N6S2: C, 32.2; H, 4.8; N, 25.0%. UV-Vis absorptions:  
ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 23 400), 350 (sh), 484 (8 800) and 530 (sh). Mass 
spectrometry (ESI): m/z (Calc.) 336.0247 (336.00252) {M + H+}. 
Cu-PDO-NH2-Et 
IR (neat): cm-1= 3347 (w), 3157 (w), 2963 (w), 1628 (w), 1587 (w), 1537 (m), 1506 (m), 1476 (m), 
1445 (m), 1416 (s), 1366 (m), 1335 (m), 1310 (m), 1221 (s), 1184 (m), 1142 (m), 1061 (m), 955 (w), 
787 (m), 689 (m), 597 (m), 419 (s). Raman (neat), laser = 632.81 nm: cm-1=  3329 (w), 1584 (w), 
1533 (s), 1504 (m), 1479 (s), 1371 (m), 1352 (m), 1330 (m), 1248 (m), 1230 (m), 1172 (m), 1030 
(w), 999 (w), 957 (w), 787 (w), 602 (m), 338 (m), 317 (w), 261 (w), 221 (w), 157 (m). Melting point: 
>210 oC (decomposed). Elemental analysis: Found: C, 32.3; H, 4.8; N, 24.85. Calc. for 
Cu1C9H16N6S2: C, 32.2; H, 4.8; N, 25.0%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 
cm-1 25 500), 350 (sh), 480 (8 200) and 530 (sh). Mass spectrometry (ESI): m/z (Calc.) 336.0287 
(336.0252) {M + H+}. 
Cu-PDO-Me-NH2 
IR (neat): cm-1= 3281 (w), 3119 (w), 1643 (w), 1622 (w), 1541 (m), 1504 (m), 1441 (s), 1350 (m), 
1281 (m), 1240 (m), 1215 (s), 1186 (s), 1150 (m), 1101 (m), 1076 (m), 1028 (m), 943 (m), 800 (m), 
719 (m), 638 (m), 615 (m) 471 (s). Raman (neat), laser = 632.81 nm: cm-1= 1582 (w), 1532 (m), 
1497 (s), 1433 (w), 1380 (w), 1321 (w), 1281 (m), 1238 (m), 1190 (w), 1031 (w), 987 (w), 943 (w), 
848 (w), 801 (w), 702 (w), 610 (w), 395 (w), 351 (w), 320 (w), 139 (w). Elemental analysis: Found: 
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C, 29.8; H, 4.5; N, 26.0. Calc. for Cu1C8H14N6S2: C, 29.85; H, 4.4; N, 26.1%. UV-Vis absorptions:  
ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 16 600), 350 (sh), 478 (5 200) and 520 (sh). Mass 
spectrometry (ESI): m/z (Calc.) 322.0092 (322.0096) {M + H+}. 
Cu-PDO-Et-Et 
IR (neat): cm-1= 3323 (m), 2972 (w), 2928 (w), 2876 (w), 1543 (w), 1506 (m), 1481 (m), 1435 (s), 
1381 (m), 1342 (m), 1265 (m), 1234 (m), 1211 (s), 1142 (m), 1096 (m), 1055 (m), 1034 (m), 959 
(m), 843 (w), 802 (w), 596 (w), 550 (m), 515 (m), 471 (m), 413 (m). Raman (neat), laser = 532.00 
nm: cm-1= 2149 (w), 2091 (w), 1542 (s), 1484 (s), 1462 (m), 1376 (w), 1333 (m), 1234 (m), 1034 
(w), 1002 (w), 959 (w), 605 (w). Elemental analysis: Found: C, 36.2; H, 5.4; N, 23.0. Calc. for 
Cu1C11H20N6S2: C, 36.3; H, 5.5; N, 23.1%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 
cm-1 21 600), 360 (sh), 480 (7 200) and 530 (sh). Mass spectrometry (ESI): m/z (Calc.) 364.0560 
(364.0565) {M + H+}. 
Cu-PDO-Et-NH2 
IR (neat): cm-1= 3374 (w), 3339 (m), 3152 (w), 2972 (w), 1630 (m), 1593 (w), 1539 (w), 1508 (m), 
1479 (m), 1437 (s), 1381 (m), 1329 (m), 1304 (m), 1261 (w), 1236 (m), 1211 (s), 1173 (m), 1142 
(m), 1103 (m), 1032 (m), 951 (m), 841 (w), 820 (w), 802 (w), 731 (m), 600 (m), 540 (m), 505 (s), 
484 (s), 415 (s). Raman (neat), laser = 632.81 nm: cm-1=  1591 (w), 1533 (s), 1482 (m), 1460 (m), 
1374 (w), 1355 (w), 1324 (m), 1299 (m), 1228 (m), 1171 (w), 1033 (m), 951 (w), 840 (w), 778 (w), 
602 (w), 336 (w), 265 (w), 165 (m). Elemental analysis: Found: C, 32.3; H, 4.8; N, 24.9. Calc. for 
Cu1C9H16N6S2: C, 32.2; H, 4.8; N, 25.0%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 
cm-1 22 100), 350 (sh), 480 (7 100) and 530 (sh). Mass spectrometry (ESI): m/z (Calc.) 336.0297 
(336.0252) {M + H+}. 
Unexpected results 
Cu-PADA-Et-Et 
IR (neat): cm-1= 3271 (w), 2967 (w), 2872 (w), 1499 (m), 1422 (m), 1375 (m), 1337 (s), 1229 (s), 
1157 (s), 1086 (s), 800 (m), 521 (s). Raman (neat), laser = 532.00 nm: cm-1= 1483 (s), 1235 (m). 
UV-Vis absorptions:  ʄmax/nm (DMSO) 306, 450. 
Cu-PDO-Me-Me 
IR (neat): cm-1= 3321 (w), 3265 (w), 1530 (m), 1479 (m), 1454 (m), 1402 (m), 1383 (m), 1217 (m), 
1157 (m), 655 (m), 577 (s), 484 (s). Raman (neat), laser = 632.81 nm: cm-1= 1543 (m), 1586 (m), 
1477 (s), 1372 (w), 1344 (m), 1245 (s), 1025 (w), 988 (w), 954 (w), 842 (w), 808 (w), 762 (w), 593 
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(m), 527 (w), 440 (w), 359 (w), 332 (w). UV-Vis absorptions:  ʄmax/nm (DMSO) 312, 360 (sh), 480 
and 530 (sh). 
3.2.4. Spectral examples of copper bis(thiosemicarbazone) complexes 
Cu-PADA-Me-Ph 
Figure 3.2.4.1., figure 3.2.4.2. and figure 3.2.4.3. show an example of a FTIR spectrum, a Raman 
spectrum and a mass spectrum of the complex Cu-PADA-Me-Ph. 
Figure 3.2.4.1. A FTIR spectrum of Cu-PADA-Me-Ph. This complex was synthesised by reacting PADA-Me-Ph 
with copper (II) acetate. 
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Figure 3.2.4.2. A Raman spectrum of Cu-PADA-Me-Ph. 
 
Figure 3.2.4.3. A mass spectrum of Cu-BDO-Me-NH2. The spectrum in the top right hand corner is the 
predicted expected spectrum of the M + H
+









Figure 3.2.4.4., figure 3.2.4.5. and figure 3.2.4.6. show an example of a FTIR spectrum, a Raman 
spectrum and a mass spectrum of the complex Cu-PDO-Et-Et.  
Figure 3.2.4.4. A FTIR spectrum of Cu-PDO-Et-Et. This complex was synthesised by reacting PDO-Et-Et with 
copper (II) acetate. 
Figure 3.2.4.5. A Raman spectrum of Cu-PADA-Et-Et. 
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Figure 3.2.4.6. A mass spectrum of Cu-PDO-Et-Et. The spectrum in the top right hand corner is the predicted 
expected spectrum of the M + H
+




Table 3.2.4.7. illustrates the Cu(II/I) reduction potentials of selected copper complexes. 
 
Complex 
E1/2 Cu(II/I) (V) 
(Non-normalised) 
E1/2 Cu(II/I) (V)     
(normalised against ferrocene) 
Cu-GLY-Me-Me* -0.24 -0.96 
Cu-GLY-Et-Et -0.37 -1.06 
Cu-PADA-Me-(Me)2 -0.39 -1.01 
Cu-PADA-Ph-Ph -0.29 -0.88 
Cu-PADA-Et-Me -0.37 -1.08 
Cu-PADA-Me-Ph -0.24 -0.93 
Cu-PADA-Ph-Me -0.33 -1.04 
Cu-PADA-Et-Ph -0.31 -1.06 
Cu-BDO-Me-Me -0.51 -1.12 
Cu-BDO-Et-Et -0.37 -1.13 
Cu-BDO-Me-NH2 -0.19 -1.12 
Cu-BDO-Me-O-Ph* -0.46 -1.24 
Cu-BDO-Me-(Me)2* -0.41 -1.05 
Cu-BDO-NH2-(Me)2 -0.50 -1.13 
Cu-BDO-Me-Et-(Me)2* -0.49 -1.11 
Cu-BDO-Me-But-NH2*
 -0.62 -1.30 
Cu-BDO-NH2-NH2 -0.37 -1.11 
Cu-PDO-Me-Me -0.60 -1.14 
Cu-PDO-Et-Et -0.47 -1.13 
Cu-PDO-NH2-Me -0.36 -1.13 
Cu-PDO-Et-NH2 -0.51 -1.14 
Cu-PDO-NH2-NH2 -0.49 -1.16 
Cu-PDO-NH2-Et -0.48 -1.11 
Cu-PDO-Me-NH2 -0.42 -1.13 
Cu-PDO-NH2-(Me)2 -0.44 -1.10 
Cu-DTS* -0.58 -1.12 
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Table 3.2.4.7. Copper (II/I) reduction potentials for copper bis(thiosemicarbazone) complexes, obtained by 
Julia Baguña Torres from the Division of Imaging Sciences & Biomedical Engineering at King's College 
London. The potentials were obtained using cyclic voltammetry using a glassy carbon electrode as the 
working electrode, a silver wire electrode as the reference one and a platinum wire electrode as the auxiliary 
electrode. The complexes marked with (*) where synthesised by Julia. Cu-DTS: Q1=Et, Q2=Et, R1=H, R2=H, 
R3=H, R4=H. Cu-BDO-Me-Et-(Me)2: Q1=Me, Q2=Me, R1=Me, R2=H, R3=H, R4=C2H4-N(Me)2. Cu-BDO-Me-But-
NH2: Q1=Me, Q2=Me, R1=Me, R2=H, R3=H, R4= C4H8-NH2. Cu-BDO-Me-O-Ph: Q1=Me, Q2=Me, R1=Me, R2=H, the 
R3&R4 positions are taken up with a single phenyl ring directly bound to the terminal carbon. Cu-BDO-Me-O-
Ph also has an oxygen instead of a sulphur atom on the R3/R4 side.  
3.2.5. Discussion 
Except for a few unexpected results, all the reactions produced a brown solid with relatively good 
yields, normally between 40-60%. The method was relatively straight forward and conveniently 
formed a brown precipitate that could be easily filtered off. Out of the twenty copper complexes 
made nine were symmetric and eleven were dissymmetric. Out of these twenty, twelve 
complexes are believed to be novel. The symmetric ligands were firstly made in order to test if the 
method of synthesis was suitable for all the range of complexes with their solubilities.      
Unfortunately due to the paramagnetic properties of copper, the resulting copper complexes 
yielded NMR spectra of very poor quality that contained very broad peaks from which little useful 
information could be extracted.  This meant that it was not possible to rely on NMR for confirming 
if the complexes have been synthesised.  Melting point data was taken on only a selection of 
complexes, the selected complexes were chosen in order to incorporate complexes with a diverse 
range structural of substituents. It was found that it was very hard, due to the dark brown colour 
of the samples, to identify the precise stage of decomposition. It was noticed upon heating that 
thĞƐĂŵƉůĞ ?ƐĐŽůŽƵƌƚƵƌŶƐďůĂĐŬĞƌ ?then heating is continued the solid sample would melt to form 
a dark black liquid. As this transition was the easiest to observe this was the point which was 
reported as the decomposition temperature. For the six samples that were analysed this 
decomposition was observed between 210-266oC.  L. Ackerman et al.80 have reported successfully 
obtaining melting points of nickel and copper derivatives of the PADA backbone (Q1=Me, Q2=H) 
however none these complex were synthesised during this project. The most similar copper 
complexes L. Ackerman obtained had melting points between 204-210oC.  
Obtaining infrared spectra of all the copper complexes was extremely straight forward when using 
the Golden Gate Diamond ATR attachment. This meant that highly quality spectra could be taken 
of all the complexes relatively quickly and easily. L.J. Ackerman et al80. and D. West et al.78 both 
published some infrared data on copper bis(thiosemicarbazones) . From these two articles the 
only copper complex that was also made during this project was Cu-BDO-Me-Me of which the IR 
data was in close agreement. Peak assignments given in the literature78, 80, 207, 208 were used to look 
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for similar peak locations in the previously unreported complexes. All complexes had peaks in the 
region of 3450-3250 cm-1, 1550-1420 cm-1, 840-700 cm-1 and 500-415 cm-1 corresponding to R-N-
H, C=N, C-S and Cu-N bonds respectively. The Cu-S bond appears around 300-315 cm-1 which is 
outside the range recorded when collecting the infrared spectra. IR data for Cu-GLY-Ph-Ph was 
also located within the literature172 which also agreed with the data obtained in this project.  
Collecting suitable Raman spectra of the complexes was a little more challenging. It was found 
that the complexes are relatively sensitive to laser light often resulting in the burning of the 
sample. This was observed when using the red laser (632.81 nm) with a filter that blocked less 
than 50% of the laser light or 10% of the light when using the blue laser (472.98 nm). Unlike with 
the characterisation of the bis(thiosemicarbazone) ligands, with the related copper complexes it 
seems that there is no one laser that can be used for all.  Even with complexes with minor 
structural differences it was observed that some may fluoresce while the others would not 
fluoresce when exposed to the same colour laser. It does not seem possible to predict the best 
colour laser to use by just looking at the structure of the complex in order to give a respectable 
spectrum, free of fluoresce. It was found that when analysing the copper complexes, the red 
(632.81 nm) laser was a good starting point and when the red laser did not give an acceptable 
spectrum it was best to turn to the green (532.00 nm) laser. The resulting spectra obtained were 
of mixed quality, some spectra had very strong, sharp peaks with a relatively flat base line while 
other spectra contained very weak peaks, some of which were very broad and with an often 
messy or rising baseline.   
Due to the large number of copper complexes that were synthesised CHN analysis was only ran on 
complexes that were believed to be novel. The first round of CHN analysis, disappointingly only 
three out of the nine samples sent came back with acceptable percentages. It is expected this 
could be due to either impurities being brought out of solution upon precipitation or solvent 
molecules/ acetate molecules being incorporated in to the complex, thus giving rise to the diverse 
results. A study by M. Shebl et al.214 looked into relatively similar complexes where it was found 
that the anion of the copper salt they used to make the copper complexes also co-ordinated to 
the copper alongside the main complex. Particularly it was reported the acetate ion behaving in 
this way by co-ordinating to copper that was already bound to a tri-dentate ligand and a mono-
dentate water molecule.   
Evidence in the NMR spectra of the zinc bis(thiosemicarbazone) complexes, which are reported 
later in this Chapter, has also shown a presence of what is thought to be acetate molecule acting 
as a ligand. It was not possible to utilise NMR in order to elucidate the cause of the divergence in 




The copper complexes were purified using a DMSO/H2O recrystallisation method. Other solvents 
were tested (ethanol, methanol, dichloromethane, acetonitrile) but it was found that the copper 
complexes were poorly soluble in these solvents and consequently full dissolution was not 
achieved. The copper complexes were dissolved in the minimum volume of DMSO and double the 
volume of water was pipetted down the side of the test tube in order to form a layer of water on 
top of the DMSO. The solution was then allowed to diffuse over the course of a week. The 
product was then recovered by filtration and washed with water and diethyl ether. The solid 
allowed to dry overnight in air. It was discovered that if the water was not allowed to diffuse with 
the DMSO layer slowly over a couple of days then the resulting precipitate would be very fine and 
thus very hard to recover via filtration. The slow recrystallisation method used the purification 
step was relatively inefficient, with yields typically between 20-30%. Despite the low yields the 
purifications were highly successful with six out of the eight recrystallised product giving 
acceptable CHN results.  
Mass spectra of all dissymmetric copper complexes were obtained. All the copper complexes 
tested were detected as M+ H+ and the theoretical m/z values where in close agreement with the 
experimental results. The theoretical m/z values where calculated by ChemCalc.213 The isotope 
patterns of the spectra obtained all matched the predicted pattern produced by ChemCalc. 
Figures 3.2.4.3. and 3.2.4.6. illustrate examples of the mass spectrum of Cu-PADA-Me-Ph and Cu-
PDO-Et-Et respectively. In the top right hand corner of both the spectra is the ChemCalc predicted 
spectra. An additional peak was observed in the majority of the spectra which was not present in 
the predicted spectra, this extra peak has an m/z value of roughly 1.008 lower than the main m/z 
peak. This peak is expected to attribute to the M+ ion without the additional proton.   
UV-visible absorption spectra were obtained from DMSO solutions of each of the synthesised 
copper bis(thiosemicarbazone) complexes. It was decided to record the spectra from 285-800nm 
in order to stay outside the absorption range of DMSO.  The UV-vis absorption spectra obtained 
had strong similarity between them. Every spectrum showed two absorptions, the first maxima 
was between 498-450 nm with an extinction coefficient of around 6-10,000 dm3 mol-1 cm-1, a 
shoulder around 530 nm was always present. The second was between 306-318 nm with an 
extinction coefficient of around 21-23,000 dm3 mol-1 cm-1, a shoulder around 350 nm was always 
present. With complexes containing a phenyl group the shoulder around 350 nm would often 
increase in absorbance so that it resembled an extra peak with an extinction coefficient ranging 
from 13-15,000 dm3 mol-1 cm-1.  
There is a little UV-visible data in the literature57, 172, whose ࡥmax and ɸǀĂůƵĞƐĂƌĞǁŝƚŚŝŶ
agreement. A study on nickel bis(thiosemicarbazone) complexes by Ackerman et al.80 suggests 
that for all the d9 copper bis(thiosemicarbazone) complexes analysed the  absorption between 
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498-450 nm is due to a d-d transition80 and the absorption between 306-318nm is due to metal-
to-ligand transfer.57 
There were two unexpected results, these were Cu-PDO-Me-Me and Cu-PDO-Et-Et. Despite the 
same method being followed as the rest of the copper complexes, there is doubt that the 
expected complexes had been obtained. Concerns where first experienced when the products 
was obtained were both dark brown/ black in colour and that they were formed in unusually low 
yields. This ĂƉƉĞĂƌĂŶĐĞǁĂƐĂůƐŽŶŽƚŝĐĞĚǁŚĞŶƵƐŝŶŐƚŚĞZĂŵĂŶ ?ƐŵŝĐƌŽƐĐŽƉĞƚŽĨŽĐƵƐƚŚĞůĂƐĞƌ ?
In the case of Cu-PADA-Et-Et the Infrared spectrum had very poorly defined peaks and the Raman 
spectrum has a very broad peak at 1489 cm-1, with no other distinguishable peaks against a rolling 
base line. With Cu-PDO-Me-Me the infrared spectrum also had only a few peaks, with low 
intensity when compared to the baseline. Surprisingly the Raman spectrum looks relatively 
sensible when compared to the spectra of the other copper complexes. It is suspected that both 
these samples decomposed somehow during the reaction yielding these black samples. If these 
samples mostly contained degraded products which do not absorb much infrared radiation, this 
would explain the poor infrared spectra. A reason why Cu-PDO-Me-Me still gave a Raman 
spectrum could be that if the laser was fortuitously focused on an area of sample were the some 
of the non-degraded product was, due tŽZĂŵĂŶ ?ƐĂďŝůŝƚǇƚŽƚĂŬĞƐƉĞĐƚƌĂŽĨĂǀĞƌǇƐŵĂůůĂƌĞĂŽĨ
the sample the rest of the degraded sample may not of had much influence on the resulting 
spectrum.  
The reduction potential data for the copper bis(thiosemicarbazone) ligands (Table 3.2.4.7.)  
indicates that out of all the complexes tested, the complexes with Me/Et on the backbone (except 
Cu-PDO-NH2-Et) all have Cu (II/I) reduction potentials lower than Cu-BDO-Me-Me (-1.12V, 
referenced to ferrocene),  Cu-BDO-NH2-(Me)2 also has a lower reduction potential than Cu-BDO-
Me-Me with -1.13V. Cu-BDO-Me-O-Ph (Q1=Me, Q2=Me, R1=Me, R2=H, the R3&R4 positions are 
taken up with a single phenyl ring directly bound to the terminal carbon. Cu-BDO-Me-O-Ph also 
has an oxygen instead of a sulphur atom on the R3/R4 side) and Cu-BDO-Me-But-NH2
 (Q1=Me, 
Q2=Me, R1=Me, R2=H, R3=H, R4= C4H8-NH2) have a significantly lower reduction potential than Cu-
BDO-Me-Me, with a reduction potential of -1.24V and -1.30V, respectively. J. Dearling et al.77 
reports that Cu-BDO-Me-Me (Cu-ATSM) with a Cu(II/I) reduction potential of -0.59V (referenced 
to Ag/AgCl) had the greatest hypoxia selectively at 60 minutes post injection out of the range of 
symmetric copper complexes tested. The paper by J. Dearling et al.77 shows a strong relationship 
between the reduction potential of a copper complex and its hypoxia selectivity. Different 
electrodes and references where used in this project, making direct comparison of the reduction 
potentials impossible. However, it is possible to suggest that based on their reduction potentials 
copper complexes with Me/Et on the backbone as well as Cu-BDO-NH2-(Me)2, Cu-BDO-Me-O-Ph 
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and Cu-BDO-Me-But-NH2 would be good candidates for further screening in order to establish 
their hypoxia selectivity. PADA related dissymmetric complexes containing Ph substituents on the 
terminal amines may also be of interest for hypoxia selectivity testing because J. Dearling77 
reported that despite Cu-PADA-Ph-Ph having a high reduction potential it still had a little hypoxia 
selectivity. This may mean that even though PADA based copper complexes containing phenyl 
substituents may have relatively high reduction potentials they still may be hypoxia selective.    
In the same paper Cu-GLY-Me-Me (Cu-GTSM) is reported to be non-hypoxia selective. If this idea 
is transferred to this data set, with GLY-Me-Me having a reduction potential of -0.96V then Cu-
PADA-Me-Ph and Cu-PADA-Ph-Ph with reduction potentials of -0.93 and -0.88 respectively, may 
be good candidates for evaluating their accumulation and retention with in the brain. It is worth 
noting that for all the complexes tested with Me/H on their backbone they had lower reduction 
potentials than those with either Me/Me or Me/Et on their backbone. This suggests that even 
though complexes with Me/H on their backbone may have a higher reduction potential than GLY-
Me-Me, if their other pharmacokinetics are favourable, such as lipophilicity, they may still be 
candidates for evaluation as brain imaging agents.  
Unfortunately at the time of writing LogP data was not available for the above complexes, so in 
order for the suggested complexes to remaining strong candidates for further testing their logP 
values will have to be favourable for their respective uses. J. Dearling77 reports a graph which can 
be found in the introduction of this thesis (Figure 1.6.2.1.6.). From this graph there seems to be a 
slight trend. For complexes with the same backbone, the ones with more lipophilic substituents 
on the terminal amines have slightly higher hypoxia selectivity. With this trend in mind it would be 
sensible to suggest that, in regards to hypoxia selectivity, PDO based copper complexes with more 
lipophilic substituents such as dimethyl and ethyl may have higher hypoxia selectivity than PDO 










3.3. Zinc bis(thiosemicarbazone) complexes 
3.3.1. Reaction overview 
The complex formation process for zinc complexes is the same as for the copper complexes. The 
pro-ligand is de-protonated to un-cover the ligand which when reacted with a zinc (II) salt, forms a 
complex by chelating between the two sulphur atoms and the lone pairs from both the imine 




Figure 3.3.1.1. The general reaction for the synthesis of zinc bis(thiosemicarbazone) complexes.  
3.3.2. Synthesis of zinc bis(thiosemicarbazone) complexes 
Method selection: 
A few studies have previously looked at synthesising zinc bis(thiosemicarbazone) complexes 
which resulted in a small number of articles in the literature that could be used as a starting point 
when devising methods for forming zinc bis(thiosemicarbazone) complexes in milligram to gram 
quantities.  Two articles were identified by J. Holland et al.57 and S. Kadowaki et al.75 which report 
a method that involves the chosen bis(thiosemicarbazone) ligand being refluxed in methanol with 
zinc acetate. An alternative study by L. Ackerman et al.80 was found, the study itself does not 
cover the synthesis of zinc bis(thiosemicarbazone) complexes but it does cover the synthesis of 
the related copper and nickel complexes.  L. Ackerman reports a similar reflux reaction but the 
solvent of choice was ethanol.  A number of articles report methods that are also comparable to 
the ones used by J. Holland and L. Ackerman with the main difference being that the authors ran 
the reaction under a N2 atmosphere.
76, 83, 84 
As all the methods are very similar in that a chosen bis(thiosemicarbazone) ligand is refluxed in 
either ethanol or methanol in the presence of a zinc salt it was chosen that the methods by J. 
Holland and L. Ackerman would be tried out, alongside the method  used in the formation of the 
copper complexes in order to see if it could be adapted.  Due to limitations in the lab facilities 





Copper derived method: 
BDO-Me-Me (0.312 g, 0.012 mol) was added to a NaOH solution (1M, 25 mL, 50 oC), the minimum 
amount of DMF was added in order to achieve full dissolution. Anhydrous zinc (II) acetate (0.257 
g, 0.014 mol) was dissolved in de-ionised water (10 mL). The solutions were combined and left to 
stir over night (whilst cooling down to room temperature). Water was added to try to form a 
precipitate. The volume of the solvent was reduced via rotary evaporation by roughly 9/10 ƚŚ ?Ɛ
and returned to the fridge overnight. When no precipitate was formed the reaction solution was 
allowed to evaporate in air over the weekend. The crystalline solid was recovered by filtration and 
washed with methanol (3 x 20 mL) and a little di-ethyl ether. The solid was dried in air.  A white 
crystalline solid (0.366 g) was recovered. 
> ?ĐŬĞƌŵĂŶ ?ƐŵĞƚŚŽĚ: 
BDO-Me-Me (0.312 g, 0.0012 mol) was added to ethanol (30 mL), anhydrous zinc (II) acetate 
(0.257 g, 0.0014 mol) was added to the suspension. The suspension was then brought under 
reflux (2 hours). The precipitate was recovered via filtration, washed with ethanol (1 x 30 mL) and 
diethyl ether (5 x 30 mL). The solid was dried in air.  A yellow solid (0.282 g) was recovered (73% 
yield).  
 : ?,ŽůůĂŶĚ ?Ɛmethod: 
BDO-Me-Me (0.312 g, 0.0012 mol) was added to methanol (30 mL). Anhydrous zinc (II) acetate 
(0.257 g, 0.0014 mol) was added to the suspension. The suspension was then brought under 
reflux (4 hours). The precipitate was recovered via filtration, washed with methanol (2 x 20 mL) 
and diethyl ether (3 x 20 mL). The solid was dried in air.  A yellow solid (0.199 g) was recovered 
(51% yield).  
Discussion  
The copper derived method was not successful because when a precipitate was finally produced, 
the white crystalline solid did not give a NMR spectrum. It is thought that the solid produced is 
likely to contain mostly sodium hydroxide. Both the L. Ackerman and J. Holland methods 
produced the desired products in acceptable yields and NMR confirmed that the products where 
present in high purity. The L. Ackerman product contained no sight of unreacted ligand but the J. 
Holland product had a small presence of unreacted BDO-Me-Me which was estimated to be less 
than 1 %. 
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As the L. Ackerman method produced a slightly purer product with a higher yield than the J. 
Holland method, it was decided that the L. Ackerman method was the method that would be used 
in the synthesis of the remaining zinc complexes.          
General methods: 
Depending on the amount of the ligand that was available the general methods used was either:  
General method A: 
The chosen bis(thiosemicarbazone) ligand ( X g, 0.0006 mol) was added to ethanol (15 mL). 
Anhydrous zinc (II) acetate (0.128 g, 0.0007 mol) was added to the suspension. The suspension 
was then brought to reflux (2 hours). The precipitate was recovered via filtration, washed with 
ethanol (1 x 15 mL) and diethyl ether (5 x 15 mL). The solid was dried in air.   
General method B: 
The chosen bis(thiosemicarbazone) ligand ( X g, 0.0004 mol) was added to ethanol (10 mL). 
Anhydrous zinc (II) acetate (0.092 g, 0.0005 mol) was added to the suspension. The suspension 
was then brought to reflux (2 hours). The precipitate was recovered via filtration, washed with 
ethanol (1 x 10 mL) and diethyl ether (5 x 10 mL). The solid was dried in air.   
General method C: 
The chosen bis(thiosemicarbazone) ligand ( X g, 0.0003 mol) was added to ethanol (7.5 mL). 
Anhydrous zinc (II) acetate (0.073 g, 0.0004 mol) was added to the suspension. The suspension 
was then brought to reflux (2 hours). The precipitate was recovered via filtration, washed with 
ethanol (1 x 7.5 mL) and diethyl ether (5 x 7.5 mL). The solid was dried in air.   
The method used for each complex is summarised in table 3.3.2.1., along with the reaction yield 









Zn-GLY-Et-Et A 62% Orange solid No76, 180  
Zn-GLY-Ph-Ph A 85% Orange solid No76, 180  
Zn-PADA-Me-Me A 48% Yellow solid No202  
Zn-PADA-Me-Ph B 21% Orange solid Yes  
Zn-PADA-Et-(Me)2 A 42% Orange solid Yes  
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Zn-PADA-Et-Ph A 26% Orange solid Yes  
Zn-PADA-Ph-Ph B 49% Orange solid Yes  





Zn-PADA-Ph-Me B 48% Orange solid Yes  
Zn-BDO-NH2-NH2 A 69% Yellow solid No
202, 215  







73% Yellow solid No75, 76, 189  
Zn-BDO-Me-NH2 B 55% Yellow solid No
83  
Zn-PDO-NH2-NH2 A 53% Yellow solid Yes Expected 
ethanol ligands 
Yield (40%) 
Zn-PDO-NH2-Me B 51% Yellow solid Yes  
Zn-PDO-NH2-(Me)2 A 9% Yellow solid Yes  
Zn-PDO-NH2-Et A 33% Yellow solid Yes  
Zn-PDO-Me-NH2 A 34% Yellow solid Yes  
Zn-PDO-Et-Et A 38% Yellow solid Yes  
Zn-PDO-Et-NH2 A 33% Yellow solid Yes A small 
quantity of  
acetate ligand 
expected 







3.2.3. Characterisation data for zinc bis(thiosemicarbazone) complexes 
Zinc bis(thiosemicarbazone) complexes with H/H on the backbone 
Zn-GLY-Et-Et 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ?Ɛ, 1 H, C-NH), 7.90 (s, 1 H, C-NH), 7.50 (s, 2 H, N=C-H), 3.49 
(m, 4 H, H2C-NH), 1.01 (m, 6 H, H2C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? (C-S), 135.3 
(C=N), 38.24 (N-CH2), 37.36 (N-CH2), 15.25 (H2C-CH3), 14.89 (H2C-CH3). IR (neat): cm
-1= 3296 (w), 
3246 (w), 3036 (w), 2980 (w), 2922 (w), 1541 (m), 1495 (m), 1468 (m), 1443 (m), 1420 (m), 1389 
(m), 1375 (m), 1342 (m), 1244 (s), 1163 (s), 1080 (s), 1045 (s), 930 (m), 916 (m), 826 (m), 766 (m), 
704 (m), 644 (m), 629 (m), 561 (m), 488 (m). Raman (neat), laser = 784.15 nm: cm-1= 1573 (s), 
1520 (w), 1502 (w), 1469 (w), 1452 (w), 1425 (w), 1393 (w), 1174 (s), 1167 (s), 929 (w), 919 (w), 
719 (w), 464 (w), 413 (w), 332 (w), 291 (w), 274 (w), 236 (w). UV-Vis absorptions:  ʄmax/nm 
 ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 9 700) and 440 (sh), 458 (43 700). 
Zn-GLY-Ph-Ph 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ?Ɛ ? ?, ?WŚ-NH), 7.78 (s, 2 H, N=C-H), 7.71 (d, 4 H, H(2,6) aryl, 
J= 7.6 Hz), 7.21 (t, 4 H, H(3,5) aryl, J= 7.6 Hz), 6.92 (t, 2 H, H(4) aryl, J= 7.6 Hz). 
13C {1H} NMR (DMSO-
d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 141.09 (C(1) aryl), 138.46 (C=N), 128.93 (C(3,5) aryl), 122.70 (C(4) aryl), 
121.24 (C(2,6) aryl). IR (neat): cm
-1= 3370 (w), 1595 (w), 1541 (m), 1495 (m), 1449 (m), 1400 (s), 
1325 (s), 1298 (m), 1252 (s), 1177 (m), 1088 (m), 1067 (m), 1028 (w), 918 (m), 893 (w), 868 (w), 
841 (w), 808 (m), 746 (s), 685 (s), 611 (m), 586 (m), 557 (m), 501 (s), 438 (w). Raman (neat), laser 
= 784.15 nm: cm-1= 1568 (m), 1541 (m), 1473 (m), 1461 (m), 1430 (w), 1365 (w), 1319 (w), 1257 
(w), 1175 (w), 1146 (s), 1121 (w), 997 (w), 921 (w), 837 (w), 691 (w), 523 (w), 412 (w), 359 (w), 
268 (w). Melting point: >270 oC (decomposed). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 
mol-1 cm-1 13 400) and 472 (23 200). 
Zinc bis(thiosemicarbazone) complexes with Me/H on the backbone 
Zn-PADA-Me-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?7.54 (s, 1 H, N=CH), 7.41 (s, 1 H, H3C-NH), 7.22 (s, 1 H, H3C-NH), 
2.78, 6 H, HN-CH3), 2.06 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?29.79 (HN-CH3), 
16.32 (N=C-CH3). IR (neat): cm
-1= 3374 (m), 3204 (w), 2924 (m), 1585 (w), 1514 (s), 1433 (m), 1402 
(s), 1342 (s), 1271 (s), 1233 (s), 1184 (s), 1136 (m), 1115 (m), 1053 (s), 986 (m), 922 (m), 853 (m), 
795 (m), 723 (m), 669 (s), 598 (m), 581 (m), 546 (m), 523 (s), 453 (s), 428 (m). Raman (neat), laser 
= 784.15 nm: cm-1= 1608 (w), 1574 (w), 1526 (m), 1495 (s), 1486 (s), 1376 (w), 1271 (m), 1242 (m), 
1199 (m), 986 (w), 921 (m), 852 (w), 722 (w), 662 (w), 601 (w), 580 (m), 867 (w), 452 (w), 431 (w), 
380 (w), 339 (w), 275 (w). Elemental analysis: Found: C, 27.3; H, 3.85; N, 26.9. Calc. for 
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Zn1C7H12N6S2: C, 27.15; H, 3.9; N, 27.1%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 
cm-1 13 800) and 444 (13 000). 
Zn-PADA-Me-Ph 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?9.48 (s, 1 H, Ph-NH), 7.76 (s, 1 H, N=CH), 7.72 (m, 2 H, H(2,6) 
aryl),7.43 (s, 1 H, CH3-NH), 7.43 (t, 2 H,  H(3,5)  aryl, J= 7.2 Hz), 6.89 (d, 1 H, H(4) aryl, J= 7.2 Hz ), 2.81 
(s, 3 H, N-CH3), 2.10 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?141.87 (C=N), 141.35 
(C(1) aryl), 128.86 (C(3,5) aryl), 122.31 (C(4) aryl), 120.88 (C(2,6) aryl), 29.69 (N-CH3), 16.26 (N=C-CH3). IR 
(neat): cm-1= 3451 (w), 3267 (w), 3130 (w), 3071 (w), 1597 (w), 1545 (m), 1493 (m), 1477 (m), 
1450 (m), 1416 (s), 1398 (s), 1348 (m), 1319 (m), 1308 (m), 1263 (m), 1242 (m), 1221 (s), 1171 (s), 
1130 (s), 1072 (m), 1030 (m), 997 (m), 959 (m), 922 (m), 895 (m), 885 (m), 831 (m), 824 (m), 795 
(m), 743 (s), 683 (s), 658 (m), 617 (s), 584 (s), 501 (s), 474 (m), 430 (m). Raman (neat), laser = 
632.81 nm: cm-1= 3273 (w)1619 (w), 1602 (w), 1549 (m), 1536 (s), 1477 (s), 1454 (m), 1516 (m), 
1370 (w), 1347 (w), 1318 (w), 1310 (m), 1246 (m), 1225 (m), 1187 (w), 1132 (m), 1034 (w), 996 
(w), 923 (m), 831 (w), 656 (w), 618 (w), 591 (w), 583 (w), 472 (w), 457 (w), 348 (w). Elemental 
analysis: Found: C, 38.8; H, 3.9; N, 22.6. Calc. for Zn1C12H14N6S2: C, 39.0; H, 3.8; N, 22.7%. UV-Vis 
absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 18 200) and 450 (15 800). Mass 
spectrometry (ESI): m/z (Calc.) 371.0093 (371.0091) {M + H+}. 
Zn-PADA-Et-(Me)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?7.53 (s, 1 H, N=CH), 7.28 (s, 1 H H2C-NH,), 3.15 ( s, 6 H, HN-
(CH3)2), 2.05 (s, 3 H, N=C-CH3), 1.06 (t , 3 H, H2C-CH3, J= 7.2 Hz). 
13C {1H} NMR (DMSO-d6, 100 
D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 137.31 (C=N), 37.46 (N-CH2), 16.27 (N=C-CH3), 15.16 (H2C-CH3). IR (neat): 
cm-1= 3304 (m), 2970 (w), 2928 (w), 2870 (w), 1514 (m), 1508 (m), 1437 (s), 1375 (s), 1339 (s), 
1317 (s), 1263 (s), 1248 (s), 1217 (s), 1179 (s), 1128 (s), 1053 (m), 934 (m), 907 (s), 891 (s), 818 
(m), 723 (m), 650 (m), 621 (m), 613 (m), 586 (m), 559 (m), 540 (m), 457 (m), 417 (s). Raman 
(neat), laser = 632.81 nm: cm-1= 3304 (w), 1611 (w), 1541 (s), 1499 (s), 1482 (s), 1450 (s), 1404 
(w), 1378 (w), 1369 (w), 1321 (s), 1249 (w), 1219 (s), 1182 (w), 1133 (w), 1122 (w), 1002 (m), 931 
(s), 892 (w), 725 (w), 651 (w), 586 (m), 493 (w), 456 (w), 418 (w), 332 (w), 279 (w). Elemental 
analysis: Found: C, 32.1; H, 4.7; N, 25.0. Calc. for Zn1C9H16N6S2: C, 32.0; H, 4.8; N, 24.9%. UV-Vis 
absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 11 900) and 454 (13 700). Mass 
spectrometry (ESI): m/z (Calc.) 337.0272 (337.0248) {M + H+}. 
Zn-PADA-Et-Ph 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ?Ɛ ? ?, ?WŚ-NH), 7.75 (s, 1 H, N=CH), 7.71 (m, 2 H, H(2,6) aryl), 
7.47 (s, 1 H H2C-NH), 7.19 (t, 2 H,  H(3,5)  aryl, J=7.2 Hz), 6.88 (dd, 1 H, H(4) aryl, J=7.2 Hz ), 3.4-3.3 
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(under water peak, 2 H expected, H2C-NH), 2.08 (s, 3 H, N=C-CH3), 1.07 (t , 3 H, H2C-CH3, J= 7.6 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? ?C-S), 141.88 (C=N), 141.35 (C(1) aryl), 128.84 (C(3,5) 
aryl), 122.28 (C(4) aryl), 120.85 (C(2,6) aryl), 37.45 (N-CH2), 16.22 (N=C-CH3), 15.08 (H2C-CH3). IR 
(neat): cm-1= 3418 (w), 3267 (m), 3071 (w), 1595 (m), 1541 (m), 1481 (s), 1450 (s), 1416 (s), 1312 
(s), 1242 (s), 1223 (s), 1165 (s), 1134 (s), 928 (m), 901 (m), 800 (m), 748 (s), 689 (s), 642 (s), 615 (s), 
588 (s), 478 (s). Raman (neat), laser = 632.81 nm: cm-1= 3278 (w), 1601 (w), 1537 (s), 1482 (s), 
1461 (s), 1415 (s), 1338 (w), 1314 (m), 1246 (m), 1222 (m), 1180 (w), 1138 (w), 1002 (w), 930 (m), 
821 (w), 659 (w), 613 (w), 589 (w), 478 (w), 413 (w). Elemental analysis: Found: C, 40.4; H, 4.1; N, 
21.7. Calc. for Zn1C13H16N6S2: C, 40.5; H, 4.2; N, 21.8%. UV-Vis absorptions:  ʄmax/nm (DMSO) 334 
 ?ɸ ?Ěŵ3 mol-1 cm-1 12 600) and 456 (17 900). Mass spectrometry (ESI): m/z (Calc.) 385.0249 
(385.0248) {M + H+}. 
Zn-PADA-Ph-Ph 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?9.64 (s, 1 H, Ph-NH), 9.50 (s, 1 H, Ph-NH), 7.83 (s, 1 H, N=CH), 
7.78 (m, 2 H, H(2,6) aryl), 7.72 (m, 2 H, H(2,6) aryl), 7.22 (t, 4 H,  H(3,5)  aryl, J= 7.6 Hz), 6.91 (m, 2 H, H(4) 
aryl), 2.22 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 173.92 (C-S), 
147.32 (C=N), 143.53 (C=N), 141.15 (C(1) aryl), 141.00 (C(1) aryl), 128.93 (C(3,5) aryl), 128.90 (C(3,5) 
aryl), 122.65 (C(4) aryl), 122.19 (C(4) aryl), 121.21 (C(2,6) aryl), 120.61 (C(2,6) aryl), 16.94 (N=C-CH3). IR 
(neat): cm-1= 3422 (m), 3414 (m), 3022 (w), 1597 (m), 1547 (w), 1516 (m), 1491 (m), 1472 (m), 
1452 (m), 1410 (s), 1352 (m), 1308 (m), 1252 (m), 1233 (m), 1184 (m), 1138 (s), 1074 (m), 1028 
(m), 932 (m), 908 (m), 893 (m), 845 (m), 822 (m), 745 (s), 685 (s), 652 (m), 611 (m), 586 (m), 540 
(m), 498 (s), 422 (m). Raman (neat), laser = 632.81 nm: cm-1= 3416 (w), 3051 (w), 1622 (w), 1602 
(w), 1545 (s), 1526 (s), 1466 (s), 1430 (w), 1406 (w), 1351 (w), 1313 (w), 1237 (s), 1180 (w), 1140 
(w), 996 (w), 934 (m), 845 (w),662 (w), 613 (w), 595 (w), 476 (w), 355 (w). Elemental analysis: 
Found: C, 46.9; H, 3.7; N, 19.3. Calc. for Zn1C17H16N6S2: C, 47.1; H, 3.7; N, 19.4%. UV-Vis 
absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 13 100) and 462 (21 400). Mass 
spectrometry (ESI): m/z (Calc.) 433.0241 (433.0247) {M + H+}. 
Zn-PADA-Ph-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?9.34 (s, 1 H, Ph-NH), 7.77 (m, 2 H, H(2,6) aryl), 7.54 (s, 1 H, N=CH), 
7.36 (s, 2 H, C-NH), 7.19 (t, 2 H,  H(3,5)  aryl, J=7.2 Hz), 6.86 (t, 1 H, H(4) aryl, J=7.2 Hz ), 2.17 (s, 3 H, 
N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 172.93 (C-S), 147.94 (C=N), 141.71 
(C=N), 135.66 (C(1) aryl), 128.88 (C(3,5) aryl), 121.85 (C(4) aryl), 120.33 (C(2,6) aryl), 17.02 (N=C-CH3). IR 
(neat): cm-1= 3402 (w), 3316 (w), 1612 (m), 1537 (m), 1514 (m), 1495 (m), 1456 (m), 1408 (s), 
1327 (m), 1314 (m), 1256 (w), 1233 (w), 1192 (w), 1150 (m), 1026 (w), 928 (w), 901 (w), 851 (w), 
814 (w), 752 (m), 691 (m), 615 (m), 552 (m), 503 (m), 465 (m). Raman (neat), laser = 632.81 nm: 
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cm-1=  2918 (w), 1635 (w), 1600 (w), 1551 (s), 1516 (m), 1474 (m), 1376 (w), 1334 (w), 1312 (w), 
1229 (m), 1193 (w), 1155 (w), 999 (w), 930 (w), 850 (w), 741 (w), 698 (w), 647 (w), 617 (w), 599 
(w), 539 (w), 493 (w), 360 (w), 324 (w), 302 (w). Melting point: >250 oC (decomposed). UV-Vis 
absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 9 600) and 452 (12 900). 
Zn-PADA-Ph-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? (s, 1 H, Ph-NH), 7.77 (m, 2 H, H(2,6) aryl), 7.63 (s, 2 H, H3C-NH 
and N=CH), 7.20 (t, 2 H,  H(3,5)  aryl, J=7.2 Hz), 6.87 (t, 1 H, H(4) aryl, J=7.2 Hz ), 2.78 (s, 3 H, N-CH3),  
2.18 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?141.71 (C(1) aryl), 128.90 (C(3,5) aryl), 
121.89 (C(4) aryl), 120.34 (C(2,6) aryl), 17.02 (N=C-CH3). IR (neat): cm
-1= 3316 (w), 3265 (w), 3210 (w), 
3125 (w), 3051 (w), 3005 (w), 2916 (w), 1597 (m), 1543 (m), 1504 (s), 1493 (s), 1464 (s), 1429 (s), 
1352 (s), 1319 (s), 1302 (s), 1240 (m), 1200 (s), 1182 (m), 1173 (m), 1148 (m), 1119 (m), 1076 (m), 
1042 (m), 932 (m), 868 (m), 845 (m), 820 (m), 750 (s), 387 (m), 675 (m), 627 (m), 608 (m), 592 (m), 
581 (m), 530 (m), 503 (m), 469 (m), 419 (m). Raman (neat), laser = 632.81 nm: cm-1= 3319 (w), 
3034 (w), 1616 (w), 1599 (w), 1540 (w), 1507 (s), 1462 (s), 1427 (w), 1382 (w), 1316 (m), 1298 (m), 
1243 (s), 1184 (m), 994 (w), 933 (s),869 (w), 845 (w), 720 (w), 668 (w), 609 (w), 593 (m), 535 (w), 
461 (w), 414 (w), 384 (w), 353 (w), 328 (w), 287 (w), 239 (w). Elemental analysis: Found: C, 38.85; 
H, 3.8; N, 22.6. Calc. for Zn1C12H14N6S2: C, 38.8; H, 3.8; N, 22.6%.Melting point: >270 
oC 
(decomposed). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 13 100) and 454 (18 
800). Mass spectrometry (ESI): m/z (Calc.) 371.0093 (371.0091) {M + H+}. 
Zinc bis(thiosemicarbazone) complexes with Me/Me on the backbone 
Zn-BDO-NH2-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?6.83 (s, 4 H, C-NH), 2.13 (s, 6 H, N=C-CH3). 13C {1H} NMR (DMSO-
d6 ? ? ? ?D,ǌ ) PɷA?178.48 (C-S), 144.75 (C=N), 14.48 (N=C-CH3). IR (neat): cm-1= 3395 (w), 3283 (w), 
3138 (w), 1632 (m), 1603 (m), 1533 (w), 1472 (m), 1427 (m), 1356 (m), 1290 (m), 1211 (m), 1184 
(m), 1144 (m), 1070 (m), 1045 (m), 988 (m), 827 (m), 737 (w), 710 (m), 598 (m), 588 (m), 525 (m), 
476 (m), 420 (s). Raman (neat), laser = 632.81 nm: cm-1= 1611 (w), 1532 (s), 1476 (m), 1420 (w), 
1287 (s), 1214 (w), 1188 (m), 1004 (w), 823 (w), 704 (w), 598 (w), 392 (w), 310 (w), (fluorescence 
present). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 10 900) and 434 (9 500). 
Mass spectrometry (ESI): m/z (Calc.) 294.9793 (294.9778) {M + H+}. 
Zn-BDO-NH2-(Me)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?6.86 (s, 2 H, C-NH), 3.14 (s, 6 H, N-(CH3)2), 2.15 (s, 3 H, N=C-CH3), 
2.12 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 178.12 (C-S), 145.25 
(C=N), 144.78 (C=N), 40.62-39.36 (under solvent peak, N-(CH3)2), 11.96 (N=C-CH3), 11.70 (N=C-
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CH3). IR (neat): cm
-1= 3422 (w), 3283 (w), 3159 (w), 2916 (w), 1622 (m), 1601 (m), 1541 (m), 1501 
(m), 1433 (s), 1389 (s), 1375 (s), 1364 (s), 1294 (s), 1261 (s), 1207 (m), 1165 (s), 1136 (m), 1107 
(m), 1055 (m), 903 (s), 835 (s), 758 (m), 700 (m), 619 (m), 590 (m), 567 (w), 519 (m), 478 (m), 457 
(m), 432 (s). Raman (neat), laser = 632.81 nm: cm-1= 2916 (w), 1609 (w), 1543 (m), 1508 (s), 
1466(w), 1434 (w), 1375 (w), 1327 (w), 1293 (s), 1264 (w), 1205 (w), 1171 (w), 1141 (w), 1006 (w), 
989 (w), 835 (w), 752 (w), 698 (w), 626 (w), 567 (w), 588 (w), 567 (w), 429 (w), 380 (w), 335 (w), 
294 (w). Elemental analysis: Found: C, 29.6; H, 4.4; N, 25.8. Calc. for Zn1C8H14N6S2: C, 29.7; H, 4.7; 
N, 26.0%.Melting point: >250 oC (decomposed). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 
mol-1 cm-1 12 600) and 442 (12 900). 
Zn-BDO-Me-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?7.15 (s, 2 H, H3C-NH), 2.79 (m, 6 H, HN-CH3), 2.16 (s, 6 H, N=C-
CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? (C-S), 145.8 (C=N), 29.74 (HN-CH3), 14.42 (N=C-
CH3). IR (neat): cm
-1= 3333(w), 2922 (w), 2882 (w), 1557 (w), 1522 (s), 1493 (s), 1452 (s), 1402 (m), 
1379 (s), 1369 (s), 1219 (s), 1157 (s), 1119 (m), 1074 (m), 982 (m), 833 (s), 793 (w), 768 (m), 596 
(m), 538 (m), 645 (s), 449 (s), 442 (s), 417 (s). Raman (neat), laser = 632.81 nm: cm-1= 3333 (w), 
1611 (w), 1547 (m), 1492 (s), 1461 (w), 1368 (w), 1327 (m), 1251 (m), 1188 (w), 992 (w), 837 (w), 
769 (w), 585 (w), 433 (w), 334 (w), 298 (w). Melting point: >310 oC (decomposed). UV-Vis 
absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 14 000) and 432 (13 400). 
Zn-BDO-Me-NH2 
1H NMR (DMSO-d6, 400 MHz): ɷA? 7.16 (1 H, H3C-NH), 6.86 (s, 2 H, C-NH), 2.77 (m, 3 H, HN-CH3), 
2.15 (s, 3 H, N=C-CH3), 2.12 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?178.47 (C-S), 
144.60 (C=N), 29.72 (HN-CH3), 14.46 (N=C-CH3). IR (neat): cm
-1= 3464 (w), 3404 (w), 3352 (m), 
3277 (w), 3134 (m), 1628 (m), 1607 (w), 1547 (m), 1516 (m), 1487 (m), 1431 (s), 1396 (s), 1375 (s), 
1315 (m), 1300 (m), 1223 (s), 1184 (m), 1153 (m), 1094 (m), 1057 (m), 999 (m), 982 (m), 831 (s), 
727 (s), 696 (m), 654 (m), 588 (m), 522 (m), 501 (m), 444 (s). Raman (neat), laser = 632.81 nm: cm-
1=3351 (w), 2927 (w), 1614 (w), 1538 (s), 1483 (s), 1454 (w), 1425 (w), 1317 (m), 1302 (m), 1264 
(w), 1236 (m), 1192 (m), 999 (w), 831 (w), 785 (w), 718 (w), 653 (w), 593 (w), 450 (w), 394 (w), 325 
(m), 290 (w). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 13 900) and 432 (12 
800). 
Zinc bis(thiosemicarbazone) complexes with Me/Et on the backbone 
Zn-PDO-NH2-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?6.86 (d, 4 H, C-NH), 2.63 (q, 2H, C-CH2, J= 7.2 Hz), 2.14 (s, 3 H, 
N=C-CH3), 0.99 (t, 3 H, C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 
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178.50 (C-S), 149.17 (C=N), 144.13 (C=N), 20.83 (C-CH2), 14.21 (N=C-CH3), 11.34 (C-CH2-CH3). IR 
(neat): cm-1= 3294 (w), 3165 (w), 2974 (w), 1630 (w), 1599 (m), 1537 (w), 1416 (s), 1323 (m), 1298 
(m), 1242 (w), 1204 (m), 1175 (m), 1144 (m), 1043 (m), 943 (m), 874 (m), 837 (m), 789 (m), 706 
(s), 588 (m), 536 (m), 469 (m). Raman (neat), laser = 632.81 nm: cm-1= 1618 (w), 1537 (s), 1454 
(w), 1325 (w), 1295 (m), 1243 (w), 1208 (w), 1183 (m), 1025 (w), 995 (w), 946 (w), 789 (w), 708 
(w), 591 (w), 390 (w), 307 (w), 242 (w), 219 (w). Elemental analysis: Found: C, 27.3; H, 4.0; N, 
26.9. Calc. for Zn1C7H12N6S2: C, 27.15; H, 3.9; N, 27.1%. UV-Vis absorptions:  ʄmax/nm (DMSO) 312 
 ?ɸ ?Ěŵ3 mol-1 cm-1 12 000) and 438 (10 000). 
Zn-PDO-NH2-Me 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?7.18 (s, 1 H, C-NH), 6.87 (s, 2 H, H3C-NH), 2.77 (m, 3 H, HN-CH3), 
2.64 (q, 2H, C-CH2, J= 7.6 Hz), 2.13 (s, 3 H, N=C-CH3), 1.00 (t, 3 H, C-CH2-CH3, J=7.6 Hz). 
13C {1H} 
NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 144.04 (C=N), 29.79 (HN-CH3), 20.93 (C-CH2), 14.22 
(N=C-CH3), 10.83 (C-CH2-CH3). IR (neat): cm
-1= 3445 (w), 3399 (w), 3275 (w), 3140 (w), 2972 (w), 
2928 (w), 1624 (w), 1605 (w), 1541 (m), 1489 (m), 1425 (s), 1395 (s), 1333 (m), 1294 (m), 1231 
(m), 1204 (m), 1180 (m), 1148 (m), 1098 (m), 1059 (m), 953 (m), 841 (m), 787 (m), 772 (m), 723 
(m), 646 (m), 621 (m), 596 (m), 532 (m), 501 (m), 459 (m), 415 (s). Raman (neat), laser = 632.81 
nm: cm-1= 3446 (w), 2972 (w), 2923 (w), 1611 (w), 1538 (m), 1492 (s), 1426 (w), 1397 (w), 1331 
(w), 1298 (w), 1244 (w), 1233 (w), 1206 (w), 1184 (w), 1153 (w), 1083 (w), 989 (w), 954 (w), 840 
(w), 783 (w), 594 (w), 429 (w), 396 (w), 328 (w), 244 (w). Elemental analysis: Found: C, 29.8; H, 
4.5; N, 25.9. Calc. for Zn1C8H14N6S2: C, 29.7; H, 4.4; N, 26.0%. UV-Vis absorptions:  ʄmax/nm 
 ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 13 900) and 436 (12 800). Mass spectrometry (ESI): m/z (Calc.) 
323.0102 (323.0091) {M + H+}. 
Zn-PDO-NH2-(Me)2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?6.87 (s, 2 H, C-NH), 3.15 (s, 6 H, N-(CH3)2), 2.66 (q, 2H, C-CH2, J= 
7.6 Hz), 2.14 (s, 3 H, N=C-CH3), 1.02 (t, 3 H, C-CH2-CH3, J=7.6 Hz). 
13C {1H} NMR (DMSO-d6, 100 
D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 178.31 (C-S), 149.70 (C=N), 144.23 (C=N), 20.96 (C-CH2), 14.20 (N=C-CH3), 
10.71 (C-CH2-CH3). IR (neat): cm
-1= 3418 (w), 3285 (w), 3157 (w), 2922 (w), 1620 (w), 1597 (w), 
1539 (m), 1495 (m), 1429 (m), 1391 (s), 1327 (m), 1298 (m), 1265 (s), 1244 (m), 1207 (s), 1169 (m), 
1142 (m), 1107 (m), 1053 (m), 949 (m), 905 (s), 839 (m), 785 (m), 745 (m), 700 (m), 669 (m), 617 
(m), 588 (m), 482 (s), 461 (s), 432 (s). Raman (neat), laser = 632.81 nm: cm-1= 3285 (w), 2919 (w), 
1603 (w), 1539 (s), 1500 (s), 1457 (m), 1443 (m), 1385 (w), 1367 (w), 1330 (s), 1302 (s), 1266 (w), 
1244 (m), 1207 (w), 1174 (w), 1081 (w), 1029 (w), 996 (w), 951 (w), 905 (w), 842 (w), 783 (w), 740 
(w), 700 (w), 672 (w), 620 (w), 588 (m), 495 (w), 430 (w), 400 (w), 379 (w), 327 (w), 290 (w), 259 
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(w). Elemental analysis: Found: C, 32.1; H, 4.7; N, 24.75. Calc. for Zn1C9H16N6S2: C, 32.0; H, 4.8; N, 
24.9%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 12 200) and 446 (13 000). 
Zn-PDO-NH2-Et 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?7.23 (s, 1 H, H2C-NH, J= 6.0 Hz), 6.84 (s, 2 H, C-NH),  3.31 (m, 2 H, 
HN-CH2), 2.64 (q, 2H, C-CH2, J= 7.6 Hz), 2.14 (s, 3 H, N=C-CH3), 1.06 (t, 3 H, N-CH2-CH3, J=7.6), 1.00 
(t, 3 H, C-CH2-CH3, J=7.6 Hz). 
13C {1H} NMR (DMSO-d6,  ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 144.13 (C=N), 
37.56 (HN-CH2), 20.95 (C-CH2), 15.27 (N-CH2-CH3), 14.20 (N=C-CH3), 11.01 (C-CH2-CH3). IR (neat): 
cm-1= 3422 (m), 3285 (w), 3161 (w), 2976 (w), 2932 (w), 2870 (w), 1603 (m), 1541 (m), 1466 (s), 
1425 (s), 1383 (m), 1369 (m), 1350 (m), 1329 (m), 1296 (m), 1231 (m), 1204 (s), 1171 (m), 1144 
(m), 1059 (m), 951 (m), 783 (m), 723 (m), 656 (w), 530 (w), 442 (s). Raman (neat), laser = 784.15 
nm: cm-1= 1614 (m), 1539 (s), 1490 (s), 1468 (m), 1423 (m), 1368 (m), 1350 (m), 1328 (m), 1299 
(m), 1243 (m), 1231 (m), 1206 (m), 1178 (m), 1030 (w), 990 (w), 953 (w), 782 (w), 719 (w), 655 
(w), 594 (w), 585 (w), 409 (w), 391 (w), 344 (w), 290 (w). Elemental analysis: Found: C, 32.2; H, 
4.6; N, 24.8. Calc. for Zn1C9H16N6S2: C, 32.0; H, 4.8; N, 24.9%. UV-Vis absorptions:  ʄmax/nm 
 ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 12 900) and 438 (12 100). Mass spectrometry (ESI): m/z (Calc.) 
337.0276 (337.0248) {M + H+}. 
Zn-PDO-Me-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ?Ɛ, 1 H, H3C-NH), 6.88 (s, 2 H, C-NH), 2.78 (m, 3 H, HN-CH3), 
2.63 (q, 2H, C-CH2, J= 7.6 Hz), 2.17 (s, 3 H, N=C-CH3), 0.99 (t, 3 H, C-CH2-CH3, J=7.6 Hz). 
13C {1H} 
NMR (DMSO-d6, 100 D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 149.74 (C=N), 29.73 (HN-CH3), 20.83 (C-CH2), 14.18 
(N=C-CH3), 11.36 (C-CH2-CH3). IR (neat): cm
-1=  3242 (m), 3103 (m), 2967 (w), 1643 (m), 1547 (m), 
1508 (m), 1435 (s), 1366 (s), 1327 (s), 1283 (s), 1242 (m), 1204 (s), 1180 (s), 1148 (s), 1096 (m), 
1074 (s), 1030 (s), 943 (s), 839 (m), 799 (m), 745 (m), 698 (m), 658 (s), 611 (s), 584 (s), 530 (s), 465 
(s). Raman (neat), laser = 632.81 nm: cm-1=  3252 (w), 1607 (w), 1545 (w), 1508 (s), 1430 (w), 
1379 (w), 1327 (w), 1288 (m), 1243 (m), 1206 (w), 1186 (w), 1031 (w), 984 (w), 943 (w), 843 (w), 
799 (w), 701 (w), 591 (w), 525 (w), 386 (w), 320 (w), 229 (w). Elemental analysis: Found: C, 29.7; 
H, 4.3; N, 26.0. Calc. for Zn1C8H14N6S2: C, 29.7; H, 4.4; N, 26.0%. Melting point: >245 
oC 
(decomposed). UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 12 800) and 436 (11 
800). Mass spectrometry (ESI): m/z (Calc.) 323.0102 (323.0091) {M + H+}. 
Zn-PDO-Et-Et 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?7.21 (s, 2 H, H2C-NH), 3.36-3.32 (under water peak, 4 H 
expected, HN-CH2), 2.64 (q, 2H, C-CH2, J= 7.2 Hz), 2.16 (s, 3 H, N=C-CH3),1.06 (t, 6 H, N-CH2-CH3, 
J=7.2), 1.01 (t, 3 H, C-CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?37.48 (HN-CH2), 
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20.95 (C-CH2), 15.29 (N-CH2-CH3), 14.12 (N=C-CH3), 11.02 (C-CH2-CH3). IR (neat): cm
-1= 3429 (w), 
3296 (m), 2970 (w), 2932 (w), 2872 (w), 1539 (w), 1516 (m), 1429 (s), 1325 (m), 1258 (m), 1223 
(m), 1202 (s), 1140 (m), 1092 (m), 1020 (m), 951 (m), 833 (m), 802 (m), 575 (m). Raman (neat), 
laser = 632.81 nm: cm-1= 3294 (w), 2928 (w), 2879 (w), 1611 (w), 1539 (s), 1487 (s), 1469 (m), 
1435 (w), 1373 (w), 1354 (w), 1328 (m), 1229 (s), 1205 (w), 1166 (w), 1093 (w), 1027 (w), 996 (w), 
958 (w), 807 (w), 774 (w), 591 (w), 479 (w), 410 (w), 323 (w), 299 (w). Elemental analysis: Found: 
C, 36.1; H, 5.5; N, 23.1. Calc. for Zn1C11H20N6S2: C, 36.1; H, 5.5; N, 23.0%. UV-Vis absorptions:  
ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 13 600) and 440 (13 800). Mass spectrometry (ESI): m/z 
(Calc.) 365.0583 (365.0561) {M + H+}. 
Zn-PDO-Et-NH2 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?7.14 (s, 1 H, H2C-NH), 6.75 (s, 2 H, C-NH), 3.31 (m, 2 H, HN-CH2), 
2.61 (q, 2H, C-CH2, J= 7.2 Hz), 2.15 (s, 3 H, N=C-CH3), 1.05 (t, 3 H, N-CH2-CH3, J=7.2), 0.97 (t, 3 H, C-
CH2-CH3, J=7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C-S), 149.70 (C=N), 37.48 (HN-
CH2), 20.83 (C-CH2), 15.13 (N-CH2-CH3), 14.12 (N=C-CH3), 11.31 (C-CH2-CH3). IR (neat): cm
-1= 3424 
(w), 3283 (w), 3163 (w), 2978 (w), 2870 (w), 1603 (m), 1543 (m), 1477 (m), 1466 (m), 1425 (s), 
1371 (m), 1329 (m), 1298 (m), 1258 (m), 1233 (m), 1204 (s), 1171 (m), 1146 (m), 1022 (m), 945 
(m), 839 (m), 802 (m), 775 (m), 725 (m), 654 (m), 588 (m), 538 (m), 438 (s), 432 (s). Raman (neat), 
laser = 784.15 nm: cm-1= 1614 (w), 1541 (s), 1492 (s), 1465 (w), 1423 (w), 1372 (w), 1355 (w), 
1327 (w), 1303 (w), 1259 (w), 1234 (m), 1204 (m), 1156 (w), 1023 (w), 999 (w), 947 (w), 839 (w), 
803 (w), 777 (w), 719 (w), 589 (w), 412 (w), 382 (w), 320 (w), 287 (w). Elemental analysis: Found: 
C, 31.7; H, 4.7; N, 24.7. Calc. for Zn1C9H16N6S2: C, 32.0; H, 4.8; N, 24.9%. UV-Vis absorptions:  
ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 13 900) and 436 (12 800). Mass spectrometry (ESI): m/z 
(Calc.) 337.0245 (337.0248) {M + H+}. 
3.3.4. Spectral examples of zinc bis(thiosemicarbazone) complexes 
Zn-PADA-Et-(Me)2 





Figure 3.3.4.1. An assigned proton NMR spectrum of the complex Zn-PADA-Et-(Me)2. The red boxes 
illustrates the location of the N-N-H protons would be if there was any PADA-Et-(Me)2 ligand present. 
Environment C is located underneath the water peak, this is has been shown with other complexes where a 
HMQC NMR spectrum has been acquired, this has been covered in more detail the discussion section.  
 
Figure 3.3.4.2. An assigned carbon NMR spectrum of the complex Zn-PADA-Et-(Me)2. It is believed that 
environment H is not visible because the signal is particularly weak, instead of it being completely absent or 
under the DMSO-d6 solvent peak. It is unclear if the peaks at 180.44 ppm and 137.31 ppm are both or one of 
environments C/G and E/F respectively.   
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Figure 3.3.4.3. A FTIR spectrum of the complex Zn-PADA-Et-(Me)2. This complex was synthesised by reacting 
PADA-Et-(Me)2 with zinc (II) acetate in refluxing ethanol. 




Figure 3.3.4.5. A mass spectrum of Zn-PADA-Et-(Me)2. The spectrum in the top right hand corner is the 
predicted expected spectrum of the M + H
+




Figure 3.3.4.6-11. shows a 1H, 13C and HMQC NMR, FTIR, Raman and mass spectrum of the 
complex Zn-PDO-NH2-Et. 
Figure 3.3.4.6. An assigned proton NMR spectrum of the complex Zn-PDO-NH2-Et. The red boxes illustrates 
the location of the N-N-H protons would be if there was any PDO-NH2-Et ligand present. Environment F is 
overlapped by the water peak, this is has been shown with the HMQC NMR spectrum below (Figure 3.3.4.3.). 
The purple box shows this presence of an extra peak, which is thought to be due to some acetate forming 
part of the complex, this is discussed further in unexpected results.  
202 
 
Figure 3.3.4.7. An assigned carbon NMR spectrum of the complex Zn-PDO-NH2-Et. 
Figure 3.3.4.8. A HMQC NMR spectrum of the complex Zn-PDO-NH2-Et. The red box highlights the coupling 
between the carbon environment H to the hydrogen environment F which is very close to the position were a 
water peak would be. This shows that the signal for proton will be found underneath the water peak.  
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Figure 3.3.4.9. A FTIR spectrum of the complex Zn-PDO-NH2-Et. This complex was produced by reacting PDO-
NH2-Et with zinc (II) acetate in refluxing ethanol. 
Figure 3.3.4.10. A Raman spectrum of the complex Zn-PDO-NH2-Et. 
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Figure 3.3.5.11. A mass spectrum of Zn-PDO-NH2-Et. The spectrum in the top right hand corner is the 
predicted expected spectrum of the M + H
+




All the zinc bis(thiosemicarbazone) complex forming reactions produced yellow or orange solids 
with yields that on the whole were slightly poorer than the yields for the copper 
bis(thiosemicarbazone) complexes, but they were still acceptable. The majority of the complexes 
yields where in the range of 30-70%. The entire range of yields experienced was 9-85%.  The main 
factor that seems to dictate the yield is the lipophilicity of the resulting complex, which would 
dictate how readily the complex will dissolve in boiling ethanol. There seems to be a rough 
correlation between the complexes with lipophilic substituents on the backbone or side arms and 
lower reaction yields. If in future it became desirable to improve the reaction yields,  it may be 
possible to improve these yields by using an alternative reaction solvent that is slightly less 
lipophilic, for example methanol . This may increase the yield of the more lipophilic complexes but 
may reduce the yields of the more hydrophilic complexes.  
As zinc is diamagnetic, it was possible to use NMR in order to analyse if the zinc complex had been 
successfully synthesised. The Zn-BDO-Me-Me NMR data obtained closely matches to the data 
reported by J. Holland et al.91 Some problems were encountered during the analysis of the 
resulting complexes.  In the proton spectra it was observed that most of the peaks experienced a 
chemical shift as well as some broadening of the peaks which in some cases caused the expected 
splitting pattern to be obscured.  It was found that the proton peak from the CH2 group from the 
ethyl substituent on the side arm was often shifted to a lower chemical shift so that the peak was 
situated fully or partially underneath the proton peak of water as shown in figures 3.3.4.6. and 
3.3.4.7. The example of a peak of GLY-Et-Et being obscured by the water peak was also reported 
by P. Donnelly et al.76   
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Figure 3.3.4.6. An assigned proton NMR spectrum of the complex Zn-PDO-Et-Et. The red box illustrates that 
the protons environments C and G are expected to be located underneath the water peak at 3.33 ppm.   
Figure 3.3.4.7. A HMQC NMR spectrum of the complex Zn-PDO-Et-Et. The carbon peak found at 37.48 ppm 
that relates to the carbon environments C and G have a coupling (illustrated by the red box) to the proton 
peak at 3.32 ppm which is normally were the water peak is found.     
A similar problem was sometimes observed in the carbon spectra of the dimethyl side arm, where 
the peak was shifted to a lower chemical shift so that it was located underneath the DMSO-d6 
solvent peak, an specific example of this would be Zn-BDO-NH2-(Me)2. It was also noticed that a 
lot more sample had to be dissolved in order to obtain an acceptable spectrum than if a NMR 
spectrum was ran of the corresponding ligands. This did not cause much problem in the proton 
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NMR but caused some peaks in the carbon NMR not to be detected despite dissolving a relatively 
large amount of sample. This caused some carbon NMR data to not be reported in the 
characterisation section. When the carbon peak was particularly weak or broad the chemical 
shifts were only reported to one decimal place instead of two. Carbon environments that were 
directly bound to a nitrogen atom or a sulphur atom seem to be particularly prone to being too 
weak to be detected, presumably this is due to the relaxation time of the environments being 
particularly long. The addition of the relaxation agent chromium(III) acetylacetonate (Cr (acac)3) 
was tried in order to see the carbon spectra could be improved. At first only a tip of a micro 
spatulas worth of Cr (acac)3 was added to a sample before analysis, then a second sample with as 
much Cr (acac)3 added as possible was ran. Unfortunately the addition of the chromium(III) 
acetylacetonate resulted in a weaker carbon spectra on both accounts. A report of the proton 
NMR spectra of Zn-GLY-Ph-Ph and Zn-Gly-Et-Et was found in the literature76 were the data very 
closely agreed with the data obtained in this project.    
It was very easy and straight forward to quickly obtain high quality infrared spectra of the zinc 
complexes when using the Golden Gate Diamond ATR attachment. No previously reported 
infrared data for zinc bis(thiosemicarbazone) complexes was found. By using data reported on 
similar copper and nickel complexes78, 80 and text books on vibrational spectroscopy207, 208 peaks 
that are in the regions of 3470-3200 cm-1, 1550-1450 cm-1, 800-680 cm-1 and 500-410 cm-1 are 
likely to correspond to R-N-H, C=N, C-S and Zn-N bonds, respectively.  
As with the copper complexes, obtaining suitable Raman spectra of the zinc complexes was not 
possible by just using one laser. It was found that when analysing the zinc complexes the red 
(632.81 nm) laser was a good starting point and when the red laser did not give an acceptable 
spectrum, changing to the near infrared (784.15 nm) laser would normally give an improved 
spectrum . When the near infrared laser was used the spectrum was only recorded between 200 
and 2000 cm-1 because it was observed that very little useful information could be extracted from 
the spectrum between 2000 and 4000 cm-1.  The majority of zinc complexes gave more than 
acceptable spectra, with strong sharp peaks and a relatively flat baseline, only a few complexes 
giving weaker spectra but the majority of these still contained sharp peaks. M. Betts et al.137 
reported using Raman spectroscopy for characterising Zn-ATSM (Zn-BDO-Me-Me) for the 
application of transmetalation (please refer to Chapter 4). Besides this report, it is believed that 
no comprehensive Raman characterisation data for neither zinc nor copper 
bis(thiosemicarbazone) complexes has been reported.  That Raman spectrum of Zn-ATSM 
reported by M. Betts and co-workers137 shows a very strong resemblance to the Raman spectrum 
of Zn-BDO-Me-Me that was synthesised.   
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Similarly to the copper complexes, due to the large number of zinc complexes that were 
synthesised CHN analysis was only run on complexes that were believed to be novel. The first 
round of CHN analysis was significantly more successful than the copper CHN results with ten out 
of the eleven coming back with acceptable percentages. It is believed that during the reaction the 
zinc complexes continuously dissolved and precipitated out of the boiling ethanol, effectively 
acting as a purification step as well. Two samples show signs of a large presence of what is 
thought to be an acetate molecule acting as a second ligand, this is explored in section 3.4. below.  
A preliminary study was carried out with Zn-BDO-Me-Me in order to discover if it was possible to 
purify the zinc complexes by recrystallisation. A range of solvents mixtures were tried in order to 
achieve full dissolution of the complexes, these included methanol, ethanol, dichloromethane and 
dimethyl-sulfoxide. It was found that DMSO, hot ethanol or hot methanol could be used to 
dissolve the complexes. Warm dichloromethane or warm acetonitrile partially dissolved the 
complexes, but full dissolution was only achieved on the addition of a few drops of dimethyl-
sulfoxide. It was discovered that whilst the complex was relatively easy to get in to solution it was 
particularly difficult to get the complex to recrystallise out, neither cooling the solutions or adding 
a solvent that it was perceived the complex would not be soluble in (petroleum spirit 40-60 oC, 
diethyl ether and water) yielded a successful recrystallisation. About 20 different combinations 
where tried without success. As most the CHN results came back acceptable and most the NMR 
spectra showed little or no sign of impurity, the pursuit for a recrystallisation method was 
discontinued. It is expected that due to the range of solubility zinc bis(thiosemicarbazone) 
complexes can possess finding a recrystallisation method that is quick, straight forward and that 
can be applied to the whole range of zinc bis(thiosemicarbazone) complexes will be particularly 
challenging.  
As zinc complexes are able to be analysed by NMR for characterisation purposes and due to the 
large number of zinc complexes synthesised mass spectrometry was not utilised routinely as a 
form of characterisation, mass spectra of only a handful of compounds were collected to show 
that mass spectrometry could be used to aid identification of the zinc complexes. Similarly to the 
copper complexes both zinc complexes were detected as M+ H+ and were in close agreement to 
the theoretical m/z values and isotope pattern as calculated by ChemCalc.213 Figures 3.3.4.5. and 
3.3.4.11. illustrate examples of the mass spectrum of Zn-PADA-Et-(Me)2 and Zn-PDO-NH2-Et 
respectively. In the top right hand corner of both the spectra is the ChemCalc213 predicted spectra. 
As with the copper complexes, melting point data was taken on a selection of zinc complexes, 
again the selected complexes were chosen in order to incorporate complexes with a diverse range 
structural of substituents. Instead of melting all zinc complexes seemed to decompose upon 
heating. It was observed that when the yellow zinc complexes were heated they would become 
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darker orange in colour as the temperature increased. If the decomposition temperature had not 
been reached then on cooling of the sample the colour would revert back to yellow. Due to this 
effect it was a lot harder to monitor with the complexes that were orange to start with.  Upon 
decomposition the samples would turn to a brownish orange colour and would not revert back to 
their initial colour when cooled.  For the six samples that was analysed this decomposition was 
observed between 245-310oC. J. Holland et al.57 also reported that similar zinc complexes 
decomposed above 230OC.    
UV-visible absorption spectra were obtained from DMSO solutions of each of the synthesised zinc 
bis(thiosemicarbazone) complexes. It was decided to record the spectra from 285-800nm in order 
to stay outside the absorption range of DMSO.  The UV-vis absorption spectra obtained had 
strong similarity between them. Every spectrum showed two absorptions, the first with maxima 
between 432-472nm and the second between 308-348nm. The vast majority of the extinction 
coefficient where found to be around 12,000-14,000 dm3 mol-1 cm-1, with some being as low as 
9,500 and others being as high as 23,000. However, there does seem to be a trend that the 
complex will have a higher extinction coefficient if a phenyl group is present presumably due to 
the effect of addition conjugation within the complex. One spectrum that seems to lie outside the 
trend is the spectrum of Zn-Gly-Et-Et while having a maximum absorption at 458nm with an 
extinction coefficient of 9,700 dm3 mol-1 cm-1 which is within the expected range, the second 
absorption at 328nm which has an extinction coefficient of over 43,600 dm3 mol-1 cm-1 which is 
significantly higher than any other extinction coefficient measured. The only previously reported 
UV-vis data on zinc bis(thiosemicarbazone) complexes is for Zn-BDO-Me-Me137 which are in close 
accord with the experimental data.      
3.4. Unexpected results 
3.4.1. Acetate ligand  
It was noticed in the NMR spectra of some of the zinc complexes that extra peaks were present. 
Zn-PADA-Ph-NH2 and Zn-PADA-BDO-NH2-(Me)2 are complexes with the presence of these extra 
peaks are the most obvious, however the majority of zinc complexes that were made show no 
noticeable signs of these extra peaks.  
The NMR spectra of Zn-PADA-Ph-NH2 (Figures 3.4.1.1-3.) illustrate the presence of these extra 




Figure 3.4.1.1. An assigned proton NMR spectrum of the complex Zn-PADA-Ph-NH2. The red box highlights 
the extra peak at 1.76 ppm with an integral equal to 3 protons.  
Figure 3.4.1.2. An assigned carbon NMR spectrum of the complex Zn-PADA-Ph-NH2. The red box highlights 
the extra peaks at 22.94 and 177.13 ppm.  
A HMQC NMR spectrum (Figure 3.4.1.3.) was also run in order to investigate what the new proton 
and carbon environments are bonded to.  
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Figure 3.4.1.3. A HMQC NMR spectrum of the complex Zn-PADA-Ph-NH2. This spectrum is showing that the 
extra proton peak at 1.76 ppm and carbon peak at 22.94 ppm (red boxes) have a strong coupling (blue box) 
to each other. There are no other couplings between any other peaks and the new additional peaks.  
Discussion 
Based on the evidence from the NMR spectra it is thought that the extra peaks are coming from 
an acetate ion that is also co-ordinating with the zinc atom. Other possible candidates for the 
extra ligands based on what is present in the reaction mixture could be ethanol or an ethoxide 
ion.    
The proton NMR spectrum (Figure 3.4.1.1.) shows one extra singlet peak at 1.76 ppm with and 
integral of 3 protons. The carbon NMR spectrum (Figure 3.4.1.2.) shows two extra peaks at 22.94 
ppm and 177.13 ppm and the HMQC spectrum (Figure 3.4.1.3.) confirms that the protons giving 
rise to the singlet at 1.76 ppm are bound to the carbon giving rise to the peak at 22.94. The NMR 
ƐƉĞĐƚƌĂƚŚĞƌĞĨŽƌĞƐƵŐŐĞƐƚƐƚŚĂƚƚŚĞŵŽůĞĐƵůĞƚŚĞƐĞĞǆƚƌĂƉĞĂŬƐĂƌĞĂƌŝƐŝŶŐĨƌŽŵŚĂƐŚǇĚƌŽŐĞŶ ?Ɛ
attached to a carbon, which by looking at their chemical shifts is likely to be an alkyl group, most 
possibly a methyl group depending on how much confidence is drawn from the integral of the 
proton peak. There is also evidence of a second carbon atom which does not seem to have any 
hydrogen atoms bound to it and due to the large chemical shift of the carbon peak there is a 
suggestion that the carbon has an electronegative atom attached to it, maybe in the form of a 
carbonyl group.  For comparison a proton and carbon NMR spectra was taken of zinc (II) acetate, 
the resulting proton spectra contained a singlet at 1.80 ppm and the carbon showed two 
environments one at 23.05 ppm and the other at 177.47 ppm.  All the observations from the NMR 
spectra supports that the extra ligand is an acetate ion.   
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Similar observations were observed in the NMR spectra of the complex Zn-BDO-NH2-(Me)2. A 
HMBC NMR spectrum (Figure 3.4.1.4) was ran in order to establish if the acetate is coordinated to 
the zinc or bound to another part of the complex.  
Figure 3.4.1.4. A HMBC NMR spectrum of the complex Zn-BDO-NH2-(Me)2.  
At the first instance the HMBC NMR spectrum (Figure 3.4.1.4) of the complex Zn-BDO-NH2-(Me)2 
shows that there could be long range coupling between the methyl protons of the acetate ion and 
the C-S groups of the bis(thiosemicarbazone) ligand suggesting that the acetate may be co-
ordinating directly to the zinc ion.  However, if this is the case it is a bit suspicious that a coupling 
can be seen 6 bonds away and that there is not coupling between the protons at X and the 
carboxylate carbon environment. It is expected that the carbon environments b, of which in a 
standard carbon NMR spectrum forms two peaks at 182.16 ppm and 179.35 ppm, cannot be 
resolved in the HMBC spectrum and hence resemble just one peak.  The carboxylate found at 
177.47 ppm may also of merged with peak b, so instead of the red box showing a coupling with 
the acetate ion and the zinc complex it is actually showing the coupling between the X protons 
and its carboxylate ĐĂƌďŽŶǁŚŽ ?ƐƉĞĂŬhappens to lie under the peak attributing to carbon 
environment b.  
On consulting the infrared spectra of the complexes that are expected to have the extra acetate 
ligand there are no obvious extra peaks compared to other zinc complexes.  Zinc (II) acetate has 
acetate ions bound via the acetates oxygen to a Zn2+ ion,216 this Zn-O bond is similar to what is 
expected to be formed in the case of when an acetate molecule acts as a ligand to the zinc 
bis(thiosemicarbazone) complexes.  A reference IR spectrum of zinc (II) acetate gives a strong C=O 
stretch at 1539cm-1, off course once bound to zinc complex the C=O position is expected to shift a 
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little but this value gives an idea of the rough area of the IR spectrum that the C=O stretch of the 
acetate compound would arise. The C=O peak was chosen because it is likely that due to its 
characteristic strong absorbance it would be the environment that would be most visible in the 
spectra of the Zn complexes. IR spectra of all zinc bis(thiosemicarbazone) complexes contain 
ƉĞĂŬƐǁŝƚŚǁĂǀĞŶƵŵďĞƌƐŝŶƚŚĞ ? ? ? ? ?ƐƚŽůŽǁ ? ? ? ? ?Ɛ ?ƵĞƚŽƚŚŝƐŝƚǁĂƐŶŽƚƉŽƐƐŝďůĞƚŽĐŽŶĨŝƌŵ
the presence of the expected acetate group with infrared spectroscopy. Unfortunately neither Zn-
PADA-Ph-NH2 or Zn-BDO-NH2-(Me)2 formed crystalline products meaning X-ray diffraction could 
not be utilised to gather further information about the products.  
In the literature there is evidence that zinc atoms are willing to form complexes with five 
coordinate bonds.217 This principle was exploited in a study by H Betts et al.137 for the 
transmetalation reaction with zinc bis(thiosemicarbazone) complexes with copper to form copper 
bis(thiosemicarbazone) complexes. This application is explored further in the next Chapter. 
However, if it is the case that acetate ion has bound to the zinc of the above complexes then the 
resulting complex would mean that zinc is in the 3+ oxidation state, which is not feasible. If the 
ligand happens to be singly de-protonated instead of doubly de-protonated then the zinc in the 
resulting complex would be in the 2+ oxidation state. This extra proton would be visible in the 
proton NMR spectrum (probably around 9-11 ppm) with an integral of 1 proton but there is no 
extra proton peak in either of the proton NMR spectra of Zn-PADA-Ph-NH2 or Zn-BDO-NH2-(Me)2. 
An alternative explanation could be that the acetate ion is actually an acetic acid molecule, as 
acetic acid is neutral this would keep the zinc in the sensible oxidation state of 2+. Unfortunately 
the spectroscopic data does not support the presence of the acetic acid. The infrared spectra of 
both samples do not contain a broad O-H peak nor do their NMR proton spectra contain an extra 
peak around 12 ppm, which would indicate the presence of a hydroxyl group. An acetic acid 
reference NMR shows that the carboxylate carbon should be present around 172 ppm instead 
177 ppm. This coupled with a literature search which failed to identify any previously reported 
cases of just an acetic acid molecule acting as a ligand to a zinc ion produces doubt that the 
impurity can be an acetic acid molecule.   
To summarise, the spectroscopic data suggests a complex with an extra acetate ligand but which 
would result in a zinc ion with an unrealistic oxidation state. Whilst an acetic acid ligand would 
give a sensible oxidation state for zinc but the spectroscopic data does not support the presence 
of the acetic acid molecule. Within the time frame of this project it has not been possible to 




3.4.2. Ethanol ligand  
The complex Zn-PDO-NH2-NH2 also seems to only be isolated with an impurity, but in this case it is 
believed that the impurity is an ethanol molecule. The proton and carbon NMR spectra of this 
complex show a strong presence of peaks attributing to ethanol. The proton NMR integrals of 
these peaks suggest that the ethanol impurity is about 1:1 ethanol to complex (Figure 3.4.2.1.).  
Figure 3.4.5.1. An assigned proton NMR spectrum of Zn-PDO-NH2-NH2. This shows the presence of the extra 
environments X, Y and Z which are thought to be due to the presence of ethanol.   
A second NMR was run on the same sample to ascertain if the ethanol is uniformly spread 
through the dry solid. The NMR integrals were almost identical to the first NMR integrals which 
suggest that ethanol is uniformly distributed in the product either as a bound ligand or a co-
recrystallized product. The use of HMBC NMR did not show evidence of any coupling to the 
ethanol molecules and the zinc complex. The IR spectrum of the sample contains peaks at 2974, 
1043 and 874 cm-1 which a close the peak positions in the ethanol reference spectrum (2972, 
1045 and 880 cm-1) suggesting that ethanol is present in the sample.  
However, despite ethanol consistently being observed by NMR experiments, the CHN analysis 
results were correct for the complex without an ethanol impurity. It may be the case that during 
the heating of the sample in the CHN instrumentation the ethanol evaporated off from the 
sample before the combustion of the sample took place hence giving the result correct for the 











Carbon 27.15 27.3 
Nitrogen 3.91 4.0 
Hydrogen 27.1 26.9 
Table 3.4.5.2. Expected and obtained CHN results for Zn-PDO-NH2-NH2. 
It is feasible to say that complex Zn-PDO-NH2-NH2 has successfully been synthesised and 
depending on which analytical method is used, there may also be ethanol as an impurity.  
3.5. Conclusions 
Bis(thiosemicarbazone) pro-ligands readily chelate with either copper or zinc 2+ ions to form the 
corresponding bis(thiosemicarbazone) complex. 18 copper complexes and 20 zinc complexes have 
been successfully synthesised with varying substituents on the imine backbone and terminal 
amines. There is ambiguity if the complexes Cu-PADA-Et-Et and Cu-PDO-Me-Me have been 
successfully made, which warrants further investigation if these complexes become of particular 
interest. It is believed that 12 of the copper complexes and 14 of the zinc complexes are novel. 
The complexes have been characterised by infra-red spectroscopy and Raman spectroscopy. Zinc 
complexes have been subjected to NMR spectroscopy. Selected complexes have also been 
characterised by elemental analysis and mass spectrometry. Some of the zinc complexes seem to 
have the propensity to encompass reagent impurities making it not possible to isolate the pure 
complex. It is important that this is kept in mind as it is unclear if the presence of any impurity 
would affect the transmetalation reaction explored in Chapter 4.  Despite the 
ďŝƐ ?ƚŚŝŽƐĞŵŝĐĂƌďĂǌŽŶĞ )ĐŽŵƉůĞǆĞƐďĞŝŶŐŽĨŝŶƚĞƌĞƐƚĞĚƐŝŶĐĞƚŚĞ ? ? ? ? ?Ɛ57, 58 the literature is still 
incomplete in regards to characterisation data. Hopefully this Chapter goes some way to fill this 
gap in this knowledge.   
Cyclic voltammetry testing of a range of copper complexes has suggested groups of complexes 
which would be of interest for further biological screening. For the application of hypoxia imaging, 
complexes Me/Et on the backbone as well as Cu-BDO-NH2-(Me)2, Cu-BDO-Me-O-Ph and Cu-BDO-
Me-But-NH2 would be good candidates for further testing in order to obtain their hypoxia 
selectivity. For the application of copper metabolism imaging within the brain, complexes with 
Me/H on the backbone particularly, Cu-PADA-Me-Ph and Cu-PADA-Ph-Ph are good contenders for 
further testing in order to establish their accumulation and retention with in the brain. Good 
candidates have been initially identified based only on their reduction potentials however, in light 
of further pharmacokinetic data such as lipophilicity, there may be a requirement to revise the list 
of candidates for further testing.   
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4. Transmetalation of bis(thiosemicarbazone) complexes. 
4.1. Introduction 
J.Holland et al.57 used zinc bis(thiosemicarbazone) complexes as a precursor for desired copper 
bis(thiosemicarbazone) complexes by reacting them with copper acetate in water. This reaction is 
illustrated in Figure 4.1.1. 
Figure 4.1.1. Formation of a copper bis(thiosemicarbazone) complex by transmetalation, based on 57. 
Copper (II) acetate
H2O, 22.5oC
This synthetic approach could be very useful in the quick, clean synthesis of radio-copper 
complexes, particularly if the copper isotope has a short half live. This method was taken one step 
forward by H. Betts et al.137 who attached the zinc bis(thiosemicarbazone) complex to a solid 
support and eluted the desired radio-copper complex by the addition of a [64Cu]Cu-acetate 
solution. This approach is illustrated in figure 4.1.2.  A. Aphaiwong194 and co-workers tested a 
number of different polymers for zinc-copper bis(thiosemicarbazone) transmetalation reactions. 
They concluded out of the polymers that they tested a pyridine functionality is optimal. The 
authors also stated that further work to improve loading and release of metal ligands from their 
polymeric supports is warranted.    
Figure 4.1.2. The formation of a copper bis(thiosemicarbazone) complex by using polymer bound zinc 













The aim of this section is to further explore the use of dimethylaminopyridine on a polystyrene 
(Figure 4.1.3.) support, along with another polymer, poly-(4-vinylpyridine) (Figure 4.1.3.), for the 
application of synthesis of copper bis(thiosemicarbazone) complexes via the transmetalation 
approach.     
Figure 4.1.3. The structure of poly-(4-vinylpyridine)(PVP) and polystyrene bound dimethylaminopyridine (PS-









4.2. Transmetalation of zinc bis(thiosemicarbazone) complexes.  
To verify that the transmetalation works for a range of zinc bis(thiosemicarbazone) complexes 
besides Zn-BDO-Me-Me,57, 137, 194 the reaction was tested on five of zinc complexes.  
An altered version of the method followed by P. Holland57 and co-workers was used in order to 
allow for the reaction to be suitable for a wide range of zinc bis(thiosemicarbazone) complexes. 
The new method was particularly designed so that a solid product could be obtained so that the 
products identity could be verified by analytical techniques. The general protocol for the altered 
method was: 
A chosen zinc bis(thiosemicarbazone) complexes was dissolved in the minimum volume of DMSO. 
A 10% excess of copper acetate monohydrate was dissolved in the minimum volume of deionised 
water. Solutions were combined and stirred for 5 minutes. The precipitate was recovered by 
filtration. The product was washed with water (10 mL), ethanol (10 mL) and diethyl ether (10 
mL).The product was left to dry.  
4.2.1. Methods 
Cu-GLY-Et-Et 
O.015g (0.00005 mol) of Zn-GLY-Et-Et was dissolved in DMSO (4 mL, warm). 0.012g (0.00006 mol) 
of copper acetate monohydrate was dissolved in deionised water (0.5 mL). The solutions were 
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combined and stirred solution for 5 minutes. The solution changed rapidly to a brown coloured 
solution. Water (9 mL) was added to the solution. The precipitate was recovered by filtration. The 
product was washed with water (10 mL), ethanol (10 mL) and diethyl ether (10 mL).The product 
was left to dry. A brown solid (0.008 g) was recovered (48% yield). 
Cu-PADA-Me-Me 
O.012g (0.00004 mol) of Zn-PADA-Me-Me was dissolved in DMSO (1 mL). 0.010g (0.00005 mol) of 
copper acetate monohydrate was dissolved in deionised water (0.5 mL). The solutions were 
combined and stirred solution for 5 minutes. The solution changed rapidly to a brown coloured 
solution. Water (3 mL) was added to the solution. The precipitate was recovered by filtration. The 
product was washed with water (10 mL) and diethyl ether (10 mL).The product was left to dry. A 
brown solid (0.012 g) was recovered (97% yield). 
Cu-BDO-NH2-NH2 
O.021g (0.00007 mol) of Zn-BDO-NH2-NH2 was dissolved in DMSO (2.5 mL). 0.016g (0.00008 mol) 
of copper acetate monohydrate was dissolved in deionised water (0.5 mL). The solutions were 
combined and stirred solution for 5 minutes. The solution changed rapidly to a brown coloured 
suspension. The precipitate was recovered by filtration. The product was washed with water (10 
mL), ethanol (10 mL) and diethyl ether (10 mL).The product was left to dry. A brown solid (0.011 
g) was recovered (53% yield). 
Cu-BDO-Me-Me 
O.050g (0.00015 mol) of Zn-BDO-Me-Me was dissolved in DMSO (2 mL). 0.034g (0.00017 mol) of 
copper acetate monohydrate was dissolved in deionised water (1 mL). The solutions were 
combined and stirred solution for 5 minutes. The solution changed rapidly to a brown coloured 
suspension. The precipitate was recovered by filtration. The product was washed with water (10 
mL), ethanol (10 mL) and diethyl ether (10 mL).The product was left to dry. A brown solid (0.040 
g) was recovered (82% yield). 
Cu-PDO-Et-Et 
O.019g (0.00005 mol) of Zn-PDO-Et-Et was dissolved in DMSO (1 mL). 0.012g (0.00006 mol) of 
copper acetate monohydrate was dissolved in deionised water (0.5 mL). The solutions were 
combined and stirred solution for 5 minutes. The solution changed rapidly to a brown coloured 
suspension. The precipitate was recovered by filtration. The product was washed with water (10 
mL), ethanol (10 mL) and diethyl ether (10 mL).The product was left to dry. A brown solid (0.012 




0.027g (0.00008 mol) of Zn-PADA-Et-(Me)2 was dissolved in DMSO (1 mL).  0.018g (0.00009 mol) 
of copper acetate monohydrate was dissolved in deionised water (1 mL).  The solutions were 
combined and stirred for 5 minutes. The solution changed rapidly to a brown colour. The 
precipitate was recovered by filtration and was washed with water (10 mL) and diethyl ether (10 
mL).  The product was left to dry. A brown solid (0.026 g) was recovered (91% yield).  
Cu-PADA-Ph-Me 
0.020g (0.00005 mol) of Zn-PADA-Ph-Me was dissolved in DMSO (1 mL).  0.012g (0.00006 mol) of 
copper acetate monohydrate was dissolved in deionised water (1 mL).  The solutions were 
combined and stirred for 5 minutes. The solution changed rapidly to a brown colour. The 
precipitate was recovered by filtration and was washed with water (10 mL) and diethyl ether (10 
mL).  The product was left to dry. A brown solid (0.009 g) was recovered (49% yield).  
Cu-PDO-Me-NH2 
0.026g (0.00008 mol) of Zn-PDO-Me-NH2 was dissolved in DMSO (1 mL).  0.018g (0.00009 mol) of 
copper acetate monohydrate was dissolved in deionised water (1 mL).  The solutions were 
combined and stirred for 5 minutes. The solution changed rapidly to a brown colour. The 
precipitate was recovered by filtration and was washed with water (10 mL) and diethyl ether (10 
mL).  The product was left to dry. A dark brown solid (0.019 g) was recovered (74% yield).  
4.2.2. Characterisation data for the transmetalated copper complexes.  
Cu-GLY-Et-Et 
IR (neat): cm-1= 3325 (m), 2970 (w), 2926 (w), 1518 (s), 1437 (s), 1416 (s), 1385 (m), 1371 (m), 
1339 (s), 1290 (m), 1234 (s), 1202 (s), 1190 (s), 1119 (m), 1092 (m), 1055 (m), 1013 (m), 926 (w), 
860 (m), 824 (w), 760 (w), 685 (m), 604 (m), 597 (m). Raman (neat), laser = 632.81 nm: cm-1= 
1582 (w), 1539 (m), 1445 (s), 1342 (w), 1300 (w), 1219 (w), 1055 (w), 1019 (m), 684 (w), 606 (w), 
500 (w). Mass spectrometry (ESI): m/z (Calc.) 322.0096 (322.0115) {M + H+}. 
Cu-PADA-Me-Me 
IR (neat): cm-1= 3325 (m), 3273 (m), 2924 (w), 2886 (w), 1531 (s), 1449 (s), 1379 (s), 1348 (m), 
1240 (m), 1223 (m), 1179 (s), 1132 (m), 924 (m), 870 (m), 808 (m), 775 (w), 664 (m), 613 (m). 
Raman (neat), laser = 532.00 nm: cm-1= 2972 (w), 2915 (w), 2056 (w), 1548 (w), 1514 (w), 1470 
(s), 1245 (w), 1180 (w), 997 (w), 924 (w), 663 (w), 590 (w). Mass spectrometry (ESI): m/z (Calc.) 




IR (neat): cm-1= 3404 (m), 3287 (m), 3146 (m), 1628 (s), 1593 (m), 1539 (w), 1479 (m), 1422 (s), 
1362 (m), 1304  (m), 1217 (s), 1186 (m), 1138 (m), 1078 (m), 995 (m), 835 (m), 748 (w), 718 (m), 
673 (m), 658 (m), 602 (m), 517 (m). Raman (neat), laser = 632.81 nm: cm-1= 1534 (s), 1470 (m), 
1367 (w), 1290 (s), 1182 (m), 1003 (m), 829 (m), 705 (w), 606 (w), 395 (w), 339 (w). Mass 
spectrometry (ESI): m/z (Calc.) 293.9783 (293.9805) {M + H+}. 
Cu-BDO-Me-Me 
IR (neat): cm-1= 3321 (s), 2928 (w), 1524 (s), 1495 (m), 1468 (s), 1385 (s), 1242 (m), 1223 (s), 1188 
(m), 1157 (m), 1117 (m), 1078 (m), 841 (m), 773 (w), 606 (m), 546 (s), 509 (m). Raman (neat), 
laser = 532.00 nm: cm-1= 1556 (s), 1492 (s), 1328 (m), 1265 (m), 1244 (m), 842 (w), 603 (m). Mass 
spectrometry (ESI): m/z (Calc.) 322.0096 (322.0113) {M + H+}. 
Cu-PDO-Et-Et 
IR (neat): cm-1= 3321 (m), 2974 (w), 2930 (w), 2874 (w), 1543 (w), 1506 (m), 1481 (m), 1433 (s), 
1381 (m), 1342 (m), 1265 (w), 1234 (s), 1211 (s), 1140 (m), 1096 (w), 1055 (w), 1034 (w), 959 (w), 
843 (w), 802 (w), 596 (w), 546 (m), 515 (w). Raman (neat), laser = 532.00 nm: cm-1= 1540 (s), 
1483 (s), 1466 (m), 1333 (m), 1233 (m), 605 (w). Mass spectrometry (ESI): m/z (Calc.) 364.0565 
(364.0579) {M + H+}. 
Cu-PADA-Et-(Me)2 
IR (neat): cm-1= 3323 (m), 2966 (w), 1514 (s), 1483 (m), 1464 (s), 1391 (s), 1368 (s), 1339 (s), 1310 
(s), 1258 (s), 1237 (s), 1179 (s), 1140 (s), 1059 (m), 1022 (w), 916 (m), 862 (m), 826 (m), 800 (w), 
658 (m), 625 (m), 594 (m), 544 (m), 527 (m), 474 (m). Raman (neat), laser = 632.81 nm: cm-1= 
1591 (w), 1539 (m), 1507 (w), 1482 (s), 1460 (m), 1373 (w), 1312 (m), 1225 (m), 1010 (m), 930 
(m), 660 (w), 595 (m), 511 (w), 376 (w), 350 (w). Mass spectrometry (ESI): m/z (Calc.) 336.0252 
(336.0238) {M + H+}. 
Cu-PADA-Ph-Me 
IR (neat): cm-1= 3314 (w), 3194 (w), 2974 (w), 1599 (w), 1530 (m), 1481 (s), 1456 (s), 1435 (s), 
1383 (s), 1354 (m), 1317 (m), 1244 (m), 1233 (m), 1192 (m), 1177 (s), 1146 (s), 1126 (m), 1026 (w), 
935 (w), 895 (w), 866 (w), 812 (w), 754 (s), 689 (m), 669 (m), 631 (m), 583 (m), 507 (m), 492 (w), 
449 (m), 436 (m). Raman (neat), laser = 632.81 nm: cm-1= 1578 (w), 1508 (s), 1471 (s), 1430 (w), 
1313 (w), 1273 (w), 1243 (m), 1193 (w), 995 (w), 932 (m), 676 (w), 601 (m), 542 (w), 479 (w), 369 




IR (neat): cm-1= 3287 (m), 3121 (m), 2971, (m), 1643 (w), 1628 (w), 1614 (w), 1589 (w), 1543 (m), 
1504 (m), 1435 (s), 1435 (m), 1354 (m), 1319 (m), 1277 (s), 1238 (m), 1213 (s), 1184 (s), 1148 (s), 
1101 (m), 1076 (s), 1028 (s), 943 (s), 847 (m), 800 (m), 750 (m), 708 (m), 640 (m), 613 (s), 594 (s), 
532 (s), 474 (s). Raman (neat), laser = 632.81 nm: cm-1= 1586 (w), 1539 (m), 1500 (s), 1436 (w), 
1384 (w), 1320 (w), 1282 (m), 1239 (m), 1188 (w), 1032 (w), 987 (w), 945 (w), 846 (w), 802 (w), 
706 (w), 611 (w), 395 (w), 351 (w), 322 (w). Mass spectrometry (ESI): m/z (Calc.) 322.0096 
(322.0051) {M + H+}. 
4.2.3. Spectral comparisons 
Figures 4.2.3.1.-4.2.3.4. illustrates the IR and Raman spectral comparisons of the copper 
complexes that have been synthesised in Chapter 3 and the copper complexes made via the 
transmetalation approach. Figures 4.2.3.5-6. illustrates the mass spectra of the copper complexes 
synthesised by the transmetalation method.  
Figure 4.2.3.1. A comparison of the infrared spectra of Cu-BDO-NH2-NH2 synthesised via the method in 




Figure 4.2.3.2. A comparison of the infrared spectra of Cu-PDO-Et-Et synthesised via the method in chapter 3 
(top) and Cu-PDO-Et-Et synthesised via the transmetalation approach (bottom).  
Figure 4.2.3.3. A comparison of the Raman spectra of Cu-BDO-NH2-NH2 synthesised via the method in 
chapter 3 (green) and Cu-BDO-NH2-NH2 synthesised via the transmetalation approach (blue). 
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Figure 4.2.3.4. A comparison of the infrared spectra of Cu-PDO-Et-Et synthesised via the method in chapter 3 
(green) and Cu-PDO-Et-Et synthesised via the transmetalation approach (blue). The peak labels have not 
been included as it was not possible to label the spectra sensibly by using the software.  The very sharp 
peak in the green spectra just below 2000 wavenumbers is believed to be an artefact and not a real peak 
from the sample. 
Figure 4.2.3.5. A mass spectrum of Cu-BDO-NH2-NH2 synthesised by the transmetalation approach. The 
spectrum in the top right hand corner is the predicted expected spectrum of the M + H
+
 ion of Cu-BDO-NH2-
NH2 generated by ChemCalc.
213
 The peak at 1.008 m/z unit below the M + H
+






Figure 4.2.3.6. A mass spectrum of Cu-PDO-Et-Et synthesised by the transmetalation approach. The 
spectrum in the top right hand corner is the predicted expected spectrum of the M + H
+
 ion of Cu-PDO-Et-Et 
generated by ChemCalc.
213
 The peak at 1.008 m/z unit below the M + H
+
 ion (363.0499) is expected to be the 
M
+
 ion.   
4.2.4. Discussion 
 
The transmetalation reaction for the sample of symmetric and dissymmetric zinc complexes 
tested was found to be particularly straight forward. Upon addition of the copper acetate solution 
the reaction mix turned very rapidly to brown which was indicative of a copper complex being 
formed. The reactions either yield a precipitate upon addition of the copper solution or upon 
further addition of water to the reaction mixture. The product recovered was of sufficient 
quantities in order to obtain characterisation data by infrared spectroscopy, Raman spectroscopy 
and mass spectrometry, for the purposes of identifying it as the expected copper complex.   
The use of infra-red spectroscopy was particularly simple for establishing if the transmetalation 
reaction was successful. For all complexes tested, the infrared spectra of the copper complexes 
synthesised in Chapter 3 bore very strong similarities to the transmetalated copper complexes. 
The spectral examples of two complexes (Cu-PDO-Et-Et and Cu-BDO-NH2-NH2) are shown above 
(Figure 4.2.3.1. and Figure 4.2.3.2.) were the infrared spectra of the relevant copper complex that 
was synthesised in Chapter 3 is compared to the resulting product of the transmetalation 
reactions. There are very strong similarities between the spectra. When the individual peak 
wavenumbers were compared (Table 4.2.4.1.) a large number of peaks in both spectra were 
positioned at exactly the same wavenumbers (to 2 decimal places) and for the peaks that are not 
located at exactly the same wavenumber the discrepancy is only between 2-3 wavenumbers. So 
by using infrared spectroscopy alone it suggests that the transmetalation reactions have been 























3323.35 3321.42 1.93 3402.43 3404.36 1.93 
2972.31 2974.23 1.92 3284.77 3286.70 1.93 
2927.94 2929.87 1.93 3143.97 3145.90 1.93 
1543.05 1543.05 0 1627.92 1627.92 0 
1506.41 1506.41 0 1593.20 1593.20 0 
1481.33 1481.33 0 1541.12 1539.20 1.92 
1435.04 1433.11 1.93 1479.40 1479.40 0 
1381.03 1381.03 0 1421.54 1421.54 0 
1342.46 1342.46 0 1359.82 1361.74 1.92 
1265.30 1265.30 0 1303.88 1303.88 0 
1234.44 1234.44 0 1217.08 1217.08 0 
1211.30 1211.30 0 1186.22 1186.22 0 
1141.86 1139.93 1.93 1138.00 1138.00 0 
1095.57 1095.57 0 1078.21 1078.21 0 
1055.06 1055.06 0 995.27 995.27 0 
1033.85 1033.85 0 835.18 835.18 0 
958.62 958.62 0 748.38 748.38 0 
842.89 842.89 0 715.59 717.52 1.93 
802.39 802.39 0 657.73 657.73 0 
596.00 596.00 0 601.79 601.79 0 
549.71 545.85 3.86 514.99 516.92 1.93 
Table 4.2.4.1. Showing the comparison of the twenty largest peaks in the infrared spectra shown in Figure 
4.4.3.1. and Figure 4.4.3.2. Cu-PDO-Et-Et and Cu-BDO-NH2-NH2 represents the copper complexes that were 
made in chapter 3 whilst transmetalated Cu-PDO-Et-Et and transmetalated Cu-BDO-NH2-NH2 represents the 
copper complexes synthesised by the transmetalation approach. The emboldened numbers highlight were 
exact matches were obtained. 
Using Raman spectroscopy was not as straight forward as using infrared spectroscopy. All the 
spectra obtained from the transmetalated copper complexes did show strong resemblances to 
the Raman spectra of the respective copper complexes synthesised in Chapter 3, examples for Cu-
PDO-Et-Et (Figure 4.2.3.4.) and Cu-BDO-NH2-NH2 (Figure 4.2.3.3.) are included. However, despite 
using the same acquisition parameters as in Chapter 3 for the Raman, the resulting spectra of 
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most the transmetalated complexes were significantly weaker. This meant that less peaks could 
be use in the comparison of the Raman spectra of the transmetalated copper complexes and 
copper complexes synthesised in Chapter 3. The comparison data for the example spectra (Figure 
4.2.3.3-4.) is tabulated below (Table 4.2.4.2.) where despite fewer exact matches than the 
infrared results the differences in peaks wavenumbers are still small, on average around 1-2 
wavenumbers. Raman spectroscopy further supports that the expected copper complexes have 
been successfully synthesised by the transmetalation approach.     
Cu-PDO-Et-Et Cu-BDO-NH2-NH2 


















1541.9 1539.7 2.2 1532.7 1533.7 1.0 
1484.3 1482.5 1.8 1470.3 1470.3 0 
1461.8 1466.2 4.4 1290.0 1290.0 0 
1333.1 1332.6 0.5 1181.7 1181.8 0.1 
1234.0 1233.2 0.8 1003.0 1003.0 0 
604.6 604.7 0.1 828.8 828.9 0.1 
   704.8 704.8 0 
   606.1 606.1 0 
   393.5 394.7 1.2 
   340.2 339.1 1.1 
Table 4.2.4.2. Showing the comparison of the largest peaks in the Raman spectra shown in Figure 4.4.3.1. 
and Figure 4.4.3.2. Cu-PDO-Et-Et and Cu-BDO-NH2-NH2 represents the copper complexes that were made in 
chapter 3 whilst transmetalated Cu-PDO-Et-Et and transmetalated Cu-BDO-NH2-NH2 represents the copper 
complexes synthesised by the transmetalation approach. The emboldened numbers highlight were exact 
matches were obtained. 
All the transmetalated copper complexes were analysed by mass spectrometry. All complexes 
yielded a mass spectrum that was in accord to the molecular ion m/z value and the isotopic 
distribution as predicted by ChemCalc213 for the relevant copper complex. Examples of Cu-PDO-Et-
Et and Cu-BDO-Me-Me synthesised by the transmetalation approach are illustrated above (Figure 
4.2.3.5 and Figure 4.2.3.6.). This data coupled with the supporting infrared and Raman data 




4.3. Zinc complexes + pyridine 
 
Initial investigations were under taken in order to establish if pyridine can act as an form a 5th 
ligand with the zinc ion within a zinc bis(thiosemicarbazone) complex. Besides H. Betts137 and co-
workers other reports of similar ligands to pyridine being bound to the zinc atom of a 
bis(thiosemicarbazone) complex have also been found. S. Pascu et al.191 used ligands containing 
ƚǁŽŶŝƚƌŽŐĞŶĂƚŽŵƐ ? ? ? ? ?-bispyridyl and 1,4-diazabicyclo[2.2.2]octane) in order to link two zinc 
complexes together by forming a bond between the nitrogen of the ligand bridge and the zinc 
atom of the zinc complex. Unfortunately no IR, NMR or Raman data was reported.  V.Bocokic et 
al.
190 has also reported co-ordinating phosphine based pyridine ligands to the zinc atom of a zinc 
bis(thiosemicarbazone) complex.  
4.3.1. Methods 
 
Three different methods were tried to see if it was possible to synthesise the complex Zn-BDO-
Me-Me-pyridine. One approach was adding the pyridine at the same time as zinc (II) acetate was 
reacted with the ligand BDO-Me-Me and the other two were adding the pyridine to the complex 
Zn-BDO-Me-Me. The methods that were followed are: 
Approach 1: 
BDO-Me-Me (0.312 g, 0.0012 mol) was added to ethanol (15 mL). Anhydrous zinc (II) acetate 
(0.257 g, 0.0014 mol) along with pyridine (0.49 mL, 0.479 g, 0.0061 mol) was added to the 
suspension. The suspension was then brought to reflux (2 hours). The precipitate was recovered 
via filtration, washed with ethanol (1 x 30 mL) and di-ethyl ether (5 x 30 mL). The solid was dried 
in air.  A yellow solid (0.196 g) was recovered (35% yield). 
Approach 2: 
Zn-BDO-Me-Me (0.194 g, 0.0006 mol) was dissolved in DMSO (2 mL). Pyridine (0.06 mL, 0.059 g, 
0.0007 mol) was added to the solution and left to stir overnight. Water (5 mL) was added to 
solution. The precipitate was recovered via filtration, washed with ethanol (1 x 10 mL) and di-
ethyl ether (5 x 10 mL). The solid was dried in air.  A yellow solid (0.125 g) was recovered (52% 
yield). 
Approach 3: 
Zn-BDO-Me-Me (0.194 g, 0.0006 mol) was added to ethanol (15 mL). Pyridine (0.06 mL, 0.059 g, 
0.0007 mol) was added to the suspension. The suspension was then brought to reflux (2 hours). 
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The precipitate was recovered via filtration, washed with ethanol (3 x 10 mL) and di-ethyl ether (3 
x 10 mL). The solid was dried in air.  A yellow solid (0.111 g) was recovered. 
It was found via NMR spectroscopy that approach 1 and 2 both yielded the desired product while 
approach 3 mostly yielded the complex Zn-BDO-Me-Me with only a small proportion of the 
desired product.  
Approach 2 was then used to attach pyridine to four more zinc complexes as it is believed to be 
the most versatile when investigating if pyridine can chelate to a range of zinc complexes with 
varying substituents. Complexes with bulky phenyl substituents were particularly of interest to 
investigate if the extra steric hindrance due to the phenyl functionality would impede the bonding 
of the pyridine to zinc.   
Zn-PADA-Me-Me-Pyridine 
Zn-PADA-Me-Me (0.0.031 g, 0.0001 mol) was dissolved in DMSO (1.5 mL). Pyridine (0.1 mL, 0.10 g, 
0.0012 mol) was added to the solution and left to stir overnight. Water (10 mL) was added to the 
solution. The precipitate was recovered via filtration, washed with water (10 x 2 mL). The solid 
was dried in air.  An orange solid (0.012 g) was recovered (31% yield). 
Zn-PADA-Ph-Ph-Pyridine 
Zn-PADA-Ph-Ph (0.013 g, 0.00003 mol) was dissolved in DMSO (0.5 mL).  Pyridine (0.1 mL, 0.10 g, 
0.0012 mol) was added to the solution and left to stir overnight. Water (5 mL) was added to the 
solution. The precipitate was recovered via filtration, washed with water (5 x 2 mL). The solid was 
dried in air. An orange solid (0.005 g) was recovered (32% yield). 
Zn-GLY-Ph-Ph-Pyridine 
Zn-GLY-Ph-Ph (0.0126 g, 0.0003 mol) was dissolved in DMSO (2 mL, warm). Pyridine (0.03 mL, 0.30 
g, 0.037 mol) was added to the solution and left to stir overnight. Water (10 mL) was added to the 
solution. The precipitate was recovered via filtration, washed with water (10 x 2 mL). The solid 
was dried in air. A bright orange solid (0.123 g) was recovered (82% yield). 
Zn-BDO-NH2-NH2-Pyridine 
Zn-BDO-NH2-NH2 (0.059 g, 0.0002 mol) was dissolved in DMSO (3 mL, warm). Any insoluble 
particulates were removed by filtration. Pyridine (0.2 mL, 0.20 g, 0.025 mol) was added to the 
solution and left to stir overnight. Water (10 mL) was added to the solution. The precipitate was 
recovered via filtration, washed with water (5 x 2 mL). The solid was dried in air.  A yellow solid 
(0.037 g) was recovered (49% yield). 
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4.3.2. Characterisation data for zinc complexes with pyridine 
 
Zn-BDO-Me-Me- Pyridine 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?8.49 (m, 2 H,  H(2,6)  pyridyl), 7.79 (m, 2 H,  H(4)  pyridyl), 7.39 (m, 2 
H,  H(3,5)  pyridyl), 7.18 (s, 2 H, H3C-NH), 2.79 (m, 6 H, HN-CH3), 2.26 (s, 6 H, N=C-CH3). 
13C {1H} NMR 
(DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C(2,6) pyridyl), 137.57 (C(4) pyridyl), 124.90 (C(3,5) pyridyl), 29.81 
(HN-CH3), 14.47 (N=C-CH3). IR (neat): cm
-1= 3273 (w), 3217 (w), 3001 (w), 2938 (w), 1603 (w), 
1530 (m), 1510 (m), 1476 (m), 1447 (m), 1396 (m), 1337 (m), 1250 (s), 1213 (s), 1157 (m), 1072 (s), 
1040 (s), 1013 (m), 974 (m), 839 (m), 760 (m), 694 (s), 648 (m), 635 (m), 590 (m), 446 (s). Raman 
(neat), laser = 632.81 nm: cm-1= 3285 (w), 1613 (w), 1544 (s), 1513 (s), 1478 (m), 1377 (w), 1337 
(w), 1285 (m), 1254 (m), 1217 (w), 1190 (w), 1037 (w), 1013 (w), 989 (w),841 (w), 795 (w), 726 
(w), 592 (w), 538 (w), 448 (w), 375 (w), 334 (w), 289 (w). Elemental analysis: Found: C, 38.8; H, 
4.6; N, 24.3. Calc. for Zn1C13H19N7S2: C, 38.8; H, 4.75; N, 24.3%. UV-Vis absorptions:  ʄmax/nm 
 ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 12 600) and 434 (12 800). 
Zn-PADA-Me-Me-Pyridine 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?8.50 (m, 2 H,  H(2,6)  pyridyl), 7.77 (m, 2 H,  H(4)  pyridyl), 7.55 (s, 1 
H, N=CH), 7.43 (s, 1 H, H3C-NH), 7.38 (m, 2 H,  H(3,5)  pyridyl), 7.24 (s, 1 H, H3C-NH), 2.78, 6 H, HN-
CH3), 2.06 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?149.91 (C(2,6) pyridyl), 137.11 
(C(4) pyridyl), 124.66 (C(3,5) pyridyl), 29.80 (HN-CH3), 16.32 (N=C-CH3). IR (neat): cm
-1= 3210 (w), 
3007 (w), 1603 (w), 1533 (m), 1499 (m), 1464 (w), 1447(w), 1396(w), 1333(w), 1271 (s), 1215 (m), 
1184 (s), 1128 (m), 1072 (m), 1042 (m), 1015 (m), 918 (m), 881 (m), 692 (s), 665 (m), 635 (m), 596 
(m). Raman (neat), laser = 632.81 nm: cm-1= 1608 (w), 1546 (m), 1501 (s), 1470 (s), 1397 (w), 
1374 (w), 1276 (w), 1226 (m), 1188 (m), 1131 (w), 996 (w), 921 (m), 882 (w), 666 (w), 585 (w), 544 
(w), 455 (w), 338 (w). Elemental analysis: Found: C, 37.1; H, 4.5; N, 25.1. Calc. for Zn1C12H17N7S2: 
C, 37.1; H, 4.5; N, 25.2%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 14 200) and 
447 (12 000). 
Zn-PADA-Ph-Ph-Pyridine 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?9.65 (s, 1 H, Ph-NH), 9.51 (s, 1 H, Ph-NH), 8.50 (m, 2 H,  H(2,6)  
pyridyl), 7.76 (m, 6 H, N=CH, H(2,6) aryl, H(4) pyridyl), 7.35 (m, 2 H,  H(3,5)  pyridyl), 7.21 (t, 4 H,  H(3,5)  
aryl, J= 7.6 Hz), 6.90 (m, 2 H, H(4) aryl), 2.21 (s, 3 H, N=C-CH3). 
13C {1H} NMR (DMSO-d6, 100 MHz): 
ɷA? ? ? ? ? ? ?(C-S), 173.92 (C-S), 150.10 (C(2,6) pyridyl), 147.31 (C=N), 141.54 (C=N), 141.15 (C(1) aryl), 
141.00 (C(1) aryl), 136.78 (C(4) pyridyl), 128.90 (C(3,5) aryl), 124.49 (C(3,5) pyridyl), 122.63 (C(4) aryl), 
122.16 (C(4) aryl),121.19 (C(2,6) aryl), 120.60 (C(2,6) aryl), 16.94 (N=C-CH3). IR (neat): cm
-1= 3364 (w), 
3312 (w), 1591 (w), 1522 (m), 1493 (m), 1464 (m), 1450 (m), 1393 (s), 1308 (m), 1250 (m), 1225 
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(m), 1190 (m), 1140 (m), 1074 (m), 1040 (m), 1015 (m), 930 (m), 899 (m), 826 (m), 746 (s), 691 (s), 
650 (m), 635 (m), 615 (m). Raman (neat), laser = 632.81 nm: cm-1= 1600 (w), 1543 (s), 1526 (s), 
1466 (s), 1429 (w), 1403 (w), 1347 (w), 1309 (w), 1231 (m), 1136 (w), 997 (w), 931 (m), 661 (w), 
624 (w), 594 (w), 504 (w), 466 (w), 230 (w). Elemental analysis: Found: C, 51.5; H, 4.0; N, 19.0. 
Calc. for Zn1C22H21N7S2: C, 51.5; H, 4.1; N, 19.1%. UV-Vis absorptions:  ʄmax/nm (DMSO) 343 and 
462. 
Zn-GLY-Ph-Ph-Pyridine 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ?Ɛ ? ?, ?WŚ-NH), 8.52 (m, 2 H,  H(2,6)  pyridyl), 7.79 (m, 3 H, 
N=C-H, H(4) pyridyl ), 7.72 (d, 4 H, H(2,6) aryl, J= 7.6 Hz), 7.38 (m, 2 H,  H(3,5)  pyridyl), 7.22 (t, 4 H, H(3,5) 
aryl, J= 7.2 Hz), 6.92 (t, 2 H, H(4) aryl, J= 7.2 Hz). 
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA? ? ? ? ? ? ? (C-
S), 149.90 (C(2,6) pyridyl), 141.09 (C(1) aryl), 138.46 (C=N), 137.18 (C(4) pyridyl), 128.92 (C(3,5) aryl), 
124.70 (C(3,5) pyridyl), 122.72 (C(4) aryl), 121.28 (C(2,6) aryl). IR (neat): cm
-1= 1593 (w), 1531 (w), 
1495 (w), 1447 (w), 1393 (w), 1315 (m), 1283 (m), 1242 (m), 1169 (m), 1069 (w), 1040 (w), 1001 
(w), 880 (w), 750 (m), 691 (m), 633 (m), 588 (m). Raman (neat), laser = 784.15 nm: cm-1= 1598 
(w), 1523 (s), 1452 (s), 1418 (s), 1313 (w), 1300 (w), 1245 (w), 1176 (w), 1158 (w), 1001 (s), 606 
(w), 589 (w), 476 (w). Elemental analysis: Found: C, 50.5; H, 3.8; N, 19.6. Calc. for Zn1C21H19N7S2: 
C, 50.55; H, 3.8; N, 19.7%. UV-Vis absorptions:  ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 13 500) 
and 472 (25 400). 
Zn-BDO-NH2-NH2-Pyridine 
1H NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?8.48 (m, 2 H,  H(2,6)  pyridyl), 7.79 (m, 2 H,  H(4)  pyridyl), 7.39 (m, 2 
H,  H(3,5)  pyridyl), 6.86 (s, 4 H, C-NH), 2.12 (s, 6 H, N=C-CH3).
13C {1H} NMR (DMSO-d6 ? ? ? ?D,ǌ ) PɷA?
178.50 (C-S), 149.75 (C(2,6) pyridyl), 144.78 (C=N), 137.40 (C(4) pyridyl), 124.79 (C(3,5) pyridyl),14.48 
(N=C-CH3). IR (neat): cm
-1= 3368 (w), 3291 (w), 3121 (w), 1626 (w), 1603 (m), 1537 (w), 1416 (s), 
1290 (m), 1207 (m), 1177 (m), 1138 (m), 1067 (m), 1040 (m), 988 (m), 827 (m), 752 (m), 692 (s), 
633 (m), 596 (m). Raman (neat), laser = 632.81 nm: cm-1= 1666 (w), 1537 (s), 1464 (m), 1289 (s), 
1214 (w), 1183 (m), 997 (w), 827 (w), 603 (w), 389 (w), 309 (w). Elemental analysis: Found: C, 
32.8; H, 4.4; N, 24.3. Calc. for Zn1C11H15N7S2: C, 35.25; H, 4.0; N, 26.2%. UV-Vis absorptions:  
ʄmax ?Ŷŵ ?D^K ) ? ? ? ?ɸ ?Ěŵ3 mol-1 cm-1 13 800) and 433 (12 400). 
4.3.3. Spectral and X-ray diffraction illustrations of Zn-BDO-Me-Me-Pyridine 
Figure 4.3.3.1-4. shows examples of a proton and carbon NMR spectra, a FTIR spectrum and a 
Raman spectrum of Zn-BDO-Me-Me-Pyridine. Figures 4.3.3.5-8. displays the X-ray diffraction data 
obtained from the crystal structure of Zn-BDO-Me-Me-pyridine.  
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Figure 4.3.3.1. An assigned proton NMR spectrum of Zn-BDO-Me-Me-Pyridine. This adduct was synthesised 
by reacting Zn-BDO-Me-Me with pyridine.  
 
Figure 4.3.3.2. A assigned carbon NMR spectrum of Zn-BDO-Me-Me-Pyridine. The purple and red boxes 
highlights two very faint peaks which potentially could be environments B/G and D/E respectively.  
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Figure 4.3.3.3. A FTIR spectrum of Zn-BDO-Me-Me-Pyridine. 




Figure 4.3.3.5 The X-ray crystal structure of Zn-BDO-Me-Me-pyridine showing that the pyridine is bound 
between the zinc of Zn-BDO-Me-Me and the nitrogen of the pyridine in the axial position.  
 
Atom Atom Length/Å   Atom Atom Length/Å 
Zn1 S1 2.3635(6)   N4 C5 1.288(3) 
Zn1 S2 2.3718(6)   N5 C7 1.337(3) 
Zn1 N3 2.1218(18)   N6 C7 1.344(3) 
Zn1 N4 2.1241(17)   N6 C8 1.452(3) 
Zn1 N7 2.0900(18)   N7 C9 1.341(3) 
S1 C2 1.760(2)   N7 C13 1.341(3) 
S2 C7 1.738(2)   C3 C4 1.491(3) 
N1 C1 1.450(3)   C3 C5 1.482(3) 
N1 C2 1.347(3)   C5 C6 1.495(3) 
N2 N3 1.372(3)   C9 C10 1.385(3) 
N2 C2 1.321(3)   C10 C11 1.385(4) 
N3 C3 1.294(3)   C11 C12 1.379(4) 
N4 N5 1.369(2)   C12 C13 1.382(3) 







Atom Atom Atom ŶŐůĞ ?ȗ   Atom Atom Atom ŶŐůĞ ?ȗ 
S1 Zn1 S2 113.40(2)   C7 N6 C8 125.71(19) 
N3 Zn1 S1 80.75(5)   C9 N7 Zn1 118.66(15) 
N3 Zn1 S2 144.85(5)   C13 N7 Zn1 123.45(15) 
N3 Zn1 N4 74.45(7)   C13 N7 C9 117.86(19) 
N4 Zn1 S1 150.39(5)   N1 C2 S1 114.89(16) 
N4 Zn1 S2 80.36(5)   N2 C2 S1 127.89(17) 
N7 Zn1 S1 102.52(5)   N2 C2 N1 117.2(2) 
N7 Zn1 S2 101.09(5)   N3 C3 C4 124.0(2) 
N7 Zn1 N3 107.07(7)   N3 C3 C5 114.89(18) 
N7 Zn1 N4 100.05(7)   C5 C3 C4 120.98(18) 
C2 S1 Zn1 95.38(7)   N4 C5 C3 114.89(18) 
C7 S2 Zn1 94.57(7)   N4 C5 C6 124.51(19) 
C2 N1 C1 123.16(19)   C3 C5 C6 120.51(18) 
C2 N2 N3 111.67(18)   N5 C7 S2 127.03(16) 
N2 N3 Zn1 123.07(13)   N5 C7 N6 114.16(19) 
C3 N3 Zn1 117.35(14)   N6 C7 S2 118.75(17) 
C3 N3 N2 119.53(18)   N7 C9 C10 122.9(2) 
N5 N4 Zn1 120.87(13)   C11 C10 C9 118.4(2) 
C5 N4 Zn1 117.43(14)   C12 C11 C10 119.1(2) 
C5 N4 N5 121.53(18)   C11 C12 C13 118.9(2) 
C7 N5 N4 112.29(17)   N7 C13 C12 122.8(2) 
Table 4.3.3.7. Bonding angles for the crystal structure of Zn-BDO-Me-Me-pyridine. 
 
Table 4.3.3.8. Experimental details for the collection of the crystal structure of Zn-BDO-Me-Me-pyridine. 












The chelation of an additional pyridine ligand to the zinc atom of a zinc bis(thiosemicarbazone) 
complex was successfully undertaken. For the complexes Zn-BDO-Me-Me, Zn-PADA-Me-Me, Zn-
PADA-Ph-Ph and Zn-GLY-Ph-Ph one pyridine molecule coordinates with the zinc atom of the 
chosen zinc bis(thiosemicarbazone) complex. This is backed up by the proton integrals of NMR 
spectra and CHN analysis. However, with Zn-BDO-NH2-NH2 the proton NMR spectra suggests that 
one pyridine is bound to the zinc atom of the complex but the CHN results are out by up to 2%, 
which suggest that the complex has not been made pure.  It was also attempted to co-ordinate 
pyridine with Zn-GLY-Et-Et. In this case the NMR suggested that pyridine is present with in the 
product but in a ratio of 2:1 (complex: pyridine) and the CHN analysis also was out be a few 
percent. Even though the last two complexes were not recovered with one pyridine chelated to 
one zinc atom, they still confirm the aim of this investigation which was to determine if pyridine is 
able to complex to zinc bis(thiosemicarbazone) complexes. It is believed that BDO-Me-Me, PADA-
Me-Me, Zn-PADA-Ph-Ph and GLY-Ph-Ph with the pyridine adduct are novel. 
 In order to establish if pyridine was indeed bound to the zinc of the complexes instead of being 
contained within the lattice of the product it was hoped that HMBC NMR experiments would 
shows some through bond coupling. However, the only through bonding couplings observed with 
the hydrogen environments of pyridine was just to the pyridines carbon environments. It was also 
attempted to detect through space interactions between the pyridine and the rest of complex by 
running an NOESY NMR experiment. Couplings were observed between the different 
environments of the pyridine. The complexes also showed couplings between the different 
environments of the complex however, no through space coupling was observed between the 
pyridine and the rest of the complex.  
When the pyridine proton environments are compared to the proton NMR spectrum (Figure 
4.3.4.1.) of Zn-BDO-Me-Me-Pyridine and pyridine it is possible to see that the peaks have shifted. 
Protons in environment A have shifted by about -0.05 ppm (values taken from the middle of each 
peak), and proton environments C and B have both shifted by around +0.08 ppm.  The presence of 
the changes in chemical shift suggests that the pyridine protons must be in a slightly different 
chemical environment. Thus, supporting that the pyridine may be chelated to the zinc ion of the 
zinc bis(thiosemicarbazone) complex.  The splitting of the pyridine peaks of Zn-BDO-Me-Me-
Pyridine has also become more complicated. It is thought that this is due to the pyridine 




Figure 4.3.4.1. A comparison proton NMR spectra of Zn-BDO-Me-Me-Pyridine (top) and pyridine which has 
been zoomed in to highlight the pyridine proton environments in the two molecules. In both spectra the 
DMSO- d6 peak is position at 2.459 ppm.    
It was attempted to obtain a mass spectrum of Zn-BDO-Me-Me-Pyridine but the results showed 
only Zn-BDO-Me-Me without the presence of the pyridine. It is expected that during ionisation in 
the mass spectrometer the pyridine molecule gets stripped from the complex. A similar 
observation was reported by E. Lopez-Torres et al.222  where two absent nitrate groups were 
observed in the mass spectrum of their zinc benzyl bis(thiosemicarbazone) complexes.    
Vibrational spectroscopy was used in order to show the presence of the pyridine within the zinc 
complex. Infrared spectra of the product (Figure 4.3.4.2.) suggests that the pyridine is present as 
it shows peaks that are only found in the pyridine spectra and peaks that are only found in the 
zinc bis(thiosemicarbazone) complex.  It was observed that the more substituted the zinc 
complexes were the harder it was to find regions of the infra-red spectrum from the product 
which could only be attributed to the pyridine. This was particularly to case for phenyl 
substituents on the terminal amine, which make sense as the phenyl substituent shares similar 
bonds to parts of the pyridine ligand. A similar situation was also encountered with Raman 
spectroscopy as illustrated in the comparison spectra of pyridine, Zn-PADA-Me-Me and Zn-PADA-




Figure 4.3.4.2. A comparison of the infra-red spectra of pyridine, Zn-BDO-Me-Me and Zn-BDO-Me-Me-
Pyridine. The red boxes highlight the similar peaks between pyridine and Zn-BDO-Me-Me-Pyridine. The 
purple boxes highlight the similar peaks between Zn-BDO-Me-Me and Zn-BDO-Me-Me-Pyridine. 
Figure 4.3.4.3. A comparison of the Raman spectra of pyridine, Zn-PADA-Me-Me and Zn-PADA-Me-Me-






Reports223-225 in the literature suggests that the zinc-nitrogen bond, where the nitrogen is part of a 
pyridine ligand, can be found in an infrared or Raman spectrum at around 200-260 cm-1.  
Unfortunately 200 cm-1 is below the detection range of the infrared spectrometer used. The 
Raman spectra were collected up to 200 cm-1 which do show peaks in the region reported for Zn-
N bonds. However, it not possible to say with any level of certainty that these peaks are due to 
the Zn-N bond of the pyridine coordinating with the zinc atom as the zinc atom is also bound to 
the bis(thiosemicarbazone) ligand via two Zn-N bonds.   
The UV-vis spectra of the zinc complexes with the pyridine adduct was taken. The spectra 
obtained were all very similar to the zinc complexes without the pyridine adduct. The position of 
ƚŚĞʄmax varied only by a couple of nanometres which could be due to error in the labelling of the 
peak by the software.  It seems that the presence of the pyridine adduct does not have much of 
an effect on the UV-vis spectrum of the resulting zinc complex.  
The complex Zn-PADA-Ph-Ph-pyridine was re-synthesised with aim of sending the sample for 
analysis by X-ray diffraction, the integrals of proton NMR suggested that despite the same 
method being followed the product had two equivalents of pyridine per zinc 
bis(thiosemicarbazone) complex. This result seems to suggest that the number of pyridines that 
chelate to a zinc complex may be variable however, even though the number of pyridines may 
differ this still shows that pyridine is able to chelate to a zinc atom of a bis(thiosemicarbazone) 
complex. It was later decided that Zn-PADA-Ph-Ph-pyridine produced a product in the form of a 
powder which was not suitable for X-ray diffraction studies. Zn-BDO-Me-Me-pyridine did produce 
a crystalline product which was sent off to UCL for X-ray diffraction studies which generated an X-
ray crystal structure (Figure 4.3.3.5). 
The crystal structure data is in close agreement when the bonding lengths (Table 4.3.3.6.)  and 
bonding angles (Table 4.3.3.7.)  are compared to published data on related complexes.57, 191 The 
crystal structure very strongly supports that the nitrogen of the pyridine adduct does indeed co-
ordinate with the zinc atom with the Zn-BDO-Me-Me complex in the axial position.  H. Betts et 
al.
137 has published some X-ray crystal data on Zn-BDO-Me-Me that has been co-ordinated with 
dimethylaminopyridine (DMAP), a table tabulating the zinc bonds lengths within this complex can 










Zn1-S1 2.3725 (7) Å 2.3635 (6) Å 
Zn1-S2 2.3946 (6) Å 2.3718 (6) Å 
Zn-N3 2.117 (2) Å 2.1218 (18) Å 
Zn-N4 2.112 (2) Å 2.1241 (17) Å 
Zn-N7 2.0688 (19) Å 2.0900 (18) Å 
Table 4.3.5.4. A comparison of the zinc bond lengths in Zn-BDO-Me-Me-pyridine and Zn-BDO-Me-Me-DMAP 
as reported by H.Betts
137
 and co-workers. Estimated standard deviations (esd) are shown in parentheses. 
  
Table 4.3.5.4. shows that despite the pyridine/DMAP ligands having slightly different structures 
the bonding lengths between the zinc ion and nitrogen and sulphur atoms are similar. In both 
cases the bond length between the zinc and the nitrogen of the pyridine (Zn-N7) is slightly shorter 
ƚŚĂŶƚŚĞďŽŶĚůĞŶŐƚŚďĞƚǁĞĞŶƚŚĞǌŝŶĐĂŶĚŝŵŝŶĞŶŝƚƌŽŐĞŶ ?Ɛ ?dŚĞĐƌǇƐƚĂůƐƚƌƵĐƚƵƌĞŝůůƵƐƚƌĂƚŝŽn 
(Figure 4.3.3.5.) shows that the zinc atom is a little bit above the N2S2 plane, the distance between 
the zinc atom and the N2S2 plane has not been established in this project but in the case of Zn-
BDO-Me-Me-DMAP it was reported to be 0.517 Å.137 
4.4. Zn-BDO-Me-Me on PS-DMAP and PVP 
 
After establishing that pyridine can form a fifth coordinate bond with a zinc in a 
bis(thiosemicarbazone) complex the next step was to bind a chosen complex (Zn-BDO-Me-Me) to 
both the polymer supports. It was desirable to create a polymer-complex binding method that 
could be easily applied to all of the synthesised zinc complexes, as all these zinc complexes are 
readily soluble in DMSO it was decided to use a variation of approach 2, which was used in the Zn-
BDO-Me-Me + pyridine reactions.   
4.4.1. Methods 
Zn-BDO-Me-Me + PS-DMAP 
Zn-BDO-Me-Me (0.089 g, 0.00027 mol) was dissolved in DMSO (8 mL). Polystyrene bound 
Dimethylaminopyridine (0.029 g) was added to the solution and left to stir (2 days). The product 
was recovered via filtration, washed with diethyl ether (5 x 10 mL). The solid was dried in air.  An 
orange solid (0.033 g) was recovered. 
Zn-BDO-Me-Me + PVP 
Zn-BDO-Me-Me (0.089 g, 0.00027 mol) was dissolved in DMSO (8 mL). Poly-(4-vinylpyridine) 
(0.029 g) was added to the solution and left to stir (2 days). The product was recovered via 
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filtration, washed with diethyl ether (5 x 10 mL). The solid was dried in air. A yellow solid (0.018 g) 
was recovered. 
4.4.2. Infra-red and Raman analysis of the products 
As the products could not be readily analysed by NMR spectroscopy due to the insolubility of the 
product, IR and Raman spectroscopy were the principle techniques used to analyse the products. 
Zn-BDO-Me-Me on PS-DMAP 
IR (neat): cm-1= 3260 (w), 2924 (w), 1611 (m), 1510 (m), 1454 (m), 1375 (s), 1346 (s), 1281 (m), 1211 (s), 
1155 (m), 1109 (m), 1013 (s), 949 (m), 928 (m), 853 (s), 806 (s), 768 (m), 700 (s), 530 (s), 446 (s). Raman 
(neat), laser = 632.81 nm: cm-1= 1610 (w), 1540 (m), 1474 (m), 1372 (w), 1321 (m), 1282 (m), 1228 (m), 
1183 (m), 1030 (m), 1000 (m), 986 (m), 856 (m), 775 (m), 668 (m), 594 (m), 564 (m), 445 (s), 431 
(s), 328 (s). 
Figures 4.4.2.1. and 4.4.2.2. shows stacked infra-red and Raman spectra of the product, Zn-BDO-
Me-Me and the PS-DMAP.  
 
Figure 4.4.2.1. A comparison of the infra-red spectra of PS-DMAP, Zn-BDO-Me-Me and Zn-BDO-Me-Me on 
PS-DMAP. The red boxes highlight the similar peaks between PS-DMAP and Zn-BDO-Me-Me on PS-DMAP. 
The purple boxes highlight the similar peaks between Zn-BDO-Me-Me and Zn-BDO-Me-Me on PS-DMAP. 
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Figure 4.4.2.2. A comparison of the Raman spectra of PS-DMAP (green), Zn-BDO-Me-Me (blue) and Zn-BDO-
Me-Me on PS-DMAP (red).  
Zn-BDO-Me-Me on PVP 
IR (neat): cm-1= 3285 (w), 2920 (w), 1595 (m), 1555 (m), 1493 (m), 1458 (m), 1414 (m), 1379 (m), 
1279 (m), 1215 (s), 1157 (m), 1069 (m), 1043 (m), 1024 (m), 993 (m), 818 (m), 743 (m), 561 (s). 
Raman (neat), laser = 632.81 nm: cm-1= 3051 (w), 1610 (s), 1542 (s), 1499 (s), 1481 (s), 1324 (s), 
1283 (s), 1237 (s), 993 (s), 838 (s), 668 (s), 594 (s), 429 (s), 332 (s). 
Figure 4.4.2.3. and 4.4.2.4. shows stacked infra-red and Raman spectra of the product, Zn-BDO-




Figure 4.4.2.3. A comparison of the infra-red spectra of PVP, Zn-BDO-Me-Me and Zn-BDO-Me-Me on PVP. 
The red boxes highlight the similar peaks between PVP and Zn-BDO-Me-Me on PVP. The purple boxes 
highlight the similar peaks between Zn-BDO-Me-Me and Zn-BDO-Me-Me on PVP. 
Figure 4.4.2.4. A comparison of the Raman spectra of PVP (green), Zn-BDO-Me-Me (blue) and Zn-BDO-Me-
Me on PVP (red).  
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A blank procedure was run in order to look at the effect that solvents used in the reaction have on 
the polymer. The chosen polymer was added to DMSO and left to stir overnight. The polymer was 
then recovered via filtration and washed with 5 lots of 10 mL of diethyl ether. The polymer was 
then left to dry in air. With the poly-(4-vinylpyridine) very minimal change was observed in the IR 
or Raman spectra of the product when compared to the reference spectra of stock polymer. The 
IR spectrum of dimethylaminopyridine however, suggests that either the polymer was still wet or 
that the solvents have interacted with the polymer in some way as peaks for diethyl ether and 
DMSO were observed in the spectrum. The Raman spectrum of dimethylaminopyridine had extra 
peaks even though these were not directly attributed to solvents. It is suspected that the 
presence of solvents in the polymer would not adversely affect the linking reaction between 
polymer and zinc complex but it should still be noted as it may give raise to variations in the 
products spectra.  
The attempts to bind Zn-BDO-Me-Me to the pyridine based polymer supports DMAP and PVP 
seem to be successful. In both cases the infrared spectrum in the final loaded polymer contains 
peaks which can be attributed to both the Zn-BDO-Me-Me complex and the unloaded polymer. 
Through Raman spectroscopy it was found a lot harder to identify peaks that are likely to 
attribute to both the Zn-BDO-Me-Me complex and the unloaded polymer. This is mostly likely due 
to the Raman spectra containing weaker peaks which were less prominent against the baseline. 
However there are slight signs of the two individual components being present in the polymers 
which are expected to be loaded with the zinc complex. Given more time, further investigations 
into optimising the Raman acquisition parameters may solve this issue and hopefully produce 
more compelling evidence that the polymers are bound with the Zn-BDO-Me-Me.   
Attempts to bind a selection of zinc bis(thiosemicarbazone) complexes to both the polymers PS-
DMAP and PVP where undertaken. However by just using infrared and Raman spectroscopy alone 
it was not possible to say confidentially that the zinc complexes were successfully loaded on to 
the polymers and due to time constraints of this project it was not possible to pursue this further. 
The results of the investigations earlier in this chapter about the proof of concept of zinc 
bis(thiosemicarbazone) complexes being able to bind to pyridine functionalised polymers are 
positive. Therefore further instigations in to the loading of different bis(thiosemicarbazone) 
complexes on both the PS-DMAP and PVP polymer support is warranted.  
A preliminary transmetalation reaction was carried out on a sample of the PS-DMAP and PVP 
which were loaded with Zn-BDO-Me-Me. The hope was that upon the addition of a copper 
acetate solution the reaction mix would turn to a brown colour suggesting the formation of Cu-
BDO-Me-Me. Both the loaded polymers were stirred in a 0.1 M solution of copper (II) acetate for 
3 days. Control experiments were ran where each of the polymers free of Zn-BDO-Me-Me were 
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also stirred for 3 days in a 0.1 M solution of copper (II) acetate The resulting solutions of the PVP 
loaded with Zn-BDO-Me-Me and the controls all were the same colour as the starting solutions 
however for all the solutions appeared a slightly lighter blue. The PS-DMAP loaded with Zn-BDO-
Me-Me produced a solution which was a littler greener in colour than the starting solution. 
It is hard to tell if the PVP polymer was able to undergo the transmetalation reaction. Without 
knowing the loading of each polymer with Zn-BDO-Me-Me it is not possible to know the best 
concentration of copper (II) acetate solution to use. It is expected the even if Zn-BDO-Me-Me 
bound to both the polymers did undergo transmetalation, the amount of Cu-BDO-Me-Me 
produced may not be enough to inflect a noticeable colour change within the initial blue solution. 
Further investigation is required for both polymers where a method that needs to be developed 
that can produce a transmetalated copper complex in a suitable quantity in order to allow 
characterisation of the product. Once this is established then the reaction conditions can be 
optimised for the production of the radio-copper complexes for diagnostic imaging. 
4.5. Conclusions 
 
It was found that for a selection of five symmetric and three dissymmetric zinc 
bis(thiosemicarbazone) complexes that they underwent transmetalation with copper (II) acetate 
very rapidly in order to form the corresponding copper bis(thiosemicarbazone) complex. Using 
infrared, Raman spectroscopy and mass spectrometry the identity of the products were 
confirmed as the expected copper complexes. There is no reason not to expect the 
transmetalation reaction would work for any of the other zinc complexes synthesised in chapter 
3.    
Attempts to chelate a pyridine ligand to the zinc ion of a selected zinc bis(thiosemicarbazone) 
complexes was also successful. Out of the six of the selected zinc complexes, four bound with one 
pyridine molecule in order to form what is believed to be four novel complexes. It was found that 
the remaining two zinc complexes bound to pyridine in a different ratio than one to one. Despite 
this, all six selected zinc complexes demonstrated that pyridine is able to bind via the zinc ion of a 
zinc bis(thiosemicarbazone) complex in a range of zinc complexes. A crystal structure of Zn-BDO-
Me-Me with the pyridine adduct was successfully obtained via X-ray diffraction which further 
demonstrated that pyridine can form a fifth coordinate bond with the zinc core of the zinc 
bis(thiosemicarbazone) complex.  
Attempts were undertaken to attach a zinc bis(thiosemicarbazone) complex to the pyridine 
functionalised polymers DMAP and PVP. It is believed that this is the first study with using PVP as 
a polymer platform for the transmetalation reaction for zinc bis(thiosemicarbazone) complexes. It 
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is expected that Zn-BDO-Me-Me as been successfully attached to the both DMAP and PVP. 
Infrared and Raman spectroscopy supports that this is the case, however it was found that the 
evidence collected by Raman spectroscopy was not as compelling as the evidence collected by 
infrared spectroscopy. Attempts to load alternative zinc bis(thiosemicarbazone) complexes on 
both DMAP and PVP were undertaken however the results from IR and Raman spectroscopy were 
not convincing in terms of if the zinc complex had bound to the polymers. If more time was 
available then this would most certainly be an area which is worth pursuing further.    
Preliminary transmetalation reactions have been under taken but the results were inconclusive. 
Much more investigation is called for before the polymer based transmetalation reaction can be 


















Overall conclusions and future work 
Thirty bis(thiosemicarbazone) ligands have been successfully synthesised, of which seventeen of 
these are dissymmetric ligands. It is believed that 13 ligands are novel. Experience showed that 
the exploitation of carbonyl reactivity was a superior approach compared to the synthesis via the 
acetal protection method. This is because using this method a mono-subtituted-3-
thiosemicarbazone intermediate could be synthesised in a good yield with a relatively high level 
of purity. A particularly convenient point is that the intermediate precipitates out of solution 
which made recovery very straight forward. The acetal protection method on the other hand 
required two steps to create the same mono-subtituted-3-thiosemicarbazone intermediate which 
normally required DMF as a solvent which had to be removed. The critical disadvantages about 
this method are that the yields were often low and that after the DMF was removed a sludge like 
product was left over which was very difficult to work with. However, this being said the 
protection approach could have the potential to synthesise ligands with Me/Et on the backbone 
free of isomeric impurities. If biological screening data shows that this was vital for the 
optimisation of imaging quality then one area of future investigation would be synthesising 
ligands with Me/Et on the backbone via the acetal protection approach, or by using another 
protecting group. This could also be applied to complexes with or H/H on the backbone, if they 
become of interest. In the terms of the first aim and the first objective of this project (page 46), 
which relates to being able to synthesise dissymmetric bis(thiosemicarbazone) ligands, it can be 
said that they have been achieved. However in the future, depending on the results of the 
biological data, there may be a call to expand this aim and objective so that they cover 
synthesising a wider range of ligands with substituents different from those which were made 
during this project. There may also be an interest in attaching pendant arms to the ligands in 
order to impart further desirable properties on to the complex.  All efforts have been made in 
order to design a generic synthesis method that can be used to make a range of 
bis(thiosemicarbazone) ligands. This has been achieved for the most part. However, ligands from 
each subclass explored during this thesis still possess unique challenges for their clean synthesis. 
In our hands attempts to create dissymmetric ligands with hydrogen atoms on the di-imine 
backbones were unsuccessful.   
Project aim 2 and objective 2, called for the synthesis of a range of symmetric ligands containing 
each backbone (H/Me, Me/Me and Me/Et) for comparison both in characterisation and biological 
screening. A total of 13 symmetric ligands have been synthesised which covers the range of 
substituents used in the synthesis of the dissymmetric ligands. All of the symmetric ligands have 
been fully characterised.  
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In terms of objective 3, partial optimisation of each synthetic step was undertaken in order to 
produce products with the highest yield and purity in the least number of manipulations. 
Whenever possible the reactions would be carried out in more biologically compatible solvents, 
such as water and ethanol, if purity and yield were not compromised.  
The ligands were successfully chelated with zinc or copper 2+ ions in order to yield the resulting 
zinc or copper bis(thiosemicarbazone) complexes, respectively. Eighteen copper complexes were 
synthesised of which twelve are expected to be novel and out of the twenty zinc complexes that 
were produced, fourteen are believed to be first reported in this thesis. If there was a call for a 
copper or zinc complex that had not been synthesised but the related ligand had been made 
during this project, it is expected that this could be done by following the methods established in 
this project. In respects to the initial aim and objectives of this project which relates to complex 
synthesis (aim 3, objective 4 & 5), it is regarded that these have been successfully met as it is 
believed that the synthetic methods reported can be applied to entire library of ligands produced 
in this project. Even though in some cases complications may be encountered as some complexes 
maybe susceptible to forming a fifth coordinate bond with solvent or reagent molecules. 
Investigations in to synthesising copper bis(thiosemicarbazone) complexes by transmetalating the 
zinc from a zinc bis(thiosemicarbazone) complex precursor with copper have been under taken. 
Early results suggest that the transmetalation reaction works for a range of zinc 
bis(thiosemicarbazone) complexes. A handful of zinc bis(thiosemicarbazone) complexes 
containing a pyridine adduct have also been synthesised and characterised for the investigation of 
carrying out the transmetalation reaction on pyridine based solid supports. A previously reported 
polymer alongside a cheaper, more readily available polymer support has been loaded with a zinc 
complex. Initial spectroscopic data shows promising results. Preliminary transmetalation reactions 
using the polymer support were inconclusive.  
Further investigation in to the transmetalation reaction on the polymer supports is warranted. 
The key areas of interest would be loading both PS-DMAP and PVP with a large range of zinc 
complexes and verifying if the zinc complexes successfully bind to the polymers. In order to verify 
binding optimisation of spectroscopic techniques, particularly Raman, may be required.  
Identifying the level of loading of each zinc complex on both polymers would be valuable 
information for optimisation of the transmetalation process. Once all this is achieved, work on 
development of a generic and simple method for the transmetalation of zinc complexes on a 
polymer support, which can be applied to the range of complexes synthesised in this project 
would provide a very convenient method for synthesising the related radio-copper complexes for 
future biological screening.    
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Additional work on identifying the impurity, expected to be related to the acetate ion, found in a 
number of zinc complexes can be pursued as well as verifying if this impurity is also present in any 
of the copper complexes. If a reagent impurity is present in the related zinc complex ascertaining 
if it interferes with the transmetalation reaction would be of interest. If a reagent impurity was 
found to be present in a copper complex, a key thing to gather would be if the impurity can be 
removed via purification techniques. If this is not possible then whether the impurity has an 
effect, either positively or negatively, on the pharmacokinetics of the complex in regards to 
imaging hypoxia or copper metabolism in the brain.     
 All intermediates, ligands and complexes, both novel and previously reported, were 
comprehensively characterised by a range of techniques, which has filled some gaps in the 
reported literature. Due to restrictions in resources and time, it was not possible to obtain mass 
spectrometry and CHN data on all complexes and ligands made in this project however it was 
possible to obtain this data for the vast majority of the novel compounds. It is regarded that aim 4 
and objective 6 of this project have been mostly achieved.  
The Cu (II/I) reduction potential data collected on a selection of the copper complexes showed 
that complexes with Me/Et on the back bone had lower reduction potentials than Cu-BDO-Me-
Me, this may suggest that they have greater hypoxia selectivity than Cu-BDO-Me-Me and 
therefore are good candidates for further testing for hypoxia selectivity. Unfortunately at the time 
of writing no lipophilicity data was available but if a trend observed in a paper by J. Dearling et 
al.
77 PDO based copper complexes with more lipophilic substituents such as dimethyl and ethyl 
may have higher hypoxia selectivity than PDO complexes with NH2 and methyl on the terminal 
amines.  Objectives 7, 8 and 9 are regarded as being partially achieved. Future work in order to 
meet the remainder of the objectives would be to collect lipophilicity values for the copper 
complexes, particularly the copper complexes identified by their reduction potentials as good 
candidates.  
Due to the lack of personnel and recurrent problems in radio-copper supply, it has not been 
possible to directly measure hypoxia selectivity or brain accumulation/retention.  So in this regard 
it has not been possible to meet the biological screening components of objective 8 and 9. 
Assuming that the required personnel and radio-copper is available to screen candidate 
compounds, future experiments would be to establish if the dissymmetric compounds 
synthesised in this project are superior imaging agents for hypoxia by testing them in the isolated 
heart model.  
The hypothesis of this thesis was: 
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The use of radio labelled dissymmetric copper bis(thiosemicarbazone) complexes offers the 
opportunity to achieve superior imaging capabilities in diagnostic imaging of hypoxia by positron 
emission tomography, than currently used symmetric copper bis(thiosemicarbazone) complexes.   
Even though the work in this thesis has made progress towards showing that dissymmetric copper 
bis(thiosemicarbazone) complexes have a potential to offer superior imaging capabilities, without 
the direct measuring of their hypoxia selectivity it is not possible to prove or disprove this 
hypothesis at this point in time. However, with a little further biological screening it should 
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Appendix 1 Materials used 
Name Quantity Supplier CAS number Purity 
Acetone 2.5l Fisher Scientific 67-68-5 >99% 
Acetonitrile 2.5l Fisher Chemicals 75-05-8 99.99% 
2,3 Butanedione 100ml Aldrich 431-03-8 97% 
Copper acetate monohydrate 500g Fisons Scientific Equipment 142-71-2 99% 
Diethyl ether 2.5l Fisher Scientific 60-29-7 99.98% 
3,3-Dimethoxy-2-butanone 25g Acros organics 21983-72-2 98% 
Dimethyl aminopyridine on polystyrene 
crosslinked with 2% divinyl benzene 
5g Aldrich 82942-26-5  
Dimethyl sulfoxide 500ml  Fisher Scientific 67-68-5 99.99% 
Dimethyl sulfoxide D-6 10g  Cambridge isotope 
laboratories inc 
2206-27-1 99.9% 
4,4-Dimethyl-3-thiosemicarbazide 1g  Aldrich 6926-58-5 98% 
Ethanol (absolute) 2.5l  Fisher Scientific 64-17-5 99.99% 
4-Ethyl-3-thiosemicarbazide 25g Aldrich 13431-34-0 97% 
Glyoxal solution 100g Sigma-Aldrich 107-22-2 40% wt 
in H20 
Hydrochloric acid 2.5l Fisher Scientific 7647-01-0 32% 
Lithium tetraflouroborate 10g Alfa Aesar 14283-07-9 98% 
Lithium tetraflouroborate 10g Aldrich 14283-07-9 98% 
Magnesium sulfate 2Kg Aldrich 7487-88-9 97% 
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Methyl glyoxal-1,1-dimethyl acetal 25g Acros Organics 6342-56-9 97+% 
Methanol 2.5l Fisher Scientific 67-56-1 99.99% 
4-Methyl-3-thiosemicarbazide 50g Aldrich 6610-29-3 97% 
Molecular Sieves (3Å) 1Kg Sigma-Aldrich 308080-99-1  
N,N-Dimethyl formamide 2.5l Fisher Scientific 68-12-2 99% 
2,4-Pentanedione 250ml Aldrich 123-54-6 99+% 
4-Phenylthiosemicarbazide 10g Aldrich 5351-69-9 99% 
Poly (4-vinyl pyridine) crosslinked with 2% divinyl 
benzene 
25g Aldrich 9017-40-4  
Pyridine 100ml Sigma-Aldrich 110-86-1 99.8% 
Sodium carbonate 500g Aldrich 497-19-8 97% 
Sodium hydroxide 1Kg Fisher Scientific 1310-73-2 99% 
Thiosemicarbazide 100g  Aldrich 79-19-6 99% 







Appendix 2 Instrumental conditions 
Instrumentation and conditions used for analysis of the bis(thiosemicarbazone) ligands, 
intermediates and their corresponding copper and zinc complexes. 
NMR spectroscopy conditions 
A Jeol JNM ECS400 Nuclear Magnetic Resonance Spectrometer was used.  
1H: Field strength: 9.4 T (400 MHz), X freq: 400 MHz, scans: 8. 
13C: Field strength: 9.4 T (400 MHz), X freq: 101 MHz, scans: 1024. 
Infrared spectroscopy conditions 
A Shimadzu IR Affinity-1 Fourier Transform Infrared Spectrometer with a Golden Gate Diamond 
Attenuated Total Reflectance (ATR) attachment was used.  
Range: 400 cm-1-4000 cm-1, number of scans: 16, resolution: 4.0, measurement mode: % 
transmittance 
Raman spectroscopy conditions 
A LABRAM HR800 Raman Spectrometer was used. 
Bis(thiosemicarbazone) ligands & monosubstituted-3-thiosemicarbazone intermediates: 
Red laser: Laser: 632.81 nm, range: 200 cm-1-4000 cm-1, hole: 800, slit: 100, grating: 600, filter: 10 
%, accumulation time: 2 seconds, accumulations: 5.   
Copper bis(thiosemicarbazone) complexes: 
Red laser: Laser: 632.81 nm, range: 200 cm-1-4000 cm-1, hole: 800, slit: 100, grating: 600, filter: 10 
%, accumulation time: 20 seconds, accumulations: 4.   
Green laser: Laser: 532.00 nm, range: 200 cm-1-4000 cm-1, hole: 800, slit: 100, grating: 1800, filter: 
0.1 %, Accumulation time: 2 seconds, Accumulations: 5. 
Zinc bis(thiosemicarbazone) complexes: 
Red laser: Laser: 632.81 nm, range: 200 cm-1-4000 cm-1, hole: 800, slit: 100, grating: 600, filter: 10 
%, accumulation time: 2 seconds, accumulations: 5.   
Near infrared: Laser: 784.15 nm, range: 200 cm-1-2000 cm-1, hole:  200, slit: 100, grating: 600, 




Elemental analysis conditions 
A Thermo Scientific (Carlo Erba) Flash 2000 Elemental Analyser was used which was configured for 
A?,E ?dŚĞƐĂŵƉůĞƐǁĞƌĞƌƵŶďǇ^ƚĞƉŚĞŶŽǇĞƌĨƌŽŵ>ŽŶĚŽŶDĞƚƌŽƉŽůŝƚĂŶhŶŝǀĞƌƐŝƚǇ ?ƐůĞŵĞŶƚĂů
Analysis Service. 
Melting point analysis conditions 
A Stuart SMP10 melting point apparatus was used. 
An initial melting point was obtained by using the fast ramp rate (20oC per min). The apparatus 
was allowed to cool by 30oC and a fresh sample was heated up using the slow ramp rate (2 oC per 
min).  
UV-vis spectroscopy conditions 
A Shimadzu UV-1800 UV Spectrophotometer was used.  
Scan Range: 285-800nm, Scan Speed: slow, Solvent: DMSO, Cuvette: Quartz, 1 cm path length.  
Mass spectrometry conditions 
A Bruker micrO_TOF-Q mass spectrometer was used. 
Samples were dissolved in DMSO at a concentration of 1 mg/ml before being diluted 1 in 100 in 
methanol.  10 µl of sample was injected into a flowing stream of 10 mM ammonium acetate in 
95% methanol in water (flow rate: 0.02 ml/min) and the flow directed into the electrospray 
source of the spectrometer. Mass spectra were acquired in the positive ion mode and data 
processed in ƌƵŬĞƌ ?ƐŽŵƉĂƐƐĂƚĂ Analysis software utilising a lock mass. 
 
Source type: ESI, Scan begin: 100 m/z, Scan end: 1250 m/z, Ion polarity: positive, Set capillary: 
4500 V, Set end plate offset: -100 V, Set Collision Cell RF: 150.0 Vpp, Set nebulizer: 0.4 Bar, Set dry 
heater: 180oC, Set dry gas: 4.0 l/min, Set divert valve: Source.   
Reduction potential measurement conditions: 
The reduction potentials were gathered by Julia Baguña Torres from the Division of Imaging 
Sciences & Biomedical Engineering at King's College London. The potentials were obtained using 
cyclic voltammetry using a glassy carbon electrode as the working electrode, a silver wire 
electrode as the reference one and a platinum wire electrode as the auxiliary electrode. The 
values were normalised against ferrocene. 
 
